WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 96/30849 (11) International Publication Number: G06F 17/50, 159/00, G06G 7/58, G01N (43) International Publication Date: 3 October 1996 (03.10.96) 24/12, 33/53 PCT/US96/04229 (81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, (21) International Application Number: CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, (22) International Filing Date: 27 March 1996 (27.03.96) LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO. RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, (30) Priority Data: BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, 418,992 31 March 1995 (31.03.95) GN, ML, MR, NE, SN, TD, TG). (71) Applicant: CURAGEN CORPORATION [US/US]; 322 East Main Street, Branford, CT 06405 (US). **Published** (72) Inventors: DEEM, Michael, W.; 24 Highland Avenue #14, With international search report. Cambridge, MA 02139 (US). ROTHBERG, Jonathan, M.; Before the expiration of the time limit for amending the 49 Old Quarry Road, Guilford, CT 06437 (US). WENT, claims and to be republished in the event of the receipt of Gregory, T.; 34 Scotland Avenue, Madison, CT 06443 (US). omendments. (74) Agents: MORRIS, Francis, E. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).

(54) Title: CONSENSUS CONFIGURATIONAL BIAS MONTE CARLO METHOD AND SYSTEM FOR PHARMACOPHORE STRUCTURE DETERMINATION

(57) Abstract

6

In a specific embodiment, this invention comprises a method for selecting highly targeted lead compounds for design of a drug that binds to a target molecule. The method comprises screening a diversity library against the target molecule of interest to pick the selectively binding members. Next the structure of the selected members is examined and a candidate pharmacophore responsible for the binding to the target molecule is determined. Next, preferably by REDOR nuclear magnetic resonance, several highly accurate interatomic distances are determined in certain of the selected members which are related to the candidate pharmacophore. A highly accurate consensus, configurational bias, Monte Carlo method determination of the structure of the candidate pharmacophore is made using the structure of the selected members and incorporating as constraints the shared selected members and incorporating as constraints the shared candidate pharmacophore and the several measured distances. This determination is adapted to efficiently examine only relatively low energy configurations while respecting any structural constraints present in the organic diversity library. If the diversity library contains short peptides, the determination respects the known degrees of freedom of peptides as well as any internal constraints, such as those imposed by disulfide bridges. Finally, the highly accurate pharmacophore so determined is used to select lead organics for drug development targeted at the initial target molecule.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	ireland	NZ	New Zealand
BG	Bulgaria	IT	kaly	PL.	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	. RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Coago	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	и	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoelovakia	LT	Lithmania	Ī	Chad
CZ	Czech Republic	LU	Laxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Mosaco	77	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Utraine
ES	Spain	MG	Madagascar	UG	Uganda
n	Finland	ML	Mali	us	United States of America
FR	France	MN	Mongolia	UZ	Uzhekistan
GA	Gabon	MIR	Mauritania	VN	Viet Nam

CONSENSUS CONFIGURATIONAL BIAS MONTE CARLO METHOD AND SYSTEM FOR PHARMACOPHORE STRUCTURE DETERMINATION

This specification includes in Sec. 8 computer program

5 listings that are exemplary embodiments of the computer programs of this invention.

A portion of the disclosure of this patent document contains material which is subject to copyright protection.

The copyright owner has no objection to the facsimile reproduction by any one of the patent disclosure, as it appears in the Patent and Trademark Office patent files and records, but otherwise reserves all copyright rights whatsoever.

This invention was made with Government support under Grant number 1R43CA62752-01 awarded by the National Institutes of Health. The Government has certain rights in the invention.

1. FIELD OF THE INVENTION

The field of this invention is computer assisted methods of drug design. More particularly the field of this invention is computer implemented smart Monte Carlo methods which utilize NMR and binders to a target of interest as inputs to determine highly accurate molecular structures that must be possessed by a drug in order to achieve an effect of interest. Illustrative U.S. Patents are 5,331,573 to Balaji et al., 5,307,287 to Cramer, III et al., 5,241,470 to Lee at al., and 5,265,030 to Skolnick et al.

30

2. BACKGROUND

Protein interactions have recently emerged as a fundamental target for pharmacological intervention. For example, the top two major uncured diseases in the United States are atherosclerosis (the principal cause of heart attack and stroke) and cancer. These diseases are

responsible for greater than 50% of all U.S. mortality and cost the U.S. economy over \$200 billion per year. A consistent picture of these dis ases, which has gradually emerged during the past ten y ars of molecular biological and 5 medical research, views both as triggered by disordering of specific molecular recognition events that take place among sets of proteins present in both the normal and disease states.

Hierarchical, organized patterns of protein-protein

10 interactions are often referred to as "pathways" or

"cascades." At the molecular level, cancers have been
determined to be the deregulation of pathways of interacting
proteins responsible for guiding cellular growth and
differentiation. During the past year, individual cellular

15 events have been organized into nearly complete mechanistic
explanations of how a cell's behavior is controlled by its
environment and how communication pathway errors lead to
uncontrolled proliferation and cancer. Disruption in similar
pathways are responsible for the proliferation of blood

20 vessel walls marking the atherosclerotic disease state (Cook
et al., 1994, Nature 369:361-362; Hall, 1994, Science
264:1413-1414; Ross, 1993, Nature 362:801-809; Zhang et al.,
1993, Nature 364:308-313).

Inhibition or stimulation of particular protein25 substrate interactions have long been known drug targets.

Many important anti-hypertensives, neurotransmitter
analogues, antibiotics, and chemotherapeutic agents act in
this fashion. Captopril, an antihypertensive drug, was
designed based on its ability to antagonize a focal blood30 pressure-regulating enzyme.

Proteins involved in biological processes, either as part of protein-protein pathways or as enzymes, are composed of domains (Campbell et al., 1994, Trend. BioTech. 12:168-172; Rothberg et al., 1992, J. Mol. Biol.

35 227:367-370). Domains, or regions of the protein of stable three dimensional (secondary and t rtiary) structures, play several major roles, including providing on their surface

small regions ("examples of targ ts"), wher proteins and substrat s are abl to bind and interact, and functioning as structural units holding other domains together as part of a large protein (tertiary and quaternary structure). The 5 interaction surface of a domain or target is fundamental to

- interaction surface of a domain or target is fundamental to determining binding specificity. Targets are often small enough that the principal contribution to the binding energy is short range, highly localized to several amino acids (Wells, 1994, Curr. Op. Cell Biol. 6:163-174). The
- 10 functional specificity of targets and domains, responsible for the incredible diversity of cellular function, ultimately rests with the arrangement of amino acid side chains forming their interaction surfaces, or targets (Marengere et al., 1994, Nature 369:502-505).
- It can be appreciated, therefore, that pharmacological intervention affecting the specific protein-protein and protein-substrate recognition events occurring at protein targets is of fundamental importance, particularly for effective drug design.
- However, achieving desired pharmacological interventions in a predictable manner remains as elusive as ever. Early approaches to drug design depended on the chance observation of biological effects of a known compound or the screening of large numbers of exotic compounds, usually derived from 25 natural sources, for any biological effects. The nature of the actual protein target was usually unknown.

2.1. TARGET STRUCTURE-BASED APPROACHES TO DRUG DESIGN

Rational approaches to drug design have met with only limited success. Current rational approaches are based on first determining the entire structure of the proteins involved in particular interactions, examining this structure for the possible targets, and then predicting possible drug molecules likely to bind to the possible target. Thus the location of each of the thousands of atoms in a protein must be accurately determined before drug d sign can begin.

Direct experimental and indirect computational methods for protein structure determination are in current use. However, none of these methods appears to be sufficiently accurate for drug design purposes according to current rational

5 approaches. The primary direct experimental methods for determining the structure of proteins involved in particular interactions are X-ray crystallography, relying on the interaction of electron clouds with X-rays, and liquid nuclear magnetic 10 resonance (NMR), relying on correlations between polarized nuclear spins interacting via indirect dipole-dipole interactions. X-ray methods provide information on the location of every heavy atom in a crystal of interest accurate to 0.5-2.0 Å (1 Å = 10^{-8} cm). Drawbacks of x-ray 15 methods include difficulties in obtaining high-quality crystals, expense and time associated with the crystallization process, and difficulties in resolving whether or not the structure of the crystalline forms is representative of the in vivo conformation (Clore et al., 20 1991, J. Mol. Biol. 221:47; Shaanan et al., 1992, Science 227:961-964). High resolution, multidimensional, liquid phase NMR techniques represent an attractive alternative, to the extent that they can be applied in situ (i.e., in aqueous environment) to the study of small protein domains (Yu et 25 al., 1994, Cell 76:933-945). However, the complexity of the analysis of the various mutual correlations is time consuming, and the correlations (primarily from the nuclear Overhausser effect) provide no better accuracy than X-ray methods. Isotopic enrichment of proteins with 13C and 15N 30 reduces the time associated with analysis, but at a great expense (Anglister et al., 1993, Frontiers of NMR in Biology III LZ011).

Protein structures determined by any of these current methods do not predict success in subsequent drug design.

35 Resolution obtainable either by measurement or computation, g nerally 0.5-2 Å, has oft n been found to be inadequate for effectiv direct drug design, or for selection of a lead

compound from organic compound libraries. The resolution required to understand both drug affinity and drug specificity, although not precisely known, is probably measured in fractions of an Å, down to 0.1 Å (MacArthur et al., 1994, Trend. BioTech. 12:149-153). This accuracy appears to be beyond the capabilities of many current methodologies.

Prior research has identified tools which, although promising, cannot be used in a coordinated manner for drug design. One promising measurement approach with speed, simplicity, accuracy, and the ability to carefully control the measurement environment is rotational echo double resonance (REDOR) NMR, a type of solid state NMR (Guillion and Schaefer, 1989, J. Magnetic Resonance 81:196; Holl et al., 1990, J. Magnetic Resonance 81:620-626 and McWherter, 1993, J. Am. Chem. Soc. 115:238-244). REDOR accuracy can be below the 0.1 Å believed to be sufficient for direct drug design. However, since REDOR measures only a few selected distances, it is not usable in drug design methods which depend on the initial determination of the complete structure of the protein containing the target of interest.

Once a target's structure is determined by the above methods, most rational drug design paradigms call for the prediction of small drug structures that will bind (or dock) 25 to the target. This prediction is generally done by computational methods, of which several are in current use. Most seek to predict the position of all the thousands of atoms in a drug structure. Purely ab initio computational approaches to high resolution structure analysis, such as 30 quantum statistical mechanics and molecular dynamics, require prohibitive computing resources. To apply either approach, the potential energy, or Hamiltonian, of the entire system must be known. Statistical mechanics provides an expression for the probability of any given protein configuration as a 35 ratio of partition functions. Proper quantum statistical mechanics required for an exact evaluation of full protein partition functions is not curr ntly computationally

feasibl, as it would involve many thousands of atoms including the target, the protein, and the aqueous environment. The application of even simple, approximate quantum statistical mechanics to simple systems in aqueous 5 environments is currently a non-trivial task (Chandler, 1991, in Liquids, Freezing, and Glass Transitions, Elsevier, NY, p. 195). Molecular dynamics computes the dynamics of a molecule's motion in time. Computing the atomic dynamics of all the perhaps thousands atoms of a protein is an extreme 10 computational burden. Only picoseconds, or at most a few nanoseconds, of molecular time can be simulated, which is insufficient to determine a high resolution, equilibrium, structure (Smit et al., 1994, J. Phys. Chem. 98:8442-8452). In any case, most of the information determined is wasted, 15 since only the structure of the protein binding target are of interest in drug design.

Further, current approximate computational techniques for protein structure determination are in need of greater accuracy or efficiency. The most common techniques depend on 20 Molecular Dynamics or Monte Carlo methods (Nikiforovich, 1994, Int. J. Peptide Protein Res. 44:513-531; Brunger and Karplus, 1991, Acc. Chem. Res. 24:54-61). These methods randomly alter initial molecular structures by generating simulated thermal perturbations, and then average the 25 ensemble of results to determine a final structure. generated perturbation must preserve all structural constraints and be energetically favorable. If both conditions are not met, the perturbation will be discarded. Current Monte Carlo methods applied to constrained protein 30 structure determinations productively use only approximately 1 out of 105 perturbed structures generated (Siepmann et al., 1993, Nature 365:330-332). This extreme waste of computer rescurces results in time consuming, low resolution structure determinations.

To summarize, existing rational drug design methods bas d on identification of target structure fail to r liably yield drug molecules du to experimental structure

5

determination difficulties and computational difficulties associated with predicting drug structures with ill-defined Hamiltonians.

2.2. DIVERSITY-BASED APPROACHES TO DRUG DESIGN

Another method for exploring protein target interactions utilizes "recognition systems" which comprise huge libraries of related molecules (Clarkson et al., 1994, Trend. BioTech. 12:173-184). From such a library only those members binding 10 to the target of interest are selected. Such recognition systems must encompass the structural diversity of protein targets while being amenable to serve for the selection of lead compounds for drug design. Antibodies are one classic example of such a system that certainly meets the recognition 15 requirement. Unfortunately, there is a need to determine the antibody structures needed for lead compound selection more rapidly and accurately. While about 2000 recognition regions have been sequenced, only about 23 in the Brookhaven Protein Structural Database have structures determined to even within 20 2 Å (Rees et al., 1994, Trends in Biotech. 12:199-206).

Promising recognition systems at the opposite extreme comprise huge libraries of small peptides. The small peptides must be sufficiently diverse so that they attain a level of affinity and specificity similar to that obtained by 25 protein domains. Given the role peptides play in nature, this condition can be met by surprisingly small structures, with 6 to 12 amino acids. However, linear peptides are either unstructured or weakly structured at room temperature in aqueous solutions (Alberg et al., 1993, Science 262:248;

- 30 Skalicky et al., 1993, Protein Science 10:1591-1603). From a practical viewpoint, linear peptides must be constrained to reduce their degrees of freedom (reduced conformational entropy) and to increase their chances for strongly binding. These constraints, or scaffolds, limit the range of stable
- 35 conformations and make more straightforward determining bound structure (Olivera et al., 1990, Science 249:259; Tidor et al., 1993, Prot ins: Structure Function and Genetics 15:71).

Methods are now available to create such libraries and to sel ct library members that recognize a specific protein target. The production of constrained peptide diversity libraries requires synthesizing oligonucleotides with the desired degeneracy to code for the peptides and ligating them into selection vectors (Goldman et al., 1994, Bio/Tech. 10:1557-1561). Once a constrained structured diversity library is created, it is a source from which to select specific members that bind to a target of interest. Beginning with a known pathway involving specific domain-domain or protein-substrate interactions at a target, molecular biological methods can be used to identify in a matter of days small ensembles of highly constrained peptides from these huge libraries that bind to these domains with high 15 affinity and specificity.

While this field has been exploding in the last few years and showing great potential, it is severely limited by its use in isolation without the benefit of integrated structural analysis needed both to derive the high resolution 20 structures of binding peptides and also to direct the construction of additional structured libraries. Drug design is not aided by having library members recognizing the protein target of interest but without any understanding of why the recognition occurs. This is entirely similar to the 25 random screening methods of early fortuitous drug design efforts.

Unfortunately, rational drug design according to current approaches (target structure-based) remains an inefficient, laborious process with a disproportionately high lead30 compound failure rate. Presently, about 90% of lead compounds fail to emerge successfully from clinical trials (Trends in U.S. Pharmaceutical Sales and Research and Development, Pharmaceutical Manufacturing Association, Washington, D.C., 1993).

It is becoming clear that low-resolution structures of an entire protein or target (at 0.5-2 Å), or an

uncharacterized lead, such as produced by chemical diversity methods, leave much to be desired for use in drug design.

If the limitations of prior art methods were overcome and a sufficiently accurate structure needed by a molecule to 5 bind to a target of interest could be determined, existing chemical libraries could be searched for highly targeted lead compounds with similar structure (Martin, 1992, J. Medicinal Chem. 35:2145-2154). This database search can be based not only on chemical and electronic properties, but also on 10 geometric information. Such searches that have high resolution (better than 0.25 Å), would provide a vast improvement over the prior art, as lower resolutions lead to an exponentially increasing number of potential leads.

Computational methods to determine high resolution drug 15 structures from recognition system binding information or NMR partial distance measurements are not currently available. No current structure determination methods uses such additional information to make more efficient or more accurate determination of high resolution structures 20 (Holzman, 1994, Amer. Sci. 872:267).

Citation of a reference or discussion hereinabove shall not be construed as an admission that such is prior art to the present invention.

25 3. SUMMARY OF THE INVENTION

It is a broad object of this invention to address the prior art problems of drug design by providing a method of rational design of drugs that achieve their effect by binding to a target molecule or molecular complex of interest.

- 30 Importantly, this object is achieved without requiring determination of the structure of the molecule or molecular complex ("target molecule") bearing the target or even of the target itself. The method is target structure independent. The method of the invention uses an interdisciplinary
- 35 combination of computational modeling and simulation, experimental distance constraints, and molecular biology.

In an important aspect, the invention provides a computer implemented modeling and simulation method to determine a highly accurate consensus structure for the pharmacophore and a structure for the remainder of the 5 molecule from diversity library members that bind to the protein target of interest. Where prior structure determination methods focused on the structure of the target molecule or of the target, the method of this invention is uniquely adapted to focus instead on the structures of 10 molecules that bind to the target. Such structural information is directly applicable to drug design since it defines the structure a drug must possess to bind to the target of interest. Also, this structural information is much easier to determine by use of the present invention, 15 since it concerns molecules with many fewer atoms than the target molecule. The method of the invention achieves accuracy by improving upon the accuracy and utility of the input structural information. In a further embodiment of the invention, the method employed for structural determination 20 is a smart Monte Carlo technique adapted to small constrained molecules.

The structure determination method of the invention allows one to take maximum advantage of the information obtained from the molecular biological selection of the 25 diversity library members that tightly and specifically bind to the target molecule of interest. The selected library members must share some common structure to bind to the same target molecule. The smart Monte Carlo computer method of this invention specifically seeks and provides this common structure.

The invention also provides a method of performing REDOR NMR measurements of molecules on a solid phase substrate. In a preferred embodiment, the substrate is a solid phase on which the molecule (e.g., peptide) has been synthesized, with 35 a high degree of purity. In another pr ferred mbodiment, performing REDOR measurements of such a molecule on a substrate can be done in a dry nitrogen atmospher, under

hydrated conditions, and when the molecule is either free or bound to a target. In a specific embodim nt, the REDOR measurements are accurate to better than 0.05 Å from 0 to 4 Å, and to better than 0.1 Å from 4 to 8 Å. In an 5 advantageous aspect of the invention, the structure determination method makes maximum use of these highly accurate internuclear distance measurements to constrain the determined common structure for the binding library members.

The invention also provides methods of identifying a

10 compound that specifically binds to a target molecule, by
first screening a diversity library, and then using a genetic
selection method for screening the compounds identified from
the diversity library.

In broad aspects, the invention provides a method and
15 apparatus for rational and predictable design of new and/or
improved drugs that achieve their effect by binding to a
specified target molecule. More particularly, the invention
is directed to a method for the rational selection of highly
specific lead compounds for such drug design, including the
20 computer implemented step of highly accurate determination of
the structure responsible for this target binding by the
highly accurate, consensus, configurational bias Monte Carlo
method.

A lead compound serves as a starting point for drug

25 development both because it specifically binds to the protein target of interest, achieving the biological effect of interest, and because it has or can be modified to have good pharmacokinetics and medicinal applicability. A final drug may be the lead compound or may be derived therefrom by

30 modifying the lead to maximize beneficial effects and minimize harmful side-effects. Although any lead compound is useful, a lead that tightly and specifically binds to the target molecule of interest in a known manner, such as can be provided by the invention, is of great use. Knowledge of the 35 high resolution structures in a lead compound responsible for its binding and activity provides a more focused and fficient drug dev lopment process.

The methods of the invention improve lead compound determination, by determining the "pharmacophore", the precise structural characteristics needed for a lead compound to specifically bind to a target of interest. The most 5 fundamental specification of a pharmacophore is in terms of the electronic properties necessary for a molecule to specifically bind to the surface of a target molecule. These properties may be fundamentally represented by requirements on the ground and low lying excited state wave functions of a 10 pharmacophore, such as, for example, by specifying requirements on the well known multiple expansion of these wave functions.

The preferred pharmacophore specification according to the invention is in terms of both the chemical groups making 15 up the pharmacophore and determining its electronic properties and also the geometric relationships of these groups. This chemical representation is not the only possible representation of the pharmacophore. Several chemical arrangements may have similar electronic properties.

- 20 For example, if a pharmacophore specification included an -OH group at a particular position, a substantially equivalent specification might include an -SH group at the same position. Equivalent chemical groups that may be substituted in a pharmacophore specification without substantially
- 25 changing its nature are called "homologous".

In particular embodiments, therefore, this invention provides a method and apparatus for the highly accurate determination of the pharmacophore needed to specifically bind to the target molecule of interest, by a specification of the geometric relationships of the important chemical

- groups. The pharmacophore is preferably determined by a smart Monte Carlo method from molecular biological input specifying molecules (preferably selected from among diversity libraries) that specifically bind to the target
- 35 molecule and also preferably from REDOR NMR data specifying a few highly accurate distances in these select d molecules.

An important advantage provided by the invention is the ability to make a pharmacophore structure determination without relying on any knowledge of the structure of the target molecule or target. Where the target molecule is a 5 protein, conventional prior art methods have sought to sequence and determine the structure of the protein containing the target, hoping thereby to determine active sites by examination of the structure. A further important advantage of the invention is that this structure 10 determination can be made by use of a relatively small number of actual physical position measurements. In contrast, conventional methods using X-ray crystallography and liquid NMR require determination of positions of all atoms in the molecule ("binder") that specifically binds to the target, 15 and the target. An additional advantage provided by the invention is that, in a preferred embodiment wherein REDOR structural measurements provide input information, the accuracy of the pharmacophore structure determination can be at least approximately 0.25-0.50 Å or better. This accuracy 20 is provided by the combination of an efficient, Monte Carlo technique for structure determination with a few highly accurate distance determinations.

4. BRIEF DESCRIPTION OF THE DRAWINGS

- 25 These and other features, aspects, and advantages of the present invention will become better understood by reference to the accompanying drawings, following description, and appended claims, where:
- Fig. 1 is the overall method of this invention in its 30 broadest aspect;
 - Fig. 2A and 2B are more detail for the step of Fig. 1 for selecting candidate pharmacophore structures;
 - Fig. 3 is more detail for the step of Fig. 1 for preforming distance measurements;
- Fig. 4 is more detail for the step of Fig. 3 for performing NMR measur ments;

Fig. 5 is REDOR NMR signal response details for step of Fig. 3 of data analysis;

- Fig. 6 is sample REDOR NMR spectra according to the method of Fig. 3;
- Fig. 7 is sample data analysis according to the method of Fig. 3;
 - Fig. 8 is more detail for the Step of Fig. 1 for configurational bias Monte Carlo structure determination;
 - Fig. 9 is a sample of simulation completion data;
- 10 Fig. 10 is further detail of peptide memory representation used in the method of Fig. 8;
 - Fig. 11 is additional detail of peptide memory representation used in the method of Fig. 8;
- Fig. 12 is more detail for the step of Fig. 8 of
 15 processor generation of proposed modified structures by Type
 I moves:
 - Fig. 13 is more detail for the step of Fig. 8 of processor generation of proposed modified structures by Type II moves;
- 20 Fig. 14 is additional detail for the step of Fig. 8 of processor generation of proposed modified structures by Type

 II moves;
 - Fig. 15 is a structure for implementing the method of Fig. 8;
- 25 Fig. 16 is the main program structure of Fig. 15; Fig. 17 is the structure modification program structure of Fig. 15;
 - Fig. 18A and 18B are the Type I move generator program structure of Fig. 17;
- Fig. 19A and 19B are the Type II move generator program structure of Fig. 17.

5. DETAILED DESCRIPTION

For clarity of disclosure, and not by way of limitation,

35 the detailed description of the invention is described as a
series of steps. A broad view of the ex mplary steps of
which the invention is comprised is presented in Fig. 1, a

brief overview of which is presented in the text that follows.

The invention method preferably begins with a target molecule (or molecular complex) 1 having a binding target of 5 biological or pharmacological interest. Specific binding of a molecule to the target is predicted to affect its biological activity and may provide biological effects of interest. For example, these effects might include amelioration of a disease process or alteration of a 10 physiological response. Lead compounds 8 output from the invention are able to specifically bind to target molecule 1 and can serve as starting points for the design of a drug able to specifically bind to the target.

Diversity library screening, step 2, allows the

15 selection from among library members of a plurality of
molecules [hereinafter called "binders"] that specifically
bind to target molecule (or molecular complex) 1; the
chemical building block structure (e.g., sequence, structural
formula) is then determined. If predetermined binders and

- 20 their structure are already available, the invention can use this information directly without the need for library screening. If library screening is done, one or more libraries may be screened. The selected binders all share a common pharmacophore structure, allowing their specific
- 25 binding to the target in a chemically and physically similar manner. This common structure is preferably iteratively determined by a select and test method. Candidate pharmacophore selection, step 3, is based upon chemical structure homologies. Geometric and conformational
- 30 information is not needed to be used at this step and is preferably not considered. A candidate pharmacophore shared by all the N binders is selected, step 3, for structure determination by subsequent steps. The binders will typically present several candidate chemical pharmacophores,
- 35 ignoring conformation considerations. These candidates are small groups of library building blocks, often contiguous, ach candidate group in on binder being homologous to the

candidate groups in all the other binders. Building block homologies are determined by applying rules appropriat to the diversity library. In the preferred embodiment, homologous building blocks have similar surface chemical 5 groups, since pharmacophores are defined by a similar geometric arrangement of chemical structures. In the case of the preferred library, CX,C, candidate pharmacophores are amino acid sequences whose side chain surface groups have similar chemical properties. Amino acid homologies are 10 determined by mechanical rules described below. These candidate sequences are typically 3 amino acids long, but may range from 2 all the way to 6. Where pharmacophores are defined by their charge distributions, homologous library building blocks must have similar charge distributions.

15 Having selected N binders by screening one or more libraries and determined a candidate pharmacophore in each binder, the subsequent steps of distance measurement, step 4, and Monte Carlo structure determination, step 5, determine a highly accurate structure for the candidate pharmacophore, if 20 possible. This determination will be possible if the candidate is the actual pharmacophore. A subsequent test, step 6, checks for success of this structure determination. In particular cases, distance measurements may not be necessary in order to determine an adequately precise 25 pharmacophore structure.

Measurements are made, step 4, of a few strategic distances in the binders, that will be most useful for the subsequent structure determination step. A minimum number of strategic interatomic distances in the binders are measured 30 in step 4. These few distances constrain possible binder structures and make the subsequent complete structure determination more efficient and more accurate. In preferred but not limiting embodiments, measurement methods yielding distances accurate to at least approximately 0.25 Å or less 35 are used. The preferred methods use nuclear magnetic resonanc ["NMR"] techniques. Particularly preferred is the rotational-echo double resonance ["REDOR"] NMR method for

directly measuring ¹³C-¹⁵N internuclear distances in peptides, the most accurate current method for simply and inexpensively obtaining such distances. It is generally capable of accuracy to 0.1 Å and a span of 8 Å. In a specific

- 5 embodiment, peptide binders are synthesized from amino acids labeled with ¹³C and ¹⁵N. Labeling is chosen to obtain the most useful distance data about the selected candidate pharmacophore structures. Either backbone nuclei, side chain nuclei, or both can be labeled. The step is detailed below.
- 10 Liquid NMR techniques can also be used to indirectly determine internuclear distances in peptides, but are less preferred since they require considerable data interpretation to obtain distances of less accuracy than those obtained by use of REDOR.
- Structure determination, step 5, determines a precise geometric conformation for both the candidate shared chemical structures, if possible, and the remainder of the binders. The preferred but not limiting method, consensus, configurational bias, Monte Carlo ["CCBMC"] determination,
- 20 step 5, is an efficient smart Monte Carlo method uniquely able to incorporate knowledge from prior steps to obtain highly accurate physical binder structures. From library screening, step 2, it is deduced that the binders have a shared, actual pharmacophore, structure because they all bind
- 25 specifically to the same target molecule (hence, a "consensus" method). It is not significant to the method if the binders come from more than one library as long as they all have a structure adaptable to representation in the consensus structure determination step (see infra). From
- 30 distance measurements, step 4, a few strategically chosen distances are accurately known. This information is heuristically utilized along with an accurate model of the physical atomic interactions and the allowed molecular conformations.
- 35 Further, these means are particularly adapted for determining structures of molecules having limited conformational degrees of freedom at the temperature of

interest and conformationally constrained by, e.g., internal bonds. Potential conformations are generated and selected by smart configuration bias techniques which avoid generation of unnecessarily improbable new conformations. (Hence, a

- 5 "configuration bias" method.) The technique is preferably applied herein to conformationally constrained peptides. A concerted rotation technique is combined with configurational bias conformation generation so that new conformations automatically preserve the internally linked backbone
- 10 structure constraints. This technique is preferably applied to the preferred constrained peptide library, of a sequence comprising CX,C (wherein X is any amino acid). The technique is also applicable to other constrained peptide libraries, to peptoid libraries, and to any more general organic diversity
- 15 libraries that meet certain geometric limitations (i.e., that have structures adaptable to representation in the consensus structure determination step (see *infra*)).

The methods of the invention are not limited to the use of CCBMC for determining a consensus pharmacophore structure.

- 20 Alternative embodiments of this invention may use alternative structure determination methods to determine a consensus pharmacophore structure. For example, a simple yet expensive method is to make exhaustive REDOR NMR measurements characterizing the candidate pharmacophore in each binder and
- 25 then average these measurements. A somewhat less expensive method is to use a conventional Monte Carlo molecular structure determination method to limit somewhat the number of REDOR NMR measurements required to characterize the candidate pharmacophore. Conventional Monte Carlo methods,
- 30 being unable to directly make use of partial distance measurements or consensus binding information, are less efficient than the CCBMC method and require more distance measurements. Further, other known techniques of molecular structure determination, for example folding rules or
- 35 molecular dynamics, can be used in place of conventional Monte Carlo.

The success of the structure determination is tested, step 6, against various convergence and success criteria. Consistency tests, step 6, are applied to the resulting structure to determine whether the candidate pharmacophore 5 previously selected is the actual pharmacophore. One set of tests checks predicted distances against new distance measurements or against previous measurements temporarily not used as structure constraints. A second set of tests checks heuristically whether the candidate pharmacophore exhibits 10 the expected low energy consensus structure. The test are described further below. If a shared structure is found, the candidate pharmacophore must be the actual pharmacophore. If not, another candidate pharmacophore and another shared structure is determined, if possible. An actual 15 pharmacophore exists and will eventually be found and accurately structured.

Upon passing these tests, the methods of the invention have provided a consensus structure for the selected candidate pharmacophore, preferably accurate to at least 20 approximately 0.25-0.50 Å, as well as structures for the remainder of the binder molecules. Lead compound selection, step 7, uses these structures to determine or select highly targeted lead compounds 8. One method of lead selection is to design new organic molecules of pharmacologic utility with 25 the determined pharmacophore structure. Another method selects leads from databases of molecular descriptions. Conventionally known to medicinal chemists are databases of potential drug compounds indexed by their significant chemical and geometric structure (e.g., the Standard Drugs 30 File (Derwent Publications Ltd., London, England), the Bielstein database (Bielstein Information, Frankfurt, Germany or Chicago), and the Chemical Registry database (CAS, Columbus, Ohio)). The determined pharmacophore, being a

35 is used to query such a database. Search results will be those compounds with homologous chemical groups arrayed in a very closely similar geometric arrangement. These are lead

chemical and geometric structure in the preferred embodiment,

compounds 8 output from this invention and input to the process of drug testing and development.

Although the preferred identity and ordering of the method steps is presented in Fig. 1, the invention is not 5 limited to this identity and ordering. Other orderings, especially of steps 3, 4, and 5, are possible to achieve certain efficiencies. Steps can be inserted and deleted, for optimal effect. For example, an additional partial structure determination step can be inserted between existing steps 3 10 and 4 to provide information on how best to make the step 4 strategic measurements. As another example, in an alternative aspect, in lieu of screening one or more libraries to select binders, predetermined binders can be obtained and used (e.g., binders determined by any means to 15 be specific to the same target molecule); thus, step 2 can be omitted. In another embodiment, step 4, the measurement step, can be omitted. While all method steps in the preferred embodiment assume an aqueous environment at body temperature (37 °C), to the extent these parameters are 20 relevant to the particular step, the invention is not limited to human environmental parameters.

Screening against a diversity library consists of selecting by assay those library members which bind specifically to the target molecule of interest. Binding 25 specificity is preferably a binding constant of less than 1 µm (micromolar), and more preferably less than 100 nm (nanomolar). Preferably, an assay is done that detects an effect of binding of the binder to the target molecule on the target molecule's biological activity, to ensure that the 30 binding is actually to the biological target of interest. Also, preferably, the selected binders are tested to further select those binders that bind to the target molecule competitively, to ensure that each binds to the same target in the target molecule.

35 The output of the screening step is a number, N, of binders select d from one or more libraries for use by the subsequent steps of the method. The binders with highest

affinity are preferably selected for use by the subsequent steps. The chemical structure of each of the N binders selected for use is determined as part of the member synthesis and library screening. The primary chemical structure of the preferred constrained peptide library is specified by the amino acid sequence of the -X₆- portion of the CX₆C molecule. For more general organic diversity libraries, the selection and arrangement of library building blocks in the binders must be determined.

- It is a preferred aspect of this invention that the set of determined lead compounds is selective and small. Example 1 illustrates that as pharmacophore distance tolerances are relaxed, the number of compounds retrieved by drug database searches increases geometrically. As this invention
- 15 determines high resolution pharmacophore geometries, it can be expected that database searches, or other methods of determining leads from pharmacophore structure, will return only a few, selective, targeted leads. Methods limiting the number of leads decrease the cost of drug development and are
- 20 consequently of considerable utility to the pharmaceutical industry and medical community. The expense of developing and evaluating lead compounds for biological effect and medicinal usefulness is well known. Each lead compound must be screened for pharmacological usefulness, efficacy, and
- 25 safety. Often chemical modifications are required and the process must be repeated. Finally, the required in vivo pharmacologic toxicity and clinical trials alone can consume years of time and millions of dollars.

Therefore, starting with a target molecule 1 having a 30 biologically or pharmacologically interesting target, the method and apparatus of this invention determines a consensus pharmacophore structure. This consensus pharmacophore structure can then be used to determine a selective set of highly specific lead compounds 8 (Fig. 1) for rational design 35 of drugs, e.g., capable of acting as ligand-mimics (agonists or antagonists) for the particular target molecule.

In the following discussion and examples, each of these steps will be more fully described.

5.1. SELECTION OF A TARGET MOLECULE

- The target molecule is any one or more molecules containing a target or putative target of interest. The target is a binding interaction region. The target can be in a single molecule or can be a product of a molecular complex. The target can be a continuous or discontinuous binding
- 10 region. The target molecule selected for use (Fig. 1, step
 1) is preferably any molecule that is found in vivo
 (preferably in mammals, most preferably in humans) and that
 has biological activity, preferably involved or putatively
 involved in the onset, progression, or manifestation of a
- 15 disease or disorder. The target molecule can also be a fragment or derivative of such an in vivo molecule, or a chemical entity that contains the same target as the in vivo molecule. Examples of such molecules are well known in the art. Such molecules can be of mammalian, human, viral,
- 20 bacterial, or fungal origin, or from a pathogen, to give just some examples. The target molecule is preferably a protein or protein complex. The target molecules that can be used include but are not limited to receptors, ligands for receptors, antibodies or portions thereof (e.g., Fab, Fab',
- 25 F(ab')₂, constant region), proteins or fragments thereof, nucleic acids, glycoproteins, polysaccharides, antigens, epitopes, cells and cellular components, subcellular particles, carbohydrates, enzymes, enzyme substrates, oncogenes (e.g., cellular, viral; oncogenes such as ras, raf,
- 30 etc.), growth factors (e.g., epidermal growth factor, platelet-derived growth factor, fibroblast growth factor), lectins, protein A, protein G, organic compounds, organometallic compounds, viruses, prions, viroids, lipids, fatty acids, lipopolysaccharides, peptides, cellular
- 35 metabolites, steroids, vitamins, amino acids, sugars, lipoproteins, cytokines, lymphokines, hormones, T cell surface antigens (e.g., CD4, CD8, T c ll antigen r ceptor),

ions, organic chemical groups, viral antigens (hepatitis B
virus surface or core antigens, HIV antigens (e.g., gp120,
 gp46)), hepatitis C virus antigens, toxins (e.g., bacterial
 toxins), cell wall components, platelet antigens (e.g.,
5 gpiibiiia), cell surface proteins, cell adhesion molecules,
 neurotrophic factors, and neurotrophic factor receptors.

In specific embodiments, vEGF (vascular endothelial growth factor) or KDR (the receptor for vEGF) (Terman et al., 1992, Biochem. Biophys. Res. Comm. 187:1579-1586) is the 10 target molecule. vEGF and its receptor are the major regulators of vasculogenesis and angiogenesis (Millauer et al., 1993, Cell 72:835). Inhibition of the vEGF and the concomitant inhibition of its mitogenic activity and angiogenic capacity has been shown to suppress tumor growth 15 in vivo (Kendall et al., 1993, Proc. Natl. Acad. Sci. USA 90:10705-10709; Kim et al., 1993, Nature 362:841-844). Use of vEGF or KDR or portions thereof, as a target molecule is a preferred embodiment for use of the present invention to develop lead molecules as drugs in the area of cardiovascular 20 disease or cancer.

The proteins ras and raf, or portions thereof (e.g., modules -- functional portions), are also preferred target molecules, particularly in an embodiment wherein the methods of the present invention are employed to develop lead 25 molecules for drugs that are cancer therapeutics. ras is a member of an intracellular signaling cascade that controls cell growth and differentiation (Cook and McCormick, 1994, Nature 369:361-362). ras functions in signal transduction by specifically recognizing the protein raf and bringing it to 30 the cell membrane (Hall, 1994, Science 264:1413-1414; Vojtek et al., 1993, Cell 74:205-214). The recognition modules in both ras and raf have been determined (Zhang et al., 1993, Nature 364:308-313; Warne et al., 1993, Nature 364:352-355; and Vojtek et al., 1993, Cell 74:205-214); in a specific 35 embodiment, such a recognition module is used as a target molecule according to the invention.

In another specific embodiment, an integrin is used as a target molecule. Such molecules are known to function in clot formation, and can be used according to the present invention to develop lead molecules for drugs in the area of cardiovascular disorders.

Target molecules for use can be obtained commercially (where the target is commercially available), or can be synthesized or purified from natural or recombinant sources. In a specific embodiment, a target molecule is prepared that

- 10 has been modified to incorporate an "affinity tag," i.e., a structure that specifically binds to a known binding partner, to facilitate recovery/isolation/immobilization of the target molecule. In a preferred aspect, recombinant expression methods well known in the art can be used to produce a
- 15 protein target molecule as a fusion protein, incorporating a peptide affinity tag. Such affinity tags include but are not limited to epitopes of known antibodies (e.g., c-myc epitope (Evan et al., 1985, Mol. Cell. Biol. 5:3610-3616)), a series (e.g., 5-7) of his residues (which bind to zinc), maltose
- 20 binding sequences such as pmal, etc. Tags are incorporated into protein targets at either the amino or carboxy-terminus. In another embodiment, the target is chemically attached to a tag (e.g, biotin (which binds to avidin, streptavidin), streptavidin), e.g., by biotinylation.
- The target molecule is purified by standard methods.

 For example, a protein target can be purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins; in a preferred embodiment, reverse phase HPLC (high performance liquid chromatography) is employed

Once the target molecule has been purified, it is preferably tested to ensure that it retains its biological activity (and thus retains its native conformation). Any suitable in vitro or in vivo assay can be used. In instances where the desired target molecule is a fragment or derivative

of a molecule found in vivo, or is a chemical entity putatively containing the same target as a molecule found in vivo, it is highly preferred that testing be done of such desired target molecules prior to their use, so that among 5 such desired target molecules, only those that have the same biological activity as the in vivo molecule or compete with a known ligand to the in vivo molecule, are selected for actual use as target molecules according to the invention. In the event that biological activity has been reduced or lost in a 10 recombinant protein relative to the native form of the protein, the protein can be recombinantly expressed in a different host (e.g., yeast, mammalian, or insect) and/or with a variety of tags and location of tags (on either the amino- or carboxy-terminal side), in order to attempt to 15 achieve, or to optimize, recovery of biological activity.

5.2. DIVERSITY LIBRARIES

According to a preferred embodiment of the invention, diversity libraries are screened to select binders, which 20 specifically bind to the target molecule. Diversity libraries are those containing a plurality of different members. Generally, the greater the number of library members and the greater the probability that all possible members are represented, the more preferred the library. In 25 preferred embodiments, the diversity libraries have at least 104 members, and more preferably at least 106, 108, 1010, or 1014, members.

Many libraries suitable for use are known in the art and can be used. Alternatively, libraries can be constructed

30 using standard methods. Chemical (synthetic) libraries, recombinant expression libraries, or polysome-based libraries are exemplary types of libraries that can be used.

In a preferred embodiment, the library screened is a constrained, or semirigid library (having some degree of 35 structural rigidity). Examples of constrained libraries are described below. A linear, or nonconstrained library, is

```
less Preferred although it may be used.
                                                                                                                      less Preferred although it may be used.

In a Dreferred embodiment, the library contains Deptide
                                                                                                                or peptide analogs having a length in the library contains peptide in each library member.
                                                                                                                                    In a Preferred embodiment, the library contains peptide of S-18 amino
                                                                                                      or peptide analogs having a length in the range of invariance are identified are identified.
                                                                                                      In specific embodiments, binders are identified from a library. The term "random" Deptide libraries
                                                                                                                           In specific embodiments each library member.

Expression library or a chemically everther; see
                                                                                                  random Peptide expression library or a chemically synthesized of both
                                                                                                                                                                                                                                                                  Additionally, one or
                                                                                                random peptide is meant to include within its scope libraries of both
                                                                                   10 partially and totally tandom (variant) peptides.
                                                                                                          In one embodiment, the (variant) peptiaes.

In one may he libraries used in the
                                                                                     present one embodiment, the peptide libraries used in vitro. Examples of such libraries are on
                                                                              in Fodor et al. vitro.

the synthesis of a known array of short Debtides on an estimate of a known array of short Debtides on an
                                                                  in Fodor et al., 1991, Science synthesis of a known array of short peptides on an 1991, National Natio
                                                                        5 the synthesis of a known array of short pertides on an describes mixtures of free hexapentides in
                                                                    individual microscopic slide; which the first and second residues in each peptide were
                                                                                                                                                              Examples of such libraries are siven
                                                                  which the first and second residues of free hexapeptides
and specifically defined ham et al 1991
                                                               which the first and second residues in each peptide were bead. one Deptid
                                                 individually and specifically defined; Lam et al. solid phase split synthesis scheme
                                                        approach in which a solid phase split synthesis scheme

each bead in the
                                                    approach in which produced a library of peptides in which each bead in the random sequer
                                                 produced a library of peptides in which each bead in the action of amino acid residues: Medynski. 1994. Bio/Technology
                                             of amino acid residues; Medynski, 1994, Bio/Technology

solit synthesis and T-bao
                                 25 12:709.710, which describes split synthesis and T-bag

and Gallon et al. 1994. J. Medicin.
                                      Synthesis methods; and Gallop et al. 1994, J. Medicinal Simply by Way of Other example
                                    Chemistry 37(9): 1233-1251. Pet al. 1994 J. Medicinal be Drebared for use. according to
                                Chemistry 37(9):1233-1251.

the Methods of Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci.
                             the methods of Ohlmeyer et al. 1993, Proc. Natl. Acad. Sci.
                the methods of Ohlmeyer et al.

USA 90:10922-10926; Erb et al., 1993, Proc. Natl. Acad. Sci.

HOUGhten et al., 1992, Natl. Acad. Sci.

1992, Biotechniques
                       USA 90:10922-10926; Erb et al., 1994; Proc. Natl. Acad. et al., 1995; Proc. Natl. Acad. et al.
                   USA 91:11422-11426; Houghten et al., 1992, Biotechniques or Salmon et al., 1993, Proc., Natl., Acad., Sci., USA
                13:412; Jayawickreme et al., USA 90:11708-11712. PCT Publication No. Wo 93/20242 and
             USA 90:11708-0r Salmon et al.

Brenner and Larner PCT Publication No. Wo 93/20242 and

Sci. USA

OS. 1092

Brenner Acad. Sci. USA
USA 9U:11708-11712.

89:5381-5383 Lerner, PCT PUDITCALION No. WO 93/20242

Mescribe "encoded combinatoria" Sci. USA chemical
       89:5381-5383 describe "encoded combinatorial chemical
```

libraries," that contain oligonucleotide identifiers for each chemical polymer library member.

In another embodiment, biological random peptide libraries are used to identify a binder which binds to a 5 target molecule of choice. Many suitable biological random peptide libraries are known in the art and can be used or can be constructed and used to screen for a binder that binds to a target molecule, according to standard methods commonly known in the art.

According to this approach, involving recombinant DNA techniques, peptides are expressed in biological systems as either soluble fusion proteins or viral capsid fusion proteins.

In a specific embodiment, a phage display library, in 15 which the protein of interest is expressed as a fusion protein on the surface of a bacteriophage, is used (see, e.g., Smith, 1985, Science 228:1315-1317). A number of peptide libraries according to this approach have used the M13 phage. Although the N-terminus of the viral capsid

- 20 protein, protein III (PIII), has been shown to be necessary for viral infection, the extreme N-terminus of the mature protein does tolerate alterations such as insertions. The protein PVIII is a major M13 viral capsid protein, which can also serve as a site for expressing peptides on the surface
- 25 of M13 viral particles, in the construction of phage display libraries. Other phage such as lambda have been shown also to be able to display peptides or proteins on their surface and allow selection; these vectors may also be suitable for use in production of libraries (Sternberg and Hoess, 1995, 30 Proc. Natl. Acad. Sci. USA 92:1609-1613).

Various random peptide libraries, in which the diverse peptides are expressed as phage fusion proteins, are known in the art and can be used. Examples of such libraries are described below.

Scott and Smith, 1990, Science 249:386-390 describe construction and expression of a library of hexapeptid s on the surface of M13. The library was made by inserting a 33

base pair Bgl I digested oligonucleotide sequence into an Sfi I digested phage fd-tet, i.e., fUSE5 RF. The 33 base pair fragment contains a random or "degenerate" coding sequence (NNK), where N represents G, A, T or C and K represents G or 5 T. Cwirla et al., 1990, Proc. Natl. Acad. Sci. USA 87: 6378-6382 also described a library of hexapeptides expressed as pIII gene fusions of M13 fd phage. PCT publication WO 91/19818 dated December 26, 1991 by Dower and Cwirla describes a library of pentameric to octameric random amino 10 acid sequences.

Devlin et al., 1990, Science, 249:404-406, describes a peptide library of about 15 residues generated using an (NNS) coding scheme for oligonucleotide synthesis in which S is G or C.

- 15 Christian and colleagues have described a phage display library, expressing decapeptides (Christian, R.B., et al., 1992, J. Mol. Biol. 227:711-718). The DNA of the library was constructed by use of an oligonucleotide comprising the degenerate codons [NN(G/T)]₁₀ (SEQ ID NO:8) with a self-
- 20 complementary 3' terminus. This sequence forms a hairpin which creates a self-priming replication site that was used by T4 DNA polymerase to generate the complementary strand. The double-stranded DNA was cleaved at the SfiI sites at the 5' terminus and hairpin for cloning into the fUSE5 vector 25 described by Scott and Smith, supra.

Lenstra, 1992, J. Immunol. Meth. 152:149-157 describes a library that was constructed by annealing oligonucleotides of about 17 or 23 degenerate bases with an 8 nucleotide long palindromic sequence at their 3' ends. This resulted in the

- 30 expression of random hexa- or octa-peptides as fusion proteins with the β-galactosidase protein in a bacterial expression vector. The DNA was then converted into a double-stranded form with Klenow DNA polymerase, blunt-end ligated into a vector, and then released as Hind III fragments.
- 35 These fragments were then cloned into an expression vector at the sequence encoding the C-terminus of a truncated β -galactosidase to gen rate 10' recombinants.

Kay et al., 1993, Gene 128:59-65 describes a random 38 amino acid peptide phage display library.

PCT Publication No. WO 94/18318 dated August 18, 1994 describes random peptide phage display "TSAR libraries" that 5 can be used.

Other biological peptide libraries which can be used include those described in U.S. Patent No. 5,270,170 dated December 14, 1993 and PCT Publication No. WO 91/19818 dated December 26, 1991.

- In a specific embodiment, a "peptide-on-plasmid" library, containing random peptides fused to a DNA binding protein that links the peptides to the plasmids encoding them, can be used (Cull et al., 1992, Proc. Natl. Acad. Sci. USA 89:1865-1869).
- Another alternative to phage display or chemically synthesized libraries is a polysome-based library, which is based on the direct in vitro expression of the peptides of interest by an in vitro translation system (in some instances, coupled to an in vitro transcription system).
- 20 These methods rely on polysomes to translate the genomic information (in this case encoded by an mRNA molecule, in some instances made in vitro by transcription from synthetic DNA) (see, e.g., Korman et al., 1982, Proc. Natl. Acad. Sci. USA 79:1844-1848). Such in vitro translation-based libraries
- 25 include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

Diversity library screening, step 2 of Fig. 1,

30 determines a few, N, members (compounds) from one or more
libraries and their primary sequences all of which
specifically bind to target molecule 1 in a similar manner.
A structured organic diversity library is a prescription for
the creation of a huge number of related molecules all built

35 from combinations of a small number of chemical building blocks. Preferred div rsity libraries for use according to the invention have m mbers whose binding to a targ t molecule

is characterized by configurational entropy change that are relatively small to the binding energy. This means that library members have definite structures in the bound and, especially, the unbound states. A preferred example of a 5 chemical diversity library for use in the invention contains short peptides with a constrained conformation. Short peptides without constrained conformations are often freely flexible in an aqueous environment and adopt no fixed unbound structure. The binding of such library members is

10 complicated by significant configurational entropy changes.

To eliminate this complication, it is preferred that all

library members have a constrained structure and bind to the
target molecule in a specific and identifiable manner. One
method of achieving constrained conformation is to require

15 internal linking, such as by disulfide bonds.

In one embodiment, disulfide bond formation is achieved by use of libraries that contain peptides having a pair of invariant cysteine residues, preferably positioned in the range of 2-16 residues apart, most preferably 6-8 residues

- 20 apart, that cross-link in an oxidizing environment to form cystines (disulfide bonds between cysteines). An example of such libraries are those containing or expressing peptides of the form R¹CX_nCR² wherein R¹ is a sequence of 0-10 amino acids, C is cysteine, X_n is a sequence of n variant amino acids
- 25 (e.g., if all 20 classical amino acids are represented, X means any one of the 20 classical amino acids); n is an integer ranging from 2 to 16; and R² is a sequence of 0-10 amino acids. R¹ and R² can contain invariant or variant amino acids. Another example is such libraries are those
- 30 containing or expressing peptides of the form R¹CX_nR², where R¹, X, n, and R² are as described above; n is preferably 8 or 9. A preferred constrained peptide library, of at least 10⁶ members, consists of peptides comprising the sequence CX₆C (SEQ ID NO:1), wherein C is cysteine, X is any naturally
- 35 occurring amino acid, and a disulfide bond is formed between the two cysteines. Additional invariant amino acids (.g., preferably no more than 5-10 amino acids) on either the

amino- or carboxy-terminus of CX,C can be incorporated as part of the peptide in this preferred embodiment. Fig. 10 schematically illustrates such a molecule. The disulfide bridge between the two cysteines acts as a sufficient 5 conformational constraint for the preferred practice of this invention. By way of example, the library is constructed by generating oligonucleotides with the desired degeneracy to code for the peptides and ligating them into vectors of - choice. These inserted oligonucleotides are suitable for 10 both use in in vivo genetic expression systems exemplified by phage display, or in vitro translation methods based on coupled transcription and translation from DNA of interest (see below). The creation and use of an exemplary library is described in Section 6.3 hereinbelow. The invention is 15 easily and readily adaptable to other alternative peptide libraries which include short peptides with alternative disulfide scaffolding, for example, comprising the sequence CX_CX_CC with two disulfide bridges, wherein n and m are each . independently an integer in the range of 2-10, and X is any 20 amino acid. More generally, any peptide library containing

Further, more general, structurally constrained, organic diversity (e.g., nonpeptide) libraries, can also be used. By 25 way of example, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) may be adapted for use.

molecule in a specific and identifiable manner may be used.

members of definite conformation which bind to a target

Constrained libraries that can be used are also known in the art. For example, PCT Publication No. WO 94/18318 dated 30 August 18, 1994 describes semirigid phage display libraries, in which the plurality of expressed peptides can adopt only a single or a small number of conformations. Examples of such libraries have a pair of invariant cysteine residues positioned in or flanking random residues which, when 35 expressed in an oxidizing environment, are most likely crosslink d by disulfid binds to form cystin s. Also disclosed are librari s having a cloverleaf structure by appropriate

γ-carboxyglutamic acid.

arrang ment of cysteine residues. Also disclosed are libraries with peptides having invariant cysteine and histidine residues positioned within the random residues, or invariant histidines alone within the random residues.

5 TSAR-13 and TSAR-14 are exemplary semirigid libraries disclosed therein.

Other conformationally constrained libraries that can be used include but are not limited to those containing modified peptides (e.g., incorporating fluorine, metals, isotopic 10 labels, are phosphorylated, etc.), peptides containing one or more non-naturally occurring amino acids, non-peptide structures, and peptides containing a significant fraction of

As stated above, libraries of non-peptides, e.g.,

15 peptide derivatives (for example, that contain one or more non-naturally occurring amino acids) can also be used. One example of these are peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371). Peptoids are polymers of non-natural amino acids that have naturally

20 occurring side chains attached not to the alpha carbon but to the backbone amino nitrogen. Since peptoids are not easily degraded by human digestive enzymes, they are advantageously more easily adaptable to drug use. Another example of a library that can be used, in which the amide functionalities

25 in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al., 1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The peptide or peptide portions of members of the libraries that can be screened according to the invention are 30 not limited to containing the 20 naturally occurring amino acids. In particular, chemically synthesized libraries and polysome based libraries allow the use of amino acids in addition to the 20 naturally occurring amino acids (by their inclusion in the precursor pool of amino acids used in 35 library production). In specific embodiments, the library memb rs contain one or more non-natural or non-classical amino acids or cyclic peptides. Non-classical amino acids

PCT/US96/04229

WO 96/30849

include but are not limited to the D-isomers of the common amino acids, α-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid; γ-Abu, ε-Ahx, 6-amino hexanoic acid; Aib, 2-amino isobutyric acid; 3-amino propionic acid; 5 ornithine; norleucine; norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, fluoro-amino acids and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

By way of example, the incorporation of non-standard or modified amino acids into libraries can be done by taking advantage of concurrent development in reassigning the 15 genetic code (Noren et al., 1989, Science 244:182-188; Benner, 1994, Trend. BioTech. 12:158-163) and the charging of specific tRNAs with the desired amino-acid (Cornish et al., 1994, Proc. Natl. Acad. Sci. USA 91:2910-2914). See also Ibba and Hennecke, 1994, Bio/Technology 12:678-682

- 20 (particularly Table I), and references cited therein. These pre-charged tRNAs are then utilized in the in vitro translation system to incorporate the non-standard amino acid into the library of choice. The position of incorporation can be either random (variant) or defined (invariant). The
- 25 defined case can be chosen to maximize the utility of the resulting placement of the non-natural functional group to maximize either binding properties or the ability to perform structural measurements. Similar techniques may be used to incorporate non-standard amino acids into the peptides.
- In a specific embodiment, an iterative approach to library construction can be taken, as structural information on the mode of binding to a given target is obtained. For example, information from structural analysis can be used to make libraries with library members containing chemical
- 35 backbones that match known chemical scaffolds, enhance solubility or membrane perm ability, r duce effect of water on structure, and incorporate other physical parameters

suggested by structural analysis. Use of algorithmically optimized library inserts can be used to increase the chances of finding binders of interest (see e.g., Arkin and Youvan, 1992, Bio/Technology 10:297-300).

In other embodiments, the following can be used to improve library use in both phage and bacterial systems: production of libraries in bacteria which overproduce the chaperonins GroES and GroEL (Soderlind et al., 1993, Bio/Technology 11:503-507), and production in E. coli strains which prevent degradation in the periplasmic space (Strauch and Beckwith, 1988, Proc. Natl. Acad. Sci. USA 85:1576-1580; Lipinska et al., 1989, J. Bacteriology 171:1574-1584). Purified cofactors such as GroES and GroEL could also be directly added to an in vitro expression and selection 15 system.

5.3. SCREENING OF DIVERSITY LIBRARIES

Once a suitable diversity library has been constructed (or otherwise obtained), the library is screened to identify 20 binders having binding affinity for the target. Screening is done by contacting the diversity library members with the target molecule under conditions conducive to binding and then identifying the member(s) which bind to the target molecule. Screening the libraries can be accomplished by any 25 of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide

- following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et
- 30 al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Patent No. 5,096,815,
- 35 U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318. See also the references

cited in Section 5.2 hereinabove (disclosing libraries) regarding methods for screening.

Screening can be carried out by contacting the library members with an immobilized target molecule and harvesting 5 those library members that bind to the target. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited 10 hereinabove. In panning methods that can be used to screen the libraries, the target molecule can be immobilized on plates, beads, such as magnetic beads, sepharose, etc., or on

beads used in columns. In particular embodiments, the immobilized target molecule has incorporated an "affinity 15 tag," as described above, which can be used to effect immobilization by attaching the tag's binding partner to the desired solid phase.

In one embodiment, the primary method of selecting from libraries is the use of solid phase plastic affinity capture 20 to immobilize the target molecule prior to its use in the selection (screening) process. This method can be improved upon to increase throughput, selectivity and specificity. Solid phase plastic supports can be replaced with magnetic particles. In phage-based systems, large beads can be used,

- 25 but these are not believed to be suitable, due to steric hindrance, for use in bacterial systems. This steric hindrance can be avoided by using high gradient magnetic cell separation with small particles (<<0.5μm) (Miltenyi et al., 1990, Cytometry 11:231-238).
- In a specific embodiment involving the use of a peptide phage display library, selection of a binder protein expressed on the surface of a bacteriophage thus selects both the binder protein and the DNA that encodes it (the DNA being within the phage particle). Following binding between the 35 target molecule and library members, phage are releas d from
- a solid support on which the binder-target molecule complex is immobilized, and are amplified, e.g., by infecting E. coli

and propagating each isolated binding phage. Repeating this process of affinity capture and amplification allows those peptides which bind with the highest affinity to the target molecule to be selectively enriched from the original.

5 library.

In one particular embodiment, presented by way of example but not limitation, a phage display library can be screened as follows using magnetic beads (see PCT Publication No. WO 94/18318):

Deads, according to the instructions of the manufacturers. The beads are incubated with excess bovine serum albumin (BSA), to block non-specific binding. The beads are then washed with numerous cycles of suspension in phosphate buffered saline (PBS) with 0.05% Tween® 20 and recovered by drawing a strong magnet along the sides of a plastic tube. The beads are then stored under refrigeration, until use.

20 An aliquot of a library is mixed with a sample of resuspended beads, at 4°C for a time period in the range of 2-24 hrs. The magnetic beads are then recovered with a strong magnet and the liquid is removed by aspiration. The beads are then washed by resuspension in PBS with 0.05% Tween® 20, and then drawing the beads to the tube wall with the magnet. The contents of the tube are removed and washing is repeated 5-10 additional times. 50 mM glycine-HCl (pH 2.0), 100 µg/ml BSA solution is 30 added to the washed beads to denature proteins and release bound phage. After a short incubation, the beads are drawn to the side of the tubes with a strong magnet, and the liquid contents are then transferred to clean tubes. 1 M Tris-HCl (pH 7.5) 35 or 1 M NaH,PO4 (pH 7) is added to the tubes to neutralize the pH of th phage sample. The phage are then dilut d, e.g., 10-3 to 10-6, and aliquots

PCT/US96/04229 WO 96/30849

5

20

25

30

35

plat d with E. coli DH5 α F' cells to determine the number of plaque forming units of the sample. certain cases, the platings are done in the presence of XGal and IPTG for color discrimination of plagues (i.e., lacZ+ plagues are blue, lacZplaques are white). The titer of the input samples is also determined for comparison.

Alternatively, as yet another non-limiting example, screening a diversity library of phage expressing peptides 10 can be achieved by panning using microtiter plates (see PCT Publication No. WO 94/18318) as follows:

The target molecule is diluted and a small aliquot of target molecule solution is adsorbed onto wells of microtiter plates (e.g. by incubation overnight at 4°C). An aliquot of BSA solution (1 15 mg/ml, in 100 mM NaHCO3, pH 8.5) is added and the plate incubated at room temperature for 1 hr. contents of the microtiter plate are flicked out and the wells washed carefully with PBS-0.05% Tween® 20. The plates are repeatedly washed free of unbound target molecules. A small aliquot of phage solution is introduced into each well and the wells are incubated at room temperature for 2-24 hrs. The contents of microtiter plates are flicked out and washed repeatedly. The plates are incubated with wash solution in each well for 20 minutes at room temperature to allow bound phage with rapid dissociation constants to be released. The wells are then washed five more times to remove all unbound phage.

> To recover the phage bound to the wells, a pH change is used. An aliquot of 50 mM glycine-HCl (pH 2.0), 100 μ g/ml BSA solution is added to the washed wells to denature proteins and release bound phage. After 10 minutes at 65°C, the contents are then transferred into clean tubes, and a small aliquot of 1 M Tris-HCl (pH 7.5) or 1M NaH,PO, (pH

10

7) is added to neutralize the pH of the phage sample. The phage are then diluted, e.g., 10⁻³ to 10⁻⁶ and aliquots plated with E. coli DH5αF' cells to determine the number of the plaque forming units of the sample. In certain cases, the platings are done in the presence of XGal and IPTG for color discrimination of plaques (i.e., lacZ+ plaques are blue, lacZ- plaques are white). The titer of the input samples is also determined for comparison (dilutions are generally 10⁻⁶ to 10⁻⁹).

By way of another example, diversity libraries expressing peptides as a surface protein of either a particle or a host cell, e.g., phage or bacterial cell, can be screened by passing a solution of the library over a column 15 of the target molecule immobilized to a solid matrix, such as sepharose, silica, etc., and recovering those particles or host cells that bind to the column after washing and elution.

In yet another embodiment, screening a library can be performed by using a method comprising a first "enrichment"

20 step and a second filter lift step as described in PCT

Publication No. WO 94/18318.

Several rounds of serial screening are preferably conducted. In a particularly preferred aspect, each round is varied slightly, e.g., by changing the solid phase on which 25 immobilization occurs, or by changing the method of immobilization on (e.g., by changing the linker to) the solid phase. When using a phage display library, the recovered cells are then preferably plated at a low density to yield isolated colonies for individual analysis. By way of 30 example, the following is done: The individual colonies are selected, grown and used to inoculate LB culture medium containing ampicillin. After overnight culture at 37°C, the cultures are then spun down by centrifugation. Individual cell aliquots are then retested for binding to the target 35 molecule attached to the beads. Binding to other beads, having attached thereto a non-relevant molecule, can be used as a negativ control.

In a specific embodiment, different rounds of screening can respectively involve selection against targets in primarily their purified form, and then in their natural state (e.g., on the surface of a mammalian cell) (see, e.g., 5 Marks et al., 1993, Bio/Technology 11:1145-1149, describing selection against cell surface blood group antigens).

In other examples, subsequent rounds of screening can involve immobilization of the target molecule by attachment at different ends (e.g., amino or carboxy-terminus) of the 10 target molecule to a solid support, or presentation of library members by attachment to or fusion at different ends of the library members.

By way of other examples of screening methods that can

be used, genetic selection methods can be adapted for 15 screening of libraries, or can be used in a recursive scheme. Thus, in a specific aspect, the invention provides screening methods in which methods allowing high throughput and diversity screening (e.g., screening phage display or polysome libraries against a ligand) are utilized in initial 20 rounds, with subsequent rounds employing a genetic selection technique, in which the presence of a binder of appropriate specificity increases the activity of or activation of a transcriptional promoter or origin of replication. Genetic selection techniques that can be adapted for use (e.g., by 25 inserting random oligonucleotides in the test plasmid) include the two-hybrid system for selecting interacting proteins in yeast, replicative based systems in mammalian cells, and others (see, e.g., Fields & Song, 1989, Nature 340:246-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 30 88:9578-9582; Vasavada et al., 1991, Proc. Natl. Acad. Sci. USA 88:10686-10690). Thus, in a specific embodiment, compounds are produced as fusion proteins, and contacted with a different fusion protein comprising a target fused to another molecule, in which specific binding of the fusion 35 proteins to each other results in an increase in activity or activation of a transcriptional promoter or an origin of replication. In a specific embodiment, a genetic selection

method is used in a later round of screening to either select directly for a library member that binds to a target molecule, or to select a library member that competitively inhibits binding of a ligand to the target molecule.

Several exemplary methods for screening a phage/phagemid library are presented by way of example in Section 6.4 hereinbelow. An exemplary method for screening a polysomebased library is presented in Section 6.3.3 hereinbelow.

Once binders are selected from a diversity library which 10 bind to a target molecule of interest, additional assays are preferably, although optionally, performed, including but not limited to those described below. Thus, in vivo or in vitro assays can be performed to test whether binding of a binder to the target molecule affects the target molecule's

15 biological activity; binders that exert such an effect are preferred for use in subsequent steps of the invention.

Alternatively, or in addition, competitive binding assays can be carried out to test whether the binder competes with other binders or with a natural ligand of the target molecule, for

20 binding to the target molecule; binders that compete with each other, and that compete with the natural ligand, are preferably selected for use in subsequent steps of the invention. Alternatively, or in addition to the above assays, the binding affinity of binders for the target

25 molecule is determined, by standard methods, or by way of example, as described in Section 6.5 infra. Binders of the highest affinity are preferred for use in subsequent steps of the invention.

30 5.4. DETERMINING THE SEQUENCE OR CHEMICAL FORMULA OF BINDERS

Many of the references cited in Section 5.2 and 5.3 hereinabove, which disclose library construction and/or screening, also disclose methods that can be used to determine the sequence or chemical formula of binders isolated from such libraries. By way of exampl, a nucleic acid which xpresses a binder can be identified and recovered

from a peptide expression library or from a polysome-based library, and then sequenced to determine its nucleotide sequence and hence the deduced amino acid sequence that mediates binding. (In an instance wherein the sequence of an 5 RNA is desired, cDNA is preferably made and sequenced.) Alternatively, the amino acid sequence of a binder can be determined by direct determination of the amino acid sequence of a peptide selected from a peptide library containing chemically synthesized peptides. In a less preferred aspect, direct amino acid sequencing of a binder selected from a peptide expression library can also be performed.

Nucleotide sequence analysis can be carried out by any method known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-15 560), the Sanger dideoxy method (Sanger et al., 1977, Proc. Natl, Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699; Sequenase¹¹⁴, U.S. Biochemical Corp.), or Taq polymerase, or use of an automated DNA sequenator (e.g., Applied Biosystems, 20 Foster City, CA).

Direct determination of the chemical formulas of nonpeptide or peptide binders can be carried out by methods well known in the art, including but not limited to mass spectrometry, NMR, infrared analysis, etc.

- In preferred aspects involving certain types of libraries well known in the art, sequencing or the use of known analytic techniques for chemical formula determination will not be necessary. In some such libraries, the identity and composition of each member of the library is uniquely
- 30 specified by a label or "tag" which is physically associated with it and hence the compositions of those members that bind to a given target are specified directly (see, e.g., Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Brenner et al., 1992, Proc. Natl. Acad. Sci. USA
- 35 89:5381-5383; Lerner et al., PCT Publication No. WO 93/20242). In other examples of such libraries, the library members are creat d by step wise synthesis protocols

accompanied by complex record keeping, complex mixtures are scr ened, and deconvolution methods are used to elucidate which individual members were in the sets that had binding activity, and hence which synthesis steps produced the 5 members and the composition of individual members (see, e.g., Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426).

Step 2 of the invention provides as output N binding library members (binders) and their sequences or chemical formulas.

10

5.5. CANDIDATE PHARMACOPHORE SELECTION

The prior diversity library screening, step 2, determines a set of size N of specifically binding members from one or more diversity libraries. While the binders are 15 preferably but not necessarily isolated from one or more diversity libraries (e.g., binders need not be isolated from diversity libraries; known binders can be simply provided), the following description shall refer to the preferred embodiment wherein diversity library members are the binders.

20 It will be apparent that the description is also readily applicable to binders that are not isolated from diversity libraries.

The pharmacophore responsible for the library member binding is preferably determined by an overall select and 25 test method in this and subsequent steps. In general, a pharmacophore is specified by the precise electronic properties on the surface of the binder that causes binding to the surface of the target molecule. In the preferred embodiment, these properties are specified by the underlying, 30 causative, chemical structures. Chemical structures are specified generally by groups such as -CH₂-, -COOH, and -CONH₂. The preferred pharmacophore representation consists of a specification of the underlying chemical groups and their geometric relations. The more precisely the geometric 35 relations are specified, the more preferred. In preferred but not limiting aspects, the geometric relations ar precise to at least 0.50 Å, and most pref rably, at least 0.25 Å. A

pharmacophore will usually comprise 2 to 4 of such groups, with 3 being typical. However, for complex protein recognition targets, a pharmacophore may comprise a greater number of groups. For example, it is possibl that the 5 entire 6 amino acid sequence, -X_i-, may be needed for a member of the preferred CX_iC library to bind to complex targets, in which case the pharmacophore includes the entire binder.

Considering by way of example, the case of binders isolated from the preferred library, of sequence CX₆C, the 10 chemical groups defining a peptide pharmacophore are terminal groups on amino acid side chains. Typically, therefore, a sequence of two to four contiguous amino acids will contain the pharmacophore of interest. For example, Fig. 11 illustrates an Arginine-Glycine-Aspartate sequence forming a 15 well known platelet aggregation inhibiting pharmacophore, which is defined by the positions and orientations of the adjacent -CN₃H₄, -CαH₂-, and -COOH groups. Pharmacophores formed by discontiguous amino acids are not likely to occur in the preferred library due to the conformational constraint 20 on the short peptide imposed by the disulfide bridge.

The selection step determines candidate amino acid sequences in each binder that define a candidate pharmacophore by the positions of their terminal groups. Candidate selection depends substantially only on the 25 chemical structures of the amino acid side chains and terminal groups (only very rarely on backbone groups). Geometric structure is not yet available and cannot be used for candidate selection. In the preferred embodiment, amino acids are grouped into homologous groups defined by group 30 members having similar side chain structure and activity (see infra). Candidate pharmacophores are found by searching the sequences of the N binders for short sequences of homologous amino acids. This search will produce at least one candidate, because all the binders share the actual 35 pharmacophore. Several candidates will usually be found since geometric information is ignored, and the search is thereby underdetermined.

Fig. 2A illustrates an exemplary method of performing the search for homologous sequences. Although this method is illustrated as searching for homologous contiguous sequences of length 3, it is easily adaptable to search for homologies 5 of other lengths and also for discontiguous homologous sequences. If no candidate pharmacophores of length 3 have a consistent consensus structure, then pharmacophores of length 2, 4, or longer or discontiguous sequences must be searched and selected for test. For some complex targets, the 10 pharmacophore may include the entire variable part of the library member. The exemplary method is a simple depth-first search for matching amino acid strings. More sophisticated string search methods are known and are equally applicable to this invention.

- The method begins with the administrative steps 201 and 202 of labeling the binders with integers from 1 to N and assigning the string variable 'ABC' to the next left most sequence of three amino acids to test in binder 1. If this is the first candidate selection, 'ABC' will be at the left
- 20 most position in binder 1. If prior candidates have been selected, 'ABC' will be assigned one amino acid to the right of its prior assignment. The FOR loop, formed by steps 203, 206, and 207, then selects each binder from 2 to N for scanning for a sequence homologous to 'ABC'. Step 203 does
- 25 loop administration. Step 206 does the scanning. If homologous sequences are found, test 207 loops back to scan the next binder. If homologous sequences have been found in all binders from 2 to N, the loop exits at step 204. In this case 'ABC' is a string in binder 1 which is homologous to
- 30 other strings in all remaining binders and is thus a candidate pharmacophore. The method exits at 205 for this candidate to be structured and tested for whether it is the actual pharmacophore. If a binder does not have a sequence homologous to 'ABC', then this string is not a candidate. In
- 35 this case, test 208 determines if 'ABC' is at the right end of binder 1. If so, there are no more homologies to t st for and the method exits at 209. If not, then 'ABC' is advanced

one amino acid to the right 210 and the scan of all binders is repeated beginning at 203.

Fig. 2B illustrates how string variable 'ABC' is scanned across binder 1, represented schematically by 220. First, 5 'ABC' is assigned to $X_1X_2X_3$ at 221, then to $X_2X_3X_4$ at 222, to $X_3X_4X_5$ at 223, and finally to $X_4X_5X_6$ at 224.

Given an assignment to 'ABC', step 206 scans each other binder, for example binder K with K>1, for homologous sequences. This is simply done by comparing all contiguous 10 substrings of binder K with 'ABC' to determine if they are homologous. They are homologous if corresponding amino acids in the substring and 'ABC' are homologous. In turn, two amino acids are homologous if they satisfy established homology rules. Each homologous sequence found in binder K 15 defines a separate candidate pharmacophore, if sequences homologous to 'ABC' are found in all other binders.

In a case where discontiguous homologous sequences are sought, 'ABC' is assigned to amino acids in discontiguous positions in binder 1 and then compared for homologies to 20 amino acids in the same relative positions throughout the other binders.

Various rules of amino acid homology may be used in this invention. In the preferred embodiment, amino acids are homologous if they are found in the same class of amino 25 acids, based on side chain activity (see Lehninger, Principles of Biochemistry, (1982), chap. 5). Preferred homologous groups of amino acids are as follows. nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and 30 methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and 35 glutamic acid. The foregoing classes may be modified by those skilled in chemical arts to create finer classifications. For example, phenylalanine and tryptophan

could be placed in a separate aromatic nonpolar group. Further, homology rules could depend on amino acid sequence, such as by dividing contiguous doublets or triplets of amino acids into homology groups.

5 The invention is not limited to the above-described exemplary method of selecting candidate pharmacophores. Any automatic method of selecting candidates that depends only on chemical structure of binder library members, preferably expressed in terms of building block composition and 10 sequence, can be used. For example, in the case of the preferred CX₆C library, candidates could be selected by a clustering analysis performed on the entire amino acid string in a multi-dimensional space.

This above method of selecting candidate pharmacophores 15 is not limited to the preferred CX,C diversity library. example, this method is immediately applicable to any diversity library having members comprising building blocks linked by a linear backbone by simply specifying rules of homology appropriate for the building blocks. These homology 20 rules would group building blocks presenting similar structure and reactivity to targets. This method then selects candidates comprising sequences of homologous building blocks present on all the binding library members. If the library members do not have a linear backbone, a 25 related candidate selection method can be used. In this case, the search for homologous building blocks would need to be confined to adjacent building blocks. Adjacent building blocks in this case are those building blocks brought physically close by whatever chemical structures form the 30 library members (instead of simply being linearly adjacent on a backbone). An adjacency determination would be specific to the particular chemical structure and would be algorithmicly specified. In addition appropriate rules of homology would be specified. The method would then select candidates 35 comprising groups of adjacent, homologous building blocks, a group being present on each binding library member.

The above-described step is the selection step of the overall select and test method. Distance measurements and Monte Carlo structuring, steps 4 and 5, determine a consensus pharmacophore structure for the candidate, if possible. If a consensus is found, the candidate is the actual pharmacophore. If a consensus is not found, this selection step must be revisited, and a new candidate selected for test.

10 5.6. <u>INTRAMOLECULAR DISTANCE MEASUREMENTS</u>

Having obtained N binders, their chemical building block structures (chemical formula or primary sequence), and the identification of a candidate pharmacophore in each binder, steps 4 and 5 of the method of this invention cooperatively

- 15 determine a precise spatial structure for the candidate pharmacophore (if it exists; if not, a new candidate pharmacophore is selected.) In the preferred (but not limiting) embodiment of this invention, N members of the CX₆C library that specifically bind to the protein target of
- 20 interest have been screened; their sequences determined; and a candidate pharmacophore consisting of homologous triplets (more generally from 2 to 6 mers) of amino acids has been determined in each binder.

Step 4 measures one or more strategic distances,

25 preferably no more than 10-20, e.g., 1-10 or, more
preferably, 1-5 interatomic distances are measured. The
remainder of the structure is determined in subsequent steps,
other than by direct measurement. The interatomic distances

30 least 2 Å, more preferably at least 1 Å or 0.5 Å or 0.25 Å, and most preferably at least 0.05 Å. Thus, in a preferred but not limiting embodiment, distances in the pharmacophore are specified to at least approximately 0.25 Å. Step 5, using the CCMBC computational method, then completes

measured in step 4 are preferably with an accuracy of at

35 determination of the pharmacophore structure at a high resolution and the structures of the rest of the binder molecules with a secondary resolution. Having a high

resolution structure for the pharmacophore of interest is orders of magnitude more useful than having a low resolution structure for an entire binder. Consequently, steps 4 and 5 focus resources on the former problem.

- A distance measurement method is preferred for use if it meets certain conditions, as follows. First, accuracy of distance measurements is preferably better than at least 0.25 Å for distances on the order of those between amino acids in a peptide. Second, measurement conditions preferably
- 10 approximate target binding conditions, i.e., are approximately physiologic. For example, crystallization, which may induce conformational changes, is preferably avoided. Also, the employed measurement methods preferably allow one binder sample to be measured when dry, when
- 15 hydrated and when bound to the target molecule of interest, thereby observing the effects of water and conformational changes on binding. Third, the measurement method is preferably quick and inexpensive.
 - Important advantages are conveyed by these certain

 20 conditions. First, as the method of the invention determines high resolution pharmacophore structures, use of distances less accurate than the intended results would almost certainly result in decreased resolution. Second, as the CCMBC structure determination method approximates the
- 25 structural effects of hydration and target binding, use of accurate distances including the physical effects of hydration or binding helps increase the resolution of the computational results. These distances as used in the CCMBC method pull the binder structures towards a more accurate
- 30 representation both of the bound, hydrated pharmacophore and also of the remainder of the binder molecule without a computationally burdensome inclusion of water molecules and without knowledge of the target molecule's structure.

REDOR NMR is the preferred method of distance

35 determination. REDOR is a solid phase NMR technique which directly measures the inter-nuclear dipole-dipole interaction strength b tween two spin ½ nuclear speci s, denoted D_{AR} wh re

A and B are the two nuclear species measured. The internuclear distance between A and B is simply determined from D_{AB} by the following equation:

$$D_{AB} = \frac{h \gamma_A \gamma_B}{2\pi R_{AB}^3} \tag{1}$$

where R_{AB} is the inter-nuclear distance, h is Planck's constant, and γ_A , and γ_B are the respective gyromagnetic ratios of nuclei A and B. REDOR is typically accurate to less than 0.05 Å and can generally measure distances up to about 8 Å.

Any two nuclear species observable and resolvable by NMR methods and, preferably, adaptable to chemical inclusion in the diversity library members of interest, may be the basis of REDOR measurements. Although the subsequent description is often directed to distance determinations between ¹³C and ¹⁵N nuclei in members of a preferred library comprising the sequence CX₆C, this invention is not so limited. One skilled in the art can readily adapt the method for use in making measurements of other types of molecules (e.g., peptides and nonpeptides); additionally, other nuclear species may be used. Other common spin % species that can be used include but are not limited to ³¹P and the halogen ¹⁹F.

- 25 General references on NMR techniques are Slichter,
 Principles of Magnetic Resonance, Berlin, Springer-Verlag,
 (1989) and Mehring, High Resolution NMR in Solids, Berlin,
 Springer-Verlag (1983). REDOR references include Gullion et
 al., Rotational-echo double-resonance NMR, J. Magn. Res.
- 30 81:196-200 (1989); Pan et al., <u>Determination of C-N</u>
 internuclear distance by rotational-echo double-resonance NMR
 of solids, J. Magn. Res. 90:330-40 (1990); Garbow et al.,
 Determination of the molecular conformation of melanostatin
 using 13C, 15N-REDOR NMR spectroscopy, J. Am. Chem. Soc.
- 35 115:238-44 (1993), all of which are incorporated herein by reference.

Other solid phase NMR techniques are applicable but less preferred. These include but are not limited to those disclosed in Kolbert et al., Measurement of internuclear distances by switched angle spinning, J. Physical Chemistry 598:7936 et seq. (1994), and in Raleigh et al., Rotational Resonance NMR, Chemical Physics Letters 146:71 (1988). These techniques measure homonuclear distances only to 0.5 Å accuracy and are less accurate than REDOR. Liquid phase NMR techniques of NOE (nuclear overhausser) and COESY (correlation enhanced spectroscopy) can also be used but are less preferred. They require complex interpretation to obtain comparable distance accuracy greater than 0.5 Å in

small molecules with complete rotational freedom.

X-ray crystallography can also be used, although it is

15 much less preferred, since crystallization may induce
conformational changes in the binder, and since binding to
the target molecule may be necessary for crystallization.

In the case of REDOR measurements of the heteronuclear distances between ¹³C and ¹⁵N, ¹³C and ¹⁵N are introduced

20 ("labeled") at the positions between which a distance measurement is needed. The preferred embodiment of the invention measures the ¹⁵N NMR resonance. Since nearly all the ¹⁵N signal will originate with nuclear labels, very little background signal due to natural abundance nuclei need be

25 accounted for. Alternatively, the ¹³C resonance may be measured, in which case the natural abundance background is subtracted from the measurements.

Since REDOR depends on observing the internuclear dipole-dipole interaction, the binder being measured should 30 be substantially stationary on the time scale of the NMR signal. The measurement system preferably ensures this condition. The substrate holding the binder to be measured can be chosen so as to restrain binder motion, or the measured sample may be cooled to restrain motion, or, 35 alternatively, the binder may be bound to its target molecule in order to restrain its motion.

Further details of the REDOR distance measurements will make reference to Fig. 3. This illustrates the measurement method for one labeling of one binder, which is repeated if the binder requires multiple labelings and also is repeated for each binder. Subsequent description will focus on only one binder.

Step 41 chooses a binder labeling. Labeling is preferably done to obtain the most information about the pharmacophore consistent with chemical labeling opportunities 10 and available labeled amino acids. Backbone labeling, for example, labels the amide N of one amino acid and one of the backbone C's of a next adjacent or more distant amino acid. Backbone labeling is typically done in the backbone in the vicinity of the candidate pharmacophore. It might also be 15 done away from a candidate pharmacophore to confirm a previously determined structure as described for step 6. Side chain labeling strategies vary with the chemical opportunities offered by the candidate pharmacophore. terminal N is available, an adjacent side chain or backbone C 20 can be labeled. If not, the side chain C and backbone amino N can be labeled. Side chain labeling is preferably on side chains in the candidate pharmacophore. Preferred labeling in the candidate pharmacophore is either a backbone amino N and a nearby backbone C or a side chain C or, if available, a 25 side chain amino N and an adjacent or nearby side chain C.

In an alternative embodiment, to get the most structural information on the binders, these labelings are designed to select the actual major conformation from known possible conformations. For example, if it is known from preliminary determinations that a binder may exist in one of a few, e.g. two, major backbone or side chain folding patterns, the labelings are chosen to distinguish these conformations. Nuclear pairs labeled for measurement are preferably those that have significantly different distances in the possible conformations.

Multiple labeling of one binder to determine multiple distances at once is possible, for xample, by including one

```
The and several willing labeling is limited. however, as is more and several willing is limited.
                                                                                                             molecule. Multiple labeling is limited, however, as is shifts of the NMR arts, by chemical of the NMR REDOR measurement of REDOR measurement of obvious to one skilled in the obvious huclear resonances.
                                                                                                    "" and several "" nucled or vice versa, however, as is in one labeling or vice versa, however, as shift in labeling is limited, by chemical shift in the NMR arts. by chemical in the NMR arts. by chemical shift in one skilled in the NMR arts.
                                                                                                             the various nuclear resonance have a distinguishable chemical smultiple is not are chemical to the chemical solutions of the chemical and the chemical solutions. The chemical solutions are contained to the chemical chemical chemical solutions and cheerved is not are contained to the chemical chemica
                                                                                                                                               multiple 15N or 11C conditions are not met. several separately observed obs
                                                                                                                                                                                                                                                       or "C resonance have a distinguishable chemical separately not met, several separately not met, several and measured of the hinder are not negations are not negations are negations are negations are negations are negations of the hinder are negations of the hinder are negations.
                                                                                                                                                                      shift. If these conditions are not met, several separately one are prepared and measured, one shift. It these conditions are prepared and measured.
WO 96 30849
                                                                                                                                                                                                                                                         Jabeling after a labeling after and rules are labeled binder after and rules the labeled preferences and rules step 42 synthesizes anniving these preferences are anniving these preferences and rules are anniving these preferences and rules are labeled binder and rules are labeled binder and rules and rules are labeled binder after and rules are labeled binder and rules are labeled binder after and rules are labeled binder and rules are labeled by a subject the labeled binder are labeled by a subject 
                                                                                                                                                                                                        Step 42 synthesizes the labeled binder after and rules.

Step determined by applying these preferences and particular applying the binder is a pertide.

The an embodiment wherein the binder is a pertide.
                                                                                                                                                                                                                     has been determined by applying these preferences and rules.

the binder is a peptide, the last the binder is a peptide, amino acid reagents for the last the been determined by applying these preferences and rules.
                                                                                                                                                                                       for each internuclear distance sought.
                                                                                                                                                                                                                                In an embodiment wherein the binder is a peptide, the labeled amino acid reagents for widely available animo acid reagents available animo acid reagents for the labeled amino acid reagents for the labeled hinder are widely available animo acid reagents for the labeled hinder are widely available animo acid reagents for the labeled hinder are widely available.
                                                                                                                                                                                                                                              labeled 13C or the labeled binder are widely available for the synthesis of the labeled a preferred europier is Teored synthesis of the labeled binder as the labeled binder bind
                                                                                                                                                                                                                                                                        commercial sources. Other commercial sources include (er (Miamisburg) (Montrea). Canada) and signal (Montrea).
                                                                                                                                                                                                                                                                                  (Miamisburg, OH). Other commercial sources include Nontreal, Canada) and sigma chemical co.

(Montreal, A2 has three substens. linear new lands). Step A2 has three substens. Louis.
                                                                                                                                                                                                                                                                                         Isotopes (Montreal, 42 has three substeps: the disnifide to Louis, 800 to 12 to 12 to 15 t
                                                                                                                                                                                                                                                                                                     Louis, MO). Step 42 has three substeps: linear peptide bond).

Step 42 has three substeps.

Synthesis 43.

Synthesis 43.

Synthesis 43.

Synthesis 43.
                                                                                                                                                                                                                                                                                                                                 and deprotection of the side groups 45. Synthesis and side groups 45. Synthesis and side groups 45. As solid phase peptide and deprotection are performed by solid phase peptide (tert.butoxvcarbonvl) and solid phase peptide and solid phase peptide and solid phase peptide solid phase peptide and solid phase peptide and
                                                                                                                                                                                                                                                                                                                                          chain deprotection are performed by solid phase peptide and fmoc chain deprotection standard Boc (text-butoxycarbonyl) Exemplary synthesis using standard boxycarbonyl) chemistry.
                                                                                                                                                                                                                                                           commercial sources.
                                                                                                                                                                                                                                                                                  synthesis 43, cyclization of the side groups 45.

20 and deprotection of the side groups 45.
                                                                                                                                                                                                                                                                                                                                                         synthesis using standard Boc (tert-butoxycarbonyl) and Exemplary chemistry. J. Amer.

synthesis using standard Boc (tert-butoxycarbonyl) chemistry. J. Amer.

g-fluorenylmethyloxycarbonyl) method are Merrifield. J. Amer.

(9-fluorenylmethyloxycarbonyl) references
                                                                                                                                                                                                                                                                                                                                                               (9-fluorenylmethyloxycarbonyl) chemistry. The all of this method are (1963): Canrino et all references for this method are (1963): Canrino et all references as no 2149 er sen
                                                                                                                                                                                                                                                                                                                                        references for this method are Merrifield, J. Amer. J.

Teferences for this method are (1963); caprino solid phase (1963); and stewart et al., solid phase as soc., chem.

Amer. Chem.
                                                                                                                                                                                                                                                                                                                                                                                      Soc. Chem. Soc. Berlin. Soringer. Verlag (1984). Which Amer. de Symthesis.
                                                                                                                                                                                                                                                                                                                                                                                                 Amer. Chem. Soc. Berlin, Springer Cyclization is by reference.

Pentide Synthesis, herein incorporated by reference.
                                                                                                                                                                                                                                                                                                                                                                                                                          nerein incorporated by reference. Cyclization is by in the chemical arts. Well known in Example 2 sunra well known in Example 2 sunra conventional mild oxidation; detailed in Example 2 for these steps is detailed in Example 2. The method of these steps is detailed in Example 2.
                                                                                                                                                                                                                                                                                                                                                                                                   conventional mild oxidation; well known in the chemical articles well known in Example 2 suprates of the binder of these steps is detailed in Example the binder of these steps accurate REDOR NMR measurements.

The method of these redoction accurate redoctions accurate redoction ac
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           method of these steps is detailed in Example the binder Accordingly in it is not obtain accurate REDOR NMR measurements.

To obtain accurate highly might highly night accordingly highly night accordingly night 
                                                                                                                                                                                                                                                                                                                                                                                                                                                              To obtain accurate REDOR NMR measurements, the pinder Accordingly, not highly purified.

Sample is preferably sample he at least 90% nure (hut not preferable that the sample he at least 90% nure)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Eample is preferably nighly purified. Accordingly not be at least be discriminated.

Preferable that the sample signals can be discriminated.

Preferable if sour necessary is sourced.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Preferable that the sample be at least 90% pure (but not and least 90% pure (but not and discriminated), and preferable that the sample be at least 95% ourself. The sample be
                                                                                                                                                                                                                                                                                                                                                                                                                                                            necessary if spurious NMR signals can be at least 10 first the sample be at least 10 a first obtained as follows.

35 even more preferable can be obtained as such pure samples can be obtained as such pure samples can be obtained as follows.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             even more preferable that the sample be at least In a first de je synthesized direct such pure samples the hinder nentide is synthesized direct such pure samples the hinder nentide is synthesized the property of the hinder nentide is synthesized.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Such pure samples can be obtained as follows. In a first directly such pure samples the binder peptide is synthesized directly synthesis method.
```

```
on the substrate to be used in the subsequent MMR
                                                                                                                                                    on the measurements. In this case in the subsequent NMR standard solid Dhase synthesis preferably
                                                                                                                                                 Taken with the In this case particular care is preferance of example synthesis reagents should
                                                                                                                                 Example 2. By way of example, synthesis reagents show allowed for diffusion of the
                                                                                                                                               Example 2.
                                                                                                                                                                                                                                                                                                                                                                            PCT/US96/04229
                                                                                                                                    Teagents and solvents throughout the interstices of the
                                                                                                                                                                                             By way of example, synthesis reagents should be
                                                                                                                               reagents and solvents throughout the interstices of the resin before new reagents should be
                                                                                                                            That the Durity, reaction time, and washings are adequate is
                                                                                                                        That the purity washed from the resin before new subsequent analysis. An aliquot of the resulting
                                                                                                                  That the purity, reaction time, and washings are adequate is cleaved (Example 2)
                                                                                                               gauged by subsequent analysis.

and its nutrity analysed by mass spectroscopy or high
                                                                                                           peptiae-resin is taken, the peptiae is creaved (Example of the peptiae) is creaved that the peptiae is creaved the peptiae is created th
                                                                                                       performance liquid chromacography (MpLC).
                                                                                 In a second synthesis method, the peptide can be substrate in a The
                                                                                           standard manner and then cleaved from the substrate a work)
                                                                                     peptide is purified then cleaved to the MMR measurement substrate.

**The attachment**

**The attachment**
                                                                                  Peptiae

attached is purlived by standard methods (e.g.
                                                                               can be done by any methods known in the art, preferably at condensation
                                                             can be done by any methods known in the free carboxy terminal group on the peptide with an
                                                                      of the free amino- or carboxy-terminus, e.g., by condensation with the artachment step breededing
                                                                  or the amino labeled resin, with the artachment step preceding on the nend carboxy around on the nend 
                                                             deprotection of any side the attachment step preceding for the peptide;
                                                          by use of heterofunctional linker groups are referred in form
                                                 binder-substrate is preferably exercised in torming the directed to binder-substrate used for the REDOR NMR measurements.
                                                                           Great care is Dreferably exercised in forming the
                                             binder-substrate
invention is also directed to REDOR NMR measurements.

REDOR NMR measurements in the following environments:
                                        precise REDOR NMR measurements in the following environmental to its
                                     Precise REDOR NMR measurements in the following environments in lyophilized or hydrated
                    Jo molecular dry unbound, hydrated unbound, and bound to its forms)

conditions: dry unbound, hydrated unbound, and bound to its
                   For any binder and any MMR measurement substrate substrate motion will not average out the
                                              For any binder and any MMR measurement substrate
                sufficiently so that binder motion will not average out the REDOR
Surficiently so that binder motion will not average chartening the requires that the free
    motion of the binder be less than the frequency of the
                                                                Generally this requires that the frequency of
```

dipole-dipole interaction being observed, which varies with the nuclear species being observed and the measurement distance. For ¹³C-¹⁵N observations to 2.5 Å the binder motion frequency should be less than approximately 200 Hz; for observations to 5 Å, less than approximately 30-50 Hz; and for observations beyond 5 Å, less than approximately down to 10 Hz. The more polar the substrate, such as glass beads or p-MethylBenzhydrilamine ["mBHA"] resin, the more are polar attached binders (such as are many peptides) restrained.

10 Less polar substrates, such as polystyrene resin, provide less restraints for polar binders. In an embodiment wherein a peptide comprising the sequence CX₆C is bound to an mBHA resin with an glycine residue serving as a linker to a binding site on the resin, probably no additional steps need 15 be taken for 2.5 Å measurements. Additional steps that can be used, if needed, to slow binder motions include cooling the measurement sample to, for example, liquid N₂ temperatures (approximately 77 °K) or binding to a large, relatively immobile target molecule.

Second, the net binder density is important and 20 typically is adjusted. The substrate preferably has an adjustable number of binder synthesis sites or binding sites per unit of substrate surface area. Too high a binder density on the substrate surface will cause inter-molecular 25 nuclear dipole-dipole interactions to distort the REDOR distance measurements. To obtain accurate intra-molecular distances, the peptides should be kept sufficiently far apart so that only intra-molecular nuclear dipole-dipole interactions are significant. Inter-molecular nuclear 30 dipole-dipole interactions are preferably kept less than about 10% of the intra-molecular interaction. In the case of ¹³C-¹⁵N measurements, this criterium can be monitored by observing 13C-13C dipolar couplings. As the dipole interaction falls off as R-3, keeping adjacent binders apart by more than 35 approximately 2-3 times the distance to be measured is sufficient. For measurements to 5 Å, this criterion can be

satisfied by keeping binders approximately 10 Å or more

apart. At a 10 Å spacing interfering ¹³C or ¹⁵N signals will not exceed 2.8 hz, which is sufficient attenuation for 30 hz or greater measurements.

In an embodiment wherein the binder is a peptide 5 comprising the sequence CX,C, that is synthesized on an mBHA resin that is also to serve as the NMR substrate, there is an additional upper bound on the peptide density. To prevent disulfide dimer formation in more than approximately 5% of peptides, the peptides are preferably kept apart by at least 10 their average size. Dimer formation and incorrect disulfide scaffolds result in unconstrained, flexible peptides of altered structure distorting the REDOR distance determination of the properly conformationally constrained, cyclized binder peptides. A 10 Å or more separation will meet this 15 requirement. In this case, more than 95% of the disulfide bonds will result in intended intra-molecular constraints. This separation may be adjusted based on a determination of actual dimer formation by chromatographic (e.g., HPLC) or mass spectroscopic analysis of the peptide after cleavage 20 from the substrate (see Section 6.6, infra).

NMR instrumental sensitivity places a lower bound on binder density. By way of example, for an adequate observed signal to noise ratio using a preferred NMR spectrometer, no less than approximately 10¹⁶ observed nuclear spins should be 25 present in a 0.1 g sample. This translates to having a binder density of no less than approximately 0.017 mmole/g (1 mmole = 10⁻³ mole). For alternative NMR spectrometers with higher field magnets ('H Larmor frequency of 500 mHz), the binder density may be as low as 0.0017 mmole/g.

A third substrate condition to be considered is pore size, which is relevant when measurement of binder bound to a target molecule is desired. In a preferred method of conducting such bound measurements, the substrate must have sufficient pore size so that the target molecules can diffuse 35 to all binders on the surface of the substrate and bind to th m. For example, folded, moderate siz d protein targets of 50 kd are typically roughly sph rical with diameters of

approximately 50 Å. Preferable substrate pore sizes for use with such moderate sized protein targets are no less than 100-200 Å. Excessive pore sizes can result in a too dilute binder that decreases NMR signal intensity. The preferable 5 pore sizes also facilitate high purity peptide synthesis directly onto substrate resins by similarly facilitating diffusion of reagents and solvents to synthesis sites. Also, binder substrate binding is preferably of such a nature that it will not be disrupted under either dry conditions, aqueous 10 conditions, and conditions suitable to binder-target binding. Generally, adequate pore sizes are in the range of 100-500 Å, although this will vary with the size of the target molecule.

Solid phase substrates that can be used include but are not limited to mBHA resins, divinylbenzyl polystyrene resins, 15 and glass beads. All of these substances can be manufactured to have binding sites in the range from 0 to 1.0 mmol/g. In addition, these substrates can be made so as to have the following surface areas: for mBHA about 100 m²/g, for polystyrene from 50-100 m²/g, and for glass from 0.1-100 m²/g. 20 These substrates also can be manufactured so as to have a surface binding site density in the range of from 0 to 1.0 mmol/m². More generally any microporous material with a surface density of binding sites adjustable from 0 to at least 1.0 mmol/m², and preferably with pore sizes in the 25 preferred ranges, can be used. Suppliers of such adjustable resins include Chiron Mimotope Peptide Systems (San Diego,

Peptide binders can be synthesized directly on the surface of the substrates, by way of example as set forth in 30 Section 6.6 infra, to achieve a purity of preferably at least 90%, more preferably at least 95%. In the case of a peptide comprising the sequence CX₆C, the preferred peptide spacing on the substrate is no closer than approximately 10 Å, or a peptide density of no greater than one peptide every 100 Å².

35 Peptide synthesis on the preferred resin p-MethylBenzhydrilamine ["mBHA"] with 0.16 mmole/g of peptide binding sites, a surface of 100 m²/g, and a preferable pore

CA) and Nova Biochem (San Diego, CA).

```
size of 100-200 A results in a binder-substrate for accurate surface density and suitable for accurate preferable pentide surface
                                                                    size of 100-200 Å results in a binder-substrate having such a binder-substrate for accurate for accurate and bound and suitable for accurate density and bound and bound are preferable pertial dry, hydrated, and hydrated pertial dry, hydrated, and hydrated pertial dry, hydrated pertia
                                                                              Preferable peptide surface density and surface density and bound than hydrated, more than hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density is more than report to the rotal hinder density and surface than report to the rotal hinder density is more than report to the rotal hinder density and sound.
                                                                                                                                                                                                                                                                                                                                                                                                                                    The glycine linker provides
                                                                                                                                                                      fficient spacer from the substrate surface.

Steps are carried out by one of a number of commercial
WO 96/30849
                                                                                                            above instrumental sensitivity. The glycine link

above instrumental spacer and As in the number of the sufficient and as a sufficient and as a sufficient as sufficient as a sufficient as a sufficient as a sufficient as a 
                                                                                                                              Steps 43, 44, and 45 in the preferred embodiment of the preferred anumber of commercial by one of a number of peotide such as Chiron Mimotope peotide invention are carried out by one as Chiron Mimotope peotide invention are carried sources.
                                                                                                                                        invention are carried out by one of a number of commercial such as chiron Mimotope can be such as Biochem (San Diego, CA) and Nova Biochem (San Diego, CA) and Systems (San Diego, CA)
                                                                                 conditions. The Local publicativity.
                                                                                                                                                            Systems (San Diego) used in these of these steps are that can be preferred practice of the however.
                                                                                                                        Wethods that can be used practice of these steps is detailed in However, the preferred practice of these steps in Section 6.6.
                                                                                                                                                                                                                                           example in Section 6.6. Thus provides a method of performing solic not thus provides a measurements of molecules on the invention report not preferably report not preferably neasurements.
                                                                                                                                                                      The invention thus Provides a method of Performing solic is molecule is a method of performing solic molecule is molecule is measurements the molecule is molecule in one embodiment. The molecule is a solid phase substrate.
                                                                                                                                                                                                             state NNR, preferably REDOR NNR, measurements of molecule is the molecule is a solid phase substrate. In one embodiment, freedom at the a solid phase substrate. a solid phase substrate.
                                                                                                                                                                                                                          a solid phase substrate. In one embodiment, freedom at the the molecule is a solid phase substrate. In one embodiment, freedom at the freedom at the associational degrees of torsional degrees to torsional interest that are limited to torsional a compound having conformational limited to torsional temperature of interest that
                                                                                                                                                                                                                                           temperature of interest between any conformational rotations rotations rotations
                                                                                                                                                                                                                                  a compound having conformational limited to torsional limited to torsional limited rigid subunits of interest honds herween or herwise rigid subunits temperature of honds herween or herwise rigid subunits temperature about honds herween or herwise rigid subunits temperature about honds herween or herwise rorarions about honds herween or herwise rorarions about honds herween or herwise rorarions about honds herween or herween or herween or herwise rorarions about honds herween or 
                                                                                                                                                                                                                                                                       constraints.

The molecule is preferably a peptide, and is most constraints.

The molecule of constrained conformation, (e.d., and is most constraints) a peptide of constraints one or more cystines

preferably a peptide having one or more cystines
                                                                                                                                                                                                                          rotations about bonds between otherwise rigid subur conformational any conformations respecting any conformations respecting preferably a pentide torsional The molecule is preferably a constraints.
                                                                                                                                                                                                                                                                                 Preferably a pertide having one In other embodiments.

Preferably a pertide having one In other embodiments.

Preferably a pertide having one In other embodiments.

Comprising the sequence CX.C).
                                                                                                                                                                                                                                                                         comprising the sequence CX,C). In other embodiments, the comprising the sequence analog or derivative.

The substrate is a solid phase on which the substrate is a solid phase on which the embodiment, the substrate is a solid phase.
                                                                                                                                                                                                                                                                                                                 molecule is a peptide analog or derivative. In a preferi analog or derivative. On which a him molecule is a peptide analog or derivative. On which a him molecule is a peptide has been synthesized. With a him molecule (e.a., peptide) has been synthesized.
                                                                                                                                                                                                                                                                                                                         embodiment, the substrate has been synthesized, the REDOR in specific embodiments, the number is a solid phase on which the night is a solid phase on which a high with a high solid phase on which the night is a solid phase of the night is a solid
                                                                                                                                                                                                                                                                                                                                           degree of purity.

In specific embodiments, the REDOR done in the substrate can be and the molecule on the substrated conditions.

The molecule on the substrated conditions and the molecule on the molecule of hydrated conditions.

The molecule of the mol
                                                                                                                                                                                                                                                                                                                                   molecule (e.g., peptide) has been synthesized, with a remove the REDOR the substrate can be desired of purity.

Molecule of purity.

Molecule of the molecule on the substrate can be desired 
                                                                                                                                                                                                                                                                                                                           measurements of the molecule on the substrate can be done in the substrate can be done in the substrated conditions, and the molecule on the substrated conditions, and the molecule on hydrated conditions, and the molecule is either free or bound to a target.

30 a dry nitrogen atmosphere, free or bound to a target.
                                                                                                                                                                                                                                                                                                                                                                         when the molecule is also directed to a population of molecules invention is also which is attached a surface to which a surface to which is attached as surface to the surface to the surface to the su
                                                                                                                                                                                                                                                                                                                                                                   a dry nitrogen atmosphere, under hydrated conditions, and to a target. It when the molecule is either to a solid phase substrate hydrate to a solid phase substrate hydrate to a solid phase substrate hydrate hydrated to a solid phase substrate hydrate hydrated to a solid phase substrate hydrater hydrated to a solid phase substrate hydrater hydrated to a solid phase substrate hydrater hydrated to a solid phase substrate hydrated to a target.
                                                                                                                                                                                                                                                                                                                                                                                     invention is also directed to a solid phase substrate having a specific preferably nentides (preferably nentides)
                                                                                                                                                                                                                                                                                                                                                                           (Preferably perhides, obtaining REDOR NAM measurements of the molecules.

The molecules.
                                                                                                                                                                                                                                                                                                                                                                                                  a Surface to which is attached a population of molecule
a Surface to which is attached derivatives, or peptide
(preferably peptides, peptide for obtaining REDOR NMR measurement
(preferably suitable for obtaining REDOR NMR measurement)
analogs).
                                                                                                                                                                                                                                                                                                                                                                                                                 analogs), suitable for obtaining report when measurements of the in specific embodiments, at least 90% purity).

The molecules, the molecule consists of a single molecule for population consists of a single molecule.
                                                                                                                                                                                                                                                                                                                                                                                                                          the molecules. In specific embodiments, at least 90% purity).

the molecules of a single molecule

population consists of a
```

In a more preferred aspect, 95% purity is present. Methods of producing such solid phase substrates, as described above, are also provided.

Step 46 REDOR spectroscopy is performed on the

5 strategically labeled, binder peptide-resin sample. Step 46
details include final sample preparation, spectrometer
parameters and tuning, and excitation pulse sequence. Sample
preparation can be carried out by standard methods. The
binder peptide-substrate sample is dried in N₂, and an

10 approximately 0.1 g amount is sealed in the NMR measurement
rotor. The rotor can be cooled, if necessary, to limit
binder motion.

An alternative final sample preparation step is to bind the target molecule to the binder peptide-resin sample and 15 then dry the complex in N₂. Optionally, the binder peptide can be split from the resin before binding to the target. In this alternative, the highly accurate REDOR NMR distances are of the bound binder and thus reflect any conformational changes that occur upon binding with the target.

A triple resonance, magic angle spinning ["MAS"] NMR machine is adaptable to REDOR measurements. Such machines are commercially available from Bruker (Billerica, MA), Chemmagnetics (Fort Collins, CO), and Varian (Palo Alto, CA). An exemplary machine suitable for use is in the laboratory of Prof. Zax, Cornell University (Ithaca, NY). This machine includes a 7.05 Telsa magnet from Oxford Instruments (Oxford, United Kingdom) and RF pulse excitation and receiving hardware conventional in the NMR art. An exemplary measurement rotor is a triple resonance, MAS probe from 30 Chemmagnetics.

The exemplary magnetic field is adjusted for a ¹H Larmor frequency of 300 Mhz with, corresponding Larmor frequencies for ¹³C and ¹⁵N of 75.4 and 30.4 Mhz, respectively. An exemplary probe spin frequency (ω_r) is 4.8 kHz, with 35 corresponding rotor period (T_r) of 0.208 msec. ¹⁵N resonances are measured. The low natural abundance of ¹⁵N eliminates the ned for natural background corrections. Alternatively, ¹³C

measurements can be done with conventional background corrections.

REDOR is a pulse NMR technique requiring careful excitation of appropriate ¹H, ¹³C, and ¹⁵N resonances

5 synchronous with the MAS rotor and followed by observation of the ¹⁵N free induction decay. Many alternative REDOR excitation sequences have been described in the literature, some of which are found in the references cited hereinabove. These sequences can involve multiple ¹³C excitations per rotor period. The simple pulse sequence preferred for use in this invention requires only one ¹³C excitation per period.

The exemplary sequence for 8 rotor periods is illustrated in Fig. 4, and is detailed herein in a manner such that those skilled in the NMR arts can program an NMR spectrometer for similar measurement. Three channels excited are the ¹H channel 50, the ¹³C channel 51, and ¹⁵N channel 52. The ¹³C and ¹⁵N RF power supplies are tuned to the resonances of the nuclei whose distance is to be measured. The ¹H channel RF power is initially tuned to the resonance of a proton coupled to the ¹⁵N of interest. The time sequence, (increasing to the right) of the exciting signals (increasing vertically) in each of these channels is illustrated.

In the ^{15}N channel, an initial excitation is applied to the ^{15}N spins in either of two manners: either an initial $\pi/2$ 25 pulse may be applied or, as illustrated and preferred, a cross polarization transfer from the protons is made. Sufficient RF intensity is applied at time 54 in both the ^{1}H and ^{15}N channels, 50 and 51 respectively, to achieve a Hartman-Hahn precession match at a π spin flip time of 13.2 30 μ sec. Subsequent to the initial ^{15}N excitation, synchronous π pulses 56 are applied in phase with the MAS probe rotor for N_c rotor cycles, denoted by line 59, with sufficient RF intensity to achieve a π spin flip time of 13.2 μ sec. The phase of these π pulses is varied systematically to reduce 35 artifacts in a manner well known in the NMR arts. The preferred sequencing is detailed in Table 1.

Table 1

	15 N π Pulse Phase Sequencing	
5	Number of rotor cycles between excitation and observation	Phase sequence (in processing frame)
	2	YY
	4	хүхү
	8	XYXYYXYX

10

The phase sequence is expressed as the axis, in the frame processing with the ¹⁵N spins, about which the π spin flip is made. This axis is systematically varied depending on the number of rotor periods intervening between the ¹⁵N excitation and signal observation. The illustrated phase sequences may be varied into equivalent sequences in a conventional manner. For example, "XYXY" is equivalent to "-YX-YX". Finally, at 501 the free induction decay of the ¹⁵N spins is observed and generates the time domain output signal.

In the 'H channel, the preferred sequence is an initial exciting $\pi/2$ pulse 53 followed with the previously described cross polarization transfer 54 to the 'N spins. The less preferred sequence omits these initial pulses in favor of a $\pi/2$ 'N excitation. During the subsequent spin evolution time for N_c rotor cycles and the free induction decay time 501, a decoupling field 55 is applied to the protons. The preferred decoupling field has a 66 kHz RF intensity to achieve a 'H π spin flip in 7.6 μ sec.

In the ¹³C channel, two distinct options must be 30 measured. The first option (not illustrated) has no ¹³C exciting pulses. The second option (illustrated) has synchronous π pulses 57 applied for N_c rotor cycles at the rotor frequency but with a fixed phase delay 58, denoted by t_1 , and at sufficient signal intensity sufficient to achieve a 35 π spin flip time of 10.6 μ sec. Any value of t_1 may be used; the preferred value is 1/2 the rotor period, $T_c/2$.

Alternative REDOR pulse sequences include 2 or more ¹³C pulses per rotor cycle.

Summarizing still with reference to Fig. 4, a REDOR measurement scan is characterized by the number of rotor 5 cycles, N_c , of spin evolution. A complete scan comprises, first, an equilibration period, preceding the illustrated pulse sequences. Second, there is a 15N excitation period comprising pulses 53 and 54. Third, there is a spin evolution period for N. rotor cycles which has two options, 10 both measured. Both options comprise the application of decoupling ¹H field 55 and synchronous in phase ¹⁵N π pulses The first option has no "C excitation; the second has synchronous phase displaced 13 C π pulses 57. Fourth, and finally, there is observation of free induction decay 501 of 15 the ¹⁵N spins. Fig. 4 illustrates an N_c of 8. Each scan option is repeated, and the induction decay signal accumulated, for a sufficient number of times to obtain acceptable signal to noise ratio. With the preferred practice, this has required less than approximately 5,000 20 scans, and typically 3000 have been sufficient.

An alternative implementation of the REDOR measurement interchanges the roles of ¹³C and ¹⁵N and measures the free induction decay of ¹³C. Further, the invention is not limited to this described pulse sequence and is adaptable to ²⁵ equivalent pulse sequences yielding direct inter-nuclear dipole-dipole interaction strengths.

Following REDOR measurement step 46, is data analysis step 47. This comprises several substeps. As is conventional, the free induction decay signal is Fourier 30 transformed from the time domain to the frequency domain. The scan option without the ¹³C excitation produces a transformed signal with an observed ¹⁵N resonance peak of magnitude S; the scan option with ¹³C excitation produces an observed ¹⁵N resonance peak of magnitude S_f. The REDOR output 35 signal, denoted $\Delta S/S$, is conventionally formed according to the equation:

$$\frac{\Delta S}{S} = \frac{(S - S_f)}{S} \tag{2}$$

The output signal is observed for different N_c . Preferably 0, 5 2, 4, and 8 rotor cycles are observed. Other preferred N_c will be apparent during the following description.

Further analysis of the REDOR output signal, AS/S, is made clearer by a very brief explanation of how this output signal represents the spin 1/2 dipole-dipole interaction 10 between the 13C and 15N. In the spin evolution period, the 1H decoupling excitation eliminates all proton effects from the 13C and 15N NMR spectra. Magic angle spinning, in the scan option without any 13C excitation, eliminates all nuclear dipole-dipole and chemical shift anisotropy from the NMR 15 line. Thus signal S represents an NMR resonance without any dipole interaction. However, in the second scan option, the ^{13}C π spin flip pulses reintroduce in a controlled manner the dipole-dipole interaction. This interaction causes additional dephasing, or loss of signal strength, in the observed 15N signal. Thus signal S, represents an NMR resonance with dipole interaction and the output signal AS/S represents the percentage strength of pure dipole-dipole interaction between the 13C and 15N nuclei. The exact loss of signal strength depends on the timing of the 13C pulses and the number of rotor cycles for which they are applied.

In the alternative where a general phase delay, t_1 , is used, the expression for the REDOR signal is derived by numerically integrating the following equations from the Pan et al. reference (1990, J. Magnetic Resonance 90:330-340):

$$S_f = 1 - \frac{1}{2\pi} \int_0^{\frac{\pi}{2}2\pi} \cos \left[T_r \omega_D'(\alpha, \beta, t_1) \right] \sin \beta d\beta d\alpha$$
 (3)

35 where

30

5

25

$$\omega_{D}(\alpha,\beta,t) = \pm \frac{1}{2} D_{CN} [\sin^{2}(\beta) \cos 2(\alpha + \omega_{r}t) - \sqrt{2} \sin 2\beta \cos(\alpha + \omega_{r}t)]$$

$$\omega_{D}'(\alpha,\beta,t_{1}) = \frac{1}{T_{r}} [\int_{0}^{t_{1}} \omega_{D}(\alpha,\beta,t') dt' - \int_{t_{1}}^{T_{r}} \omega_{D}(\alpha,\beta,t') dt']$$
(4)

This integration can be done by standard numerical integration techniques such as are found in Press et al.,

Numerical recipes: the art of scientific computing,
Cambridge, U.K., Cambridge University Press, (1986), chapter
4, which is herein incorporated by reference. Alternatively
the expression can be directly evaluated from the symbolic
representations by numerical tools such as Mathematica from

15 Wolfram Research Inc. (Champaign, IL) or Mathcad from Mathsoft Inc. (Cambridge, MA). In a preferred embodiment, however, a much simpler approach is used.

In the preferred embodiment, the ¹³C pulse phase delay is 1/2 the rotor period, T_r, and the preceding equations can be simply expressed (Mueller et al., 1995, J. Magnetic Resonance, in press):

$$\frac{\Delta S}{S} = 1 - \{J_0(\sqrt{2})\lambda\}^2 + 2\sum_{k=1}^{n} \frac{1}{16k^2 - 1} \{J_k(\sqrt{2}\lambda)\}^2$$

$$\lambda = N_c T_c D_{CN}$$
(5)

where J_k is a Bessel function of the first kind. Adequate accuracy is obtained by limiting the summation of equation 5 to its first five terms. Fig. 5 is a graph of this equation. Vertical axis 61 represents $\Delta S/S$; horizontal axis 62 represents λ ; and graph 63 represents equation 5.

In detail, step 47 of Fig. 3 uses equation 5 and the REDOR output signal, $\Delta S/S$, for various values of N_c to obtain a best value for D_{CN} , the dipole interaction strength. The internuclear distance is simply and directly determined from D_{CN} by equation 1. An exemplary method for finding the best

value of D_{CN} is to use a least squares method. First, form the sum of the squares of the differences of the observed $\Delta S/S$ and $\Delta S/S$ computed from equation 5, which will be a function of D_{CN} , T_r , and N_c through λ . Second, find the value D_{CN} minimizing this function by searching exhaustively in sufficiently small increments over the relevant range. For example, D_{CN} can be varied by varying R in 0.01 Å increments from 0.5 to 8 Å. More efficient minimization methods as presented in Press et al. chapter 10 can also be used.

10 Values of the Bessel functions can be simply calculated by the methods in Press et al, supra, § 6.4. Alternatively, this minimization and best value determination is easily performed directly from the symbolic representations with the previously cited mathematical packages.

The example in Section 6.6 provides typical results of this measurement and analysis method.

This completes the method of Fig. 3 and determines the internuclear distance between the ¹³C and ¹⁵N nuclei to which the excitation channels were tuned for the REDOR NMR

20 measurements. If other C-N pair distances are to be determined in the labeled binder, step 46 as detailed above is repeated for the other distinct resonances. If the alternative ¹⁵N resonances cannot be distinguished, separately labeled binders are prepared and measured.

25

5.7. CONSENSUS, CONFIGURATIONAL BIAS MONTE CARLO Broad overview

With reference to Fig. 1, having found N specifically binding members of one or more libraries, step 2, selected a 30 candidate pharmacophore shared by all these binders, step 3, and determined a few strategic distances in the vicinity of the candidate pharmacophore, step 4, precise pharmacophore and binder peptide structures are now determined by the preferred method, the consensus, configurational bias Monte 35 Carlo method. Other orderings and identities of these steps are possible. For example, the binders may be predetermined thereby rendering step 2 unnecessary. Further, no strategic

distance measurements may need to be made, and step 4 may be omitted. Alternatively, a partial structure determination step may be inserted before step 4 to guide selection of distances for measurement.

Pharmacophore structure determination of this invention is not limited to the CCBMC method to be described. CCMBC makes the most efficient use of heuristic consensus binding and partial distance measurement information. However, the consensus pharmacophore can be determined by methods

10 including but not limited to use of exhaustive REDOR NMR measurements or by extensive but fewer REDOR measurements in conjunction with a conventional molecular structure determination method, such as molecular dynamics, conventional Monte Carlo, or even peptide folding rules.

In the following description, the CCBMC method is broadly overviewed; subsequently, details of important steps are described; and finally a description of the preferred computer method and apparatus for practicing the invention is given. From the description of the methods, equations, data 20 structures, and programs provided herein, one will be able readily to translate them into implementations.

Although the following descriptions are directed to binders isolated from the preferred library of peptides comprising the sequence $CX_{\epsilon}C$ (constrained by disulfide bonds), 25 the method is applicable to more general organic diversity library members. It is immediately applicable to compounds from constrained peptide libraries with other scaffolds and also to compounds from similar peptoid libraries. It will be readily apparent that the method is applicable to any 30 compounds whose structural region of interest exhibits conformational degrees of freedom at a temperature of interest (e.g., body temperature -- 37°C) that are limited to torsional rotations of rigid molecular subunits about bonds between the subunits, in which any loops present in the 35 structural region of interest are independently rotatable by concerted rotation (se Section 7. Appendix: Concerted Rotation). Examples of such compounds include but are not

limited to peptides, peptoids, peptide derivatives, peptide analogs, etc., including members of libraries discussed in Section 5.2, supra.

General features of Monte Carlo simulation methods are known. A reference is Rowley, Statistical mechanics for thermophysical property calculations, Englewood Cliffs, N.J., PTR Prentice Hall (1994), especially chapters 5 and 7, which is herein incorporated by reference. The application of simple Monte Carlo to constrained peptides has conventionally 10 been hindered by difficulty generating geometrically proper and energetically useful conformational alterations, and by the consequent wasteful and inefficient exploration of conformational space. This method overcomes these problems for constrained peptides with a novel combination of 15 techniques. In addition, this method is uniquely able to incorporate partial information about binding affinities and distance measurements to improve determination of the pharmacophore structure, one goal of the invention.

Fig. 8 is a overview of the method. Step 91 represents
20 the initial geometric and chemical structure of each binding
peptide in computer memory. Peptide geometric structure is
represented as a set of records, each record representing one
rigid subunit or one atom of the peptide. The subunit
records are linked together as the subunits are linked in the
25 peptide molecule. Each rigid unit record includes fields for
the composition, structure, and connectivity of the rigid
unit represented. Since the rigid units only undergo
torsional rotations about mutual bonds, their internal
geometric structure is fixed.

If a previous run with these peptides has been done, peptide initial structure may be chosen as one of the structures generated late in that run. Such an initial structure is desirable since the effects of arbitrary initial conditions have been eliminated. Alternatively, an initial structure is generated from a prototypical backbone without side chains by adding sidechains with random torsional orientations. For members of each type of diversity library,

a prototypical backbone meeting structural constraints and representing an allowed configuration for a member possessing no side chains can be defined. The prototypical backbone for the CX₆C library is generated from the CCBMC model itself as 5 run for the linear peptide C(gly)₆C (SEQ ID NO:7) using a Hamiltonian consisting only on the H_{NMR} term. The H_{NMR} term contains only terms which, in the disulfide bond backbone region -C₁-S₁-S₂-C₂-, limit the S₁-S₂ distance to 2.038 Å and both the C₁-S₂ and the S₁-C₂ distances to 2.883 Å. When run 10 for a linear peptide, no Type II backbone moves are made. Only Type I backbone moves which remove and regrow randomly selected portions of the backbone are used to generate backbone alterations. The model is run with temperatures gradually decreasing from room temperature to a small temperature, approximately 1 °K. The final low temperature

structure is used for the prototyptical backbone. Backbones for similar constrained peptide libraries can be constructed in similar manners.

In memory, for each peptide, a current structure is

20 represented; the initial current structures being the just
assigned initial structures. Also in memory is represented a
proposed modified structure for one peptide. At step 92 the
processor generates "moves" that transform the current
structure of a randomly chosen peptide into a proposed

25 modified structure. The moves mimic body temperature (37 °C)
thermal agitation experienced by the binders so that their
equilibrium structure may be determined.

Generation of these moves for conformationally constrained peptides is an important aspect of this method.

- 30 There are two move types. Type I moves alter the conformation of the side chain of a randomly chosen amino acid of the randomly chosen peptide. The alteration is built by side chain removal followed by side chain regrowth into a new torsional conformation. During regrowth, unfavorable
- 35 overlap with neighboring side chains is avoided. Type II moves alter the conformation of a limited random region of the peptide backbone of a randomly chosen binder by

```
Performing linked, or four backbone rigid units are snariand being such that only
                                                                                           performing linked, or four backbone rigid units are spatially bonded ring of 8 amino that only the internally bonded ring of being such Thereby the internal displaced.
                                                                                                                           displaced. Thereby the internally bonded ring of B amil acids will not be disrupted. Molecules is bodd et al acids will not in linear alkane molecules.
                                                                                                            acids will not be disrupted. A reference describing a lacids will not be disrupted alkane nolecules is Monte carlo similar move in linear algorithm for atomistic Monte similar move to algorithm for atomistic monte carlo similar move in algorithm for atomistic monte carlo acids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference describing a lacids will not be disrupted. A reference described in a lacids will not be disrupted. A reference described in all not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted. A reference described in a lacid will not be disrupted in a lacid will no
                                                                                                                                                        similar move in linear alkane molecules is Dodd et al.

Similar move in linear melts and glasses. Molecular physiconcerted rotation of polymer melts and glasses.
                                                                                                                                                                         concerted rotation algorithm for atomistic Monte Carlo hys., which is herein incorporated hypothesis and glasses, which is herein incorporated hypothesis and glasses, which is herein incorporated hypothesis has been also as a simulation of polymer (1991). Which is herein incorporated hypothesis has been also as a simulation of polymer (1991).
                                                                                                                                                                                       Simulation of polymer melts and glasses, Molecular phys., by which is herein incorporated by which is herein and II moves is the Types I and II moves is the Types I are ratio between the
MO 36130849
                                                                                                                                                                                                                                                                                                                                                                               et seq. (1991), which is nerein incorporated by an the Types I and II moves is an the Types I are to week to be tween the restaured was incorporated by an area of a second training of a second train
                                                                                                                                                                                                                                                                                                         stable parameter with a preferred value of 4. that both manner with a preferred method is that manner aspect of this method in a seed manner aspect of this method in a seed of this method in a seed of this method is that manner aspect of this method is the manner aspect of this method is the manner aspect of this method is the manner aspect of this method is a spect of this method is manner aspect of this meth
                                                                                                                                                                         reference.

The ratio between the Types I and II months aspect of this merhod is the Types I and II months aspect of this merhod is the Types I and II months aspect of the Types I and II months as the Types I and II months are I and II months as the Types I and II months are I and II months as the Types I and II months are I and II months are I and II months as the Types I and II and II months are I and II an
                                                                                                                                                                                                                                               Another important aspect of this method is that both aspect of this method biased manner.

Another important a "configurationally biased" manner.

Mormal Monte Carlo methods use standard Metropolis

Mormal Monte
                                                                                                                                                                                                                                                                          Normal Monte Carlo methods use standard Metropolis generated as structure is generated as proposed structure structure with a proposed current structure in which each proposed current structure in which procedures in dependently of the current structure with a procedures in dependently of the current structure with a procedures in the procedure in the procedures in the procedure in the
                                                                                                                                                                                                                                                           moves are selected in a "configurationally plased" nowes are selected in methods use standard Metropolis now a normal Mormal which each aronaed ermirrium in moves are carlo methods use standard ermirrium in moves are selected in methods use standard metropolis aronaed ermirrium in moves are selected in methods use standard metropolis are selected in methods use selected in methods used in methods use selected in methods used in method
                                                                                                                                                                                                                                             procedures in which each proposed structure is generated an however. for complex molecules however, for complex molecules and independently of however.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    However, for complex molecules,
                                                                                                                                                                                                                                                                                                                     equal a priori probability. However, the generation of the generat
                                                                                                                                                                                                                                                                                                                                    it is known that this typically results in the generated for energetically unlikely structures.

it is highly improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many improbable to los wasted moves are denerated for many highly situations up to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly improbable to los wasted moves are denerated for many highly in the los wasted moves are denerated for many highly in the los wasted moves are denerated for many highly in the los wasted moves are denerated for many highly in the los wasted moves are denerated for moves are denerated for
                                                                                                                                                                                                                                                                                                                                                many highly improbable or energetically unlikely structures.

In some situations a very considerable waste of processor

of each useful move.
                                                                                                                                                                                                                                                                                                                        In some situations wery considerable waste invention

In some situations a very the method of this invention

In contrast, the method of this invention

to 10° wasted moves are generated for the processor

the method of this invention

the method of this invention

the method of this invention
                                                                                                                                                                                                                                                                                                                equal a priori probability
                                                                                                                                                                                                                                                                                                                                                                                                resources. proposed structures are current structure and the generates proposed on the current structure and the probability depending on the current structure.
                                                                                                                                                                                                                                                                                                                                                                                                            generates proposed structures according to an a priori
the current structure bias toward
probability depending on the new structure.
This bias toward
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              This bias toward more
                                                                                                                                                                                                                                                                                                                                                                                              energetic cost of the new structures energy avoids generating energy avoids much more

energetic cost of the new structures making a very much more

25 acceptable structures making a very much more highly improbable structures.
                                                                                                                                                                                                                                                                                                                                                                                                                                                        acceptable structures of lower making a very much more acceptable structures resources.

acceptable structures of processor resources.

highly improbable processor resources.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  efficient use of processor resources. Because detailed the acceptance probability in the acceptance must be satisfied, method must include factors balance must be balance configurationally biased method configurationally b
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   palance must be satisfied, the acceptance probability of include factors and the acceptance must be satisfied, the acceptance probability in a reference and the must be satisfied, the acceptance probability in a reference and configurationally blassed method must be satisfied, the usual Boltzman factor acceptance probability of the usual Boltzman factor acceptance probability of a satisfied in the usual Boltzman factor acceptance probability of the usual Boltzman factor acceptance probability of the acceptance acceptance probability of the 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      configurationally biased method must include factors applying factor. A reference et al..

configurationally biased method factor. A reference et al..

simple linear alkanes is smit et al..

addition to the usual simple linear alkanes is smit et al..
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   addition to the usual Boltzman factor. A reference applying factor. A reference at al., and similar method for of the energetics and siring of a similar method for of the energetics and siring of the computer simulations of the energetics.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 a similar method for simple linear alkanes is smit et al.

Computer simulations of the energetics and siting of no save all simple linear alkanes in zeolites, J. Phys. Chem. vol. 98, DD 8442 et salkanes in zeolites, J. Phys. Chem.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                COMPULEE Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and Eiting of he seq.

Computer Simulations of the energetics and he seq.

Computer Simulations of the energetics and he seq.

Computer Simulations of the energetics and he seq.

Computer Simulations of the energy of the energy of the energy of the seq.

Computer Simulation is herein incorporated by reference.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   alkanes in Zeolites J. Phys. chem. vol. 98, Pp 8842.

(1994) which is herein incorporated by reference.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   At Step of the proposed on the grant of the step of the proposed of the proposed of the grant of the step of the proposed of the step of the proposed of the proposed of the step 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The Hamiltonian
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Hamiltonian, of the proposed configuration. The Hamiltonian of the proposed conventional physical energy conventional physical energy contains two groups of terms:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Hamiltonian,
```

terms, and heuristic constraint terms. Conventional terms include the energies of rigid unit torsional rotations and of Lenard-Jones, electrostatic interactions, and H-bonding between atoms in different rigid units. Bond lengths and 5 angles are assumed fixed at the temperature of interest and their energies constant. These conventional interactions are exclusively intramolecular; no physical intermolecular interaction effects are considered in this invention. References for the conventional energies are Weiner et al., 10 An all atom force field for simulations of proteins and nucleic acids, J. of Computational Chem., 7:230-52 (1986); and Weiner et al., A new force field for molecular simulation of nucleic acids and proteins, J. Amer. Chem. Soc. 106:765 (1984) (herein referred to as the "AMBER references"), which 15 are herein incorporated by reference.

Another important aspect of the Monte Carlo method of this invention is the heuristic terms: the consensus term and the measurement constraint term. They uniquely make use of partial information on the binder peptides to guide the Monte 20 Carlo simulation. The consensus term, Hconsensus, is added to the Hamiltonian to represent that all the binders do in fact bind to the same protein target in the same physical and chemical manner. Since binding occurs at the shared candidate pharmacophore in each binder, this term makes 25 energetically unfavorable moves that cause the geometric structure in the shared pharmacophore to depart from an average, common structure. Pseudo chemical "bonds" to this average structure are added which mimic the actual physical bonding to the surface groups of the protein target. If the 30 candidate pharmacophore is in fact the actual pharmacophore, this energy will become minimized and small in the equilibrium configuration, since there will be an actual, shared, geometric configuration. If the candidate pharmacophore is not the actual one, this term will not 35 become minimized or small, as there is no physical reason for this region of the peptide molecules to share a common structure. This is the only Hamiltonian term which coupl s

the N binders together; no physical intermolecular effects are considered. The binders are otherwise treated independently by the method.

The measurement constraint term, H_{MR}, is added to 5 represent the distance measurements made, which are in fact actual distances in the molecules and constrain any simulated structure. This term makes energetically unfavorable, by adding pseudo chemical bonds of the measured lengths, moves that cause the constrained internuclear distance to depart 10 from their measured values. Of course if no partial distance measurements have been made or are otherwise available, this term may simply be omitted from the Hamiltonian without adversely affecting the practice of this step. Which measurements to make, if any, is guided by the results of the 15 consensus structure determined. If an adequate structure can be obtained without assistance of distance measurements, none need be incorporated. If inadequate results are obtained, additional iterations of the method will need distance measurement inputs.

Step 94 tests the proposed structure against an acceptance probability, accept(curr->prop). This acceptance probability is determined by the energy of the proposed structure previously computed in step 93. If the proposed structure fails this test and is not accepted, the method progresses immediately to step 96. If the proposed structure meets the test and is accepted, the accepted proposed structure replaces and becomes the current structure. The proposed structure of this peptide is also saved (given certain other conditions detailed later) in a separate memory store of structures for later analysis. This structure store is preferably on disk.

Repeated application of the concerted rotation may lead to a slightly imperfect structure, due to numerical precision errors. In an alternative embodiment, peptide geometry would 35 be restored to an ideal state by application of the Random Tweek algorithm after several thousand moves (Shenkin et al., 1987, Biopolymers 26:2053-85).

Step 96 tests whether enough structures of equilibrated total energy have been generated in this simulation run. The run terminates if a sufficient number have been generated. Sufficiency is determined on the basis of whether the statistical sampling errors of the average pharmacophore structure determined at step 97 is adequate (typically, less than 0.25 Å). Preferably, 25,000 equilibrated structures would be accumulated for each run. Also, preferably, three runs would be performed for a total of 75,000 saved 10 structures.

Fig. 9 illustrates energy equilibration of an actual run. Axis 101 is the total energy of a set of peptide binders; axis 102 is the number of moves accepted. Traces 103 represent total energies of all binders from each of the 15 three runs. Typically, run energy rapidly equilibrates within less than approximately 2000 moves in most cases. Subsequent saved structures are counted toward termination. Traces 103 display typical energy variations superimposed on a secular stability. The illustrated energy variations 20 typically comprise several components having different variabilities. First, there is a very high frequency oscillation with a period of a few tens of moves (known as "hair"). Second, there is a low frequency oscillation with a period of several hundred to a few thousand moves and with 25 low amplitude.

Step 97 analyzes the structure stored in memory. In the simplest preferred embodiment, the stored geometric structures for each binder are simply averaged, yielding a final structure for each binder and for the candidate

30 pharmacophore. In another alternative, clustering software seeks clusters of similar structures for each binder. The clusters are then averaged to give a final structure for each variant structure for each binder. The variants represent alternative foldings for the binder. Exemplary clustering

35 methods are found in Gordon et al. Fuzzy cluster analysis of molecular dynamics trajectories, Proteins: Structure, Function and Genetics 14:249-264 (1992).

Alternative post-processing can be done on the clustered structures to account for small bond angle vibrations. vibrations are expect d to make small perturbations to the clustered structures determined by the Monte Carlo method and 5 can be accounted for by a brief molecular dynamics simulation. Such a simulation is fully defined by the Hamiltonian, comprising the physical and heuristic energies to be described infra in Eqn. 8, and by the temperature of interest. The structures observed during the simulation are 10 averaged to determine a final more accurate equilibrium structure. A code capable of performing such a simulation is Discover® from BIOSYM (San Diego, CA). Preferably, the molecular dynamics simulation would be run for approximately 105 bond angle vibration periods. Since the typical bond 15 angle vibration period is 10^{-2} ps (1 ps = 10^{-12} sec.), such a run will encompass approximately 1 ns of molecular time.

Configurational bias move generation details

- One Type I or II move will, in general, alter the

 20 position of several rigid units on a side chain or along the
 backbone. Each altered rigid unit is sequentially considered
 during move generation. The Hamiltonian describing the
 energy of the rigid unit currently being considered in a move
 is divided into an internal, uint, and an external, uext, part,
- 25 where uext is all energy not included in uint. In the preferred embodiment, uint is set to 0; an alternative choice would be to include only the torsional interaction energy between this rigid unit and units to which it is currently bound. uint generates a probability distribution, pint, according to which
- 30 is generated a set, ϕ_k , k = 1...K, of candidate torsional angles for the bond between the rigid unit being examined and rigid units already examined. u^{ext} generates another probability distribution, p^{ext} , according to which is selected one torsional angle from the prior set as the proposed new
- 35 angle for the rigid unit being examined. These probabilities are defined by the equations:

$$p_{i}^{int}(\phi_{i,k}) \propto \exp\left[-\beta u_{i}^{int}(\phi_{i,k})\right]$$

$$p_{i}^{ext}(\phi_{i,k}) = \frac{\exp\left[-\beta u_{i}^{ext}(\phi_{i,k})\right]}{w_{i}^{ext}}$$

$$w_{i}^{ext} = \sum_{k=1}^{K} p_{i}^{ext}(\phi_{i,k})$$
(6)

In this equation, "," signifies the rigid unit being considered, K is the total number of candidate torsional angles generated by p^{int}, and β = 1/kT (k is Boltzman's constant; T the temperature, preferably 37 °C). The overall probability of generating a transition from the current to the proposed structures and accepting the proposed structure are given by the equations:

$$P(curr-prop) \propto \prod_{i=1}^{K} p_{i}^{int}(\phi_{i,k}) p_{i}^{ext}(\phi_{i,k})$$

$$W^{new} = \prod_{i=1}^{K} w_{i}^{ext}$$

$$accept(curr-prop) = min(1, \frac{W^{new}}{W^{old}})$$
(7)

25

30

20

In this equation, M is the total number of rigid units added in the move. Wold is a weight for the reverse move and will be described subsequently.

Because energy is included in the generation probabilities, proposed structures are preferentially of lower energy. Since the acceptance of proposed structures depends on their energies, the acceptance of proposed structures is thereby more probable.

Peptide memory representation details

It is well known that at body temperature peptides consist of linked rigid units capable only of torsional rotational about mutual bonds whose lengths and angles are 5 fixed. The torsional rotations respect any molecular conformational constraints. See Cantor et al., Biophysical chemistry part I the conformation of biological macromolecules, New York, W.H. Freeman and Co. (1980), which is herein incorporated by reference. Table 2 lists the rigid units encountered in the preferred embodiment of this invention utilizing libraries of conformationally constrained peptides. Table 2, where applicable, also lists dihedral bond angles between incoming and outgoing bonds to a rigid unit and the assigned unit type.

Table 2

	Туре	Chemical Structure	Bond angle (if applicable)
20	Backbone and side chain rigid units		
	A	-NH ₂	
!	В	 -CαH-	70.5°
	С	-CONH-	70.5°
25	D	-соон	
	Si	de chain on	ly rigid units
	E	- CH ₂ -	70.5°
30	F	 -CH-	70.5°
	G	-S-	70.5°
	н	-C ₆ H ₄ -	0°
	I	-CH ₃	
35	J	-OH	
	K	-SH	

Туре	Chemical Structure	Bond angle (if applicable)
L	-NH _z	
М	- C ₆ H ₅	
N	- CONH ₂	
0	- CN, H,	
P	-C ₃ N ₂ H ₃	
Q	-C,NH,	

Table 3 illustrates the decomposition of all amino acid side chains into rigid units. Glycine is a special case, without a side chain. Proline is a special case with a side chain cyclically bonded to the backbone amino N.

PCT/US96/04229

Table 3

	Amino Acid	Rigid Units
	Glycine	-CαH ₂ - (SPECIAL CASE)
5	Alanine	-СН,
	Arginine	- CH ₂ - CH ₂ - CH ₂ - CN ₃ H ₄
	Aspartate	- CH ₂ - COOH
	Asparagine	- CH ₂ - CONH ₂
10	Cysteine	-CH ₂ -SH
	Glutamate	-CH ₂ -CH ₂ -COOH
	Histidine	-CH ₂ -C ₃ N ₂ H ₃
	Isoleucine	-CH(-CH ₃)-CH ₂ -CH ₃
	Leucine	-CH ₂ -CH(-CH ₃) ₂
15	Lysine	-CH ₂ -CH ₂ -CH ₂ -CH ₂ -NH ₂
	Methionine	-CH ₂ -CH ₂ -S-CH ₃
	Phenylalanine	-CH ₂ -C ₆ H ₅
20	Serine	-CH ₂ -OH
	Threonine	-Сн (-Сн ₃) -Он
	Tryptophan	-CH ₂ -C ₂ NH ₆
	Valine	-Сн (-Сн,)-Сн,
25	Tyrosine	-CH ₂ -C ₆ H ₄ -OH

Fig. 10 illustrates a structurally correct but geometrically inaccurate decomposition of the peptide backbone CX₆C into rigid units (inessential hydrogens have been omitted). Rigid units are set off in boxes 121 and their types 122 are indicated. Fig 11 illustrates a structurally correct but geometrically inaccurate decomposition of the peptide backbone and side chains of -arginine-glycine-aspartate- ("RGD") into rigid units. Rigid units are set off in boxes 131 and their types 132 are indicat d.

Rigid units are represented as records in memory. The data structure for a peptide comprises records for its constituent rigid units linked together by data pointers exactly as the actual rigid units in the peptide are 5 chemically linked. The record representing a rigid unit comprises fields for: type of the unit, pointers to chemically bonded units, all atoms of the unit and their spatial positions, atoms of the unit that are the target of the incoming and outgoing bonds, amino acid to which the unit 10 belongs, and atomic composition of the unit.

A known, conventional representation of atoms and atomic interactions is taught by the AMBER references. Each atom is divided into a series of subtypes of specific properties. For example, for carbon there are subtypes C, C2, CA, CT, 15 etc.; for nitrogen, there are N, N2, etc.; for oxygen, there are O, O2, etc.; and for hydrogen, there are H, H2, etc. Bonds between each pair of subtypes are separately characterized by equilibrium lengths, angles, and torsional energies. Interactions between each pair of subtype atoms 20 are separately characterized by Lenard-Jones force parameters, hydrogen bonding force parameters, and electrostatic charges. Amino acid charge distributions are in Weiner et al., J. of Computational Chem., 7:230-52 (1986).

- 25 Thus each atom in each rigid unit is represented by an in-memory record comprising fields for: its AMBER reference subtype and any electrostatic charge. The atom's spatial position relative to its containing rigid unit, stored in that unit's record, is geometrically determined from the 30 unit's internal chemical structure and bonds by the AMBER bond lengths and angles defined for each of these bonds. The relative spatial positions of atoms within a rigid unit are, of course, fixed, and there is no interaction energy to consider between atoms within a rigid unit.
- Fig. 11 is a complete memory representation of a tripeptide sequence -RGD- (a known pharmacophore). Rigid units are set off in boxes 131 and their typ s 132 are

indicated. The torsional degrees of freedom between the rigid units are indicated by angle arrows 133. AMBER atoms types are indicated as at 134. Net atomic charges are indicated only for arginine as at 135. Rigid unit records are linked into a data structure modeling the rigid unit's physical linkages. Not shown are relative atomic spatial positions represented by the atoms rectangular coordinates.

All parameters defining the AMBER atomic representations and interatomic forces can be found in Weiner et al., J. of 10 Computational Chem., 7:230-52 (1986), and Weiner et al., J. Amer. Chem. Soc., 106:765 (1984). Conventionally, these parameters are obtained from computer readable files from commercial sources. The preferred computer readable source of these parameters is from Insight II[®] 2.3.5 software from 15 BIOSYM (San Diego, CA). Other sources are Tripos (St. Louis, MO) and CHARMM (Molecular Simulations, Inc., Burlington, MA).

Interaction energy evaluation details

The form of the intramolecular energy, or Hamiltonian, 20 evaluated at step 93, is an important element of this invention. The Hamiltonian consists of the components:

$$H_{\text{total}} = \sum_{\text{lebinders}} H_{1, \text{total}}$$

$$H_{1, \text{total}} = H_{1, \text{molecular}} + H_{1, \text{MMR}} + H_{1, \text{consensus}}$$
(8)

25

The $H_{1,molecular}$ component is determined from the Weiner et al. references, J. of Computational Chem., 7:230-52 (1986), and J. Amer. Chem. Soc., 106:765 (1984).

30
$$H_{1.\,\text{molecular}} = \sum_{\substack{n: 1 \in \\ rigid \, \text{unit} \\ torsional \\ angles}} \frac{V_{in}}{2} \left(\cos\left(n\phi_{1,\,i} - \gamma_{j}\right) + 1\right) + \sum_{\substack{i < j \\ i, j \in \\ atom \, pairs}} \left[\frac{A_{ij}}{R_{1,\,ij}^{12}} - \frac{B_{jj}}{R_{1,\,ij}^{6}}\right]$$

$$\sum_{\substack{i < j \\ i, j \in \\ atom \, pairs}} \left[\frac{q_{i}q_{j}}{\epsilon R_{1,\,ij}}\right] + \sum_{\substack{i < j \\ i, j \in \\ atom \, pairs}} \left[\frac{C_{ij}}{R_{1,\,ij}^{12}} - \frac{D_{ij}}{R_{1,\,ij}^{10}}\right]$$
35

Here, $\phi_{1...}$ is the i'th torsional angle between rigid units of the l'th binder peptide, and $R_{1,i}$ is the interatomic distance between the i'th and j'th atoms in different rigid units of the l'th binder. The first term in this equation is the 5 torsional energy of rigid units; the second is the interatomic Lenard-Jones energy; the third is the interatomic electrostatic energy; and the fourth is the interatomic hydrogen bond energy. Rigid unit torsional rotations directly change the first term. Such rotations indirectly 10 change all other terms as interatomic distances change.

The AMBER parameters V_{in} , A_{ij} , B_{ij} , q_i , C_{ij} and D_{ij} are obtained as stated above. The effect of water is approximated in a known manner by setting ϵ equal to $4\epsilon_0 r$, where r is distance (in Å) in the electrostatic term and ϵ_ϵ is the vacuum permeability.

The distance constraint term, as described, makes energetically unfavorable moves which cause those measured interatomic separations in the simulation to depart from their measured values. If no measured values are available, 20 this term is simply omitted from the Hamiltonian. Since this is not a physical energy and in simulation equilibrium the binders should have the measured distance, it is advantageous that this term should make only a small contribution to the equilibrium energy, no more than 10% of the total energy and 25 preferably approximately 2.5 to 5%. Further, it is advantageous that the energetic disfavor be weighted by the confidence in the measurements, so that measurements having more confidence have a greater effect.

Many forms of this energy meet these criteria. The 30 preferred form is:

$$H_{1,NMR} = \sum_{\substack{i < j \\ i,j \in \\ \text{observed} \\ \text{distance pairs}}} \frac{(R_{1,ij} - R_{1,ij}^{(o)})^2}{2w_{1,ij}}$$
(10)

where R^(o)_{1.13} is a measured distance in the l'th binder peptide between atomic pair ij. This makes the constraints appear as an elastic pseudo-bond with equilibrium length as measured. The w_{1.13} are weights designed to meet the above size criteria.

5 In the preferred embodiment, they are calculated with an overall multiplicative factor limiting the contribution of H_{1.MMG} to no more than approximately 5% of the total equilibrated energy. Their relative value is selected to reflect the lower reliability of longer measurements. Thus 10 if R^(o)_{1.13} is between 0 and 3 Å, w_{1.13} has a relative value of 1; if the measurement is between 3 and 4.5 Å, the relative value is 2; if between 4.5 and 7 Å, the value is 3; and if the distance exceeds 7 Å, the term is dropped from the sum. Other alternative weight assignments meeting the general 15 criteria are clearly possible.

The consensus constraint term, as described, makes energetically unfavorable moves which cause the candidate pharmacophore in each of the binders to depart from an average, shared configuration. In simulation equilibrium 20 when the candidate is the actual pharmacophore, the binders share the pharmacophore structure and this term should be small. Since this is not a physical energy, in the case where the candidate pharmacophore is correct, this term should not be large compared to the total energy, in 25 equilibrium no more than 10% of the total energy, and preferably approximately 5%. Further, the energetic disfavor should preferably be weighted by the affinity of each binder for the protein target, so that binders with greater affinity have a greater energetic effect.

30 Many forms of this energy meet these criteria. The preferred form is:

$$R_{ij}^{(c)} = \sum_{lebinders} \frac{R_{l,ij}}{N}$$

$$H_{l,consensus} = \sum_{\substack{i \in j \\ i,j \in \\ pharmocophore \\ distance pairs}} \frac{(R_{l,ij} - R_{ij}^{(c)})^2}{2w'_{l,ij}}$$
(11)

R(c), the shared consensus structure for the candidate pharmacophore, is an average of the interatomic distances between corresponding atomic positions, ij, in the shared pharmacophore in all binders. This makes the constraints 5 appear as a pseudo-bonds to a shared pharmacophore, which represents the binding to the protein target. The w'1.ii are weights designed to meet the above size criteria. preferred embodiment, they are calculated with an overall multiplicative factor limiting the contribution of $H_{1,consensus}$ to 10 no more than approximately 5% of the total equilibrated energy. Their relative value is selected to reflect that binders with lower affinity are less reliable indicators of actual pharmacophore structure. Thus the relative value of the weights is proportional to the logarithm of the affinity 15 of the corresponding binder with an affinity of 1 μ molar having a relative weight of 1. Other weight assignments meeting the general criteria are clearly possible. The heuristic H_{consensus} is the only Hamiltonian term linking together the various binders.

20 All Hamiltonian components change only due to the dependence of the interatomic distances, $R_{1,ij}$, on the rigid unit's torsional rotation. The $R_{1,ij}$ are the well known Euclidean distances between the atomic coordinates stored in the rigid unit records. Calculation of coordinate changes **25** due to rotation of angle ϕ about a bond with unit direction $\underline{\mathbf{n}}$ originating at atom A with position x is well known, but will be detailed. (Throughout, symbols representing vector quantities are indicated by underlining.) First, translate from the current coordinate origin to an origin at position \underline{x} 30 by adding \underline{x} to all relevant coordinate vectors. Second, apply a rotation matrix, T, to the atomic coordinate vectors. Third, translate back to the prior coordinate origin from \underline{x} by subtracting x from all relevant coordinate vectors. A rotation matrix is given by:

$$T = \cos(\varphi) I + nn^{T} [1 - \cos(\varphi)] + M \sin(\varphi)$$

$$M = \begin{bmatrix} 0 & -n_{z} & n_{y} \\ n_{z} & 0 & -n_{x} \\ -n_{y} & n_{x} & 0 \end{bmatrix}$$
(12)

5

30

A reference for this computation is Goldstein, <u>Classical</u>

mechanics, Massachusetts, Addison-Wesley (1981), especially chapter 4, which is herein incorporated by reference.

Type I move generation

Type I moves alter side chain structure of a randomly chosen amino acid in a randomly chosen binder. These random choices are conventionally made by a random number subroutine. The chosen side chain is "removed" from the binder peptide and "grown" back rigid unit by rigid unit. For the next, i'th, rigid unit to be added, K possible new torsional angles are generated according to pint. Preferably 20 K is from 10 to 100. One of these torsional angles is selected according to pext, and the rigid unit is added at this new angle. Determination of pext requires obtaining the normalization w_i^{ext} . At each step the u^{int} and u^{ext} used to calculate the respective probabilities include only 25 interaction energies with rigid units present in other amino acids or already grown back. Rigid units not yet added are ignored. After all the side chain rigid units have been added back, Wnew is computed as the product of the normalization factors.

Fig. 12 illustrates a Type I move for glutamate. At 141 the side chain has been removed. The first $-CH_2$ - unit is added back at 142 with new torsional angle ϕ_1 . The generation according to p^{int} and selection according to p^{ext} of this angle ignores energy interactions with the other side chain rigid units not yet added. At 143, the next $-CH_2$ - rigid unit is added back at angle ϕ_2 . Finally at 144, the last $-CO_2$ rigid

unit is added at angle ϕ_2 . For this last step interaction energies with all the rigid units are considered in generating and selecting the new angle.

Wold is the weight for the reverse move, the move from

5 the proposed new structure to the current configuration. For
this, the proposed side chain is removed and regrown in its
current structure unit by unit. For the next, i'th, unit
generate K-1 possible new torsional angles according to pint,
again ignoring interactions with units yet to be added. The

10 K'th new angle is the current angle for that unit. The
current torsional angle is selected. Although pext is not
used, normalization wiext is determined. After all units have
been regrown at the current angles, Wold is computed as the
product of the normalizations.

The acceptance probability for the proposed side chain configuration is determined from equation 7 using W^{new} and W^{old}

Type II move generation

Type II moves alter a limited region of the amino acid 20 backbone beginning at a randomly chosen backbone rigid unit of a randomly chosen binder peptide in a manner consistent with conformational constraints due to internal disulfide bonds. These random choices are made similarly to those for Type I moves.

In Type II moves, side chains attached to the altered rigid units move rigidly with their backbone rigid units.

For this move, important geometric constraints must be met. In a randomly chosen binder and at a randomly chosen backbone bond between adjacent rigid units, a torsional angle 30 rotation by ϕ_0 is made. Subsequent backbone torsional rotations are chosen so that a minimum number of rigid units undergo a spatial displacement. This constraint fixes a limited number (if any) of possible subsequent torsional angles as a function of ϕ_0 so that at most 4 rigid units are 35 spatially displaced and rotated with at most 3 additional rigid units undergoing a rotation. This move is an important aspect of this invention and is required to maintain the

conformational constraint due to the disulfide bridge. Since only 7 rigid units are spatially modified, the Type II move preserves the 8 amino acid cycle (20 rigid units), including the cystine side chain.

Fig. 13 illustrates a Type II move of a poly-glycine 7mer. Rigid unit positions are indicated generally by black
circles as at 1509 with incoming bonds generally as at 1502.

A C_o rigid unit (B unit) is illustrated in box 1515, and an
amide bond (C unit) in box 1516. Backbone structure 1500 in

transformed into structure 1501 by the Type II move generated
by an initial rotation about bond 1502. Subsequent rotations
about bonds 1503, 1504, 1505, 1506, 1507, and 1508 are
thereby determined so that the rigid unit 1510 and at most
three subsequent units undergo only a rotation without any

spatial displacement. The four rigid units between units
1509 and 1510 undergo both a spatial displacement and a
rotation as structure 1500 is transformed to structure 1501.

No other backbone rigid units are altered.

The derivation of these assertions, including 20 expressions for the allowed angles, is in Section 8. Appendix: Concerted Rotation. Fig. 14 defines notation used in this Appendix: Concerted Rotation. Poly-glycine 7-mer backbone 1600 is the same as in Fig. 13. Rigid unit positions are indicated generally by black circles as at 1601 25 with incoming bonds generally as at 1602. The torsional rotations ϕ_0 to ϕ_6 are about bonds 1602 to 1608, respectively, between sequential, adjacent rigid units. The rigid unit position vectors ro to ro, illustrated as vectors 1610 to 1616, respectively, define the position of these sequential 30 rigid units with respect to a laboratory coordinate system with origin 1609. Summarizing this Appendix, the determination of the fixed torsional angles proceeds as follows. The allowed values for ϕ_1 are the roots of equation 34, which depends on the ϕ_0 driver angle and ϕ_2 through ϕ_1 . 35 But ϕ_2 through ϕ_4 can be determined in terms of ϕ_1 . Two

solutions for ϕ_2 are determined by quation 25 in terms of ϕ_1 . Two solutions for ϕ_3 are determined by equation 29 in terms of

the preceding ϕ 's. Finally, a simple inversion of equation 32 determines one solution for ϕ_4 in terms of the preceding ϕ 's. Having found the allowed values of ϕ_1 , then equations 25, 29, and 32 determine corresponding allowed values for the 5 other ϕ 's, which in turn determine the alteration of the first four rigid units caused by the ϕ_0 initial rotation.

More precisely, final torsional angles ϕ_0 to ϕ_6 determine position vectors \underline{r}_1 to \underline{r}_4 by applying rotation matrix 18 to equations 17 to obtain new position vectors in the laboratory 10 coordinate system, the rotation matrices of equations 16 and 18 being determined by these final torsional angles. Position vectors \underline{r}_c and \underline{r}_s to \underline{r}_t do not change. unit 0 is translated to position \underline{r}_0 ; aligned so that its incoming bond axis is along the direction of the outgoing 15 bond of unit -1; and finally rigidly rotated so that the end of its outgoing bond is at position \underline{r}_1 . Rigid unit 1 is then translated to position \underline{r}_i ; aligned so that its incoming bond axis is along the outgoing bond of unit 0; and rigidly rotated so that the end of its outgoing bond is at position 20 r. Rigid units 2 to 6 are then added to the backbone in a similar fashion. In this fashion the Type II move geometry is determined. Any side chains attached to these rigid units are rigidly rotated when their parent unit is rotated.

The Type II rotation is chosen in the following manner.

25 Using the configurational bias prescription, the Hamiltonian is divided into uint and uext. uint is preferably 0, or alternatively is the torsional energy associated with the rigid unit of interest, while uext includes all remaining interaction energies. In the previous manner, uint determines of pint according to which are generated K' candidate \$\phi_0\$ rotation angles. Preferably K' is 1. Then the geometric constraints are solved for each candidate \$\phi_0\$. Typically, but not always, 6K', denoted K, possible backbone alterations are obtained. One of these is selected by \$p^{ext}\$, determined by:

$$p^{ext}(\phi_{0,k}) = \frac{\exp[-\beta u_0^{ext}(\phi_{i,k})]}{W^{ext}(\phi_{i,k})}$$

$$W^{ext}(\phi_{i,k}) = \sum_{k=1}^{K} \exp[-\beta u_0^{ext}(\phi_{i,k})]$$
(13)

5

uext includes all interactions not in uint, that is all other backbone and side chain interactions. Because these

10 determinations occur in torsional angle space and change the volume element in that space, the Jacobian, determined by equation 35, of the selected Type II move is also needed as a weight in the acceptance probability for detailed balance. This acceptance probability for Type II moves is:

15

$$accept(curr-prop) = min[1, \frac{W^{new}j^{new}}{W^{old}J^{old}}]$$
 (14)

The weight and Jacobian of the reverse transformation from the proposed to the current structure are also needed in the acceptance probability for Monte Carlo detailed balance. These quantities are determined as follows. Using the proposed backbone structure just selected as the basis, generate a set of K'-1 new φ₀ torsional angles according to p^{int} and also include the current φ₀ in the set. Then solve the geometric constraint to determine the permitted alterations. The current configuration, since it exists, must be among the permitted structures. From this set of permitted structures determine W^{old} per equation 13. Then select the current configuration and compute the Jacobian J^{old} per equation 35. This completes the determination or the acceptance probability.

Proline is approximated. Proline is not subject to Type I moves. However, proline is subject to normal Type II moves, with its side chain bond to the amino nitrogen broken. The side chain thus moves rigidly with its backbone rigid unit as in normal Type II move. To compensate for the broken

bond approximation, the C_o-N torsional energy amplitude in the proline backbone is set at approximately 5 kcal/mole. (By contrast the torsional energy in a typical amino acid of the C_o-N bond is approximately 0.3 kcal/mole.) This invention is adaptable to other suitable approximations for proline. Alternatively, the proline side chain may be subject to alterations which preserve its cyclicity, such as for example, by an extension of the constraint scheme just described.

10

Program detailed description

disk file(s).

The following describes the construction and use of a computer method and apparatus to perform the method of step The listing of this code is included in a microfiche 15 appendix to this specification. Fig. 15 is a general view of the computer system and its internal data and program structures. To the left in Fig. 15 are the principal data structures of this method. Current structures 1701 contains the current structures of the N binders represented in memory 20 as described. Proposed structure 1702 contains working memory areas used to generate a proposed new structure for one binder peptide. Structures 1701 and 1702 would typically be stored in RAM memory of the computer system, RAM memory being memory directly accessible to processor fetches. 25 Stored structures 1703 contain similar memory representations of all the peptide structures generated, accepted, and selected for storage. This is typically stored on permanent

Candidate pharmacophore structures 1704 are input to the 30 programs from either a disk file of the display and input unit 1712. The identified candidate structures are used to determine the w'_{1.11} in Eqn 11.

Parameters 1705 comprises several parts. First, are all the AMBER atomic interaction definitions and parameters.

35 Second, are standard representations of the amino acids including component rigid units and atomic charge assignments. Third, are parameters controlling the run.

These further comprise, by example, values for K and K', the Type I/II move branching ratio, the number of moves made in the simulations run, the simulation total energy record, etc. The parameters would typically be loaded from disk file(s) into RAM memory for manipulation during a simulation run.

Unit 1712 includes display and input devices for monitoring and control. Depicted on the display are the total number of moves made in the current run and the course of the total energy, which is similar to that illustrated in 10 Fig. 9.

Processor 1711 is loaded with necessary programs prior to a simulation run and executes the programs to perform the simulation method. The general structure consists of main program 1706, structure modification program 1707, Type I and 15 II move generators 1708 and 1709, and subroutines 1710. The

- subroutines consist of common utility subprograms, such as for performing torsional rotations about bonds and computing interaction energies by the previous methods, and conventional library subprograms, such as for performing
- 20 input and output and finding random numbers. Any scientifically adequate random number generator can be used. A reference for random number generators is Press et al., Numerical recipes: the art of scientific computing, Cambridge, U.K., Cambridge University Press, (1986), chapter
- 25 7. The invention is equally adaptable to other program structures that will occur to those skilled in computer simulation arts.

The preferred embodiment of these structure is an Indigo 2 workstation from Silicon Graphics (Mountain View, CA).

- 30 Alternatively, any high performance workstation, such as products of Hewlett-Packard, IBM or Sun Microsystems, could be used. Preferably the data and program structures are coded in the C computer language. Alternatively any scientifically oriented language, such as Fortran, could be
- 35 used. Conventional subroutine and scientific subroutine libraries are used where appropriate.

The program components will be now described in detail with reference to Figs. 16, 17, 18, and 19. Fig. 16 illustrates main program 1706. The peptide sequences of the N binders are input at step 1801. All necessary AMBER 5 parameters - bond lengths and angles, atomic types and charges, interaction parameters, amino acid definitions, etc. - are input at step 1802. Step 1803 creates initial structures from this input data. Rigid unit records for all rigid units are created and linked to represent peptides.

10 The geometric structures of these peptides either are obtained from a prior run or are built by adding side chains to a prototypical backbone characteristic of the library of the binder. A prototypical backbone for the CX_cC library is found in the microfiche appendix heading CX6C.CAR. The initial binder structures are stored in the current structure data areas in preparation for the beginning the main steps of

data areas in preparation for the beginning the main steps of the method.

Step 1804 begins the main loop of the simulation with

the generation of a proposed modified structure for one of
the binder peptides by structure modification program 1707.
As part of proposed structure generation, an acceptance
probability, accept(curr->prop) is determined as previously
described. The proposed structure will be accepted at 1805
based on this probability. For example, a random number

25 between 0 and 1 is generated, and the proposed structure accepted if the random number is less than the acceptance probability. If the proposed structure is accepted, then it is tested for sufficient distinctiveness at step-1806. This test is met if at least one atomic position in the proposed

30 structure differs from the corresponding position in the current structure by at least approximately 0.2 Å. If the proposed structure is distinct, it is stored at 1807 in the structure store for later analysis. Whether distinct or not, the accepted proposed structure for the peptide replaces the 35 corresponding current structure at step 1808.

The simulation is tested for completion at step 1809.

Completion can be controlled by the operator at station 1712

depending on display of run progress results. Alternatively, termination can be mechanically controlled. After completing a certain number of total moves after run energy equilibration, the moves being split between Types I and II according to the specified branching ratio, the run is terminated. The preferred number of total moves is 25,000, and the preferred Type I/II branching ratio is 4. Thus it is preferred to have 20,000 Type I and 5,000 Type II moves after equilibration per simulation run.

- 10 At step 1810, the stored structures are analyzed to determine both the consensus pharmacophore structure and the structures of the remainder of the binders. In the preferred embodiment, atomic positions in the equilibrated stored structures for each peptide are averaged to obtain the 15 predicted geometric structure. The shared pharmacophore structure is obtained from the predicted structure of each peptide, again by averaging the shared position information for all peptides. Alternatively, before structure averaging, the structures generated for each binder can be clustered 20 into similar groups and the clusters for each peptide separately averaged. The clusters would represent alternative peptide folding patterns. It is anticipated that because preferred binders are short peptides constrained by disulfide bridges, any alternative foldings identified will 25 be structurally similar. The clustering can be done by the exemplary methods found in the previously referenced article Gordon et al. Fuzzy cluster analysis of molecular dynamics trajectories. Proteins: Structure, Function, and Genetics
- 30 the preferred number of stored moves is adjusted to achieve adequate estimated statistical position errors. Further, preferably, the results of three runs are combined to achieve increased statistical confidence.

14:249-264 (1992). For all analysis methods, the choice of

Other information is also output. Particularly

35 important is the course of the total energy for each peptide and for all the peptides, and the intra-molecular, consensus, and constraint components of the energies. These energy

components are used in determining whether a consensus pharmacophore has been found. As previously described, this is preferably done by insuring that H_{consensus} is small compared to the total energy and is minimized by a particular 5 candidate pharmacophore. Also H_{MMR} must be relatively small.

Finally at 1811, all results are output in a form usable for the subsequent steps 6 and 7 of Fig. 1. For example, this may be a particular file format suitable for subsequent lead compound search by a database query.

Turning now to Fig. 17, structure modification program 1707 will be described. This is invoked from the main program at 1804. Upon entry, this program randomly picks one of the binder peptides at 1901 for which to generate a proposed structure and also picks which type of move to use 15 at 1902. This latter random choice is made according to an adjustable Type I/II branching ratio (preferably 4). For a Type I move, step 1903 picks a random amino acid side chain of the selected peptide, and step 1904 invokes the Type I move program. (Proline has no Type I moves.) For a Type II 20 move, step 1905 picks a random backbone bond between rigid units to rotate and also a random direction from the picked bond along which backbone rigid unit structure will be altered. Step 1906 invokes the Type II move program.

Figs. 18A and 18B illustrate the Type I move generator 25 1708, which is defined by equations 6 and 7. With reference first to Fig. 18A, the proposed structure of the selected peptide is created from its current structure by removing the selected side chain. All intra-molecular interactions are subsequently determined with respect to the proposed

- 30 structure absent side chain rigid units not yet regrown. K candidate new torsional angles for the next, i'th, rigid unit to add are generated by p_i int at 2002. Preferably K is between 10 and 100. Generation of these angles uses the conventional rejection method referenced in Press et al. at § 7.3. The
- 35 weight w_i^{ext} and p_i^{ext} are determined for each of these candidate angles. This requires the rigid unit to be added to be rotated to the candidate angle using the previous

```
candidate interaction energy is determined
                                                                                 candidate interaction energy is determine the candidate interaction method. Interaction candidate and less is candidate and less is candidate and less is candidate candidate candidate candidate candidate candidate candidate candidate.
                                                                                                         candidate rotation.

one of the candidate angles is added

one of the candidate rigid unit

f there are more

at 2003 2004.

candidate rotation.

probabilisticly selected at angle at 2004.
                                                                                               from candidate interatomic distances resulting from to the candidate rigid unit one of the candidate rigid unit candidate rotation.
                                                                                               probabilisticly selected at 2003 and the rigid unit added at 2003 and the rigid unit amore there are more from the selected at 2004. These stens are probabilisticly selected angle at 2005. These stens are probabilisticly selected at 2005. These stens are units to add, which is tested at 2005.
                                                                                                                                                      units to add, which the acceptance Lastly the old weight the old w
                                                                                                                                        back at this torsional is tested at weight were to add to not the accentance weight which the accentance weight were to add to not the accentance weight with the accentance weight with the accentance weight with the accentance weight which the accentance weight which the accentance weight with the accentance with the accentance
                                                                                                                                                                    repeated. If not, the west at 2006. Lastly the move acceptance weight the move acceptance the product of the wifer the weight the weight the weight the weight the weight the move acceptance the product of 2007.
WO 96/30849
                                                                          rotation method.
                                                                                                                                                                                                                                                                                       adultly is tound for use at 1805. Of Wold, the mire at 1805. The reperse move from the proposed to the mire fig. the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the reverse move from the proposed to the mire for the
                                                                                                                                                                                                                              Fig. 18B details the determination 2007 of wood to the current is reverse move from the proposed structure is remporarily the proposed structure.

Weight for structure.
                                                                                                                                                                                                                                            weight for the reverse move from the proposed to the current the proposed to the current the proposed structure is remporarily the proposed and then structure. Temporarily determination at 2008. and then side chain structure energy determination at 2008.
                                                                                                                                                           aeterminea at found for use at 1805.

10 probability on artistic formula for the menant of the probability of artistic formula for the menant of the menant 
                                                                                                                                                                                                                                                          side chain structure is restored at 2016. when this process used as a basis for energy the current structure is restored at 2016.
                                                                                                                                                                                                                              used as a basis for energy determination at 2008 this process when this process when this process at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the proposed side chain is removed at 2009 for the process that the process the process
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           tructure 1s restored at 2016, when this process when this process tructure 1s restored at 2016, when the proposed side chain is removed at par the proposed side chain is rice.
                                                                                                                                                                                                                                                                                                        is finished. The proposed side chain is removed at por the and the proposed side chain in Fig. 18A.

The proposed side chain is removed at por the proposed side chain is removed at proposed side cha
                                                                                                                                                                                                                                                                                                                   regrowth rigid unit to p.m. at 2010 with the current value next, are generated according to p.m. at 2010 with the current value
                                                                                                                                                                                                                                                                                                                                  next, are generated according to the K-th candidate at 2011.

next generated according to the K-th candidate at 2011.
                                                                                                                                                                                                                                                                                                        are generated according to Pine at 2010 with the current value As previously, as previously, are generated according to Pine at 2011. As previously, are generated according to Pine at 2011. As previously, are and the second date and less at 2011 the weight weight weight with the current property.
                                                                                                                                                                                                                                                                                                                                                                 of that angle for the K-th candidate at the current. K-th.

the weight w. The rigid unit is added back at the current.
                                                                                                                                                                                                                                                                                                                                                                                                            angle at 2013. If there are more units to add, tested at the acceptance of the west are are product of the west are always the product of the product o
                                                                                                                                                                                                                                                                                                                                                                               the acceptance 2006.

If not, of the w.sr. at 2006.

If not, o
                                                                                                                                                                                                                                                                                                                                                                                                                                                         Figs. 19A and 19B illustrate Type II move general the which is defined by equation 13 and 14 with reference which is defined acometric constraints.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               With reference to
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 concerted rotation geometric torsional angles for the selected torsional angles rejection the rejection torsional the rejection the rejection of the property of the property of the rejection the rejection the rejection of the property of the rejection the rejection of the property of the property of the rejection of the rejecti
                                                                                                                                                                                                                                                                                                                                                                                                                                                         Fig. 19A, K, candidate new torsional angles for the self torsional
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 bond are generated by Pink using the rejection about rotations about rotations about recrime and recri
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              method. Preferably North the concerted rotation constraints are adjacent backbone. Dermitted by the backbone.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          adjacent backbone bonds, in the selected direction along the selected direction constraints are concerted rotation constraints and at 2102.

adjacent backbone bonds, the concerted rotation 34 at 2102.

backbone, permitted by the roots of equation 34 at 2102.

determined from the roots of equation 34 at 2102.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             backbone, permitted by the concerted rotation 2102. Equation equation the roots of equation obtained from equation the roots variables obtained from intermediate variables of 34 depends on intermediate variables.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 determined from the roots of equation 34 at 2102. Equations are roots of equation 34 at 2102. equations are roots are roots of equation 34 at 2102. equation and roots are roots
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          34 depends on intermediate variables obtained from roots are in that order. in 0.04°

25, 29, found by searching the interval [-7.7]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The roots that order. The proots in that order. In 0.04° and 32 and determined in the interval [-7,7] in 0.04° simply found by searching the interval [-7,7].
```

increments. When a root is located in a 0.04° segment, it is refined with the bisection method referenced in Press et al. at § 9.1. It is expected on the average that six K' solutions will be found. If no roots are found at 2103, the 5 candidate rotation is impossible and this move is skipped. If solutions exist, next, at 2104, pext and Whee are determined. Using the described rotation method, the backbone rigid units are rotated (with consequent spatial displacement of 4 units) to a candidate torsional angle solution about their mutual 10 bonds. Additionally, any side chains attached to backbone rigid units are rigidly rotated using the same method. Having made these rotations, candidate interatomic distances and candidate interaction energies can be determined and used to obtain pext for this candidate solution. One of the 15 candidates is probabilisticly selected at 2104, and the backbone and any side chains are rotated according to this candidate into the proposed structure. The Jacobian of this transformation is determined at 2106 by equation 35. the old acceptance weight and Jacobian are determined at 20 2107. From the weights and Jacobians the move acceptance probability is found for use at 1805.

Fig. 19B details the determination 2107 of W^{old} and J^{old} for the reverse move from the proposed to the current side chain structure. Temporarily the proposed structure is used 25 as the basis for energy determination at 2008, and the current structure is restored at 2016, when this process is finished. At 2109, a set of K'-1 candidate torsional angles is generated for the selected backbone bond according to pint using the rejection method and the current torsional angle is 30 added to this set. If as preferred, K' is 1, this step results in a set with only the current angle. At 2111, similarly to 2102, the permitted torsional rotations about adjacent backbone bonds are determined from the equations expressing the concerted rotation constraints. Special care 35 is taken to ensure that the original conformation is found by the root finding proc dure. In particular, the s arch interval is c ntered on the known original ϕ_1 and is made as

small as necessary to isolate the root, which may be as small as 0.004° or smaller. The current structure must be among these solutions, since it exists. Select it at 2112. Wold is computed from the candidate angle solution, making the 5 candidate rotations and determining candidate interactions. Also the Jacobian, Jold, of the transformation is computed from the proposed to the current structure.

5.8. CONSENSUS STRUCTURE TEST

- Having selected a candidate pharmacophore and determined a best possible consensus structure and best possible structures for the remainder of the binder molecules, the consensus test, step 6, tests whether a consensus structure has actually been found. A consensus pharmacophore structure
- 15 consists of a spatial arrangement of chemically similar groups shared by all the N binders to high accuracy. Since an actual pharmacophore exists, the N specifically binding members of the screened libraries will share the actual structure. However, the remainder of binder molecules will
- 20 share no other similar structures to such a high accuracy.

 Therefore, a structure consensus of the N binders is possible only if the candidate pharmacophore is the actual physical pharmacophore responsible for the actual binding. If the candidate selected relates to other parts of the binder
- 25 molecules, no structure consensus will be found. Further, if the Monte Carlo determination attempts to impose a consensus on parts of the binder molecules that do not share structure, an inconsistent overall structure will be obtained for the remainder of the binder molecules.
- Therefore, two preferred consensus tests are applied:
 one test asks whether a consistent candidate pharmacophore
 has been obtained, and a second test asks whether consistent
 structures have been obtained for the remainder of the binder
 molecules. Both tests have a preferred absolute and a less
 preferred relative version.

There are two portions for the first t st. First, are all the consensus pharmacophore distanc s obtain d in the N

```
binders within at least a specified distance, is the second. is the annroyimarely 0.25 Å. Of each other?
                                                                                                               approximately 0.25 A, of each other? small compared to the relatively small most approximate less than at most approximate consensus energy energy total
                                                                                                binders within at least a specified distance, is the second, compared asperoximately 0.25 Å, of each other? small compared approximately H. relatively small consensus energy.
                                                                                                                        consensus energy Heomennus (e.g., energy) as determined by the total molecular energy of the total of the total molecular
                                                                                                          total molecular energy (e.g., less than at most approximate by the fotal molecular energy) as determined by the solution of the total molecular energy) as determined by the solution of the method?

Solution of the method?
                                                                                                                                                                                 There are also two portions of the second test. First, of the second the Monte?

There are also two portions predicted by the Monte?

There are also two portions predicted by the Monte?

There are also two portions predicted by additional distance measurements?
WO 96/30849
                                                                                                                                                                                               can the intramolecular distances predicted by the Monte Cine the Monte Carlo method is confirmed by additional distance measurements?
                                                                                                                                                                     method be confirmed by additional distance measurements;

method be confirmed by additional one or more of the Monte measured one or more of the Monte measured one or more of the measurements;
                                                                                                                                                                                                                              Second, since the Monte carlo method utilizes distance not these of these carlo method utilizes of these not more of the normal repairs and the normal repairs can be ignored and the normal repairs constraints can be ignored.
                                                                                                                                                                                                                                         constraints previously measured ignored distance.

constraints previously measured ignored distance.

constraints constraints that measured distance.

measurement constraints that measured distance.
                                                                                                                                                         Monte Carlo method?
                                                                                                                                                                                                                                                                   distance checked against that measured distance. Tolerances

distance checked against that measured of at least specified

agreements in each binder.

distance tests are distance agreements in each binder.

distance tests approximately 0.5 Å. in each binder.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Tolerances
                                                                                                                                                                                                                                                        measurement constraints can be ignored and the prediction of a constraints that measured distance.

Measurement constraints that measured distance checked against that agreement of a constraints that measurement of a constraint of a const
                                                                                                                                                                                                                                       for these e.g., approximately have been described in the form that the two preferred tests have been described to the t
                                                                                                                                                                                                                                                                                                                                                                    ances, two preferred tests have been described in the the two preferred tests have been described in the the two preferred tests have been the tests that the two preferred tests the two preferred te
                                                                                                                                                                                                                                                                                                                              absolute version as requiring the binders, Hamman and the binders, the binders, the binders tolerances differences among the distance differences among the binders.
                                                                                                                                                                                                                                                                                                                The two preferred tests have been described in the pharmace the two preferred tests have been described in the pharmace absolute version as requiring the values of the pharmace absolute version as remarking the values of the pharmace tolerances
                                                                                                                                                                                                                                                                                                                                          tolerances.

Alternatively the binders Heomensus can measured distances among the pharmacopho the pharmacopho and measured distances can distance differences among the binders.

Alternatively the binders Heomensus and measured distances can distance differences of the predicted and measured distance differences of the predicted and measured distance differences of the pharmacopho.
                                                                                                                                                                                                                                                                                                              distance differences among the binders. Homemour, and the be binders, Homemour, and the be among the binders, homemour, and the be distances can measured distances on an armacommorpe and measured distance of the predicted and measured to candidate on armacommorpe candidate of the possible candidate of t
                                                                                                                                                                                                                                                                                                                                                                       differences of the predicted and measured distances can be candidate pharmacophores.

differences of the predicted being that one minimizing these accumulated for all the point that one minimizing the candidate selected being that the candidate selected being the candidate.
                                                                                                                                                                                                                                                                                                                                                                                              the candidate rherefore, the differences of the pharmacophore the candidate maintum values for the minimum values 
                                                                                                                                                                                                                                                                                                                                                                                  accumulated for all the possible candidate pharmacophore that one minimizing the candidate will have the candidate that candidate the candidate the candidate that candidate the candidate that candidate the candidate th
                                                                                                                                                                                                                                                                                                                                                                                                            departures. The for the hinders the minimum value for H hinders of the minimum value for the hinders of the minimum value for the minimum 
                                                                                                                                                                                                                                                                                                                                                                                     minimum values for the differences of the pharmacophore the differences of the pharmacophore the minimum value for the minimum of predicated from the binders the differences of predicated from distances in the binders of the differences of predicated from the differences of the pharmacophore the differences of the difference
                                                                                                                                                                                                                                                                                                                                                                                                                                         distances in the binders, the minimum value for Heomentus, and the minimum values of the differences of Predicated from the minimum values of the differences of predicated from the minimum values of the differences of predicated from the minimum values of the minimum value for Heomentus, and the heoment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ared distances. is adaptable to other tests that evaluate for the this invention the conservant error of the conservant error 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   This invention is adaptable to other tests that evaluate the consensus structure obtained for the the consensus structure of the and the archivage of the consistency of the and the archivage of the consistency of the consi
                                                                                                                                                                                                                                                                                                                                                                                                                                                       the consistency of the consensus structure obtained for the structure and the accuracy of the binder molecules.

30 candidate pharmacophore and the binder molecules of the binder molecules.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  candidate pharmacophore and the accuracy or the structures.

candidate pharmacophore and the binder molecules.

obtained for the remainder of the binder molecules.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Having started 6 of Fig. 1 a high regolution of aren 6 of Fig.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Having Started at Step 1 with a target of interpretation of Step 6 of Fig. hear decembers at marking has been decembered at marking has been decembered at marking has been decembered.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    completion of structures of the N hinder nentides

pharmacophore structures of the N hinder nentides

pharmacophore structures of the N hinder nentides
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     pnarmacophore structures of the N binder peptides.
```

resolution structure is used in step 7 to determine lead compounds for use as a drug that will bind to the original target of interest.

Thus, one or more lead compounds are determined, that 5 share a pharmacophore specification with the determined consensus pharmacophore structure. This determination can be preferably done by one of several methods: by a search of a database of potential drug compounds or of chemical structures (e.g., the Standard Drugs File (Derwent

- 10 Publications Ltd., London, England), the Bielstein database (Bielstein Information, Frankfurt, Germany or Chicago), and the Chemical Registry (CAS, Columbus, OH)) to identify compounds that contain the pharmacophore specification; by modification of a known lead compound to include the
- 15 pharmacophore specification; by synthesizing a de novo structure containing the pharmacophore specification; or by modification of binders to the target molecule (e.g., isolated in step 2) outside of the pharmacophore structure to render the binder more attractive for use as a drug (e.g., to
- 20 increase half-life, solubility, ability to achieve desired in vivo localization).

Database search queries are based not only on chemical property information but also on precise geometric information. Computer-based approaches rely on database

- 25 searching to find matching templates; Y.C. Martin, <u>Database</u>
 <u>searching in drug design</u>, J. Medicinal Chemistry, vol. 35, pp
 2145-54 (1992), which is herein incorporated by reference.
 Existing methods for searching 2-D and 3-D databases of
 compounds are applicable to this step. Lederle of American
- 30 Cyanamid (Pearl River, New York) has pioneered molecular shape-searching, 3D searching and trend-vectors of databases. Commercial vendors and other research groups have enhanced searching capabilities [MACSS-3D, Molecular Design Ltd. (San Leandro, CA); CAVEAT, Lauri, G. et al., University of
- 35 California (Berkeley, CA); CHEM-X, Chemical Design, Inc. (Mahwah, N.J.)).

The pharmacophore structure determined in this invention is adaptable to any of these methods and sources of chemical database searching and to the enumerated non-database methods. Output will be lead compounds suitable for drug 5 design. An important aspect of this invention is that the high resolution pharmacophore structure will lead to highly targeted leads. Lower resolution structures result in a geometric increase in the number of lead compound query matches. Example 1 illustrates this effect.

10

5.10. APPENDIX: CONCERTED ROTATION

Since the preferred molecules under consideration are conformationally constrained by disulfide bridge(s), a Monte Carlo move that preserves this constraint is required. The 15 "concerted rotation" scheme used for alkanes can be extended to allow rotation of the torsional angles in conformationally constrained peptides. This appendix describes this extension. Dodd et al. (1993) discusses the original, restricted method. (The essential extensions are expressed in equations 27, 28, and 34.) This method is directly applicable to the cyclic residue of proline, and an alternative embodiment of this invention would thermally perturb proline with a move of similar geometric constraints.

Fig. 14 illustrates the geometry under consideration. 25 Illustrated backbone 1600 is a poly-glycine 7-mer. Rigid unit positions are indicated generally by black circles as at 1601 with incoming bonds generally as at 1602. The torsional rotations ϕ_0 to ϕ_6 are about bonds 1602 to 1608, respectively, between sequential, adjacent rigid units. The rigid unit

- 30 position vectors <u>r</u>₀ to <u>r</u>₆, illustrated as vectors 1610 to 1616, respectively, define the position of these sequential rigid units with respect to a laboratory coordinate system with origin 1609. A C_o rigid unit (B unit) is illustrated in box 1630, and an amide bond (C unit) in box 1631.
- To formulate this method, let us consider rotating about seven torsional angles, which will displace the root positions and rotate four rigid units, rotate up to three

additional ones, and leave the rest of the peptide fixed. The root position of a rigid unit is the C_o position for a B unit, the C position for a C unit, the C position for a CH_2 unit, and the S position for the S unit in cystine. If unit 5 is a C unit, however, \underline{r}_s is defined to be the backbone amino nitrogen position of that unit. For each unit, let us define θ_i to be the fixed angle between the incoming and outgoing bonds. Thus, $\theta_i = 0$ for a C unit, and $\theta_i = 70.5^\circ$ for all others.

The method leaves the positions \underline{r}_i of units $i \leq 0$ or $i \geq 5$ fixed. The torsion ϕ_o is changed by an amount $\delta \phi_o$. The values of ϕ_i , $1 \leq i \leq 6$ are then determined so that only the positions r_i of units $1 \leq i \leq 4$ are changed.

The method requires several definitions to present the 15 solution for the new torsional angles. The bond vectors are defined to be the difference in position between unit i and unit i - 1, as seen in the coordinate system of unit i:

$$I_{i} = I_{i}^{(i)} - I_{i-1}^{(i)}. \tag{15}$$

20

Bond vectors \underline{l}_1 to \underline{l}_5 are illustrated in Fig. 14 at 1620 to 1624, respectively. The length and orientations of the \underline{l}_i are determined by rigid unit structure and the length and angle AMBER parameters for bonds between atom types. The coordinate system of i is such that the incoming bond is along the \hat{x} direction. Thus $\underline{l}_i = l_i \hat{x}$ if atoms r_i and r_{i+1}

are directly bonded to each other and has x- and y-components otherwise. Here \hat{x} is a fixed unit vector along the x

direction. Now define a rotation matrix that transforms from the coordinate system of unit i+1 to unit i

$$T_{i} = \begin{cases} \cos\theta_{i} & \sin\theta_{i} & 0\\ \sin\theta_{i}\cos\phi_{i} & -\cos\theta_{i}\cos\phi_{i} & \sin\phi_{i}\\ \sin\theta_{i}\sin\phi_{i} & -\cos\theta_{i}\sin\phi_{i} & -\cos\phi_{i} \end{cases}$$
(16)

5

The positions of the units in the frame of unit 1 are, thus, given by:

$$\mathbf{I}_{1}^{(1)} = \mathbf{1}_{1}
\mathbf{I}_{2}^{(1)} = \mathbf{1}_{1} + \mathbf{I}_{1}\mathbf{1}_{2}
\mathbf{I}_{3}^{(1)} = \mathbf{1}_{1} + \mathbf{I}_{1}(\mathbf{1}_{2} + \mathbf{I}_{2}\mathbf{1}_{3})
\mathbf{I}_{4}^{(1)} = \mathbf{1}_{1} + \mathbf{I}_{1}(\mathbf{1}_{2} + \mathbf{I}_{2}(\mathbf{1}_{3} + \mathbf{I}_{3}\mathbf{1}_{4}))$$
(17)

15

Further define the matrix that converts from the frame of reference of unit 1 to the laboratory reference frame

$$T_1^{lab} = [\cos\psi I + nn^T (1 - \cos\psi) + M\sin\psi] A.$$
 (18)

20

where

$$M = \begin{pmatrix} 0 & -n_z & n_y \\ n_z & 0 & -n_x \\ -n_y & n_x & 0 \end{pmatrix}$$
 (19)

25

and

$$n = \frac{\hat{x} \times I}{|\hat{x} \times I|}$$

$$\cos \psi = \frac{I \cdot \hat{x}}{|I||\hat{x}|}$$

$$\sin \psi = \frac{|(I \times \hat{x})|}{|I||\hat{x}|},$$

where \underline{r} is the axis of the bond coming into unit 1. The matrix A is a rotation about \hat{x} and is defined so that

 $_{5}$ Al, $=\Delta r$:

$$A = \begin{pmatrix} 1 & 0 & 0 \\ 0 & c & -s \\ 0 & s & c \end{pmatrix} \tag{20}$$

10

where

$$c = (l_{1y}\Delta r_y + l_{1z}\Delta r_z) / (\Delta r_y^2 + \Delta r_z^2)
s = (-l_{1z}\Delta r_y + l_{1y}\Delta r_z) / (\Delta r_y^2 + \Delta r_z^2).$$
(21)

15

Here $\Delta R = A[T_1^{lab}]^{-1}(x_1-x_0)$ if unit 0 is a C unit. Otherwise,

 $\Delta \underline{r} = \underline{l}_1$.

The method proceeds by solving for ϕ_1 , $2 \le i \le 6$, analytically in terms of ϕ_1 . Then a nonlinear equation is solved numerically to determine which values of ϕ_1 , if any, are possible for the chosen value of ϕ_0 .

The derivation proceeds in the coordinate system of unit 25 1, after it has been rotated by the chosen ϕ_0 . Define

$$\underline{t} = \underline{r}_{5}^{(1)} - \underline{l}_{1} = [\underline{T}_{1}^{lab}]^{-1} (\underline{r}_{5} - \underline{r}_{0}) - \underline{l}_{1}. \tag{22}$$

If $\theta_3 \neq 0$ and $\theta_5 \neq 0$, one can see from Fig. 14 that the distance between unit 3 and unit 5 is known and equal to

$$q_1^2 = \frac{(l_{4x}\cos\theta_4 - l_{4y}\sin\theta_4 + l_{5x})^2 + (l_{4x}\sin\theta_4 + l_{4y}\cos\theta_4 + l_{5y})^2}{(l_{4x}\sin\theta_4 + l_{4y}\cos\theta_4 + l_{5y})^2}$$
 (23)

But this distance can also be written as 35

$$q_1^2 = |x - T_2 l_3|^2$$

 $x = T_1^2 t - l_3.$ (24)

5 Equating these two results, two values of ϕ_2 are possible

$$\phi_2^I = \arcsin(c_1) - \arctan(x_y/x_z) - H(x_z)$$

$$\phi_2^{II} = \pi - \arcsin(c_1) - \arctan(x_y/x_z) - H(x_z),$$
(25)

10 with

$$H(x) = \begin{cases} 0, & x > 0 \\ \pi, & x < 0 \end{cases}$$
 (26)

15 The constant c1 is given by

$$C_{1} = \begin{cases} \frac{q_{1}^{2} - x^{2} - l_{3}^{2} + 2x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{-2(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} \neq 0, \theta_{5} \neq 0 \end{cases}$$

$$C_{1} = \begin{cases} \frac{l_{3x} + l_{4x} + l_{5x}\cos\theta_{4} - x_{x}\cos\theta_{2}}{\sin\theta_{2}(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} = 0, \theta_{5} \neq 0 \end{cases}$$

$$C_{1} = \begin{cases} \frac{(I_{5} - I_{2}) \cdot (I_{6} - I_{5}) / l_{6} - l_{5} - l_{4x}\cos\theta_{4} - x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} \neq 0, \theta_{5} = 0 \end{cases}$$

$$\frac{l_{3x}\cos\theta_{4} - x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} = 0, \theta_{5} = 0 \end{cases}$$

$$\frac{l_{3x}\cos\theta_{4} - x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} = 0, \theta_{5} = 0 \end{cases}$$

$$\frac{l_{3x}\cos\theta_{4} - x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} = 0, \theta_{5} = 0 \end{cases}$$

$$\frac{l_{3x}\cos\theta_{4} - x_{x}(\cos\theta_{2}l_{3x} + \sin\theta_{2}l_{3y})}{(\sin\theta_{2}l_{3x} - \cos\theta_{2}l_{3y})(x_{y}^{2} + x_{z}^{2})^{1/2}}, & \theta_{3} = 0, \theta_{5} = 0 \end{cases}$$

30

where \underline{x} is given by Eqn. 24 if $\theta_s \neq 0$, and $\underline{x} = \underline{T_1}^{-1} [\underline{T_1}^{1ab}]^{-1} (\underline{r_6} - \underline{r_5})/1_6$ if $\theta_s = 0$. Clearly for there to be a solution $|c_1| \leq 1$. The last three equations for c_1 were determined by conditions similar to equating Eqns. 23 and 24. For $\theta_3 = 0$, $\theta_s \neq 0$, the

x component of $\underline{r}_5^{(3)}$ - $\underline{r}_3^{(3)}$ is known to be equal to $(l_{4x} + l_5\cos\theta_4)$. For $\theta_3 \neq 0$, $\theta_5 = 0$, the x component of $\underline{r}_5^{(5)}$ - $\underline{r}_3^{(5)}$ is known to be equal to $l_{5x} + l_{4x}\cos\theta_4$. For $\theta_3 = 0$, $\theta_5 = 0$, the angle between \underline{r}_3 - \underline{r}_2 and \underline{r}_6 - \underline{r}_5 is known to be equal to θ_4 .

To determine ϕ_3 two expressions for $|\mathbf{r}_5 - \mathbf{r}_4|^2$ are again equated to determine that:

$$c_2 = \frac{I_5^2 - y^2 - I_4^2 + 2y_x(\cos\theta_3 I_{4x} + \sin\theta_3 I_{4y})}{2(\sin\theta_3 I_{4x} - \cos\theta_3 I_{4y})(y_y^2 + y_z^2)^{1/2}}$$
(28)

10

$$\phi_3^I = \arcsin(c_2) - \arctan(y_y/y_z) - H(y_z)
\phi_3^{II} = \pi - \arcsin(c_2) - \arctan(y_y/y_z) - H(y_z),$$
(29)

15

where $y = T_2^{-1} (T_1^{-1} \underline{t} - \underline{l}_2) - \underline{l}_3$. Again, $|c_2| \le 1$ for there to be

a solution.

If $\theta_s \neq 0$, the value of ϕ_s can now be determined from:

20

$$\dot{\mathbf{I}}_{5}^{(1)} = \dot{\mathbf{I}}_{4}^{(1)} + \dot{\mathbf{T}}_{1} \dot{\mathbf{T}}_{2} \dot{\mathbf{T}}_{3} \dot{\mathbf{T}}_{4} \dot{\mathbf{I}}_{5}.$$
 (30)

Defining

$$g_{3} = T_{3}^{-1}T_{2}^{-1}T_{1}^{-1} \{T_{1}^{lab}\}^{-1} (\underline{r}_{r} - \underline{r}_{r}). \tag{31}$$

25

the equations that define ϕ_i are given by

$$q_{3y} = \cos\phi_4 (\sin\theta_4 l_{5x} - \cos\theta_4 l_{5y})$$

$$q_{3z} = \sin\phi_4 (\sin\theta_4 l_{5x} - \cos\theta_4 l_{5y})$$
(32)

30

This is a successful rotation if the position of \underline{r}_6 is successfully predicted. That is, the equation

$$\underline{\mathbf{L}}_{6}^{(1)} - \underline{\mathbf{L}}_{5}^{(1)} = T_{1}T_{2}T_{3}T_{4}T_{5}\underline{\mathbf{L}}_{6} = [T_{1}^{1ab}]^{-1}(\underline{\mathbf{L}}_{6} - \underline{\mathbf{L}}_{5}).$$
(33)

must be satisfied. Consider the x-component, which implies

$$F_{5}(\phi_{1}) = \begin{cases} (\mathcal{I}_{6}^{(1)} - \mathcal{I}_{5}^{(1)})^{T} T_{1} T_{2} T_{3} T_{4} \hat{x} - (l_{6x} \cos \theta_{5} + l_{6y} \sin \theta_{5}) = 0, & \theta_{5} \neq 0 \\ (\mathcal{I}_{4} - \mathcal{I}_{3}) \cdot (\mathcal{I}_{6} - \mathcal{I}_{5}) - l_{4} l_{6} \cos \theta_{4} = 0, & \theta_{3} \neq 0, \theta_{5} = 0 \end{cases}$$

$$|\mathcal{I}_{6} - \mathcal{I}_{4}| - [(l_{6x} + l_{5x})^{2} + l_{5y}^{2}]^{1/2} = 0, & \theta_{3} = 0, \theta_{5} = 0$$

$$(34)$$

must be satisfied if the rotation is successful. The equations for the case θ_s = 0 clearly express the geometric conditions required for a successful rotation.

5

Eqn. 34 is the nonlinear equation for ϕ_1 because ϕ_2 , ϕ_3 , and ϕ_4 are determined by Eqns. (25), (29), and (32) in terms of ϕ_1 . This equation has between zero and four values for each value of ϕ_1 , however, due to the multiple root character of Eqns. (25) and (29). The equation is solved by searching the region $-\pi < \phi < \pi$ for zero crossings. The search is in increments of $\sim 0.04^\circ$. These roots are then refined by a bisection method.

The transformation from φ₁, 0 ≤ i ≤ 6 to the new solution which is constrained to change only r₁, 1 ≤ i ≤ 4 actually implies a change in volume element in torsional angle space. This change in volume element is the reason for the appearance of the Jacobian in the acceptance probability. The Jacobian of this transformation is calculated in Dodd et al. (1993) at pp. 991-93. It is slightly different here since root position r₅ is not necessarily the head position. The Jacobian is given by.

$$J = \frac{1}{|detB|}$$
 (35)

where the 5 x 5 matrix B is given by $B_{ij} = [\underline{u}_j \times (\underline{r}_5 - \underline{h}_j)]_i$ for i

35 \leq 3 and $B_{ij} = [\underline{u}_j \times (\underline{r}_6 - \underline{r}_5)/|\underline{r}_6 - \underline{r}_5|]_{i-3}$ for i = 4,5. Here $\underline{h}_i = \underline{r}_i$, except that \underline{h}_5 is the head position even if $\theta_5 = 0$, and \underline{u}_i is the incoming bond vector for unit i.

Repeated application of the concerted rotation may lead to a slightly imperfect structure, due to numerical precision errors. In an alternative embodiment, peptide geometry would be restored to an ideal state by application of the Random 5 Tweek algorithm after several thousand moves (Shenkin et al., 1987, Biopolymers 26:2053-85).

The invention is further described in the following examples which are in no way intended to limit the scope of the invention.

10

6. EXAMPLES

6.1. RELATION BETWEEN EFFECTIVENESS OF POTENTIAL DRUG IDENTIFICATIONS AND PHARMACOPHORE GEOMETRIC TOLERANCE

Searches of a drug library well known to medicinal chemists, the Standard Drugs File (Derwent Publications Ltd., London, England), illustrate the geometric increase in the number of compounds found (and thus decrease in expected effectiveness of identification of potential drugs) as pharmacophore geometric tolerance is increased. Table 4 tabulates the results.

20

Table 4

	5HT3 (5 Hydroxytryptophan)	
	Tolerance (Å)	Number of drug compounds
25	2.0	64
	1.0	35
	0.5	27
	0.25	12
30	0.10	1

	Dopamine			
	Tolerance (Å)	Number of drug compounds		
	2.0	188		
5	1.0	185		
	Դ. ●	60 ⁻		
	0.25	48		
	0.10	5		

10 The pharmacophores are two well known neurotransmitters, 5-hydroxytryptophan and dopamine. As the tolerance of one distance in the pharmacophore structure is decreased from 2.0 to 0.1 Å, the number of compounds retrieved from the database is listed. The advantage of achieving pharmacophore

15 resolution better than approximately 0.25 Å is clear.

If the tolerance of three distances were involved, the expected number of compound retrieved would be the cube of these numbers. For the dopaminergic pharmacophore, the number of lead compounds would decrease from over 6.5x10⁶ to 20 about 125 as three tolerances were decreased from 2.0 Å to 0.1 Å.

This example illustrates the geometric increase in the number of leads identified as pharmacophore geometry is less well defined. It thus a very preferred aspect of this invention that the computational method results in determining pharmacophore structure accurate to at least approximately 0.25 to 0.30 Å. Thus an exponentially large improvement in lead compound selection for drug design can be expected to result from this invention.

30

6.2. EXPRESSION AND PURIFICATION OF TARGET PROTEINS

Target molecules that are proteins, for example ras, raf, vEGF and KDR, are expressed in the *Pichia pastoris*sexpression system (Invitrogen, San Diego, CA) and as glutathione-S-transferase (GST)-fusion proteins in *E. coli* (Guan and Dixon, 1991, Anal. Bioch m. 192:262-267).

The cDNAs of these target proteins are cloned in the Pichia expression vectors pHIL-S1 and pPIC9 (Invitrogen). Polymerase chain reaction (PCR) is used to introduce six Histidines at the carboxy-terminus of these proteins, so that 5 this His-tag can be used to affinity-purify these proteins. The recombinant plasmids are used to transform Pichia cells by the spheroplasting method or by electroporation. Expression of these proteins is inducible in Pichia in the presence of methanol. The cDNAs cloned in the pHIL-S1 10 plasmid are expressed as a fusion with the PHO1 signal peptide and hence are secreted extracellularly. Similarly cDNAs cloned in the pPIC9 plasmid are expressed as a fusion with the α -factor signal peptide and hence are secreted extracellularly. Thus, the purification of these proteins is 15 simpler as it merely involves affinity purification from the growth media. Purification is further facilitated by the fact that Pichia secretes very low levels of homologous proteins and hence the heterologous protein comprises the vast majority of the protein in the medium. The expressed 20 proteins are affinity purified onto an affinity matrix containing nickel. The bound proteins are then eluted with either EDTA or imidazole and are further concentrated by the use of centrifugal concentrators.

As an alternative to the Pichia expression system, the 25 target proteins are expressed as glutathione-S-transferase (GST) fusion proteins in E. coli. The target protein cDNAs are cloned into the pGEX-KG vector (Guan and Dixon, 1991, Anal. Biochem. 192:262-267) in which the protein of interest is expressed as a C-terminus fusion with the GST protein.

30 The pGEX-KG plasmid has an engineered thrombin cleavage site at the fusion junction that is used to cleave the target protein from the GST tag. Expression is inducible in the presence of IPTG, since the GST gene is under the influence of the tac promoter. Induced cells are broken up by 35 sonication and the GST-fusion protein is affinity purified onto a glutathione-linked affinity matrix. The bound protein is then cleaved by the addition of thrombin to the

affinity matrix and recovered by washing, while the GST tag remains bound to the matrix. Milligram quantities of recombinant protein per liter of *E. coli* culture are expected to be obtainable in this manner.

5

6.3. SYNTHESIS AND SCREENING OF POLYSOME-BASED LIBRARIES ENCODING RANDOM CONSTRAINED PEPTIDES OF VARIOUS LENGTHS

6.3.1. PREPARATION OF DNA TEMPLATES

DNA libraries with a high degree of complexity are made 10 as two components: an expression unit, and a semi-random (or degenerate) unit. The expression unit has been synthesized chemically as an oligonucleotide (termed T7RBSATG), and contains the promoter region for bacteriophage T7 RNA 15 polymerase, a ribosome binding site, and the initiating ATG codon. The random region, also synthesized as an oligonucleotide (termed MMN6) contains a region complementary to the expression unit, the antisense version of the codons specifying Cys-X₆-Cys, and a restriction site (BstXI). 20 library is constructed by annealing 100 pmol of oligonucleotide T7RBSATG [having the sequence 5 'ACTTCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCCAGAAAT AATTTTGTTTAACTTTAACTTTAAGAAGGAGATATACATATGCAT3' (SEQ ID NO:2)); and oligonucleotide MNN6 [having the sequence 5 'CCCAGACCCGCCCCAGCATTGTGGGTTCCAACGCCCTCTAGACA [MNN] ACAATG TATATCTCCTTCTT3' (SEQ ID NO:3); M = A or C, N = G, A, T, or C], and extending the DNA in a reaction mixture containing 10-100 units of Sequenase (United States Biochemical Corp., Cleveland, OH), all four dNTPS (at 1 mM), and 10 mM 30 dithiothreitol for 30 min at 37°C. The extended material is then digested with BstXI, ethanol precipitated and resuspended in water. This fragment of DNA is then ligated via the BstXI end to a 250 base pair (bp), PCR-amplified Glycine-Serine coding fragment derived from gene III of M13 35 bacteriophage DNA. The gene III fragment has been amplified by use of two primers, respectively termed FGSPCR [having the sequence 5'TCGTCTGACCTGCCTCAACCTCCCCACAATGCTGGCGGCGGCTCTGGT3'

(SEQ ID NO: 4)), and RGSPCR (having the sequence 5'ATCAAGTTTGCCTTTACCAGCATTGTGGAGCGCGTTTTCATC3'
(SEQ ID NO:5)], and Taq DNA polymerase (Gibco-BRL). The amplified DNA (250 bp) was cut with BstXI to yield a 200 bp fragment that has been gel purified. The 200 bp fragment is then ligated to the random peptide coding DNA fragment. This DNA specifies the synthesis of a peptide of the sequence Met-His-Cys-(X),-Cys- (SEQ ID NO:6) fused to the Gly-Ser rich region of the Ml3 gene III protein. The Gly-Ser rich domain is thought to behave as a flexible linker and assist in presentation of the random peptide to the target molecules.

To make constrained random peptides of different lengths, oligonucleotides are made that are similar to MNN6, except that the degenerate region is 5, 7, 8, and 9 codons long. In addition, oligonucleotides are made that code for various shapes of constrained random peptides by specifying sequences comprising three cysteine residues interspersed between 6-10 randomly specified amino acids.

20 6.3.2. IN VITRO SYNTHESIS AND ISOLATION OF POLYSOMES

An E. coli S30 extract is prepared from the B strain SL119 (Promega). Coupled transcription-translation reactions are performed by mixing the S30 extract with the S30 premix 25 (containing all 20 amino acids), the linear DNA template coding for peptides of random sequences (prepared as described in Section 6.3.1 above), and rifampicin at 20 μ g/ml. The reaction is initiated by the addition of 100 units of T7 RNA polymerase and continues at 37°C for 30 min. The reaction is terminated by placing the reactions on ice and diluting them 4-fold with polysome buffer (20 mM Hepes-NaOH, pH 7.5, 10 mM MgCl₂, 1.5 μ g/ml chloramphenicol, 100 μg/ml acetylated bovine serum albumin, 1 mM dithiothreitol, 20 units/ml RNasin, and 0.1% Triton X-100). Polysomes are isolated from a 50 μ l reaction programmed with 0.5-1 μ g of linear DNA template specifying the synthesis of random constrained peptides. To isolate polysomes, the diluted S30

reaction mixtures are centrifuged at 288,000 X g for 30-40 min at 4°C. The pellets are suspended in polysome buffer and centrifuged a second time at 10,000 X g for 5 min to remove insoluble material.

5

6.3.3. AFFINITY SELECTION/SCREENING OF POLYSOMES

The isolated polysomes are incubated in microtiter wells coated with the target proteins. Microtiter wells are uniformly coated with 1-5 μg of 6-His tagged, or glutathione S-transferase fused, target proteins (see Section 6.2 Target proteins that are used include the hereinabove). oncoproteins ras and raf, KDR (the vascular endothelial growth factor [vEGF] receptor protein) and vEGF. microtiter wells are coated with 1-5 μ g of these target proteins by incubation in PBS (phosphate-buffered saline; 10 mM sodium phosphate, pH 7.4, 140 mM NaCl, 2.7 mM KCl), for 1-5 hours at 37°C. The wells are then washed with PBS, and the unbound surfaces of the wells blocked by incubation with PBS containing 1% nonfat milk for 1 hr at 37°C. Following a wash 20 with polysome buffer, each well is incubated with polysomes isolated from a single 50 μ l reaction for 2-24 hr at 4°C. Each well is washed five times with polysome buffer and the associated mRNA is eluted with polysome buffer containing 20 mM EDTA.

After affinity selection of the polysomes, the associated mRNAs are isolated, and treated with 5-10 units of DNase I (RNase-free; Ambion) for 15 min at 37°C after addition of MgCl₂ to 40 mM. The mRNA is phenol-extracted and ethanol-precipitated and dissolved in 20 μl of RNase-free water. A portion of the mRNA is used for cDNA preparation and subsequent amplification using 15 pmol each of primers RGSPCR [5'ATCAAGTTTGCCTTTACCAGCATTGTGGAGCGCGTTTTCATC3' (SEQ ID NO:5)], and SELEXF1

[5'ACTTCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCC3'

(SEQ ID NO:9)] and rTth Reverse Transcriptase RNA PCR kit

(Perkin Elmer Cetus). Specifically, the mRNA is reverse-

transcribed into cDNA in a 20 μ l reaction containing 1 pg mRNA, 15 pmol of RGSPCR primer, 200 μM each of dGTP, dATP, dTTP, and dCTP, 1 mM MnCl2, 10 mM Tris-HCl, pH 8.3, 90 mM KCl, and 5 units of rTth DNA polymerase at 70°C for 15 min. 5 the next step, the cDNA is amplified by the addition of 2.5 mM MgCl₂, 8% glycerol, 80 mM Tris-HCl, pH 8.3, 125 mM KCl, 0.95 mM EGTA, 0.6% Tween 20, and 15 pmol of the SELEXF1 The reaction conditions that are employed are 2 min at 95°C for one cycle, 1 min at 95°C and 1 min at 60°C for 35 10 cycles, and 7 min at 60°C for one cycle. The amplified product is then gel-purified and quantitated by spectrophotometry at 260 nm. A portion of the amplified DNA is digested with NsiI and XbaI and the resulting 30 base pair fragment is directionally cloned into a monovalent phage 15 display vector. The DNAs inserted in the monovalent phage display vector are then sequenced to determine the identity of the peptides that were selectively retained by one cycle of affinity binding to the target protein. A second portion $(0.5-1 \mu g)$ of the amplified DNA is subjected to another cycle 20 of affinity selection, mRNA isolation, cDNA amplification, and cloning.

6.4. PHAGEMID SCREENING

Three different protocols for screening of a phagemid 25 library are presented in the subsections hereinbelow. These protocols, particularly the immobilization and binding steps, are readily adaptable to use for screening of different libraries, e.g., polysome libraries. Preferably, different methods are used in different rounds of screening.

30

6.4.1. PLATE PROTOCOL

In this example, a protocol is presented for screening a phagemid library, in which in the first round of screening, a 35 biotinylated target protein is immobilized (by the specific binding b tween biotin and streptavidin) on a streptavidin

coated plate. The immobilized target protein is then contacted with library members to select binders.

Reagents Used:

- 5 Purified target protein, microfuge tubes, Falcon 2059, Binding Buffer, Wash Buffer, Elute Buffer, phage display Library of >10¹¹ pfu/Screened Target, fresh overnight cultures of appropriate host cells, LB Agar plates with antibiotics as needed, biotinylating agent NHS-LC-Biotin (Pierce Cat.
- 10 #21335), streptavidin, 50 mM NaHCO₃ pH 8.5, 1 M Tris pH 9.1, M280 Sheep anti-mouse IgG coated Dynabeads (Dynal), phosphate buffered saline (PBS), Falcon 1008 petri dishes.

Wash Buffer = 1X PBS (Sigma Tablets), 1 mM MgCl₂, 1 mM CaCl₂, 15 0.05% Tween 20; (For one liter: 5 PBS tablets, 1 ml 1 M MgCl₂, 1 ml 1 M CaCl₂, 0.5ml Tween 20, nanopure H₂O to 1 liter).

Binding Buffer = Wash Buffer with 5 mg/ml bovine serum albumin (BSA).

20

Elute Buffer = 0.1 N HCl adjusted to pH 2.2 with glycine:
1 mg/ml BSA.

Procedure:

25 Protein Biotinylation:

- 1. Wash 50-100 μ g of target protein in 50 mM NaHCO, pH 8.5 in a Centricon (Amicon) of the appropriate molecular weight cut-off.
- 2. Bring the total volume to 100 μ l with 50 mM NaHCO₃ pH 30 8.5.
 - 3. Dissolve 1 mg of NHS-LC-Biotin in 1 ml H₂O. Do not store this solution.
- 4. Immediately add 37 μ l of the NHS-LC-Biotin solution to the target protein and incubate for 1 hr at room temperature 35 (RT).

5. Remove the unreacted biotin by washing 2X PBS in a Centricon (Amicon) of the appropriate molecular weight cutoff. Store the biotinylated protein at 4°C.

5 Coating a 1008 Plate with Streptavidin:

- 6. The night before the binding experiment precoat a 1008 plate with streptavidin.
- 7. Add 10 μ g of streptavidin (1 mg/ml H₂O) per 1 ml of 50 mM NaHCO₁ pH 8.5.
- 10 8. Add 1 ml of this solution to each plate and place in a humidified chamber overnight at 4°C.

Prebinding: Blocking Non-Specific Sites:

- 9. To a streptavidin coated plate add 400 μ l of Binding
- 15 Buffer (BSA blocking) for one hour at room temperature.
 - 10. Rinse wells six times with Wash Buffer by slapping dry on a clean piece of labmat.

Binding; Specific Target/Phage Complexes Round 1:

- 20 11. Add 10 μ g of biotinylated target protein in 400 μ l of Binding Buffer to the well and incubate for 2 hr at 4°C.
 - 12. Add 4 μ l of 10 mM biotin and swirl for 1 hr at 4°C.
 - 13. Wash as in step 10.
- 14. Add concentrated phage library (>10¹¹ pfu) in 400 μ l of 25 Binding Buffer and swirl overnight at 4°C.

Washing and Elution:

- 15. Slap out binding mixture and wash as in step 10.
- 16. To elute bound phage add 400 μ l of Elution Buffer and 30 rock at RT for 15 min.
 - 17. Transfer the elution solution to a sterile 1.5 ml tube which contains 75 μ l of 1 M Tris pH 9.1. Vortex briefly.

Amplification of Round 1 Eluted Phage:

35 18. Plate all of the eluted round 1 phage by adding 157 μ l cf phage to 200 μ l of cells incubated overnight (previously ch cked free of contamination) in three aliquots. Incubate

25 min in a 37°C water bath and then spread onto LB agar/antibiotics plate containing 2% glucose.

- 19. Scrape plates with 5 ml of 2XYT (growth broth)/Antibiotics/Glucose and leave swirling for 30 min at RT.
- 5 20. Add the appropriate amount of 2XYT/Antibiotics/Glucose to bring the O.D. 600 down to 0.4 and then grow at 37°C at 250 rpm until the O.D. 600 reaches 0.8.
 - 21. Remove 5 ml and add to it 1.25 x 10^{10} M13 helper phage.
- 22. Shake 30 min at 150 rpm and then 30 min at 250 rpm at 10 37°C.
 - 23. Centrifuge 10 min at 3000 X g at RT.
 - 24. Resuspend cells in 5 ml 2XYT with no glucose. (This step removes glucose).
- 25. Centrifuge as in step 23 and resuspend in 5 ml 2XYT with 15 kanamycin and the appropriate antibiotics (no glucose). Spin
 - 18 hr at 37°C and 250 rpm.
 - 26. Pellet cells at 10,000 X g and sterile filter the phage containing supernatant which is now ready for round 2 screening.
- 20 27. Titer the round 1 eluted phage stocks.

Binding; Specific Target/Phage Complexes Rounds 2-5:

- 6. Combine ~1 μg of biotinylated target protein with the eluted and titered round 1 phage (10° pfu) in 200 μl of
- 25 Binding Buffer and rock 4 hr at 4°C.
 - 7. The night before the round 2 screening is started, prewash 200 μ l/target protein to be screened of sheep antimouse IgG magnetic beads (M280 IgG Dynabeads) with 2X 1 ml of Wash Buffer using the Dynal Magnet. Let the beads collect at
- 30 least 1 min before removing the buffer. Let the beads stand 15 sec to allow residual Binding Buffer to collect and remove with a P200 Pipetman.
- Resuspend the washed beads in 200 μl of Binding Buffer and add 100 μl of mouse anti-biotin IgG (Jackson IRL). Rock
 overnight at 4°C.
 - 10. Wash the unbound anti-biotin IgG from the Dynabeads by placing th m on the Dyna magnet for at least 1 min and remove

```
all liquid as in Step 7. Remove the tube from the magnet and of Wash Buffer, rock at 4°C for all liquid as in beads in 1 ml of wash Buffer.
                                                                       Remove the tube from the magnet and return to the magnet.

Remove the tube from the magnet and pelle wash Buffer, the beads pelle wash Ruffer, the beads pelle wash Again let the beads pelle all liquid as in Step 7. Remove the tube from to keep and the magnet.

Remove the tube from the magnet the beads pelle wash Ruffer, the beads pelle wash Ruffer, and return to the magnet.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Again let the beads pellet
                                                                                               Again let the heads pellet the magnet.

Again let the heads pellet the magnet and resuspend the magnet.

Again let the heads pellet the magnet the magnet.

Again let the heads pellet the peads and resuspend the magnet.

Again let the heads pellet the heads pellet the magnet.

Again let the heads pellet the heads and resuspend the heads are heads and resuspend the heads and resuspend the heads and resuspend the heads are heads and resuspend the heads and resuspend the heads are heads are heads and resuspend the heads are heads and resuspend the heads are 
                                                                                                                                      10a. The coated beads are now ready for use the remainder can be stored to the remainder can 
                                                                                       30 min, and return to the magnet.
                                                                                                                                                                                                                    use for up to 2 weeks. I blotin coated Dynabeads rotal

Note to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I blotin coated Dynabeads rotal

I bring to 2 weeks. I 
                                                                                                                        Deads The coated beads are now ready remained to the remained to the remaining the rem
MO 36130849
                                                                                       Tor 1 min 400 pl of Binding Buffer.
                                                                                                                                    11. Add the 100 µl of anti-biotin coated Dynabeads total

10 to the protein/phage to 300 µl and rock for 2 hr at 4°C.

10 to the protein/phage to 300 µl and rock for 2 hr at 4°C.
                                                                                                                                                                                   to the protein/phage traction (Step 9) pringing the to the protein/phage traction (Step 9) pringing the protein phage to the phage to
                                                                                                                                                                                                 binding volume to 300 µl and rock tor 2 nr at 4°C. Er with the phage/protein that the beads mix thoroughly with the phage/protein that the phage/protein the phage/protein the phage/protein the phage/pr
                                                                                                                                                                                                                                            Washing and Elution:

Washing and the binding reaction into the Dynal magnet and let

12. For 1 min.
                                                                                                                                                                                                                                                                                                                          for 1 min. solution using a plood piperman and discard.

Remove the stand 15 sec to allow residual binding buffer allow the beads stand
                                                                                                                                                                                                                                                                                 13. Remove the solution using a plood pipetman. Note serial hote serial the beads stand 15 sec to plood pipetman. Note serial let the beads remove with a plood pipetman.
                                                                                                                                                                                                                                                                                                              to collect and remove with a p200 pipetman. Note serial liquid being removed all residual liquid being remove all residual liquid being removed all residual liquid being removed in the solution depends upon is 100% washing: 50 ul into 500 is 100% washing
                                                                                                                                                                                                                                                                                                                          dilution depends upon all residual liquid being removed only washing; 50 µl into 500 is 100x washing; 50 µl into 500 is 100x washing; 10x).
                                                                                                                                                                                                        15 Washing and Elution:
                                                                                                                                                                                                                                                               Let the beads stand 15 sec to allow residual limit he collect and remove with a residual limit he all the collect and remove all residual limit he allow the collect denends when all residual limit he allow the collect denends when all residual limit he allow the collect denends when all residual limit he allow the collect denends when all residual limit he collect and remove all residual limit he collect and remove with a remove
                                                                                                                                                                                                                                                                                                                                                                                                     Remove the tube from the magnet to the magnet.

Remove the tube from and return to the magnet.
                                                                                                                                                                                                                                                                                                                      Remove the tube from the magnet and resuspend the beads to the magnet.

Remove the tube from and return to the magnet.

Remove the tube from and return to the magnet.

Ithe beads by waiting 1 min.
                                                                                                                                                                                                                                                                                                                                                                                                                                      heads Pellet by Waiting 1 min. step 7 and repeat this solution as in step 7 and repeat this Remove the Wash nore times.
                                                                                                                                                                                                                                                                                                                                                                                                       Process several more times. the final wash, resuspend the beads and wash once and wash once and wash once and tube and wash once 16. After them to a fresh. labeled tube and transfer them to a fresh.
                                                                                                                                                                                                                                                                                                                                                                                     16. After the removal of the final wash, resuspend the be and wash once and transfer them to a fresh, labeled tube and wash once and and transfer them to a fresh, labeled tube and wash once.
                                                                                                                                                                                                                                                                                                                                                                           the heads pellet by waiting 1 min.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     To elute bound Phage, add 400 Ml of Elution Buffer,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     titrate and rock for 14 min at RT. for one minute and transfer of the magnet which contains 75 HI of tube which contains 18. Place the afterile 1.5 ml tube which contains 5 the eluate to a fterile 1.5 ml
                                                                                                                                                                                                                                                                                                                                                                                                                                                18. Place the tube on the magnet for one minute and transfer which contains 75 µl of tube which contains 75 µl of vortex briefly.

35 the eluate to a sterile l.5 ml vortex briefly.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Nortex briefly.
```

Amplification of Round 2-5 Eluted Phage:

15a. Plate 10 μ l and 100 μ l of round 2,3,4 eluates using 200 μ l of contamination free (previously tested) *E. coli* XL1Blue cells onto each plate containing

5 tetracycline/ampicillin/glucose and tetracycline/ampicillin and amplify as in Steps 17-25.

6.4.2. BIOTIN-ANTIBIOTIN IGG BEAD PROTOCOL

In this example, a protocol is presented for screening a 10 phagemid library, in which a biotinylated target protein is immobilized (by the specific binding between anti-biotin antibodies and biotin) on a magnetic bead containing anti-biotin antibodies on the bead surface. The immobilized target protein is then contacted with library members to 15 select binders.

Reagents Used:

M280 Sheep anti-Mouse IgG coated Dynabeads (Dynal)

20 Binding; Specific Target/Phage Complexes Round 1:

- 6. Combine 10 μ g of biotinylated target protein with the phage library (>10¹⁰ pfu) in 400 μ l of Binding Buffer and rock overnight at 4°C.
- 7. That same night prewash 50 μ l sheep anti-mouse IgG
- 25 magnetic beads (M280 IgG Dynabeads) with 500 μ l of Binding Buffer twice using the Dynal Magnet. Let the beads collect at least 1 min before removing the buffer. Let the beads stand 15 sec to allow residual binding buffer to collect and remove with a P200 Pipetman.
- 30 8. Resuspend the washed beads in 100 μ l of Binding Buffer and add 33 μ l of mouse anti-biotin IgG (40 μ g, Jackson IRL). Rock overnight at 4°C.
 - 9. Remove unbound protein from the phage/protein reaction in Step 6 with a Microcon 100. Spin at 800 X g until
- 35 exclusion volume is met and wash twice with Wash Buffer (again at 800 X g). Collect phage/protein with a Pipetman and add an additional 50 μ l of Wash Buffer to the Microcon,

```
gently titrate and combine with first fraction to ensure maximal recovery.
                                                                                                             mal recovery.

Mash the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and remning the Dyna magnet for at least 1 min and 1
                                                                           10. Wash the unbound anti-biotin for at least 1 min magnet and the Dyna magnet the tube from the magnet and placing them on step 7. Remove the tube from the placing them on step 7.
                                                                   placing them on step 7. Remove the tube from rock at 4 or for at least 1 min and remove the tube from rock at 4 or for at least 1 min and remove the tube from the magnet and the pyna magnet the tube from rock at 4 or for at least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet and the magnet and the magnet and the magnet and the magnet at a least 1 min and remove the magnet and the magnet and the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet at a least 1 min and remove the magnet 1 min and remove the magnet 1 min and remove the magnet 1 min a least 1 min and remove the magnet 1
                                                                                               all liquid as in step 7. Remove the tube from rock at 4°C for Acain. let the beads in 750 µl of Mash Buffer, the beads resuspend the beads to the magnet.
                                                                                                          resuspend the beads to the magnet. Again, and return repeat this process 3 more times and 30 min; for 1 min:
WO 96[30849
                                                                                                                    30 min, and return to the magnet. Again, let the beads this process 3 more times and repeat this process 3 more for pelet for 1 min; repeat this process 3 more for pelet for 1 min; nf Rinding Ruffer pelet for heads in 100 min of Rinding Ruffer pelet for heads in 100 min of Rinding Ruffer
                                                               waxiwal recovery.
                                                                                                                                                                                     spend the beads in 100 kl ot Binding Buffer. 10) to the beads in 100 kl of Dynabeads the rotal hinding and the anti-biotin (sten 9). hring the fraction (sten 9).
                                                                                                                               pellet tox the beads in rosted numbers resuspend the seri-hintin costed numbers and the seri-hintin costed numbers.
                                                                                                                                                 Add the anti-biotin (step 9), bring and rock for 2 hr a protein/Phage with Binding Buffer.
                                                                                                                                                           Protein/Phage fraction Binding Buffer, and rock for 2 hr at with Binding Buffer, with the heads mix thoroughly with the heads mix the heads mix the heads mix thoroughly with the heads mix the heads 
                                                                                                                                                                   Wolume to 500 MI with the heads mix thoroughly with the RT. Ensure that the heads mix thoroughly with the RT.
                                                                                                                                                                                                                                                hing and Elution:

The Dynal magnet and let place the binding reaction into the Dynal magnet and let place the binding reaction into the Dynal magnet and let
                                                                                                                                                                                                                                                                           for 1 min. solution using a plood pipetman and discard.

Box 1 min. solution using allow residual binding buffer allow residual to allow residual binding buffer allow residual binding buffer allow residual to allow residual binding buffer allow residual buffer a
                                                                                                                                                                                                           13. Remove the solution using a plood pipetman. Note that series to allow pipetman. Note that series to be beads stand 15 sec to 200 pipetman.

20 Let to collect and remove with a plood pipetman.
                                                                                                                                                                                    phage protein solution.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Note that serial
                                                                                                                                                                                                                                                            to collect and remove with a p200 pipetman. Note that se to collect and remove all residual liquid being removed all residual liquid being soo is dilution depends upon is 100% washing: 50 ul into 500 dilution dilution into 500 is 100% washing:
                                                                                                                                                                                                                                                                       dilution depends upon all residual liquid being removed only is look washing; so all into soo is look washing; into soo is look washing; so all into so is look washing; so is
                                                                                                                                                                                                      Waghing and Elution:
                                                                                                                                                                                                                                                     Let the peads stand 12 with a p200 pipetman.

to collect and remove all marketing residual armonals.
                                                                                                                                                                                                                                                                                                                                           Remove the tube from the magnet to the magnet and return to the magnet and return to the magnet.
                                                                                                                                                                                                                                                                                                   Remove the tube from the magnet and resuspend the beads and resuspend the magnet.

Remove the tube from and return to the magnet.

Remove the from the magnet to the magnet.

Id. Remove the from the magnet and resuspend the magnet.

Again let no the magnet.

Id. Remove the from the magnet and resuspend the magnet.

Again let no the magnet.
                                                                                                                                                                                                                                                                                                                                                                 beads Pellet by waiting 1 min. Step 7 and repeat this step the wash solution as in Step 7 and repeat this Remove times.
                                                                                                                                                                                                                                                                                                                                                                                    ess 3 more times. Of the fourth wash, resuspend the fourth wash, resuspend the fact the removal of the freeh land of the freeh land of the fourth wash, and ruhe and 
                                                                                                                                                                                                                                                                                                                                                   16. After the removal of the fourth labeled tube and wash beads and transfer them to a fresh, labeled tube once more
                                                                                                                                                                                                                                                                                                                the beads pellet by waiting 1 min.
                                                                                                                                                                                                                                                                                                                                                                                                                    more. To elute bound phage, add 400 Ml of Elution Buffer,
                                                                                                                                                                                                                                                                                                                                                                                                                                        ate and rock for 14 min at RT. for one minute and transfer of the magnet tube which contains 75 " of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube which contains of the place to a sterile 1 5 ml tube wh
                                                                                                                                                                                                                                                                                                                                    Process 3 more times.
                                                                                                                                                                                                                                                                                                                                                                                                      18. Place the tube on the magnet for one minute and transfer value which contains 75 µl of the eluate to a sterile briefly.

the eluate ph 9.1.
                                                                                                                                                                                                                                                                                                                                                                                     titrate and rock for 14 min at RT.
                                                                                                                                                                                                                                                                                                                     30 <sup>26</sup>·
                                                                                                                                                                                                                                                                                                                                                                      once more.
                                                                                                                                                                                                                                                                                                                                                                                                                   Tris ph 9.1.
```

Amplification of Round 1 Eluted Phage:

17. Plate all of the eluted round 1 phage by adding 157 μ l of phage to 200 ml of cells incubated overnight (previously checked to be free of contamination) in three aliquots.

- 5 Incubate 25 min in a 37°C water bath and then spread onto LB agar/antibiotics plate containing 2% glucose. Place plates upright in 37°C incubator until dry and then invert and incubate overnight.
- 18. Scrape plates with 5 ml of 2XYT/Antibiotics/Glucose and 10 leave swirling for 30 min at RT.
 - 19. Add the appropriate amount of 2XYT/Antibiotics/Glucose to bring the O.D. 600 down to 0.4 and then grow at 37°C at 250 rpm until the O.D. 600 reaches 0.8.
 - 20. Remove 5 ml and add to it 1.25 x 10^{10} M13 helper phage.
- 15 21. Shake 30 min at 150 rpm and then 30 min at 250 rpm at 37°C.
 - 22. Centrifuge 10 min at 3000 X g at RT.
 - 23. Resuspend cells in 5 ml 2XYT with no glucose. (This step removes glucose)
- 20 24. Centrifuge as in step 23 and resuspend in 5 ml 2XYT with kanamycin and the appropriate antibiotics (no glucose). Spin 18 hr at 37°C and 250 rpm.
 - 25. Pellet cells at 10,000 xg and sterile filter the phage-containing supernatant which is now ready for round 2
- 25 screening.

Binding; Specific Target/Phage Complexes Round 2, 3, & 4: 6a. Bind 1 μg of target protein with 100 μl of amplified

phage from the previous round as before, overnight at 4°C.

- 30 7a. Prepare the IgG anti biotin/anti IgG beads as in Steps 7-10 using, however, only 20 μ l of sheep anti-mouse IgG and 13 μ l of anti-biotin IgG.
 - 8a. All other binding procedures are identical with Steps 6-11.

35

Washing and Elution:

9a. Place the binding reaction into the Dynal magnet and let sit for 1 min.

- 10a. Remove the solution and discard using a P1000 Pipetman.
- 5 Let the beads stand 30 sec to allow residual Binding Buffer to collect and remove with a P200 Pipetman.
 - 11a. Remove the tube from the magnet and resuspend the beads in 750 μ l of Wash Buffer and return to the magnet. Again let the beads pellet by waiting 1 min.
- 10 12a. Remove the wash solution as in Step 11a and repeat this process 3 more times.
 - 13a. After the removal of the fourth wash, resuspend the beads and transfer them to a fresh, labeled tube and wash 4 more times.
- 15 14a. Elute and neutralize as in Step 15.

Amplification of Rounds 2, 3, & 4 Eluted Phage:

15a. Plate 10 μ l and 100 μ l of round 2,3,4 eluates and amplify as in Steps 17-25.

20

6.4.3. BIOTIN-STREPTAVIDIN, MAGNETIC BEAD PROTOCOLS

In this example, a protocol is presented for screening a phagemid library, in which a biotinylated target protein is immobilized (by the specific binding between biotin and streptavidin) on a streptavidin coated magnetic bead. The immobilized target protein is then contacted with library members to select binders.

30 Reagents Used:

Purified target protein, M280 streptavidin coated Dynabeads (Dynal)

Binding; Specific Target/Phage Complexes Round 1:

35 6. Combine 10 μ g of biotinylated target protein with the phage library (>10¹⁰ pfu) in 400 μ l of Binding Buffer and rock overnight at 4°C.

7. Remove unbound protein with a Microcon 100. Spin at 800 X g until exclusion volume is met, and wash twice with Wash Buffer (again at 800 X g). Collect phage/protein with a Pipetman and add an addition 50 μ l of Wash Buffer to the 5 Microcon, gently titrate and combine with the first fraction to ensure maximal recovery.

- 8. Prewash 50 μ l (per reaction) of streptavidin magnetic beads (M280 streptavidin Dynabeads) twice with 500 μ l of Washing Buffer using the Dynal magnet.
- 10 9. Add the prewashed Dynabeads to the protein/phage fraction (add Binding Buffer to a total of 500 μ l) and rock for 30 min. Ensure that the beads mix thoroughly with the phage/protein solution.

15 Washing and Elution:

- 10. Place the binding reaction into the Dynal magnet and let sit for 1 min.
- 11. Remove the solution using a P1000 Pipetman and discard. Let the beads stand 15 sec to allow residual Binding Buffer to
- 20 collect and remove with a P200 Pipetman. Note that serial dilution depends upon all residual liquid being removed (i.e., 5 μ l into 500 is 100X washing; 50 μ l into 500 is only 10X).
- 12. Remove the tube from the magnet and resuspend the beads in 750 μ l of Wash Buffer and return to the magnet. Again let 25 the beads pellet by waiting 1 min.
 - 13. Remove the wash solution as in step 11 and repeat this process 3 more times.
 - 14. After the removal of the fourth wash, resuspend the beads and transfer them to a fresh, labeled tube and wash once more.
- 30 15. To elute bound phage add 400 μ l of Elution Buffer, titrate and rock for 14 min at RT.
 - 16. Place the tube on the magnet for one minute and transfer the eluate to a sterile 1.5 ml tube which contains 75 μ l of 1 M Tris pH 9.1. Vortex briefly.

35

PCT/US96/04229 WO 96/30849

Amplification of Round 1 Eluted Phag:

17. Plate all of the eluted round 1 phage by adding 157 µl of phage to 200 µl of overnight cells (previously checked to be free of contamination) in three aliquots. Incubate 25 min in

- 5 a 37°C water bath and then spread onto LB agar/antibiotics plate containing 2% glucose. Place plates upright in 37°C incubator until dry and then invert and incubate overnight.
 - 18. Scrape plates with 5 μ l of 2XYT/Antibiotics/Glucose and leave swirling for 30 min at RT.
- 10 19. Add the appropriate amount of 2XYT/Antibiotics/Glucose to bring the O.D. 600 down to 0.4 and then grow at 37°C at 250 rpm until the O.D. 600 reaches 0.8.
 - Remove 5 ml and add to it $1.25 \times 10^{10} \text{ M13}$ helper phage.
- Shake 30 min at 150 rpm and then 30 min at 250 rpm at 15 37°C.
 - 22. Centrifuge 10 min at 3000 X g at RT.
 - 23. Resuspend cells in 5 μ l 2XYT with no glucose. (This step removes glucose).
- Centrifuge as in step 22 and resuspend in 5 ml 2XYT with 20 kanamycin and the appropriate antibiotics (no glucose). Shake 18 hr at 37°C and 250 rpm.
 - 25. Pellet cells at 10,000 X g and sterile filter the phage containing supernatant which is now ready for round 2 screening.

25

- Binding; Specific Target/Phage Complexes Round 2, 3, & 4: 6a. Combine 1 μ g of biotinylated target protein with 100 μ l of the previous round's phage (>109 pfu) in 400 µl of Binding Buffer and rock overnight at 4°C.
- Remove unbound protein with a Microcon 100. Spin at 800 X g until exclusion volume is met and wash twice with Wash Buffer (again at 800 X g). Collect phage/protein with a Pipetman and add an addition 50 μ l of Wash Buffer to the Microcon, gently titrate and combine with the first fraction 35 to ensure maximal recovery.

8a. Prewash 20 μ l (per reaction) of streptavidin magnetic beads (M280 streptavidin Dynabeads) twice with 500 μ l of Washing Buffer using the Dynal magnet.

9a. Add the prewashed Dynabeads to the protein/phage fraction 5 and rock for 30 min. Add Binding Buffer to a total of 500 μ l. Ensure that the beads mix thoroughly with the phage/protein solution.

Washing and Elution:

30

- 10 10a. Place the binding reaction into the Dynal magnet and let sit for 1 min.
 - lla. Remove the solution and discard using a P1000 Pipetman. Let the beads stand 30 sec to allow residual Binding Buffer to collect and remove with a P200 Pipetman.
- 15 12a. Remove the tube from the magnet and resuspend the beads in 750 μl of Wash Buffer and return to the magnet. Again let the beads pellet by waiting 1 min.
 - 13a. Remove the wash solution as in Step 11a and repeat this process 3 more times.
- 20 14a. After the removal of the fourth wash resuspend the beads and transfer them to a fresh, labeled tube and wash 4 more times.
 - 15a. Elute and neutralize as in Step 15.
- 25 Amplification of Rounds 2, 3, & 4 Eluted Phage: 16a. Plate 10 μ l and 100 μ l of round 2,3,4 eluates and amplify as in Steps 17-25.

6.5. AFFINITY MEASUREMENTS OF PEPTIDE-TARGET PROTEIN INTERACTIONS

Once peptides that bind to a target protein have been identified, the affinities of these peptides to their respective targets are measured by measuring the dissociation constants (K_d) of each of these peptides to their respective targets. Oligonucleotides that encode the peptides are constructed so as to encode also an epitope tag fused to the peptide (for example, the myc epitope) that can be detected by

a commercially available antibody. These oligonucleotides are incubated with polysome extracts to produce the peptide tagged with the epitope. Binding of the target protein to the peptide is done in solution, and separation of the bound 5 peptide from the unbound peptide is done by immunoaffinity purification using an anti-target protein antibody. immunoaffinity purification is done by a modified ELISA (enzyme-linked immunosorbent assay) protocol, in which the target protein-peptide mixture is exposed to the anti-target 10 protein antibody immobilized on a solid support such as a nitrocellulose membrane, and the unbound peptide is then washed off. In this protocol, the concentration of the target protein is varied and then the amount of bound peptide is estimated by detecting the epitope tag on the peptide by use 15 of anti-epitope antibody. In this manner, the affinity of each peptide for its target protein can be determined.

6.6. REDOR MEASUREMENTS ON A CX C PEPTIDE RESIN

This example demonstrates successful synthesis and 20 cyclization of a CX₆C peptide resin of greater than 95% purity and with a labeled glycine followed by successful REDOR distance measurements on the CX₆C peptide resin using the preferred REDOR methods of this invention. The labeled peptide used was

25 Cys-Asn-Thr-Leu-Lys-(15N-2-13C)Gly-Asp-Cys-Gly-mBHA resin, where a glycine linker attached the peptide of interest to the nBHA resin. (Cys-Asn-Thr-Leu-Lys-Gly-Asp-Cys-Gly = SEQ ID NO:10)

The peptide resin was synthesized by solid phase synthesis on p-MethylBenzhydrilamine (mBHA) resin using a 30 combination of Boc and Fmoc chemistry. MethylBenzhydrilamine resin (Subst. 0.36 meq/g) was purchased from Advanced Chem Tech (Louisville, KY). Fmoc(15N-2-13C)Gly was prepared from HCl, (15N-2-13C)Gly (Isotec Inc., Miamisburg, OH) and Fmoc-OSu. Boc-Gly, (Trt), Fmoc-Asp(OtBu), Fmoc-Lys(Boc), Fmoc-Leu,

35 Fmoc-Thr(OtBu), Fmoc-Asn and Boc-Cys(Acm) were purchased from Bachem (Torrance, CA). Reagent grad solvents were purchased from Fisher Scientific, Diisopropylcarbodiimide (DIC),

Trifluoroacetic acid (TFA) and Diisopropylethylamine (DIEA) were purchased from Chem Impex (Wooddale, IL). Nitrogen, HF were purchased from Air Products (San Diego, CA).

The first step 43 was the synthesis of

- 5 Boc-Cys (ACM) -Asn-Thr (OtBu) -Leu-Lys (Boc) -Gly-Asp (OtBu) Cys (Trt) -Gly-mBHA resin. 1.11g (0.40 meq) of mBHA resin were placed in a 150 ml reaction vessel (glass filter at the bottom) with Methylene Chloride (CH₂Cl₂) ["DCM"] and stirred 15 min with a gentle bubbling of Nitrogen in order to swell the
- 10 resin. The solvent was drained and the resin was neutralized with DIEA 5% in DCM (3X2 min). After washes with DCM, the resin was coupled 60 min with Boc-Gly (0.280 g-1.6 meq-4 fold excess-0.1M) and DIC (0.25 ml-1.6 meq-4 fold excess-0.1M) in DCM. Completion of the coupling was checked with the
- 15 Ninhydrin test. After washes, the resin was stirred 30 min in TFA 55% in DCM in order to remove the Boc protecting group. The resin was then neutralized with DIEA 5% in DCM and coupled with Fmoc-Cys(Trt)(0.937g-1.6 meq-4 fold excess-0.1M) and DIC (0.25 ml-1.6 meq-4 fold excess-0.1M) in DCM/DMF (50/50).
- 20 After washes the resin was stirred with Piperidine 20% in DMF (5 min and 20 min) in order to remove the Fmoc group. After washes, this same cycle was repeated with Fmoc-Asp(OtBu), Fmoc(15N-2-13C)Gly (2 fold excess only), Fmoc-Lys(Boc), Fmoc-Leu, Fmoc-Thr(OtBu), Fmoc-Asn and Boc-Cys(Acm). After the
- 25 last coupling, the Boc group was left on the peptide. The resin was washed thoroughly with DCM and dried under a nitrogen stream. Yield was 1.49g (Expected: -1.7g).

The next step 44 was cyclization of the Boc-Cys-Asn-Thr(OtBu)-Leu-Lys(Boc)-Gly-Asp(OtBu)-Cys-Gly-mBHA 30 resin. 600 mg of protected peptide resin were sealed in a polypropylene mesh packet. The bag was shaken in a mixture of solvent (DCM/Methanol/Water-640/280/47) in order to swell the resin. The bag was then shaken 20 min in 100 ml of a solution of iodine in the same mixture of solvent (0.4 mg I₂/ml solvent 35 mixture). This operation was performed 4 times. No

d coloration was observed after the third time. The resin was

then thoroughly washed with DCM, DMF, DCM, and methanol successively.

The last step 45 was side-chain deprotection of the Cys-Asn-Thr-Leu-Lys-Gly-Asp-Cys-Gly-mBHA resin. After 5 cyclization the resin in the polypropylene bag was reacted 1.5 hour with 100 ml of a mixture TFA/p-Cresol-Water (95/2.5/2.5). After washes with DCM and Methanol, the resin was dried 48 hours under vacuum. Yield was 560 mg.

The resulting peptide resin was analyzed for its purity

10 and the presence of the disulfide bridge. 40 mg of resin were

sealed in a propylene mesh packet and treated with HF at 0 C

for 1 hour in presence of anisole (HF/Anisole: 90/10). The

scavenger and by-products were extracted from the resin with

cold ethyl ether. The peptide was extracted with 10% Acetic

15 Acid and lyophilized 36 hours. The dry isolated peptide was

characterized by PDMS (mass spectrography) and HPLC (high

performance liquid chromatography). This analysis

demonstrated that greater than 95% of the product peptide was

of the correct amino acid composition, having a disulfide loop

20 and without inter-molecular disulfide dimers.

REDOR measurements were made on the peptide resin prepared by this method, and as a control, also on dried (15N-2-13C) labeled glycine. The preferred REDOR methods and parameters, as previously detailed, were used. Fig. 6
25 illustrates the 15N resonance spectral signals obtained. Signal 70 is the signal produced by dried glycine after no rotor periods. Signals 71, 72, 73 are glycine signals after 2, 4, and 8 rotor periods, respectively. Signals 74, 75, 76, and 77 are the peptide resin signals after 0, 2, 4, and 8
30 rotor periods, respectively.

Fig. 7 illustrates the data analysis. As in Fig. 5, axis 81 is the $\Delta S/S$ axis, and axis 82 is the λ axis. The variables are as used in equation 5. Graph 83 is defined by equation 5, and is the initial rising part of the full curve shown in Fig.

35 5. Data points 84, 85, 86, and 87 are best fits of the data for 0, 2, 4, and 8 rotor periods, respectively. At these points, the circles represent the glycine values and the

squares the peptide resin values. These values correspond to a C-N distance in glycine and the peptide of 1.55 Å (and a $D_{\rm CK}$ of 800 Hz). Repeated measurements gave a C-N distance of 1.50 Å (and a $D_{\rm CK}$ of 875 Hz). The accepted distance in glycine 5 is 1.48 Å. The above procedure was repeated for ($^{15}N-1-^{13}C$) labeled glycine in Cys-Asn-Thr-Leu-Lys-($^{15}N-1-^{13}C$)Gly-Asp-Cys-Gly-mBHA resin, and

Cys-Asn-Thr-Leu-Lys-(15N-1-13C)Gly-Asp-Cys-Gly-mBHA resin, and the measured C-N distance of 2.50 Å is in excellent agreement with the predicted value of 2.46 Å.

Thus REDOR accuracy to better that 0.1 Å is demonstrated. Also demonstrated is the peptide resin as an appropriate substrate for NMR measurements. Inter-molecular dipole-dipole interactions between adjacent peptides did not interfere. Also the overlap of the distances measured in free glycine and 15 in glycine incorporated in the peptide demonstrated that the peptide was held sufficiently rigidly by the resin that any remaining peptide motions did not interfere with the NMR measurements.

7. SPECIFIC EMBODIMENTS, CITATION OF REFERENCES

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from 25 the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

30

35

8. COMPUTER PROGRAM LISTINGS

		These	computer	program	listings	are	copyright	1995	of
CuraG :	n,	Inc.	° 199	5 CuraGe	n, Inc.				

*****	***	*****	*****	******	*****	****	******	****	* *
					LISTING .				

*****	***	*****	******	*****	*******	***	******	****	***

*****	* * *	*****	******			***	******	*****	***
				C CODE R					

****	* * *	******	******	******	*****	****	******	****	***

****	***	*****					*****	*****	rww
				•	D GO PROC		******		
MAKEFI:	LE.								
		mips2 -	ansi -g ·	-fullwarn	-00				
			_			pepi	tide2.o pe	ptide:	3.0
peptid			zomec pop			F-E	•		
.			ide5.o pe	eptide6.o	peptide7	. 0			
c	c \$		_	-			eptide.ex		
random	.0:	random	1.C			_	_		
C	c \$	(OPTION	IS) -c rai	ndom.c					
peptid	e.o	: pepti	de.c *.h						
c	c \$	(OPTION	is) -c per	ptide.c					
peptid	el.	o: pept	idel.c *	.h					
c	c \$	(OPTION	IS) -c per	ptide1.c					
peptid	e2.	o: pept	ide2.c *	.h					
С	c \$	(OPTION	IS) -c per	ptide2.c					
peptid	e3 .	o: pept	ide3.c *	.h					
С	c \$	(OPTION	IS) -c pej	ptide3.c					
peptid	e4.	o: p pt	id 4.c *	.h					
C	c \$	(OPTION	IS) -c pe	ptide4.c					

```
peptide5.o: peptide5.c +.h
     cc $(OPTIONS) -c peptide5.c
peptide6.o: peptide6.c *.h
     cc $(OPTIONS) -c peptide6.c
peptide7.o: peptide7.c *.h
     cc $(OPTIONS) -c peptide7.c
GO PROC:
peptide.ex << EOF
0.1
CGGGGGGC
EOF
                    MAIN PROGRAM - PEPTIDE.C
#define MAIN
#include "peptide.h"
/* The main program stub */
void main(int argc, char *argv[], char *envp[])
 logical *cyclic;
 int n_peptides, max_atoms_per_unit;
 int *n_amino_acids, *n_atoms_total, *n_side, *n_main;
 rigid_unit **peptide;
 torsion_list **torsion;
 hbond_list **hbond;
 atom_list **atom, **atom2;
 atom_info **atom_tmp;
 vector *twig[KMAX];
 int ***bond_table;
 string *sequence;
 int i, j;
 int list_num, max_atoms_total;
 double seed;
 regrowth **main, **side;
 printf("Enter random number seed ");
```

```
scanf("%lf", &seed);
 ran2 (seed);
/* get linear sequences */
 get sequence(&sequence, &n_peptides);
 printf("\n");
/* allocate memory for arrays */
  if ((peptide = (rigid_unit **)
    malloc(n_peptides*sizeof(rigid_unit *))) == NULL)
    out of_memory();
  if ((torsion = (torsion list **)
    malloc(n_peptides*sizeof(torsion_list *))) == NULL)
    out_of_memory();
  if ((hbond = (hbond_list **) malloc(n_peptides*sizeof(hbond_list
*))) ==NULL)
    out of memory();
  if ((atom = (atom_list **) malloc(n_peptides*sizeof(atom_list
*))) == NULL)
    out of_memory();
  if ((atom2 = (atom_list **) malloc(n_peptides*sizeof(atom list
*))) == NULL)
    out of memory();
  if ((atom_tmp = (atom_info **) malloc(n_peptides*sizeof(atom_info
*)))
     == NULL) out_of_memory();
  if ((main = (regrowth **) malloc(n_peptides*sizeof(regrowth *)))
== NULL)
    out_of_memory();
  if ((side = (regrowth **) malloc(n_peptides*sizeof(regrowth *)))
== NULL)
    out of memory();
  if ((bond_table = (int ***) malloc(n_peptides*sizeof(int **)))
== NULL)
    out_of_memory();
  if ((n_amino_acids = (int *) malloc(n_peptides*sizeof(int))) ==
NULL)
    out of memory();
  if ((n_atoms_total = (int *) malloc(n_peptides*sizeof(int))) ==
NULL)
    out of memory();
```

```
if ((cyclic = (logical *) malloc(n_peptides*sizeof(logical))) ==
NULL)
    out of m mory();
  if ((n_main = (int *) malloc(n_peptides*sizeof(int))) == NULL)
    out of memory();
  if ((n side = (int *) malloc(n peptides*sizeof(int))) == NULL)
    out of memory();
  for(i=0; i<n peptides; i++) {</pre>
    n_amino_acids[i] = (int) strlen(sequence[i]);
/* read in parameter files */
  read_torsion_data();
  read_lj_data();
  read_hbond data();
  max_atoms_per_unit = 0;
/* read in geometric sequence information */
  max_atoms_total = 0;
  for (i=0; i<n_peptides; i++) {</pre>
    peptide(i) = read_peptide_data(sequence(i), &n_atoms_total(i),
                                 &max atoms per unit);
    cyclic[i] = (n_amino acids[i] > 1) && (sequence[i][0] == 'C')
&&
                (sequence[i] [n amino acids[i]-1] == 'C');
    if (cyclic[i]) peptide[i] = modify_cystine_ends(peptide[i],
                                    n_amino_acids[i],
                                    &n_atoms_total[i]);
    if
         (n_atoms_total[i] > max atoms total) max atoms total
n_atoms_total[i];
    n_{main}(i) = (cyclic[i]) ? 2*n amino acids[i] + 3 :
2*n_amino acids[i] + 1;
    n side[i] = n amino acids[i];
/* allocate sub arrays */
  for (i=0; i<KMAX; i++)
        if ((twig[i] = (vector
malloc(max_atoms_total*sizeof(vector)))
        == NULL) out_of_memory();
  for(i=0; i<n_peptides; i++) {</pre>
       if ((atom[i] = (atom list
```

```
malloc(n_atoms_total[i]*sizeof(atom_list)))
       == NULL) out_of_memory();
             ((atom2[i] = (atom_list *)
       i f
malloc(n_atoms_total[i]*sizeof(atom_list)))
       == NULL) out_of_memory();
       if ((atom_tmp[i]=(atom_info
                                                          * )
malloc(n_atoms_total[i]*sizeof(atom_info)))
       == NULL) out_of_memory();
    if ((main[i] = (regrowth *)
      malloc(n_main[i]*sizeof(regrowth))) == NULL)
      out_of_memory();
    if ((side[i] = (regrowth *)
      malloc(n_side[i]*sizeof(regrowth))) == NULL)
      out of memory();
              ((bond_table[i] = (int **)
       i f
malloc(n_atoms_total[i]*sizeof(int *)))
        == NULL) out_of_memory();
    for (j=0; j<n_atoms_total[i]; j++)</pre>
               ((bond_table[i][j] = (int
                                                           * )
         i f
malloc(MAX_BONDS*sizeof(int)))
        == NULL) out_of_memory();
  }
/* loop over all peptides */
  for (i=0; i<n_peptides; i++) {</pre>
    get_main_side(peptide[i], main[i], side[i], &n_main[i],
 &n_side[i]);
 /* determine connections */
    initialize_connection_table(bond_table[i], n_atoms_total[i]);
    list_num = 0;
    make_connection_table(bond_table[i], &list_num, peptide[i],
 peptide[i]);
    /*print_connection_table(bond_table[i], n_atoms_total[i]);*/
     list_num = 0;
 /* assign noncoordinate information in atom array */
     assign_atom_pointers(&list_num, peptide[i], peptide[i],
 atom[i]):
 /* g t H-bonds and torsion lists */
     get_hbonds(&hbond[i], atom[i], n_atoms_total[i]);
     /*print_hbonds(hbond[i], atom[i]);*/
```

```
list num = 0;
    torsion(i) = NULL;
    get torsions(&torsion[i], bond_table[i], &list_num, atom[i],
p ptide(i),
                peptide[i]);
    assign_lj_parameters(peptide[i], peptide[i]);
/* copy noncoordinate information in atom to atom2 */
    for (j=0; j<n atoms_total[i]; j++) atom2[i][j] = atom[i][j];
  }
/* do the Monte Carlo */
  do mc(peptide[0], torsion[0], hbond[0], atom[0], atom2[0],
atom_tmp[0],
        twig, main[0], side[0], n_amino_acids[0],
        n_atoms_total[0], n_main[0], n_side[0], cyclic[0]);
  /*print torsions(torsion[0], atom[0]);*/
  "test.car");
#undef MAIN
               INPUT/OUTPUT ROUTINES - PEPTIDE1.C
              /* input/output routines */
#include "peptide.h"
/* hardcoded AMBER rules have the keyword AMBER nearby
*/
#define NT_CT_DISTANCE 1.4750
#define S_S_DISTANCE 2.0380
#define P CHARGE 0.048
#define C CHARGE1 -0.098
#define C_CHARGE2 0.050
#define C CHARGE3 0.050
#define C_CHARGE4 0.824
#define C CHARGE5 -0.405
#define C CHARGE6 -0.405
/* This function is called when out of memory
*/
```

```
void out of_memory(void)
{
 printf("Out of memory error\n");
 exit(1);
/* This routine returns the 1-letter amino acide sequences
*/
void get_sequence(string **sequence, int *n_peptides)
#define SEQUENCE LENGTH 80
 int i:
 printf("Enter number of peptides: ");
 scanf("%d", n_peptides);
  if ((*sequence = (string *) malloc(*n_peptides*sizeof(string)))
== NULL)
    out_of_memory();
  for (i=0; i<*n_peptides; i++)
            (((*sequence)[i] = (string)
malloc(SEQUENCE_LENGTH*sizeof(char)))
         == NULL) out_of_memory();
  for (i=0; i<*n_peptides; i++) {</pre>
    printf("Enter peptide sequence %d: ",i);
    scanf("%s", (*sequence)[i]);
  }
#undef SEQUENCE LENGTH
/* read in the data files associated with this sequence
*/
rigid_unit *read_peptide_data(string sequence, int *n_atoms_total,
                              int *max atoms per unit)
{
  int i, n_amino_acids;
  char name[]="?.dat";
  acid label label;
  rigid unit *u1, *u2, *ret;
/* check amino acids in sequence */
  n amino acids = strlen(sequence);
  for(i=0; i<n amino_acids; i++) {</pre>
```

```
label = amino acid code(sequence[i]);
    if (label == BAD) {
      printf("Invalid amino acid code %c\n", sequence[i]);
      exit(1);
    if (label == P) {
      printf("Proline not yet supported\n");
      exit(1);
    }
  }
  *n atoms total = 0;
/* add unit A */
  label = amino_acid_code(sequence[0]);
  u1 = read_unit("unitA.dat", label, 0, n_atoms total,
max atoms per unit);
  ret = u1;
  for(i=0; i<n_amino_acids; i++) {</pre>
    name[0] = sequence[i];
    label = amino_acid_code(sequence(i));
/* add unit B */
    u2 = read_unit("unitB.dat", label, i, n_atoms_total,
max_atoms_per unit);
    u2->type = nonCunit;
/* follow IUPAC naming rules if glycine */
    if (label == G) strcpy(u2->atom[1].name, "HA1");
/* follow AMBER charge rules if alanine or proline */
    if (label == A | | label == P) u2->atom[1].charge = P_CHARGE;
    if
         (i==0) u2->head.axis = vector_scale(u2->head.axis,
NT_CT_DISTANCE);
    couple_unit(u1,u2);
   u1 = u2;
/* add residue */
              read_unit(name, label, i, n_atoms_total,
         =
max_atoms_per unit);
    couple_unit(u1, u2);
/* add unit C or D */
        = read_unit((i==n_amino_acids-1) ? "unitD.dat" :
"unitC.dat",
      label, i, n_atoms_total, max_atoms_per unit);
```

```
if (i < n amino_acids-1) {
/* align incoming and outgoing bonds */
      u2->bond[0]->tail.axis = vector_scale(u2->head.axis, 1.0);
      u2->type = Cunit;
      label = amino acid_code(sequence[i+1]);
      u2->atom[2].residue = u2->atom[3].residue = label;
      u2->atom[2].residue_num = u2->atom[3].residue_num = i+1;
    couple unit(u1, u2);
   u1 = u2;
  return(ret);
/* This routine reads in a rigid unit data file
*/
rigid_unit *read_unit(string file, acid_label
                                                               int
                                                      label,
residue num,
                      int *n atoms total, int *max_atoms_per_unit)
#define LINE_LEN 200
  FILE *fp;
  int i, j, k, i1, n_rigid_units;
  char stmp1 (NAME_LENGTH) , stmp2 (NAME_LENGTH) , line [LINE_LEN] ;
  rigid unit **utmp;
  if ((fp = fopen(file, "r")) == NULL) {
    printf("Data file %s does not exist\n", file);
    exit(1);
  }
/* read in number of rigid units */
  getline(line, LINE_LEN, fp);
  sscanf(line, "%d", &n_rigid_units);
/* printf("%d\n",n_rigid_units); */
  if ((utmp = (rigid_unit **)
     malloc(n_rigid_units*sizeof(rigid_unit *))) == NULL)
     out of memory();
/* allocate rigid unit */
  for (i=0; i<n_rigid_units; i++) {
    if ((utmp[i] = (rigid_unit *)
       malloc(sizeof(rigid_unit))) == NULL) out_of_memory();
```

```
utmp[i]->type = UNKNOWN;
    getline(line,LINE_LEN,fp);
    sscanf(line, "%d", &utmp[i]->n_atoms);
    *n atoms_total += utmp[i]->n_atoms;
    if (utmp[i]->n atoms > *max_atoms_per_unit)
      *max atoms per_unit = utmp[i]->n_atoms;
/*
      printf("%d\n", utmp[i] ->n atoms); */
    if ((utmp[i]->atom = (atom info *)
       malloc(utmp[i]->n atoms*sizeof(atom info))) == NULL)
       out of memory();
/* read in atoms */
    for(j=0; j<utmp(i)->n_atoms; <math>j++) {
      getline(line, LINE LEN, fp);
      sscanf(line, "%s %lf %lf %lf %s %d %s %s %lf",
             utmp[i]->atom[j].name,
             &utmp[i]->atom[j].position.x,
             &utmp[i]->atom[j].position.y,
             &utmp[i]->atom[j].position.z,
             &stmpl, &il,
             utmp[i]->atom[j].type, &stmp2,
             &utmp[i]->atom[j].charge);
/*
        printf("%s %lf %lf %lf %s %lf\n",
             utmp[i]->atom[j].name,
             utmp[i]->atom[j].position.x,
             utmp[i]->atom[j].position.y,
             utmp[i]->atom[j].position.z,
             utmp[i]->atom[j].type,
             utmp[i]->atom[j].charge); */
      utmp[i]->atom[j].residue = label;
      utmp[i]->atom[j].residue_num = residue_num;
    }
  }
  for (i=0; i<n rigid units; i++) {
/* allocate incoming bond vector information */
    getline(line, LINE LEN, fp);
    sscanf(line, "%d %d %d %d", &i1, &utmp[i]->head.bond[0],
         &utmp[i]->head.bond[1], &utmp[i]->head.bond[2],
         &utmp[i]->head.bond[3]);
     printf("%d %d %d %d %d\n",i1, utmp[i]->h ad.bond[0],
/*
```

```
utmp[i]->head.bond[1], utmp[i]->head.bond[2],
           utmp[i]->head.bond[3]); */
     for (j=4; j<MAX_BONDS; j++) utmp[i]->head.bond[j] = -1;
    utmp[i]->head.atom num = i1;
    getline(line,LINE_LEN,fp);
    sscanf(line, "%lf %lf %lf", &utmp[i]->head.axis.x,
                              &utmp[i]->head.axis.v.
                              &utmp[i]->head.axis.z);
/*
      printf("%lf %lf %lf\n",utmp[i]->head.axis.x,
                              utmp[i]->head.axis.v.
                              utmp[i]->head.axis.z); */
utmp[i]->head.axis.x=utmp[i]->atom[i1].position.x-utmp[i]->head.
axis.x;
utmp[i]->head.axis.y=utmp[i]->atom[i1].position.y-utmp[i]->head.
axis.y;
utmp[i]->head.axis.z=utmp[i]->atom[i1].position.z-utmp[i]->head.
axis.z;
/* allocate outgoing bond pointers */
    getline(line, LINE LEN, fp);
    sscanf(line, "%d", &utmp[i]->n bonds);
    if ((utmp[i]->bond = (bond type **)
       malloc(utmp[i]->n_bonds*sizeof(bond_type *))) == NULL)
       out_of_memory();
    for (j=0; j<utmp[i]->n_bonds; j++) {
      if ((utmp[i]->bond[j] = (bond_type *)
         malloc(sizeof(bond_type))) == NULL)
         out_of_memory();
      getline(line,LINE_LEN,fp);
      sscanf(line, "%d", &i1);
/*
        printf("%d\n",i1); */
      utmp[i]->bond[j]->next = (i1==-1) ? NULL : utmp[i1];
      getline(line,LINE_LEN,fp);
       sscanf(line,
                          " fd
                                ₹đ
                                       % d
                                             % d
                                                    łd",
                                                             &i1,
&utmp[i]->bond[j]->tail.bond[0],
                               &utmp[i]->bond[j]->tail.bond[1],
                               &utmp[i]->bond[j]->tail.bond[2],
```

```
&utmp[i]->bond[j]->tail.bond[3]);
  /*
                       printf("%d
                                    *d
                                         ∤d
                                              *d
                                                    %d\n",
                                                             i1,
 utmp[i]->bond[j]->tail.bond[0],
                               utmp[i]->bond[j]->tail.bond[1],
                               utmp[i]->bond[j]->tail.bond[2],
                               utmp[i]->bond[j]->tail.bond[3]);*/
       for (k=4; k<MAX_BONDS; k++) utmp[i]->bond[j]->tail.bond[k]
 = -1;
       utmp[i]->bond[j]->tail.atom_num= i1;
       getline(line,LINE_LEN,fp);
       sscanf(line, "%lf %lf %lf", &utmp[i]->bond[j]->tail.axis.x,
                               &utmp[i]->bond[j]->tail.axis.y,
                               &utmp[i]->bond[j]->tail.axis.z);
          utmp[i]->bond[j]->tail.axis.x
 utmp[i]->atom[i1].position.x;
          utmp[i]->bond[j]->tail.axis.y
 utmp[i]->atom[i1].position.y;
          utmp[i]->bond[j]->tail.axis.z
 utmp[i]->atom[i1].position.z;
      utmp[i]->bond[j]->tail.axis =
               vector_scale(utmp[i]->bond[j]->tail.axis,1.0);
    }
  }
  fclose(fp);
  return(utmp[0]);
#undef LINE LEN
}
/* This routine couples two rigid units
*/
void couple_unit(rigid_unit *unit1, rigid_unit *unit2)
  bond_type **bond;
  for(bond=unit1->bond; bond[0]->next; bond++);
 bond[0]->next = unit2;
/* This routine turns a linear CX_nC peptide into a cyclic
   disulfide-bonded peptide
*/
            *modify_cystine_ends(rigid_unit *unit,
rigid_unit
                                                           int
```

```
n amino acids,
                                 int *n_atoms_total)
  int i:
  rigid_unit *unit1, *unit2, *unit3, *unit4, *unit5, *unit6;
  double len:
  vector head1, head2;
  bond type *btmp;
/* get new first unit */
  unit1 = unit->bond[0]->next;
  unit2 = unit1->bond[0]->next;
  unit3 = unit2->bond[0]->next;
/* save head vectors */
  head1 = unit1->head.axis;
  head2 = unit2->head.axis;
/* modify A unit to be a side group */
  len = vector length(unit1->head.axis);
  unit->head = unit->bond[0]->tail;
  unit->head.axis.x *= -len;
  unit->head.axis.y *= -len;
  unit->head.axis.z *= -len;
  unit->n bonds = 0;
/* modify C_alpha head */
   len = vector_length(unit2->head.axis);
   unit1->head = unit1->bond[0]->tail;
   unit1->head.axis.x *= -len;
   unit1->head.axis.y *= -len;
   unit1->head.axis.z *= -len;
/* modify C beta head */
   len = vector_length(unit3->head.axis);
  unit2->head = unit2->bond[0]->tail;
  unit2->head.axis.x *= -len;
  unit2->head.axis.y *= -len;
  unit2->head.axis.z *= -len;
/* modify S tail */
  unit3->bond = unit->bond;
  unit3->head.bond[2] = -1;
  unit3->bond[0]->tail = unit3->head;
  unit3->bond[0]->tail.axis = vector_scale(unit3->head.axis,
```

```
-1.0);
    unit3->bond[0]->next = unit2;
    unit3->n bonds = 1;
    unit3->n_atoms--;
    (*n_atoms total) --;
 /* modify S head */
   unit3->head.axis = unit3->atom[0].position;
    unit3->head.axis.x -= unit3->atom[3].position.x;
   unit3->head.axis.y -= unit3->atom[3].position.y;
   unit3->head.axis.z -= unit3->atom[3].position.z;
/* modify C_beta tail */
   unit2->bond[0]->tail.axis = vector_scale(head2, -1.0);
   unit2->bond[0]->next = unit1;
/* modify C_alpha tail */
   unit1->bond[0]->tail.axis = vector_scale(head1, -1.0);
   unit1->bond[0]->next = unit;
   unit4 = unit1:
/* find last B unit */
  for (i=1; i<n_amino_acids; i++) {</pre>
    unit4 = unit4->bond[unit4->n_bonds-1]->next;
    unit4 = unit4->bond[unit4->n_bonds-1]->next;
  }
  unit5 = unit4->bond[0]->next;
  unit6 = unit5->bond[0]->next;
/* swap bond 0 and bond1 for unit 4*/
  btmp = unit4->bond[0];
  unit4->bond[0] = unit4->bond[1];
  unit4->bond[1] = btmp;
/* modify S tail */
   if ((unit6->bond = (bond_type **) malloc(sizeof(bond_type *)))
== NULL)
      out_of_memory();
   if ((unit6->bond[0] = (bond_type *) malloc(sizeof(bond_type)))
== NULL)
      out_of_memory();
  unit6->head.bond[2] = -1;
  unit6->bond[0]->tail = unit6->h ad;
  unit6->bond[0]->next = unit3;
  unit6->n_bonds = 1;
```

```
unit6->n_atoms--;
   (*n_atoms_total)--;
   unit6->bond[0]->tail.axis = unit6->atom[3].position;
   unit6->bond[0]->tail.axis.x -= unit6->atom[0].position.x;
   unit6->bond[0]->tail.axis.y -= unit6->atom[0].position.y;
   unit6->bond[0]->tail.axis.z -= unit6->atom[0].position.z;
      unit6->bond[0]->tail.axis
vector scale(unit6->bond[0]->tail.axis, 1.0);
/* use AMBER S-S bond length */
   unit3->head.axis = vector scale(unit3->head.axis, S S DISTANCE);
/* modify cystine S types to obey AMBER rules */
   strcpy(unit3->atom[0].type, "S");
   strcpy(unit6->atom[0].type, "S");
/* modify cystine charges to obey AMBER rules */
   unit2->atom[0].charge = C_CHARGE1;
   unit2->atom[1].charge = C_CHARGE2;
   unit2->atom[2].charge = C_CHARGE3;
   unit3->atom[0].charge = C_CHARGE4;
   unit3->atom[1].charge = C_CHARGE5;
   unit3->atom[2].charge = C CHARGE6;
   unit5->atom[0].charge = C_CHARGE1;
   unit5->atom[1].charge = C CHARGE2;
   unit5->atom[2].charge = C CHARGE3;
   unit6->atom[0].charge = C_CHARGE4;
   unit6->atom[1].charge = C CHARGE5;
   unit6->atom[2].charge = C_CHARGE6;
/* reassign first unit */
  return(unit3);
/* This routine determines the main and side unit pointers
*/
void get_main_side(rigid_unit *unit, regrowth *main, regrowth
*side,
                   int *n_main, int *n side)
 rigid unit *start, *unit2, *lastmain;
  regrowth *main0;
 int i:
 main0 = main;
```

```
*n_side = 0;
   *n_main = 0;
   start = unit;
   lastmain = NULL;
   do {
     main->unit = unit;
     main->prev = lastmain;
     main++;
     (*n_main)++;
     for (i=0; i<unit->n_bonds-1; i++) {
       unit2 = unit->bond[i]->next;
       if (unit2->atom[0].residue != G) {
         side->unit = unit2;
         side->prev = unit;
         side++;
        ·(*n_side)++;
       }
     }
     lastmain = unit;
    unit = unit->bond(i)->next;
  } while (start != unit && unit->n_bonds > 0);
  if (unit->n_bonds == 0) {
    main->unit = unit;
    main->prev = lastmain;
    main++;
    (*n_main)++;
  } else {
    main0->prev = lastmain;
  }
/* This routine reads in the torsion data file
*/
void read_torsion_data(void)
#define LINE_LEN 200
 FILE *fp;
 char line[LINE_LEN];
 int n_torsions, itmp, i;
 double ftmp;
```

{

```
torsion data **data;
  if ((fp = fopen("torsion.dat", "r")) == NULL) {
    printf("Data file torsion.dat does not exist\n");
    exit(1);
  }
  getline(line, LINE_LEN, fp);
  sscanf(line, "%d", &n_torsions);
  if ((torsion_data_list = (torsion_data **)
     malloc((n_torsions+1)*sizeof(torsion data *))) ==
                                                             NULL)
out_of_memory();
  data = torsion_data list;
  data[n torsions] = NULL;
  for (i=0; i<n torsions; i++) {</pre>
    if ((data[i] = (torsion_data *) malloc(sizeof(torsion_data)))
== NULL)
      out_of_memory();
    getline(line, LINE_LEN, fp);
    sscanf(line, "%lf %d %s %s %s %s %lf %lf %lf %lf %lf %lf",
          &ftmp, &itmp, data[i]->type1,
           data[i]->type2, data[i]->type3, data[i]->type4,
           &data[i]->v0[0], &data[i]->phi0[0],
           &data[i]->v0[1], &data[i]->phi0[1],
           &data[i]->v0[2], &data[i]->phi0[2]);
    data[i]->phi0[0] *= PI/180.0;
    data[i]->phi0[1] *= PI/180.0;
    data[i]->phi0[2] *= PI/180.0;
  }
  fclose(fp);
#undef LINE LEN
/* This routine reads in the Lennard-Jones data file
*/
void read lj data(void)
#define LINE LEN 200
  FILE *fp;
  char line[LINE_LEN];
  int n terms, itmp, i;
  double ftmp;
```

```
lj data **data;
  if ((fp = fopen("lj_param.dat", "r")) == NULL) {
   printf("Data file lj_param.dat does not exist\n");
   exit(1);
  }
  getline(line, LINE_LEN, fp);
  sscanf(line, "%d", &n_terms);
                                                           * * )
   if ((lj_data_list = (lj_data
malloc((n_terms+1)*sizeof(lj_data *)))
       == NULL) out_of_memory();
  data = lj data list;
  data[n_terms] = NULL;
  for (i=0; i<n_terms; i++) {
    if ((data[i] = (lj_data *) malloc(sizeof(lj_data))) == NULL)
      out of memory();
   getline(line, LINE_LEN, fp);
   sscanf(line, "%lf %d %s %lf %lf", &ftmp, &itmp, data[i]->type,
                   &data[i]->ri, &data[i]->ei);
  }
  fclose(fp);
#undef LINE_LEN
/* This routine reads in the H-bond data file
*/
void read hbond data (void)
#define LINE_LEN 200
  FILE *fp;
  char line[LINE_LEN];
  int n_terms, itmp, i;
 double ftmp;
 hbond data **data;
  if ((fp = fopen("hbond.dat", "r")) == NULL) {
   printf("Data file hbond.dat does not exist\n");
   exit(1);
 getline(line, LINE_LEN, fp);
  sscanf(line, "%d", &n terms);
  if ((hbond_data_list = (hbond_data **)
```

```
malloc((n_terms+1)*sizeof(hbond_data
                                               *)))
                                                             NULL)
                                                       ==
out_of memory();
  data = hbond_data_list;
  data[n_terms] = NULL;
  for (i=0; i<n_terms; i++) {
    if ((data[i] = (hbond_data *) malloc(sizeof(hbond_data))) ==
NULL)
      out of memory();
    getline(line, LINE_LEN, fp);
    sscanf(line, "llf ld ls ls lf lf",
       &ftmp, &itmp, data[i]->typel,
       data[i]->type2, &data[i]->a, &data[i]->b);
  fclose(fp);
#undef LINE LEN
/* write out the BIOSYM car files associated with this sequence
*/
void write car file(int n amino acids, int n_atoms_total, atom_list
*atom,
                    string file)
{
  int i;
  char name[NAME_LENGTH];
  FILE *fp;
  time t t;
  if ((fp = fopen(file, "w")) == NULL) {
    printf("Cannot open car file %s\n", file);
    exit(1);
  fprintf(fp, "!BIOSYM archive 3\n");
  fprintf(fp, "PBC=OFF\n\n");
  t = time(NULL);
  fprintf(fp, "!DATE %s", ctime(&t));
  for (i=0; i<n atoms_total; i++) {</pre>
    amino_acid_code_3(atom[i].p->residue, name);
    capitaliz (name);
    if (atom[i].p->residue_num == n_amino_acids-1)
      strcat(name, "N");
```

```
else if (atom[i].p->residue_num == 0)
      strcat(name, "n");
    else if (atom[i].p->residue == C)
      strcat(name, "H");
    fprintf(fp, "%-5s%15.9f%15.9f%15.9f %-4s %-3d %-2s
%2c%8.3f\n",
        atom[i].p->name,
       atom[i].position.x, atom[i].position.y,
        atom(i).position.z, name, atom(i).p->residue num+1,
atom(i).p->type,
        atom[i].p->type[0], atom[i].p->charge);
  fprintf(fp, "end\nend\n");
  fclose(fp);
/* this routine returns the next valid line from the file
string getline(string line, int len, FILE *fp)
{
  string ret;
  do {
    ret=fgets(line,len,fp);
    strip(line);
  } while (ret != NULL && *line=='\x0') ;
  return(ret);
/* strip CR and LF from the end of a string
   also ignore everything to the right of !
*/
void strip(string string)
  for (; *string != '\x0' && *string != '\xA' && *string != '\xD'
         && *string != '!'; string++)
   *string = ' \times 0';
}
/* remove commas from string, replacing with spac s
*/
void decomma(string string)
```

```
for (; *string != '\0'; string++)
    if (*string == ',') *string = ' ';
}
/* This function capitalizes a string
*/
void capitalize(string s)
  int o;
  o = 'a' - 'A';
  for (; *s; s++) if (*s >= 'a' && *s <= 'z') *s -= 0;
/* This function returns the 3-letter code for the amino acid
*/
void amino_acid_code_3(acid_label label, string code 3)
  switch (label) {
    case G: strcpy(code_3, "Gly"); break;
   case A: strcpy(code_3, "Ala"); break;
   case V: strcpy(code_3, "Val"); break;
   case L: strcpy(code_3, "Leu"); break;
   case I: strcpy(code_3, "Ile"); break;
   case S: strcpy(code_3, "Ser"); break;
   case T: strcpy(code_3, "Thr"); break;
   case D: strcpy(code_3, "Asp"); break;
   case E: strcpy(code_3, "Glu"); break;
   case N: strcpy(code_3, "Asn"); break;
   case Q: strcpy(code_3, "Gln"); break;
   case K: strcpy(code_3, "Lys"); break;
   case H: strcpy(code_3, "His"); break;
   case R: strcpy(code_3, "Arg"); break;
   case F: strcpy(code_3, "Phe"); break;
   case Y: strcpy(code 3, "Tyr"); break;
   case W: strcpy(code_3, "Trp"); break;
   case C: strcpy(code 3, "Cys"); break;
   case M: strcpy(code_3, "Met"); break;
   case P: strcpy(code_3, "Pro"); break;
   default : strcpy(code 3, "???");
 }
```

```
}
/* This function returns the 1-letter code for the amino acid
*/
void amino_acid_cod _1(acid_label label, char code_1)
{
  switch (label) {
    case G: code_1 = 'G'; break;
    case A: code_1 = 'A'; break;
    case V: code_1 = 'V'; break;
    case L: code_1 = 'L'; break;
    case I: code 1 = 'I'; break;
    case S: code_1 = 'S'; break;
    case T: code 1 = 'T'; break;
    case D: code 1 = 'D'; break;
    case E: code 1 = 'E'; break;
    case N: code_1 = 'N'; break;
    case Q: code_1 = 'Q'; break;
    case K: code 1 = 'K'; break;
    case H: code 1 = 'H'; break;
    case R: code 1 = 'R'; break;
    case F: code 1 = 'F'; break;
    case Y: code_1 = 'Y'; break;
    case W: code_1 = 'W'; break;
    case C: code_1 = 'C'; break;
    case M: code 1 = 'M'; break;
    case P: code_1 = 'P'; break;
   default : code 1 = '?';
 }
/* This function returns the acid label from the 1-letter amino
acid code
*/
acid_label amino_acid_code(char code_1)
 acid label ret;
 switch (code_1) {
   case 'G': ret = G; break;
   case 'A': ret = A; break;
   case 'V': ret = V; break;
```

```
case 'L': ret = L; break;
   case 'I': ret = I; break;
   case 'S': ret = S; break;
   case 'T': ret = T; break;
   case 'D': ret = D; break;
   case 'E': ret = E; break;
   case 'N': ret = N; break;
   case 'Q': ret = Q; break;
   case 'K': ret = K; break;
   case 'H': ret = H; break;
   case 'R': ret = R; break;
   case 'F': ret = F; break;
   case 'Y': ret = Y; break;
   case 'W': ret = W; break;
   case 'C': ret = C; break;
    case 'M': ret = M; break;
    case 'P': ret = P; break;
    default : ret = BAD;
  }
 return(ret);
}
            MOLECULAR TOPOLOGY CREATION - PEPTIDE2.C
                         The topology creation routines
/±
*/
#include "peptide.h"
/* This routine initializes the bond connection table
*/
                                            **bond table, int
        initialize_connection_table(int
void
n atoms total)
  int i,j;
  for(i=0; i<n_atoms_total; i++)</pre>
    for(j=0; j<MAX_BONDS; j++)</pre>
      bond table[i][j] = -1;
}
```

```
/* This routine creates a connection table
*/
void make_connection_table(int **bond_table, int *table num,
                            rigid unit *unit, rigid unit *start)
(
  int i, *j, i1, save[MAX_BONDS];
  i1 = unit->head.atom_num + *table_num;
  for (j=unit->head.bond; *j != -1; j++) {
    add_connection(bond_table, i1, *j+*table_num);
    add_connection(bond_table, *j+*table num, i1);
  for (i=0; i<unit->n_bonds; i++) {
    i1 = unit->bond[i]->tail.atom_num + *table_num;
    for (j=unit->bond[i]->tail.bond; *j != -1; j++) {
      add_connection(bond_table, il, *j+*table_num);
      add_connection(bond_table, *j+*table num, i1);
    }
    save[i] = unit->bond[i]->tail.atom_num + *table_num;
  *table_num += unit->n atoms;
  for (i=0; i<unit->n_bonds; i++) {
    il = unit->bond[i]->next->head.atom_num;
    if (unit->bond[i]->next != start) i1 += *table_num;
    add_connection(bond_table, save[i], i1);
    add_connection(bond_table, i1, save[i]);
    if (unit->bond[i]->next != start)
       make_connection_table(bond_table, table_num,
unit->bond[i]->next, start);
 }
/* This routine adds a connection to the connection table
*/
void add_connection(int **bond_table, int i1, int i2)
  int *i, *j;
 for (i=bond_table[i1]; *i != -1; i++);
 for (j=bond_table[i1]; j<i; j++) if (*j == i2) return;</pre>
 *i = i2;
}
```

```
/* This routine prints out the connection table
void print connection table(int **bond_table, int n atoms total)
 int i, j;
 for (i=0; i<n_atoms_total; i++) {
                    ",i);
   printf("\5d
   for (j=0; j<MAX_BONDS; j++) printf("%5d ", bond_table[i][j]);</pre>
   printf("\n");
  }
/* This routine determines the torsional terms
  p is set the head pointer and it returns the tail pointer
* /
      get_torsions(torsion_list **p,
                                         int
                                               **bond table,
                                                               int
*table num,
                  atom_list *atom, rigid_unit *unit, rigid_unit
*start)
 int i, save[MAX_BONDS];
 static torsion list *q;
 static int i2, *j, *k;
 rigid unit *new unit;
 if (!*p) q = NULL;
 for (i=0; i<unit->n bonds; i++)
    save[i] = unit->bond[i]->tail.atom_num + *table num;
 *table num += unit->n atoms;
 for (i=0; i<unit->n_bonds; i++) {
   new unit = unit->bond[i]->next;
    i2 = new unit->head.atom_num;
    if (new unit != start) i2 += *table_num;
   for (j=bond table[save[i]]; *j != -1; j++)
      for (k=bond_table[i2]; *k != -1; k++)
        if (*j != i2 && save[i] != *k)
          if (!*p)
            *p = q = add torsion(bond table, atom, *j, save[i], i2,
*k);
          else
            if (q->next = add_t rsion(bond_tabl , atom, *j,
```

```
save[i], i2, *k))
              q = q->next;
    if (new_unit != start)
       get_torsions(p, bond_table, table_num, atom, new_unit,
start);
  }
/* This routine adds a torsion to the torsion list
   Wildcards on i and 1 (simultaneously) are allowed for
*/
torsion_list *add_torsion(int **bond_table, atom_list *atom, int
i, int j,
                          int k, int 1)
  torsion_list t, *v;
  char wild[]="*";
  int degen, itmp;
/* count degeneracy for "general" torsions--don't count the torsion
axis! */
/* "specific" torsions have a degeneracy of 1, "general" have a
degeneracy
    of degen */
  for (itmp=0; bond_table[j][itmp] != -1; itmp++);
  for (degen=0; bond_table[k][degen] != -1; degen++);
  itmp--;
  degen--;
  degen *= itmp;
  t.degen = 1;
/* printf("%s %s %s %s %d\n",
                          atom[i].p->name, atom[j].p->name,
atom[k].p->name,
                        atom[1].p->name, degen); */
  t.next = NULL;
 t.num[0] = i;
 t.num[1] = j;
 t.num[2] = k;
 t.num[3] = 1;
/* "specific" torsions */
       (!lookup_torsion_data(atom[i].p->type, atom[j].p->type,
 if
```

```
atom[k].p->type,
                        atom[1].p->type, &t.p)) {
/* "general" torsions */
         (!lookup_torsion_data(wild, atom[j].p->type,
atom[k].p->type,
                           wild, & t.p)) {
         printf("Torsional data not found for %s %s %s %s\n",
                     atom[i].p->type, atom[j].p->type,
atom[k].p->type,
                 atom(1).p->type);
         return (NULL);
   t.degen = degen;
    }
/* only report nonzero torsional terms--this will screw up the 1/2
factor
   for AMBER! */
     if (t.p->v0[0]==0 && t.p->v0[1]==0 && t.p->v0[2]==0)
return(NULL); */
  if ((v = (torsion_list *)
   malloc(sizeof(torsion_list))) == NULL) out_of_memory();
  *v = t;
  return(v);
}
/* This routine looks up the parameters for a torsional term in the
   torsion data base
*/
logical lookup_torsion_data(string type1, string type2, string
type3,
                           string type4, torsion_data **p)
{
  torsion data **1;
  for (l=torsion_data_list; *1; l++) {
    if (strcmp((*1)->type1, type1)==0 && strcmp((*1)->typ 2,
type2) == 0 \&\&
             strcmp((*1)->type3,type3)==0 &&
strcmp((*1)->type4,typ 4)==0)
       goto don ;
    if (strcmp((*1)->type1, typ 4)==0 \&\& strcmp((*1)->type2,
```

```
type3) == 0 &&
                                           strcmp((*1)->type3,type2)==0
                                                                                                                                                                                                        & &
  strcmp((*1)->type4,type1) ==0)
                        goto done;
        return (FALSE);
 done: ;
       *p = *1;
       return (TRUE);
 /* This routine prints out the torsion terms
 void print_torsions(torsion_list *list, atom_list *atom)
       torsion list *t;
       double theta;
       for (t=list; t; t=t->next)
                      theta
                                                                       torsion(atom[t->num[0]].position,
 atom[t->num[1]].position,
                                                                                                 atom[t->num[2]].position,
 atom[t->num[3]].position);
                printf("%4-s %4-s %4-s %4-s",atom[t->num[0]].p->name,
                                                                                                    atom[t->num[1]].p->name,
                                                                                                    atom[t->num[2]].p->name,
                                                                                                    atom[t->num[3]].p->name);
 /*
                                    printf("%4-d %4-d %4-d",t->num[0], t->num[1],
 t->num[2],
                                                                                                          t->num[3]); */
                printf("%4d ",t->degen);
                printf("%9.31f %7.31f %
                                       180.0*theta/PI,
                                       t \rightarrow p \rightarrow v0[0], t \rightarrow p \rightarrow v0[1], t \rightarrow p \rightarrow v0[2],
                                       180.0*t->p->phi0[0]/PI, 180.0*t->p->phi0[1]/PI,
                                       180.0*t->p->phi0[2]/PI);
      }
/* This routine determines the torsional angle (in radians) defined
by the
```

```
input positions--bonded in the order p1-p2-p3-p4
* /
double torsion(vector p1, vector p2, vector p3, vector p4)
 vector b1, b2, b3, n1, n2;
 double dot, len, theta;
/* define bond vectors */
 b3.x = p1.x - p2.x; b3.y = p1.y - p2.y; b3.z = p1.z - p2.z;
 b2.x = p3.x - p2.x; b2.y = p3.y - p2.y; b2.z = p3.z - p2.z;
 b1.x = p4.x - p3.x; b1.y = p4.y - p3.y; b1.z = p4.z - p3.z;
 b2 = vector_scale(b2, 1.0);
  dot = vector_dot(b1,b2);
/* project bonds onto torsion axis */
  nl.x = bl.x - dot*b2.x; nl.y = bl.y - dot*b2.y; nl.z = bl.z -
dot*b2.z;
  dot = vector dot(b3,b2);
  n2.x = b3.x - dot*b2.x; n2.y = b3.y - dot*b2.y; n2.z = b3.z -
dot*b2.z:
  len = vector_length(n1)*vector_length(n2);
  theta = vector_dot(n1,n2)/len;
/* watch out for theta=0,PI, which kill acos */
  if (theta > 1.0-EPS)
    theta = 0.0;
  else if (theta < -1.0+EPS)
    theta = PI;
  else
    theta = acos(theta);
/* get proper sign on angle */
  n1 = vector_cross(n2, n1);
  if (vector_dot(n1, b2) < 0.0) theta = -theta;</pre>
  return(theta);
/* This function assigns the lennard jones parameters
*/
void assign_lj_parameters(rigid_unit *unit, rigid_unit *start)
  int i:
  f r (i=0; i<unit->n_atoms; i++) {
    if (!lookup_lj_data(unit->atom[i].type, &unit->atom[i].ri,
```

```
&unit->atom[i].ei)) {
       printf("Lennard-Jones parameters not found for atom sn^*,
                          unit->atom[i].type);
       exit(1);
     }
   for (i=0; i<unit->n bonds; i++)
     if (unit->bond[i]->next != start)
       assign_lj_parameters(unit->bond[i]->next, start);
/ \mbox{\scriptsize +} This function looks up the lennard jones parameters for an atom
*/
logical lookup_lj_data(string type, double *ri, double *ei)
  lj_data **1;
  for (l=lj_data_list; *1; l++)
    if (strcmp((*1)->type, type)==0) {
       *ri = (*1)->ri;
       *ei = (*1)->ei;
      return (TRUE) :
  return (FALSE);
}
/\star This routine determines the H-bonds that are in the molecule
*/
void get_hbonds(hbond_list **list, atom_list *atom, int n_atoms)
  int i,j;
  hbond_list t, *u, *v;
  *list = NULL;
  t.next = NULL;
  for (i=0; i<n_atoms; i++)</pre>
    for (j=i+1; j<n_atoms; j++)</pre>
           (lookup_hbond_data(atom[i].p->type, atom[j].p->type,
&t.p)) {
        t.num[0] = i;
        t.num[1] = j;
        if ((v = (hbond list *)
          malloc(sizeof(hbond_list))) == NULL) out_of_memory();
```

```
*v = t;
         if (!*list)
           *list = u = v;
         else {
           u - next = v;
           u = u - \text{next};
       }
/* This function looks up the H-bond parameters for an atom pair
logical lookup_hbond_data(string type1, string type2, hbond_data
**p)
  hbond_data **1;
  for (l=hbond_data_list; *1; l++) {
       (strcmp((*1)->type1, type1)==0 && strcmp((*1)->type2,
type2) == 0)
       goto done;
    if (strcmp((*1)->type2, type1)==0 \&\& strcmp((*1)->type1,
type2) == 0)
       goto done;
  return (FALSE);
done: ;
  *p = *1;
  return (TRUE);
}
/* This function prints out the H-bonds
*/
void print_hbonds(hbond_list *1, atom_list *atom)
  for (; l; l=1->next) {
    printf("%s %s %lf %lf\n",
     atom[1->num[0]].p->name, atom[1->num[1]].p->name, 1->p->a,
1->p->b);
/* This function assigns the atom pointers
```

```
*/
void assign_atom_pointers(int *list num, rigid_unit *unit,
rigid_unit *start,
                       atom_list *atom)
{
 int i;
 for (i=0; i<unit->n atoms; i++) atom[i+*list_num].p =
&unit->atom[i];
 *list num += unit->n atoms;
 for (i=0; i<unit->n bonds; i++)
   if (unit->bond[i]->next != start)
     assign atom pointers(list num, unit->bond[i]->next, start,
atom);
}
**********
           GEOMETRY CREATION ROUTINES - PEPTIDE3.C
***********
/*
                     The geometry creation routines
*/
#include "peptide.h"
logical grow_backwards=FALSE;
/* This function creates the Rosenbluth factor for an old
configuration
*/
void old_unit(int *list_num, int n0, int n1, int n2, double
*logrosen,
            rigid_unit *unit, rigid_unit *start, torsion_list *t,
            hbond list *1, atom_list *atom, vector *twig[],
vector p0,
            vector b0)
 int i, j;
 vector p[MAX_BONDS], b[MAX_BONDS], p1, b1;
 double e;
 p1 = unit->atom(unit->h ad.atom num).position;
 b1 = unit->head.axis;
 do_unit_sub(list_num, n0, n1, n2, logrosen, unit, t, 1, atom,
```

```
twig,
              p1, b1, p0, b0, &e, p, b, FALSE);
  for (j=0; j<unit->n_bonds; j++)
    if (unit->bond[j]->next != start)
      old unit(list_num, n0, n1, n2, logrosen, unit->bond[j]->next,
start,
               t, 1, atom, twig, p[j], b[j]);
}
/* This function creates the geometry of a peptide
   and the Rosenbluth factor. The growth is in one direction.
* /
void do unit(int *list num, int n0, int n1, int n2, double
*logrosen,
             rigid_unit *unit, rigid_unit *start, torsion list *t,
             hbond_list *1, atom_list *atom, vector *twig[], vector
p0,
             vector b0, double *e)
{
  int i, j;
  vector p[MAX BONDS], b[MAX BONDS], p1, b1;
  unit->list num = *list num;
  pl = unit->atom[unit->head.atom num].position;
  b1 = unit->head.axis;
  do_unit_sub(list_num, n0, n1, n2, logrosen, unit, t, l, atom,
twig,
              pl, b1, p0, b0, e, p, b, TRUE);
/* loop over remaining units */
  for (j=0; j<unit->n_bonds; j++) {
/* store side-chain regrowth info */
    if (unit->bond[j]->next != start)
      do_unit(list_num, n0, n1, n2, logrosen,
              unit->bond[j]->next, start, t, l, atom, twig, p[j],
b[j], e);
/* This function creates the geometry of a peptide
   and the Rosenbluth factor. The growth is forward.
*/
void do backbone_f(int i, int n_main, int n_atoms_total,
```

```
double *logrosen,
                   regrowth *main, regrowth *side,
                   torsion list *t, hbond list *1,
                   atom list *atom, vector *twig[],
                   double *e, logical new)
  int list_num, n1, n2;
  vector p[MAX BONDS], b[MAX_BONDS], p1, b1, p0, b0;
  if (i==0) i++;
  p0 = get_main_p0(atom, main, i);
  b0 = get main b0 (atom, main, i);
  main += i;
  list num = main->unit->list num;
  n1 = n2 = n atoms total;
/* loop over backbone groups */
  for (; i<n main; i++, main++) {
    p1 = main->unit->atom[main->unit->head.atom num].position;
    b1 = main->unit->head.axis;
/* add on backbone unit */
    do unit sub(&list num, 0, n1, n2, logrosen, main->unit, t, 1,
atom, twig,
                pl, bl, p0, b0, e, p, b, new);
    if (!new && i < n_main-1) {
      p0 = get_main_p0(atom, main, 1);
      b0 = get_main b0(atom, main, 1);
    } else if (new && i < n_main-1) {
      p0 = p(main->unit->n_bonds-1);
      b0 = b[main->unit->n_bonds-1];
/* add on side chain */
    if (main->unit->n bonds == 2) {
      if (new)
        do unit (&list num, 0, n1, n2, logrosen,
                        main->unit->bond[0]->next,
main->unit->bond[0]->next,
                t, 1, atom, twig, p[0], b[0], e);
     else
        old_unit(&list_num, 0, n1, n2, logrosen,
                         main->unit->bond[0]->next,
```

```
main->unit->bond[0]->next,
                 t, 1, atom, twig, p[0], b[0]);
    }
  }
}
/* This function creates the geometry of a peptide
   and the Rosenbluth factor. The growth is forward.
   Side chains are rigidly rotated.
*/
void do backbone f_rigid(int i, int n main, int n atoms_total,
                         double *logrosen,
                         regrowth *main, regrowth *side,
                         torsion list *t, hbond list *1,
                         atom list *atom, atom info *atom_tmp,
                         vector *twig[],
                         double *e, logical new)
{
  int list_num, n1, n2;
  vector p[MAX_BONDS], b[MAX_BONDS], p1, b1, p1a, b1a, p0, b0;
  logical false=FALSE;
  int n_atoms, j;
  atom info *q;
  double len;
  vector b2 [MAX BONDS], v, v2;
  if (i==0) i++;
  p0 = get_main_p0(atom, main, i);
  b0 = get main_b0(atom, main, i);
 main += i;
  list num = main->unit->list_num;
  n1 = n2 = n atoms_total;
/* get first head vector */
               atom [main->unit->list_num
main->unit->head.atom num].position;
 bl = atom(main(-1).unit->list_num +
main[-1].unit->bond[main[-1].unit->n_bonds-1]->tail.atom_num]
          .position;
 b1.x = p1.x - b1.x;
```

```
b1.y = p1.y - b1.y;
  b1.z = p1.z - b1.z;
  for (; i<n_main; i++, main++) {
/* change unit */
    n atoms = main->unit->n atoms;
    g = main->unit->atom;
    if (i < n_main-1)</pre>
      main->unit->n atoms
                                   main[1].unit->list num
                            =
main->unit->list num;
    main->unit->atom = atom_tmp;
    for (j=0; j<main->unit->n_atoms; j++)
      main->unit->atom[j].position = atom[list_num+j].position;
    for (j=0; j<main->unit->n_bonds; j++) {
      b2[j] = main->unit->bond[j]->tail.axis;
      v = atom(main->unit->bond(j)->next->list_num +
               main->unit->bond[j]->next->head.atom_num].position;
      v2 = atom[main->unit->list num +
                main->unit->bond[j]->tail.atom num].position;
      v.x = v2.x;
      v.y -= v2.y;
      v.z = v2.z;
      main->unit->bond(j)->tail.axis = vector_scale(v,1.0);
    }
/* get next head vector */
    if (i < n_main-1) {
      pla = atom[main[1].unit->list_num +
                 main[1].unit->head.atom_num].position;
      bla = atom(main->unit->list_num +
main->unit->bond(main->unit->n bonds-1)->tail.atom num)
              .position;
      bla.x = pla.x - bla.x;
     bla.y = pla.y - bla.y;
     bla.z = pla.z - bla.z;
    }
/* add on unit */
    do_unit_sub(&list_num, 0, n1, n2, logrosen, main->unit, t, l,
atom, twig,
               p1, b1, p0, b0, e, p, b, n w);
```

```
/* change unit back */
    main->unit->n_atoms = n_atoms;
    main->unit->atom = q;
    for (j=0; j<main->unit->n_bonds; j++)
      main->unit->bond[j]->tail.axis = b2[j];
/* change head vector */
    if (!new && i < n_main-1) {
      p0 = get_main_p0(atom, main, 1);
      b0 = get main b0(atom, main, 1);
    } else if (new && i < n main-1) {
      p0 = p(main->unit->n bonds-1);
      b0 = b[main->unit->n bonds-1];
    }
    p1 = p1a;
   b1 = b1a;
}
/* This function creates the geometry of a peptide
   and the Rosenbluth factor. The growth is backward.
*/
void do_backbone_b(int i, int n_main, int n_atoms_total,
                   double *logrosen,
                   regrowth *main, regrowth *side,
                   torsion list *t, hbond list *1,
                   atom list *atom, vector *twig[],
                   double *e, logical new)
{
  int list_num, n0, n1, n2, n_bonds;
  vector p[MAX_BONDS], b[MAX_BONDS], b0, p0, tmp, p1, b1;
  if (i == n main-1) i--;
  main += i;
  n2 = n_atoms_total;
 b0 = get main b0 (atom, main, 1);
  for (; i>=0; i--, main--) {
    n1 = main(1).unit->list num;
    n0 = list num = main->unit->list_num;
/* get bond vectors */
                                          0
                                 p
atom[main[1].unit->head.atom num+main[1].unit->list num].position;
```

```
b0.x = -b0.x; b0.y = -b0.y; b0.z = -b0.z;
     n_bonds = main->unit->n bonds;
     p1 = main->unit->atom[main->unit->bond[n_bonds-1]->
                    tail.atom_num].position;
     bl = main->unit->bond[n_bonds-1]->tail.axis;
     b1.x = -b1.x;
     bl.y = -bl.y;
     b1.z = -b1.z;
     b1 = vector_scale(b1, vector_length(main[1].unit->head.axis));
     tmp = main->unit->bond[n_bonds-1]->tail.axis;
    main->unit->bond[n_bonds-1]->tail.axis = main->unit->head.axis;
 /* add on unit */
     grow_backwards = TRUE;
     do_unit_sub(&list_num, n0, n1, n2, logrosen, main->unit, t, 1,
 atom, twig,
                pl, bl, p0, b0, e, p, b, new);
    grow_backwards = FALSE;
    main->unit->bond[n_bonds-1]->tail.axis = tmp;
/* change head vector */
    if (!new && i > 0)
      b0 = get_main_b0(atom, main-1, 1);
    else if (new && i > 0)
      b0 = vector_scale(b[n_bonds-1], 1.0);
/* add on side chain */
    if (main->unit->n bonds == 2) {
      if (new)
        do_unit(&list_num, n0, n1, n2, logrosen,
                        main->unit->bond[0]->next,
main->unit->bond[0]->next,
                t, 1, atom, twig, p[0], b[0], e);
      else
        old_unit(&list_num, n0, n1, n2, logrosen,
                          main->unit->bond[0]->next,
main->unit->bond[0]->next,
                 t, 1, atom, twig, p[0], b[0]);
    }
 }
/* This function creates the geometry of a peptide
```

```
and the Rosenbluth factor. The growth is backward.
   Side chains are rigidly rotated.
*/
void do backbone_b_rigid(int i, int n_main, int n_atoms total,
                         double *logrosen,
                         regrowth *main, regrowth *side,
                         torsion_list *t, hbond_list *1,
                         atom_list *atom, atom_info *atom_tmp,
vector *twig[],
                         double *e, logical new)
  int list num, n0, n1, n2, n_bonds, n_atoms, j;
  vector p[MAX BONDS], b[MAX BONDS], b0, p0, tmp, p1, b1, pla, bla,
         b2[MAX BONDS], v, v2;
  logical false=FALSE;
  atom info *q;
  if (i == n main-1) i--;
  main += i;
  n2 = n atoms total;
/* get first head unit */
 p1 = atom[main->unit->bond[main->unit->n_bonds-1]->tail.atom num
            main->unit->list_num].position;
               atom[main[1].unit->list_num
   b 1
main[1].unit->head.atom num].position;
  b1.x = p1.x - b1.x;
  b1.y = p1.y - b1.y;
  b1.z = p1.z - b1.z;
  b0 = get main b0 (atom, main, 1);
  for (; i>=0; i--, main--) {
/* get current info */
    list num = main->unit->list num;
    n bonds = main->unit->n bonds;
                                 p
atom(main(1).unit->head.atom_num+main(1).unit->list num).position;
    b0.x = -b0.x; b0.y = -b0.y; b0.z = -b0.z;
    n1 = main[1].unit->list_num;
    n0 = list_num = main->unit->list_num;
    n_atoms = main->unit->n_atoms;
```

```
g = main->unit->atom;
/* change current unit */
    main->unit->n atoms = n1 - n0;
    main->unit->atom = atom tmp;
    for (j=0; j<main->unit->n_atoms; j++)
      main->unit->atom[j].position = atom[list_num+j].position;
/* compute bond axes */
    for (j=0; j< n \text{ bonds}; j++) {
      b2[j] = main->unit->bond[j]->tail.axis;
      v = atom[main->unit->bond[j]->next->list_num +
               main->unit->bond[j]->next->head.atom num].position;
      v2 = atom[list_num +
                main->unit->bond[j]->tail.atom num].position;
      v.x \rightarrow v2.x;
      v.y -= v2.y;
      v.z -= v2.z;
      main->unit->bond[j]->tail.axis = vector_scale(v,1.0);
    main->unit->bond(n_bonds-1)->tail.axis =
        vector_scale(get_main_b0(atom, main-i, i),
                      vector_length(main->unit->head.axis));
/* compute new head vector */
    if (i > 0) {
                                     p
                                           1
atom[main[-1].unit->bond[main[-1].unit->n bonds-1]->tail.atom num+
                main[-1].unit->list_num].position;
      bla=atom[list_num + main->unit->head.atom_num].position;
      bla.x = pla.x - bla.x;
      bla.y = pla.y - bla.y;
      bla.z = pla.z - bla.z;
/* add on unit */
    grow_backwards = TRUE;
    do_unit_sub(&list_num, n0, n1, n2, logrosen, main->unit, t, 1,
atom, twig,
                pl, bl, p0, b0, e, p, b, new);
    grow backwards = FALSE;
/* restore backbone unit */
    main->unit->n_atoms = n atoms;
```

```
main->unit->atom = q;
    for (j=0; j<n_bonds; j++) {
      main->unit->bond[j]->tail.axis = b2[j];
/* change head vector */
    if (!new && i > 0)
      b0 = get main b0(atom, main-1, 1);
    else if (new && i > 0)
      b0 = vector scale(b[n bonds-1], 1.0);
   p1 = p1a;
   b1 = b1a;
  }
}
/* This routine creates the random positions.
   For new units, it picks and copies the winner.
*/
void do unit sub(int *list num, int n0, int n1, int n2, double
*logrosen,
                 rigid unit *unit, torsion list *t, hbond list *l,
                 atom_list *atom, vector *twig[], vector p1, vector
b1,
                               vector b0,
                                             double *e, vector
                 vector
                          p0,
p[MAX BONDS],
                 vector b[MAX BONDS], logical new)
  int i, j, i0;
 vector bond(KMAX)[MAX_BONDS], point(KMAX][MAX_BONDS];
 double ftmp, cos_theta2, sin_theta2;
 double de[KMAX], sum, max;
 i0 = 0;
  if (!new) {
/* copy old configuration to first "guess" */
    i0 = 1:
    for (j=0; j<unit->n atoms; j++)
      twig[0][j] = atom[*list num + j].position;
  }
/* create gues s for new unit position */
  for (i=i0; i<KMAX; i++) {
    do {
```

```
cos theta2 = 1-2*ran2(1.0);
      sin theta2 = 1-2*ran2(1.0);
      ftmp = cos theta2*cos theta2 + sin theta2*sin theta2;
    } while (ftmp > 1.0);
    ftmp = sqrt(ftmp);
    cos theta2 /= ftmp;
    sin_theta2 /= ftmp;
    add rigid unit (unit, twig[i], pl, bl,
                   p0, b0, point[i], bond[i],
                   cos theta2, sin theta2);
  }
/* calculate probabilties -- be careful about zero of energy &
overflows */
  max = -1E99;
  for (j=0; j<KMAX; j++) {
    de[j] = -BETA * delta_energy(t, l, atom, twig[j], *list_num,
n0, n1, n2,
                                 unit->n atoms);
    if (de[j] > max) max = de[j];
  sum = 0.0;
  for (j=0; j<KMAX; j++) {
   de[j] = exp(de[j] - max);
   sum += de[j];
  *logrosen += log(sum) + max - log(KMAX);
  if (!new) {
/* determine points */
   for (j=0; j<unit->n_bonds; j++) {
                              atom[*list_num
             p [ j ]
                       =
unit->bond[j]->tail.atom_num].position;
     b[j] = atom[unit->bond[j]->next->list_num +
                 unit->bond[j]->next->head.atom_num].position;
     b[j].x -= p[j].x;
     b[j].y -= p[j].y;
     b[j].z -= p[j].z;
     b[j] = vector_scale(b[j], 1.0);
   *list_num += unit->n atoms;
```

```
} else {
/* pick winner */
    de[0] /= sum;
    for (j=1; j<KMAX; j++) de[j] = de[j-1] + de[j]/sum;
    ftmp = ran2(1.0);
    for (i=0; i<KMAX; i++) if (ftmp <= de[i]) break;</pre>
    ftmp = de[i];
    if (i > 0) ftmp -= de[i-1];
    ftmp *= sum;
    *e -= (log(ftmp)+max)/BETA;
/* copy winner to atom array */
    for (j=0; j<unit->n_atoms; j++, (*list_num)++)
       atom[*list_num].position = twig[i][j];
    for (j=0; j<unit->n_bonds; j++) {
     p[j] = point[i][j];
     b[j] = bond[i][j];
    }
  }
/* This routine adds a rigid unit to the peptide structure
* /
void add_rigid_unit(rigid_unit *unit, vector *pos,
                    vector p1, vector b1, vector p0,
                    vector b0, vector point[MAX BONDS],
                    vector bond[MAX BONDS],
                    double cos_theta2, double sin theta2)
{
  int i;
  double bond len, cos theta, sin theta;
 vector n, r0;
 bond len = vector length(b1);
 r0.x = p0.x + b0.x*bond_len;
 r0.y = p0.y + b0.y*bond_len;
 r0.z = p0.z + b0.z + bond len;
 b1.x /= bond len;
 b1.y /= bond len;
 b1.z /= bond len;
 n = vector_cross(b1,b0);
 cos_theta = vector_dot(b0,b1);
```

```
sin_theta = vector_length(n);
  if (sin theta < EPS) {
    n.x = 1.0;
  } else {
    n.x /= sin_theta;
    n.y /= sin theta;
    n.z /= sin theta;
  for (i=0; i<unit->n atoms; i++)
    pos[i] = align(unit->atom[i].position, r0, p1,
                   n, cos_theta, sin_theta,
                   b0, cos_theta2, sin_theta2);
  for (i=0; i<unit->n_bonds; i++)
    point[i] = pos[unit->bond[i]->tail.atom_num];
  r0.x = 0.0; r0.y = 0.0; r0.z = 0.0; p1=r0;
  for (i=0; i<unit->n_bonds; i++)
    bond(i) = align(unit->bond(i)->tail.axis, r0, p1,
                    n, cos_theta, sin_theta,
                    b0, cos theta2, sin theta2);
}
/* This routine aligns the position
vector align(vector p, vector r0, vector r1, vector n, double
cos_theta,
             double sin_theta, vector n2, double cos_theta2,
             double sin_theta2)
{
 vector ret;
  ret.x = p.x - r1.x;
 ret.y = p.y - r1.y;
 ret.z = p.z - r1.z;
 ret = vector rotate(ret, n, cos_theta, sin theta);
  ret = vector_rotate(ret, n2, cos_theta2, sin_theta2);
  ret.x += r0.x;
 ret.y += r0.y;
 ret.z += r0.z;
 return(r t);
}
```

```
ENERGY DETERMINATION - PEPTIDE4.C
********
                      The energy routines
/*
*/
#include "peptide.h"
#define NO 8
#define N1 11
#define N2 81
#define N3 84
#define N2 63
#define N3 66
#define SCALE 100
/* This energy routine tries to force a S-S ring-closure for
CAAAAAAC
*/
double zenergy(torsion_list *t, hbond_list *l, atom_list *atom,
             int n atoms total)
{
  double r1, r2;
 vector x, y, v;
 x = atom[N1].position;
  x.x -= atom[N0].position.x;
  x.y -= atom[N0].position.y;
  x.z -= atom(NO).position.z;
  x = vector scale(x, 2.038);
  x.x += atom[N0].position.x;
  x.y += atom[N0].position.y;
  x.z += atom[N0].position.z;
  y = atom[N3].position;
  y.x -= atom[N2].position.x;
  y.y -= atom[N2].position.y;
  y.z -= atom[N2].position.z;
  y = vector_scale(y, 2.038);
  y.x += atom[N2].position.x;
  y.y += atom[N2].position.y;
  y.z += atom[N2].position.z;
```

v = x;

```
v.x -= atom[N2].position.x;
  v.y -= atom[N2].position.y;
  v.z -= atom[N2].position.z;
  r1 = vector_length2(v);
  v = y;
  v.x -= atom[N0].position.x;
  v.y -= atom[N0].position.y;
  v.z -= atom[N0].position.z;
  r2 = vector_length2(v);
  return(SCALE*(r1+r2)/BETA);
/* This energy routine tries to force a S-S ring-closure for
CAAAAAAC
*/
double zdelta_energy(torsion_list *t, hbond_list *1, atom_list
*atom,
                    vector *twig, int n atoms, int n0, int n1, int
n2,
                    int n_twig)
 double r1, r2;
 vector x, y, v;
 r1 = r2 = 0.0;
 if (INTERVAL(NO, n_atoms, n_atoms+n_twig) &&
     INTERVAL(N2, n1, n2)) {
   x = twig[N1-n_atoms];
   x.x -= twig[N0-n_atoms].x;
   x.y -= twig[N0-n_atoms].y;
   x.z -= twig[N0-n_atoms].z;
   x = vector_scale(x, 2.038);
   x.x += twig[N0-n_atoms].x;
   x.y += twig[N0-n_atoms].y;
   x.z += twig[N0-n_atoms].z;
   y = atom[N3].position;
   y.x -= atom[N2].position.x;
   y.y -= atom[N2].position.y;
   y.z -= atom[N2].position.z;
   Y = vector_scale(y, 2.038);
   y.x += atom[N2].position.x;
```

```
y.y += atom[N2].position.y;
  y.z += atom[N2].position.z;
  v = x:
 v.x -= atom[N2].position.x;
 v.y -= atom[N2].position.y;
 v.z -= atom[N2].position.z;
 r1 = vector length2(v);
 v = y;
 v.x -= twig[N0-n_atoms].x;
 v.y -= twig[N0-n_atoms].y;
 v.z -= twig[N0-n atoms].z;
 r2 = vector_length2(v);
} else if (INTERVAL(N2, n atoms, n atoms+n twig) &&
           INTERVAL(N0, n0, n_atoms)) {
 x = atom[N1].position;
 x.x -= atom[NO].position.x;
 x.y -= atom[N0].position.y;
 x.z -= atom[N0].position.z;
 x = vector scale(x, 2.038);
 x.x += atom[N0].position.x;
 x.y += atom[N0].position.y;
 x.z += atom[N0].position.z;
 y = twig[N3-n_atoms];
 y.x -= twig[N2-n_atoms].x;
 y.y -= twig[N2-n_atoms].y;
 y.z = twig[N2-n atoms].z;
 y = vector scale(y, 2.038);
 y.x += twig[N2-n_atoms].x;
 y.y += twig[N2-n atoms].y;
 y.z += twig[N2-n atoms].z;
 \mathbf{v} = \mathbf{x};
 v.x -= twig[N2-n atoms].x;
 v.y -= twig[N2-n atoms].y;
 v.z -= twig[N2-n_atoms].z;
 r1 = vector_length2(v);
 v = y;
 v.x -= atom[N0].position.x;
 v.y -= atom[N0].position.y;
 v.z -= atom[N0].position.z;
```

```
r2 = vector length2(v);
  return(SCALE*(r1+r2)/BETA);
/* This routine returns the Coulomb, LJ, H-bond, and torsion
energies
   between the atoms in *atom and the atoms in *twig.
   The atoms in *twig must be those directly following those in
*atom.
   The atoms n atoms to n atoms+n twig are in twig.
   The atoms n0 to n_atoms and n1 to n2 are in atom.
   n0 \ll n atoms \ll n1 \ll n2
*/
double delta_energy(torsion_list *t, hbond_list *1, atom_list
*atom,
                    vector *twig, int n_atoms, int n0, int n1, int
n2,
                    int n_twig)
  return (
         d_nonbond_energy(t, atom, twig, n_atoms, n0, n1, n2,
n \text{ twig}) +
         d_hbond_energy(l, atom, twig, n_atoms, n0, n1, n2, n_twig)
         d_torsion_energy(t, atom, twig, n_atoms, n0, n1, n2,
n_twig)
        );
/* This routine returns the total energy
*/
double energy(torsion_list *t, hbond_list *1, atom_list *atom,
              int n_atoms_total)
{
 return(
         nonbond_energy(t, atom, n_atoms_total) +
        hbond energy(1, atom) +
        torsion_energy(t, atom)
        );
}
```

```
/* This routine returns the Coulomb and LJ energies
   between the atoms in *atom and the atoms in *twig.
   The atoms in *twig must be those directly following those in
*atom.
* /
double d nonbond energy(torsion_list *t, atom_list *atom, vector
*twig,
                        int n atoms, int n0, int n1, int n2, int
n_twig)
#define FACT 332.06 /* converts from ei ej/rij to Kcal/mol */
  int i, j, k;
 vector r;
  double r2, r6, e, eij, rij, rij3, term, a, b;
  e = 0.0;
 for (i=n0; i<n2; i++) {
    if (INTERVAL(i, n atoms, n1)) continue;
    for (j=0; j<n_twig; j++) {
      r.x = atom[i].position.x - twig[j].x;
     r.y = atom[i].position.y - twig[j].y;
      r.z = atom[i].position.z - twig[j].z;
      r2 = vector_length2(r);
      r6 = r2*r2*r2;
      eij = sqrt(atom[i].p->ei * atom[n_atoms+j].p->ei);
      rij = 0.5*(atom[i].p->ri + atom[n_atoms+j].p->ri);
      rij3 = rij*rij*rij;
      a = eij * rij3*rij3*rij3;
     b = 2*eij * rij3*rij3;
/* epsilon = 4*r */
      term = FACT * atom[i].p->charge * atom[n atoms+j].p->charge
/(4*r2)
                  a/(r6*r6) - b/r6;
      e += term;
    }
/* subtract off 1/2 of 1-4 interactions */
 for (; t; t=t->next)
    i = t->num[3]; j = t->num[3];
```

```
if (INTERVAL(i,n_atoms,n_atoms+n_twig)) {
       k = i;
       i = j;
       j = k;
             (INTERVAL(j,n_atoms,n_atoms+n_twig)
      if
                                                                & &
 (INTERVAL(i,n0,n atoms) ||
         INTERVAL(i, n1, n2))) {
      r.x = atom[i].position.x - twig[j-n_atoms].x;
      r.y = atom[i].position.y - twig[j-n_atoms].y;
      r.z = atom[i].position.z - twig[j-n_atoms].z;
      r2 = vector_length2(r);
      r6 = r2*r2*r2;
      eij = sqrt(atom[i].p->ei * atom[j].p->ei);
      rij = 0.5 * (atom[i].p->ri + atom[j].p->ri);
      rij3 = rij*rij*rij;
      a = eij * rij3*rij3*rij3;
      b = 2*eij * rij3*rij3;
      term = FACT * atom[i].p->charge * atom[j].p->charge / (4*r2)
             + a/(r6*r6) - b/r6;
      e -= 0.5 * term;
    }
  return(e);
#undef FACT
/* This routine returns the Coulomb and LJ energies
*/
double nonbond_energy(torsion_list *t, atom_list *atom,
                                                              int
n_atoms_total)
#define FACT 332.06 /* converts from ei ej/rij to Kcal/mol */
 int i, j;
 vector r;
 double r2, r6, e, eij, rij, rij3, term, a, b;
 e = 0.0;
 for (i=0; i<n_atoms_total; i++)</pre>
   for (j=i+1; j<n_atoms_total; j++) {</pre>
     r.x = atom[i].position.x - atom[j].position.x;
```

```
r.y = atom[i].position.y - atom[j].position.y;
      r.z = atom[i].position.z - atom[j].position.z;
      r2 = vector length2(r);
     r6 = r2*r2*r2;
      eij = sqrt(atom[i].p->ei * atom[j].p->ei);
     rij = 0.5*(atom[i].p->ri + atom[j].p->ri);
      rij3 = rij*rij*rij;
      a = eij * rij3*rij3*rij3;
     b = 2*eij * rij3*rij3;
/* epsilon = 4*r */
      term = FACT * atom[i].p->charge * atom[j].p->charge / (4*r2)
                  a/(r6*r6) - b/r6;
      e += term:
/* subtract off 1/2 of 1-4 interactions */
  for (; t; t=t->next)
    i = t - num[0]; j = t - num[3];
    r.x = atom[i].position.x - atom[j].position.x;
    r.y = atom[i].position.y - atom[j].position.y;
    r.z = atom[i].position.z - atom[j].position.z;
    r2 = vector length2(r);
    r6 = r2*r2*r2;
    eij = sqrt(atom[i].p->ei * atom[j].p->ei);
    rij = 0.5 * (atom[i].p->ri + atom[j].p->ri);
    rij3 = rij*rij*rij;
    a = eij * rij3*rij3*rij3;
    b = 2*eij * rij3*rij3;
    term = FACT * atom[i].p->charge * atom[j].p->charge / (4*r2)
           + a/(r6*r6) - b/r6;
    e -= 0.5 * term;
  return(e);
#undef fact
/* This routine returns the H-bond energy
   betw en the atoms in *atom and th atoms in *twig.
   The atoms in *twig must be those directly following those in
*atom.
```

```
*/
 double d_hbond_energy(hbond_list *1, atom_list *atom, vector *twig,
                       int n_atoms, int n0, int n1, int n2, int
 n twig)
   int i,j,k;
   vector r;
   double r2, e;
   e = 0.0;
   for (; 1; l=1->next) {
     i = 1->num[0]; j = 1->num[1];
    if (INTERVAL(i,n_atoms,n_atoms+n_twig)) {
      k = i;
      i = j
      j = k;
            (INTERVAL(j,n_atoms,n_atoms+n_twig)
      i f
                                                              & &
(INTERVAL(i,n0,n_atoms) ||
        INTERVAL(i,n1,n2))) {
      r.x = atom[i].position.x - twig[j-n_atoms].x;
      r.y = atom[i].position.y - twig[j-n_atoms].y;
      r.z = atom[i].position.z - twig[j-n_atoms].z;
      r2 = vector_length2(r);
                   1->p->a / (r2*r2*r2*r2*r2)
1->p->b/(r2*r2*r2*r2*r2);
  return(e);
/* This routine returns the H-bond energy
*/
double hbond_energy(hbond_list *1, atom_list *atom)
 vector r;
 double r2, e;
 e = 0.0;
 for (; l; l=l->next) {
   r.x = atom[1->num[0]].position.x - atom[1->num[1]].position.x;
   r.y = atom[1->num[0]].position.y - atom[1->num[1]].position.y;
```

```
r.z = atom[1->num[0]].position.z - atom[1->num[1]].position.z;
    r2 = vector length2(r);
    e += 1->p->a / (r2*r2*r2*r2*r2*r2) - 1->p->b/(r2*r2*r2*r2*r2);
  return(e);
}
/* This routine returns the H-bond energy
   between the atoms in *atom and the atoms in *twig.
   The atoms in *twig must be those directly following those in
*atom.
*/
double d_torsion_energy(torsion_list *t, atom_list *atom, vector
*twig,
                       int n_atoms, int n0, int n1, int n2, int
n_twig)
  int i, j, k, l;
  vector v[4];
  double theta, e, tmp;
  e = 0.0;
  for (; t; t=t->next)
    if (t->p->v0[0] != 0.0 || t->p->v0[1] != 0.0 || t->p->v0[2] !=
0.0) {
      i = t - num[0]; j = t - num[1]; k = t - num[2]; l = t - num[3];
      if (INTERVAL(i,n_atoms+n_twig,n1) || i >= n2 || i < n0)
continue:
      if (INTERVAL(j,n_atoms+n_twig,n1) \parallel j >= n2 \parallel j < n0)
continue;
      if (INTERVAL(k, n_atoms+n_twig, n1) \mid k >= n2 \mid k < n0)
continue;
      if (INTERVAL(1, n_atoms+n_twig, n1) \mid | 1 >= n2 \mid | 1 < n0)
continue;
      if (!(INTERVAL(i,n_atoms,n_atoms+n_twig) ||
            INTERVAL(j,n_atoms,n_atoms+n twiq) !!
            INTERVAL(k, n_atoms, n_atoms+n twig) | |
            INTERVAL(1, n_atoms, n_atoms+n_twig))) continue;
/±
        printf("%d %d %d %d", i, j, k, 1); */
      if (INTERVAL(i,n_atoms,n_atoms+n_twig))
```

```
v[0] = twig[i-n_atoms]; else v[0] = atom[i].position;
       if (INTERVAL(j,n_atoms,n_atoms+n_twig))
         v[1] = twig[j-n_atoms]; else v[1] = atom[j].position;
       if (INTERVAL(k,n_atoms,n_atoms+n_twig))
         v[2] = twig[k-n_atoms]; else v[2] = atom[k].position;
       if (INTERVAL(1,n_atoms,n_atoms+n_twig))
         v[3] = twig[1-n_atoms]; else v[3] = atom[1].position;
       theta = torsion(v[0], v[1], v[2], v[3]);
       tmp = (t->p->v0[0]*(1 + cos(theta-t->p->phi0[0])) +
             t - p - v0[1] * (1 + cos(2*theta-t-p-phi0[1])) +
             t \rightarrow p \rightarrow v0[2]*(1 + cos(3*theta-t->p->phi0[2])))
 t->degen;
 /*
         printf(" %lf %lf\n",theta,tmp); */
       e += tmp;
     }
   }
  return(e);
/* This routine returns the torsional energy
*/
double torsion_energy(torsion_list *t, atom_list *atom)
  double theta, e, tmp;
  e = 0.0;
  for (; t; t=t->next)
    if (t->p->v0[0] != 0.0 || t->p->v0[1] != 0.0 || t->p->v0[2] !=
0.0) {
                  = torsion(atom[t->num[0]].position,
        theta
atom[t->num[1]].position,
                               atom[t->num[2]].position,
atom[t->num[3]].position);
      tmp = (t->p->v0[0]*(1 + cos( theta-t->p->phi0[0])) +
            t \rightarrow p \rightarrow v0[1]*(1 + cos(2*theta-t->p->phi0[1])) +
            t \rightarrow p \rightarrow v0[2]*(1 + cos(3*theta-t->p->phi0[2])))
t->degen;
         printf("%d %d %d %d %lf %lf\n", t->num[0], t->num[1],
/*
t->num[2],
                       t->num[3], theta, tmp); */
```

```
e += tmp;
  return(e);
}
                MONTE CARLO ROUTINES - PEPTIDES.C
/*
                         The Monte Carlo routines
* /
#include "peptide.h"
/* This routine drives the configurational bias Monte Carlo
*/
void do_mc(rigid_unit *unit, torsion_list *t, hbond_list *l,
           atom_list *atom, atom_list *atom2, atom_info *atom tmp,
           vector *twig[], regrowth *main, regrowth *side,
           int n_amino_acids, int n_atoms_total, int n_main, int
n_side,
           logical cyclic)
  int list_num, i, j;
  double logrosen, e, e2, emin;
  vector p0, b0;
  vector v1, v2;
  emin = 1.0E99;
  list num = 0;
  p0.x = 0.0; p0.y = 0.0; p0.z = 0.0;
  b0.x = 0.0; b0.y = 0.0; b0.z = 1.0;
  e = 0;
  logrosen = 0;
/* create initial geomeotry */
  do_unit(&list_num, 0, n_atoms_total, n_atoms_total,
          &logrosen, unit, unit, t, l, atom, twig,
          p0, b0, &e);
/* read in initial geometry */
  if (0) read_restart(atom, n_atoms_total);
 if (cyclic)
```

```
read_cycle(t, 1, atom, main, side, twig, n_main, n_side,
n atoms total);
/*
  do_backbone_f(0, n_main, n_atoms_total, &logrosen, main,
                side, t, l, atom, twig, &e, TRUE);
  do backbone_b(n_main-1, n_main, n_atoms_total, &logrosen, main,
                side, t, l, atom, twig, &e, TRUE);
  do backbone_f_rigid(0, n main, n atoms total,
                      &logrosen, main,
                      side, t, l, atom, atom_tmp, twig, &e, TRUE);
  do backbone_b_rigid(n_main-1, n_main, n_atoms_total,
                      &logrosen, main,
                      side, t, 1, atom, atom tmp, twig, &e, TRUE);
*/
  emin = e = energy(t, 1, atom, n_atoms_total);
/* copy old positions into new */
  for (j=0; j<n_atoms_total; j++) atom2[j] = atom[j];</pre>
/* do Monte Carlo */
  for (i=0; i<16000; i++) {
    printf("%d\n",i);
    rotate main(atom, atom2, twig, main, side, t, l, n main,
    n atoms total, &e);
/*
    regrow main(t, 1, atom, atom2, atom tmp, twig, main, side,
                n_main, n_atoms_total, &e);
    regrow_side(t, 1, atom, atom2, twig, main, side,
                n_side, n_atoms_total, &e);
*/
    if (e < emin) {</pre>
      emin = e;
      write_car_file(n_amino_acids, n atoms_total,
"min.car");
    }
 printf("emin %lf\n",emin);
/* This routine reads in a restart file
*/
void read_restart(atom_list *atom, int n_atoms_total)
```

```
#define LINELEN 200
   FILE *fp;
   int i;
  char name[30], line[LINELEN];
  strcpy(name, "restart.car");
  if ((fp = fopen(name, "r")) == NULL) {
    printf("Data file %s does not exist\n", name);
    exit(1);
  fgets(line, LINELEN, fp);
  fgets(line, LINELEN, fp);
  fgets (line, LINELEN, fp);
  fgets(line, LINELEN, fp);
  for (i=0; i<n_atoms_total; i++) {</pre>
    fgets(line, LINELEN, fp);
    sscanf(line, "%s %lf %lf %lf", name,
                                        &atom[i].position.x,
                                        &atom[i].position.y,
                                        &atom[i].position.z);
  }
  fclose(fp);
/\star This routine reads in the backbone units plus one side-chain
atom
   for the geometry CXXXXXXC. It then adds on each of the side
   groups randomly
*/
void read_cycle(torsion_list *t, hbond_list *1,
                atom_list *atom, regrowth *main, regrowth *side,
                vector *twig[], int n_main, int n_side,
n_atoms_total)
#define LINELEN 200
  FILE *fp;
  int i, j, k, list_num;
  char name[30], line[LINELEN];
  double logrosen,
                   i
/* read in loop atoms plus one side group atom */
```

```
if (n_main != 2*8+3) {
  printf("This cyclic geometry is not supported\n");
  exit(1);
}
strcpy(name, "CX6C.car");
if ((fp = fopen(name, "r")) == NULL) {
  printf("Data file %s does not exist\n", name);
  exit(1);
fgets(line, LINELEN, fp);
fgets(line, LINELEN, fp);
fgets(line, LINELEN, fp);
fgets(line, LINELEN, fp);
for (i=0; i<n_main; i++) {
  /* printf("%d\n", main[i].unit->list num); */
  for (j=0; j<main[i].unit->n_atoms; j++) {
    k = main[i].unit->list_num + j;
    fgets(line, LINELEN, fp);
    sscanf(line, "%s %lf %lf %lf", name,
                                        &atom(k).position.x,
                                        &atom[k].position.y,
                                        &atom(k).position.z);
    /* printf("%d %s %lf %lf %lf\n",k,name,
                                       atom[k].position.x,
                                       atom[k].position.y,
                                       atom[k].position.z); */
 if (main[i].unit->n_bonds == 2) {
   k++;
   fgets(line, LINELEN, fp);
   sscanf(line, "%s %lf %lf %lf", name, &atom[k].position.x,
                                       &atom[k].position.y,
                                       &atom[k].position.z);
   /* printf("%d %s %lf %lf %lf\n",k,name,
                                       atom[k].position.x,
                                       atom[k].position.y.
                                       atom[k].position.z); */
 }
```

```
fclose(fp);
/* add on side groups */
  for (i=0; i<n side; i++) {
    list_num = side[i].unit->list num;
    do_unit(&list_num, 0, n_atoms_total, n_atoms_total,
          &logrosen, side[i].unit, side[i].unit, t, l, atom, twig,
          get_side_p0(atom, side, i), get_side_b0(atom, side, i),
          &e);
  }
}
/* This routine regrows from a main chain unit onwards
void regrow main(torsion_list *t, hbond list *l,
                  atom_list *atom, atom_list *atom2,
                 atom_info *atom_tmp, vector *twig[],
                 regrowth *main, regrowth *side,
                 int n_main, int n_atoms_total, double *e)
{
  logical forward;
  int list_num, i, j, k;
  double logrosen1, logrosen2, x, e2, e1;
/* pick main group to start regrowth from */
  i = n_main*ran2(1.0);
/* pick direction to regrow */
  forward = (ran2(1.0) > 0.5);
 printf("regrowing %s from unit %d\n",(forward) ? "forward" :
"backward", i);
  list_num = main[i].unit->list_num;
/* copy old positions into new */
  for
                 j<n_atoms_total; j++) atom2[j].position</pre>
        (j=0:
atom[j].position;
/* regrow new peptide */
 e2 = 0;
 logrosen2 = 0.0;
 if (forward)
   do_backbone_f_rigid(i, n_main, n_atoms_total, &logrosen2, main,
                        side, t, 1, atom2, atom_tmp, twig, &e2,
TRUE);
 else
```

```
do_backbone_b_rigid(i, n_main, n_atoms_total, &logrosen2, main,
                         side, t, 1, atom2, atom_tmp, twig, &e2,
TRUE):
  e2 = energy(t, 1, atom2, n atoms total);
/* get old Rosenbluth weight */
  list num = main[i].unit->list num;
  e1 = 0.0;
  logrosen1 = 0.0;
  if (forward)
    do backbone f rigid(i, n main, n atoms total, &logrosen1, main,
                         side, t, 1, atom, atom tmp, twig, &el,
FALSE);
  else
    do_backbone_b_rigid(i, n_main, n_atoms_total, &logrosen1, main,
                         side, t, l, atom, atom tmp, twig, &el,
FALSE);
  printf("Wn Wo %lf %lf\n",logrosen2, logrosen1);
  printf("En Eo %lf %lf\n",e2, *e);
/* perform acceptance test */
  x = 1.0;
  if (logrosen1 > logrosen2) x = exp(logrosen2-logrosen1);
/* accept new configuration */
  if (ran2(1.0) < x) {
                  j<n atoms_total; j++) atom[j].position</pre>
    for
          (j=0;
atom2[j].position;
    *e = e2;
    printf("SWAP\n");
  }
}
/* This routine regrows a side chain
*/
void regrow side(torsion_list *t, hbond list *l,
                 atom_list *atom, atom_list *atom2, vector *twiq[],
                 regrowth *main, regrowth *side,
                 int n_side, int n_atoms_total, double *e)
  int list num, i, j, k, n1;
 double logrosen1, logrosen2, x, e2;
  if (n side ==0 ) return;
```

```
/* pick main group to start regrowth from */
  i = n_side*ran2(1.0);
 printf("regrowing side chain %d\n",i);
 list num = side[i].unit->list num;
 logrosen2 = 0.0;
/* copy old positions into new */
        (j=0; j<n_atoms_total; j++) atom2[j].position
atom[j].position;
/* regrow side chain */
 e2 = 0;
/* determine n1 */
side(i).prev->bond(side(i).prev->n bonds-1)->next->list num;
  do_unit(&list_num, 0, n1, n_atoms_total,
          &logrosen2, side[i].unit, side[i].unit, t, l, atom2,
twig,
          get_side_p0(atom, side, i), get_side_b0(atom, side, i),
          &e2);
 e2 = energy(t, 1, atom2, n_atoms_total);
/* get old Rosenbluth weight */
  list_num = side[i].unit->list_num;
 logrosen1 = 0.0;
 old unit(&list_num, 0, n1, n_atoms_total, &logrosen1,
           side[i].unit, side[i].unit, t, l, atom, twig,
          get_side_p0(atom, side, i), get_side b0(atom, side, i));
 printf("Wn Wo %lf %lf\n",logrosen2, logrosen1);
 printf("En Eo %lf %lf\n",e2, *e);
/* perform acceptance test */
 x = 1.0;
 if (logrosen1 > logrosen2) x = exp(logrosen2-logrosen1);
/* accept new configuration */
 if (ran2(1.0) < x) {
   for (j=side[i].unit->list num; j<list num; j++)</pre>
      atom(j).position = atom2(j).position;
   *e = e2;
   printf("SWAP\n");
 }
}
```

```
CONCERTED ROTATION ROUTINES - PEPTIDE6.C
************
                       The concerted rotation routines
/*
* /
#include "peptide.h"
/* global variables */
vector 1[8], r[8];
double theta[8], m[3][3];
logical head[8];
/* This routine performs a concerted rotation on part of the main
chain.
*/
void rotate main(atom list *atom, atom list *atom2, vector
                *twig[], regrowth *main, regrowth *side,
                torsion list *t, hbond list *l, int n main, int
                n_atoms_total, double *e)
{
  double jo, jn, logroseno, logrosenn, x, phil, eo, en;
  int no, nn, i, j, i1, i2, i0;
  vector q;
  logical valid[4];
  double phi2[4], phi3[4], phi4[4], f[4];
  i0 = n_main * ran2(1.0);
 printf("Rotating from position %d\n",i0);
/* copy atom positions to atom2 */
        (i=0;
  for
                i<n_atoms_total; i++) atom2[i].position
atom[i].position;
/* determine theta, r, l */
 get rot params (atom, main, i0, n main);
/* get original jacobian */
 jo = jac(atom, main, i0, n_main);
/* get constants needed by F5 */
 F5init(get_main_b0(atom, main, (i0+1) % n_main), &phil);
/* get original Rosenbluth weight */
```

eo = energy(t, l, atom, n_atoms_total);

```
get_rot_rosenbluth(atom, atoms_total, sno, si, slogroseno, sen);
                                                                                                                                      PC11US96104229
               Printf("*d\n",no);

if (no == 0) return;

if (no == 0) and get new concerants
                            get new Rosenbluth weight atoms total, snn, si, slogrosenn. get_rot_rosenbluth n atoms total,
             rotate rl and get new constants
WO 96130849
                     q = rotate riation, main, io, n main);
             Printf("&d\n", no);
                      ger new Rosembluth weight
                                    Prince ("*d'n", nn); |* geometric failure *|

prince ("*d'n", nn); |* geometric failure

if (nn == 0) receivions *!
                                                          or (i=i1; ici2; i**)
aroms_total).position = twig(j)[i * n_atoms_total);
arom2[i * n_atoms_total).position = twig(j)[i * n_atoms_total);
determine new Jacobian
                                             Printf("%d\n",nn);
                                    copy atomic positions *|
                                           il main(i0) unit alist num
                                                if (i2 × i1) i2 + n_atoms_totali
                                                   EOF (1=11; 2c12; 144)
                                                                 DOLOS MOVE * | * jn|jo * nn|no; * |

|* * * exp(-BETA*(en-eo)) * jn|jo * nn|no; * |
|* * * exp(-BETA*(en-eo)) * jn|jo * nn|no; * |
                                                           jn jac(atom2) main;
                                                    determine new Jacobian
                                                                      10,0)
                                                          Doros move *
                                                                            else if (logrosenn logroseno 20.0)
                                                                CEMC MOVE
                                                                                         aeride if more in anonted to
                                                                                         decide if move is accepted *
                                                                                            Printf ("En Eo &lf &lf \n", en, eo);
                                                                                                if (ran2(1.0) ex)
                                                                                                                  i2 = main(101, in); n main to rear to 
                                                                                                       Printf("SWAP\n");
                                                                                                                il main(i0) unit alist num;
                                                                                                          copy atomic positions *
                                                                                                                     if (i2 < i1) i2 * n_atoms_total;
```

```
for (i=i1; i<i2; i++)
                   n_atoms_total].position
      atom[i
               용
                                               = twig[j][i
n_atoms total];
    } els
    *e = eo;
/* This routine gets the theta, r, and l parameters */
void get rot params(atom list *atom, regrowth *main, int i0,
                    int n main)
{
  int i;
  vector t, v, v2;
  double len;
  rigid unit *unit, *unit2, *unit3;
/* determine theta */
  for (i=0; i<8; i++) {
    unit = main[(i+i0) % n_main].unit;
    theta[i] = vector_dot(unit->head.axis,
                          unit->bond(unit->n_bonds-1)->tail.axis)
/
                          vector length(unit->head.axis);
    theta[i] = (theta[i] < 1.0-EPS) ? acos(theta[i]) : 0.0;
                                                                }
/* determine r */
  for (i=0; i<8; i++) head[i] = TRUE;
  if (fabs(theta[5]) < EPS) head[5] = FALSE;</pre>
  for (i=0; i<8; i++) {
    unit = main[(i+i0) % n main].unit;
    r[i] = atom[unit->list_num + ((head[i]) ? unit->head.atom_num
:
          unit->bond(unit->n_bonds-1)->tail.atom_num)).position;
/* determine l */
  for (i=1; i<8; i++) {
    t.x = r[i].x - r[i-1].x;
    t.y = r[i].y - r[i-1].y;
    t.z = r[i].z - r[i-1].z;
    len = vector length(t);
   /* if (2.03<len && len <2.05) len = 2.038;
    t = vector scale(t, len); */
```

```
l[i].x = len; l[i].y = l[i].z = 0.0;
   if (((main[(i+i0) % n_main].prev->type == Cunit) &&
         head[i-1]) || !head[i]) {
     1[i].x = vector_dot(t, get_main_b0(atom, main, (i+i0) %
n main));
     l[i].y = sqrt(len * len - l[i].x * l[i].x);
  }
/+
 for (i=1; i<8; i++) printf("%d %lf %lf %lf %lf\n",i, theta[i],
                             l[i].x, l[i].y, l[i].z);
 for (i=1; i<8; i++)
   printf("%d %lf %lf %lf\n",i, r[i].x, r[i].y, r[i].z);
*/
/* This routine checks the rigid unit theta values
*/
void check_theta(atom_list *atom, regrowth *main, int n_main)
  int i;
  vector t, v, v2, r;
  double len, theta;
  rigid unit *unit, *unit2, *unit3;
  for (i=0; i<n_main; i++) {
   unit = main[i % n_main].unit;
   unit2 = main[i % n main].prev;
   unit3 = main[(i+1) % n main].unit;
    r = atom[unit->list_num + unit->head.atom_num].position;
    t = atom[unit2->list_num +
unit2->bond[unit2->n_bonds-1]->tail.atom_num].position;
    t.x = r.x - t.x; t.y = r.y - t.y; t.z = r.z - t.z;
                         %lf ", vector length(t),
     printf("%lf
vector length(unit->head.axis));
    v = atom[unit3->list num + unit3->head.atom_num].position;
    v2 = atom[unit->list_num +
         unit->bond[unit->n bonds-1]->tail.atom_num].position;
    v.x = v2.x; v.y = v2.y; v.z = v2.z;
    theta = v ctor_dot(t, v) / (vector_length(v)*v ctor_length(t));
```

```
theta = (theta < 1.0-EPS) ? acos(theta) : 0.0;
     printf("%d %lf ",i, theta);
     theta = vector_dot(unit->head.axis,
                         unit->bond(unit->n_bonds-1)->tail.axis) /
                         vector_length(unit->head.axis);
     theta = (theta < 1.0-EPS) ? acos(theta) : 0.0;
     printf("%lf \n", theta);
 /* This routine determines the Rosenbluth weight */
 void get_rot_rosenbluth(atom_list *atom, atom_list *atom2,
                         vector *twig[], regrowth *main,
                         torsion_list *t, hbond_list *1, int i0,
                         int n_main, int n_atoms_total, int *n,
                         int *j, double *logrosen, double *e)
  double phi[MAX_ROOTS][5], phil, max, sum, de[MAX_ROOTS], ftmp;
  int i, k, k1, k2;
/* get phi0-phil solutions */
  get_phil(phi, n);
  if (*n == 0) return;
  if (*n > MAX ROOTS) {
    printf("too many roots\n");
    *n = 0;
    return;
/* determine energies of solutions */
  max = -1E99;
  for (i=0; i<*n; i++) {
    get_r(phi[i][1], phi[i][2], phi[i][3], phi[i][4]);
    do_rotation(atom, twig[i], main, i0, n_main, n_atoms_total);
    k1 = main[i0].unit->list_num;
    k2 = main[(i0+7) % n_main].unit->list_num;
    if (k2 < k1) k2 += n_atoms_total;</pre>
    for (k=k1; k< k2; k++)
      atom2[k % n_atoms_total].position = twig[i][k
n_atoms_total];
    de[i] = -BETA*energy(t, 1, atom2, n_atoms_total);
    if (de[i] > max) max = de[i];
```

```
}
  sum = 0.0;
  for (i=0; i<*n; i++) {
    de[i] = exp(de[i] - max);
    sum += de[i];
  *logrosen = log(sum) + max;
/* pick winner */
/* Doros move */
  /* *j = *n*ran2(1.0); */
/* CBMC move */
 de[0] /= sum;
  for (i=1; i<*n; i++) de[i] = de[i-1] + de[i]/sum;
  ftmp = ran2(1.0);
  for (*j=0; *j<*n; (*j)++) if (ftmp <= de[*j]) break;
/* get energy of winner */
  ftmp = de[*j];
  if (*j > 0) ftmp -= de[*j-1];
ftmp *= sum;
  *e = -(log(ftmp)+max)/BETA;
/* assign r to the winner */
 get_r(phi[*j][1], phi[*j][2], phi[*j][3], phi[*j][4]);
}
/* This routine calculates the jacobian
*/
double jac(atom list *atom, regrowth *main, int i0, int n main)
 int i:
 vector u[7], h[6], t, v;
 double b[5][5];
/* form ui and hi */
  for (i=1; i<7; i++) u[i] = get_main_b0(atom, main, (i0+i))
%n_main);
 for (i=1; i<5; i++) h[i] = r[i];
 h[5] = atom[main[(i0+5)%n_main].unit->list_num +
             main[(i0+5)%n_main].unit->head.atom_num].position;
 v.x = r[6].x - h[5].x; v.y = r[6].y - h[5].y;
 v.z = r[6].z - h[5].z;
```

```
v = vector scale(v, 1.0);
/* form B matrix */
  for (i=1; i<6; i++) {
    t.x = r[5].x - h[i].x;
    t.y = r[5].y - h[i].y;
    t.z = r[5].z - h[i].z;
    t = vector_cross(u[i], t);
    b[0][i-1] = t.x;
    b[1][i-1] = t.y;
    b[2][i-1] = t.z;
  }
  for (i=1; i<6; i++) {
    t = vector_cross(u[i], u[6]);
    b[3][i-1] = t.x;
    b[4][i-1] = t.y;
  return(1.0/fabs(det5(b)));
/* This routine rotates phi0 to change r[1].
   It returns the new b0 for unit i0+1.
*/
vector rotate_r1(atom_list *atom, regrowth *main, int i0, int
                 n main)
  double c, s, y;
  vector x, n;
/* choose delta phi0 */
  y = DPHI + (1-2*ran2(1.0));
  c = cos(y);
  s = sin(y);
  n = get_main_b0(atom, main, i0);
/* rotate about axis */
 x = r[1];
 x.x -= r[0].x;
 x.y -= r[0].y;
 x.z -= r[0].z;
 x = vector_rotate(x, n, c, s);
 r[1].x = r[0].x + x.x;
  r[1].y = r[0].y + x.y;
```

```
r[1].z = r[0].z + x.z;
/* compute new b0 for unit i0+1 */
  return(vector_rotate(get_main_b0(atom, main, (i0+1) % n main),
n, c, s));
/* This routine constructs r2-r4 from the theta, phi
information */
void get_r(double phi1, double phi2, double phi3, double phi4)
{
  int i;
  vector x, y;
/*
  printf("\n");
  printf("%lf %lf %lf %lf %lf\n", phi1, phi2, phi3, phi4);
* /
  x = bxm(m, l[1]);
  r[1].x = x.x + r[0].x;
  r[1].y = x.y + r[0].y;
  r[1].z = x.z + r[0].z;
  x = bxm(m, flory rot(theta[1], phi1, 1[2]));
  r[2].x = x.x + r[1].x;
  r[2].y = x.y + r[1].y;
  r[2].z = x.z + r[1].z;
  x = bxm(m, flory rot(theta[1], phil, flory rot(theta[2], phi2,
1[3])));
  r[3].x = x.x + r[2].x;
  r[3].y = x.y + r[2].y;
  r[3].z = x.z + r[2].z;
  x = bxm(m, flory_rot(theta[1], phil, flory_rot(theta[2],
          phi2, flory_rot(theta[3], phi3, 1[4]))));
  r[4].x = x.x + r[3].x;
 r[4].y = x.y + r[3].y;
 r[4].z = x.z + r[3].z;
 for (i=1; i<7; i++)
    printf("%d %lf %lf %lf\n",i, r[i].x, r[i].y, r[i].z);
*/
}
/* This routine rotates the rigid units to the positions
```

```
of the concerted rotation.
*/
void do_rotation(atom_list *atom, vector *twig, regrowth *main,
                 int iO, int n main, int n_atoms_total)
{
  int i, j, i1, i2, i3, j2;
  double m[3][3], a[3][3], tmp, len2;
  vector x1, x2, y1, y2, x;
  rigid unit *unit;
  for (i=-1; i<6; i++) {
  il = (i+i0+n main) % n_main;
  i2 = (i+i0+1) % n main;
  i3 = (i+i0+2) % n_main;
/* get x1 & x2 */
  x1 = r\{i+1\};
  x = (i > -1) ?
twig[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num+
             main[i1].unit->list_num] :
atom[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num+
             main[il].unit->list_num].position;
    x1.x = x.x; x1.y = x.y; x1.z = x.z;
    x2 = atom[main[i2].unit->list_num + ((head[i+1]) ?
              main[i2].unit->head.atom_num :
main[i2].unit->bond(main[i2].unit->n_bonds-1]->tail.atom_num)]
              .position;
                                      X
atom[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num
              main[i1].unit->list_num].position;
    x2.x -= x.x; x2.y -= x.y; x2.z -= x.z;
/* get rotation matrix */
    flory lab(a, x1, x2);
/* get y1 & y2 */
   y1 = r[i+2];
    x = (i > -1) ?
```

```
twig[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num+
              main[i1].unit->list_num] :
 atom[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num+
              main[i1].unit->list_num].position;
     y1.x = x.x; y1.y = x.y; y1.z = x.z;
     y2 = atom[main[i3].unit->list_num + ((head[i+2]) ?
               main[i3].unit->head.atom_num :
main[i3].unit->bond[main[i3].unit->n_bonds-1]->tail.atom_num)]
               .position;
atom[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num
             main[i1].unit->list_num].position;
    y2.x = x.x; y2.y = x.y; y2.z = x.z;
    y2 = mxb(a, y2);
/* get projection */
    len2 = vector_length2(x1);
    tmp = vector_dot(y2, x1) / len2;
    y2.x = x1.x * tmp;
    y2.y = x1.y * tmp;
    y2.z = x1.z + tmp;
    tmp = vector_dot(y1, x1) / len2;
    y1.x -= x1.x * tmp;
    y1.y = x1.y + tmp;
    y1.z = x1.z * tmp;
/* get rotation matrix */
    flory_lab(m, y1, y2);
    mxm (m, a);
/* perform rotation */
                                       . 1
                                 X
atom[main[i1].unit->bond[main[i1].unit->n_bonds-1]->tail.atom_num-
              main[i1].unit->list_num].position;
   x2 = (i > -1)?
twig(main(i1).unit->bond(main(i1).unit->n_bonds-1)->tail.atom_num+
          main[i1].unit->list_num] : x1;
   j2 = main(i3).unit->list num;
```

```
if (i3 == 0) j2 = n_atoms_total;
      for (j=main[i2].unit->list_num; j < j2; j++) {</pre>
        x = atom[j].position;
        x.x -= x1.x;
        x.y = x1.y;
        x.z = x1.z;
        x = mxb(m, x);
       x.x += x2.x;
       x.y += x2.y;
       x.z += x2.z;
       twig[j] = x;
     }
   }
 /* This routine determines the phil-phi3 values
 */
 void get_phil(double phi[MAX_ROOTS][5], int *n)
 #define NTRY 10000
   int i, j;
   logical valid[NTRY+1][4];
  double phi1[NTRY+1], phi2[4], phi3[4], phi4[4];
   double f[NTRY+1][4];
  *n = 0;
   i = 0;
/* Evaluate F5 */
  for (i=0; i<=NTRY; i++) {</pre>
    phil(i) = -PI + i*2*PI/NTRY;
    F5(phi1[i], phi2, phi3, phi4, f[i], valid[i]);
/* Now search for roots */
  for (i=0; i<NTRY; i++) {
    for (j=0; j<4; j++) {
      if (!valid[i][j] | !valid[i+1][j]) continue;
      if ((f[i][j] < 0 && f[i+1][j] > 0)
          (f[i][j] > 0 && f[i+1][j] < 0)) {
        if (*n >= MAX_ROOTS) {
          printf("Exc ssive number of roots
                                                     failure
                                                                in
get_phi1\n");
```

```
return;
          }
         get_root(phi1[i], phi1[i+1], &phi[*n][1], &phi[*n][2],
                   &phi[*n][3], &phi[*n][4], j);
          (*n)++;
       }
     }
 #undef NTRY
 }
 /* This routine refines a root using bisection
 void get_root(double x0, double x1, double *p1, double *p2,
 double *p3,
                            double *p4, int n)
   logical valid[4];
  double phi2[4], phi3[4], phi4[4], f[4];
/* order roots: f(x0) < 0 \&\& f(x1) > 0 */
  F5(x1, phi2, phi3, phi4, f, valid);
  if (f[n] < 0.0) {
    *p1 = x0;
    x0 = x1;
    x1 = *p1;
  }
/* do bisection to refine root */
  do {
    *p1 = 0.5*(x1+x0);
    F5(*p1, phi2, phi3, phi4, f, valid);
    if (f[n] > 0) x1 = *p1; else x0 = *p1;
  \} while (fabs(x1-x0) > EPS);
  *p2 = phi2[n];
  *p3 = phi3[n];
  *p4 = phi4[n];
/* constants */
double c10, c11, c12, q12, c20, c21, c22, fact1, fact2;
vector x0, u60;
/* This routine sets up constants that F5 uses.
   The constants are independent of phil
```

WO 96/30849 PCT/US96/04229 */ void F5init(vector q2, double *phil) int i,j; vector t; double c1, c2, a[3][3], tmp; t.x = 1.0; t.y = t.z = 0.0;flory_labinv(m, q2, t); t.x = r[1].x - r[0].x; t.y = r[1].y - r[0].y; t.z = r[1].z r[0].z; t = mxb(m, t);if (fabs(t.y) < EPS && fabs(t.z) < EPS) { C1 = 1.0;c2 = 0.0;} else { c1 = (1[1].y*t.y + t.z*1[1].z)/(t.y*t.y + t.z*t.z);c2 = (-1[1].z*t.y + t.z*1[1].y)/(t.y*t.y + t.z*t.z);if (fabs(c1) < EPS && fabs(c2) < EPS) c1 = 1.0;} a[0][0] = 1; a[0][1] = 0; a[0][2] = 0;a[1][0] = 0; a[1][1] = c1; a[1][2] = c2;a[2][0] = 0; a[2][1] = -c2; a[2][2] = c1;mxm(a, m); for (i=0; i<3; i++) for (j=0; j<3; j++) m[i][j] = a[i][j]; t.x = r[2].x - r[1].x; t.y = r[2].y - r[1].y; t.z = r[2].z r[1].z; t = mxb(m, t);tmp = $(\sin(theta[1])*1[2].x - \cos(theta[1])*1[2].y);$ *phil = atan2(t.z/tmp, t.y/tmp); x0.x = r[5].x - r[0].x; x0.y = r[5].y - r[0].y; x0.z = r[5].z - r[5]r[0].z; x0 = mxb(m, x0);x0.x -= 1[1].x;x0.y = 1[1].y;x0.z = 1[1].z;if (fabs(theta[5]) < EPS && fabs(theta[3]) < EPS) {</pre>

cl0 = 1[3].x*cos(theta[4]);

```
c11 = -(\cos(theta[2])*1[3].x + \sin(theta[2])*1[3].y);
    tmp = sin(theta[2])*1[3].x - cos(theta[2])*1[3].y;
    c10 /= tmp;
    cl1 /= tmp;
  } else if (fabs(theta[5]) < EPS && fabs(theta[3]) > EPS) {
    c10 = -1[5].x - 1[4].x*cos(theta[4]);
    c11 = -(\cos(theta[2])*1[3].x + \sin(theta[2])*1[3].y);
    c12 = 1.0/(\sin(theta[2]) + 1[3] \cdot x - \cos(theta[2]) + 1[3] \cdot y);
  } else if (fabs(theta[3]) > EPS) {
    t.z = 0.0:
   t.x = 1[4].x*cos(theta[4]) - 1[4].y*sin(theta[4]) + 1[5].x;
    t.y = 1[4].x*sin(theta[4]) + 1[4].y*cos(theta[4]) + 1[5].y;
   g12 = vector length2(t);
   c10 = q12 - vector length2(1[3]);
   c11 = 2*(cos(theta[2])*1[3].x + sin(theta[2])*1[3].y);
   c12 = -1.0/(2*(sin(theta[2])*1[3].x - cos(theta[2])*1[3].y));
  } else {
   c10 = 1[3].x + 1[4].x + 1[5].x*cos(theta[4]);
    cll = -cos(theta[2]);
   tmp = sin(theta[2]);
   c10 /= tmp;
    cl1 /= tmp;
  c20 = vector length2(1[5]) - vector_length2(1[4]);
  c21 = 2*(cos(theta[3])*1[4].x + sin(theta[3])*1[4].y);
 c22 = -1.0/(2*(sin(theta[3])*1[4].x - cos(theta[3])*1[4].y));
 fact1 = sin(theta[4])*1[5].x - cos(theta[4])*1[5].y;
 fact2 = 1[6].x*cos(theta[5]) + 1[6].y*sin(theta[5]);
 u60.x = r[6].x - r[5].x; u60.y = r[6].y - r[5].y; u60.z = r[6].z
-r[5].z;
/* This routine returns the F5 function of Doros.
   *n is the number of solutions, which are in f.
*/
void F5(double phi1, double phi2[4], double phi3[4], double
        phi4[4], double f[4], logical valid[4])
  int i, j;
  double tmp, c1, c2;
```

```
vector v1, q1, q2, x, y, t, u6;
  double a[3][3], rot1[3][3], rot2[3][3], rot3[3][3], rot4[3][3];
/* determine c1 */
  valid[0] = valid[1] = valid[2] = valid[3] = FALSE;
  flory rot matrix(theta[1], phil, rot1);
 x = bxm(rot1, x0);
 x.x = 1[2].x; x.y = 1[2].y; x.z = 1[2].z;
  if (fabs(theta[5]) < EPS && fabs(theta[3]) < EPS) {
    x = bxm(rot1, mxb(m, vector scale(u60, 1.0)));
    c1 = (c10 + x.x*c11) / sqrt(x.y*x.y + x.z*x.z);
  } else if (fabs(theta[5]) < EPS && fabs(theta[3]) > EPS) {
    x = bxm(m, flory_rot(theta[1], phil, 1[2]));
    r[2].x = x.x + r[1].x; r[2].y = x.y + r[1].y; r[2].z = x.z +
r[1].z;
    t.x = r[5].x - r[2].x; t.y = r[5].y - r[2].y; t.z = r[5].z -
r[2].z;
    x = bxm(rot1, mxb(m, vector_scale(u60,1.0)));
    c1 = c12*(c10 + vector_dot(t,
        u60)/vector_length(u60) + x.x*c11) / sqrt(x.y*x.y +
x.z*x.z);
  } else if (fabs(theta[3]) > EPS) {
    c1 = c12*(c10 - vector length2(x) + x.x*c11) / sqrt(x.y*x.y +
x.z*x.z);
  } else {
    c1 = (c10 + x.x*c11) / sqrt(x.y*x.y + x.z*x.z);
  /* printf("c1 %lf\n",c1); */
  if (fabs(c1) > 1) return;
/* determine phi2 */
 tmp = asin(c1);
 phi2[0] = phi2[2] = -atan(x.y/x.z);
  if (x.z < 0) phi2[0] = phi2[2] = phi2[0] - PI;
 phi2[0] += tmp;
 phi2[2] += PI - tmp;
 phi2[1] = phi2[0];
 phi2[3] = phi2[2];
 x = v1;
/* determine c2 and phi3 */
```

```
for (i=0; i<2; i++) {
     y = flory_rotinv(theta[2], phi2[2*i], x);
     y.x = 1[3].x; y.y = 1[3].y; y.z = 1[3].z;
     c2 = c22*(c20 - vector_length2(y) + y.x*c21) / sqrt(y.y*y.y +
 y.z*y.z);
     /* printf("c2 %lf\n",c2); */
     if (fabs(c2) <= 1) {
       tmp = asin(c2);
       phi3[2*i] = phi3[2*i+1] = -atan(y.y/y.z);
       if (y.z < 0) phi3[2*i] = phi3[2*i+1] = phi3[2*i+1] - PI;
      phi3[2*i] += tmp;
      phi3[2*i+1] += PI - tmp;
      valid[2*i] = valid[2*i+1] = TRUE;
    }
  for (i=0; i<4; i++) {
    if (!valid[i]) continue;
/* determine r4 */
    flory_rot_matrix(theta[2], phi2[i], rot2);
    flory_rot_matrix(theta[3], phi3[i], rot3);
    x = mxb(rot3, 1[4]);
    x.x += 1[3].x; x.y += 1[3].y; x.z += 1[3].z;
    x = mxb(rot2, x);
    x.x += 1[2].x; x.y += 1[2].y; x.z += 1[2].z;
    x = mxb(rot1, x);
    x.x += 1[1].x; x.y += 1[1].y; x.z += 1[1].z;
    x = bxm(m, x);
    x.x += r[0].x; x.y += r[0].y; x.z += r[0].z;
/* determine F5 */
    if (fabs(theta[5]) < EPS && fabs(theta[3]) < EPS) {</pre>
      vl.x = r[6].x - x.x; vl.y = r[6].y - x.y; vl.z = r[6].z -
x.z;
      f[i] = sqrt((1[6].x+1[5].x)*(1[6].x+1[5].x) +
                  1[5].y*1[5].y) - vector_length(v1);
    } else if (fabs(theta[5]) < EPS && fabs(theta[3]) > EPS) {
     x = bxm(m, mxb(rot1, mxb(rot2, mxb(rot3, 1[4]))));
      f[i] = vector_dot(x, u60) /
            (vector_length(x)*vector_length(u60)) - cos(theta[4]);
    } else {
```

```
x.x = r[5].x - x.x; x.y = r[5].y - x.y; x.z = r[5].z - x.z;
     x = mxb(m, x);
     x = bxm(rot3, bxm(rot2, bxm(rot1, x)));
     phi4[i] = atan2(x.z/fact1, x.y/fact1);
     u6 = mxb(m, u60);
     x.x = 1.0; x.y = 0; x.z = 0;
     f[i] = vector_dot(u6, mxb(rot1, mxb(rot2, mxb(rot3,
                      flory rot(theta[4], phi4[i], x)))) -
fact2;
  }
}
********************
           GEOMETRY/ROTATION ROUTINES - PEPTIDE7.C
******************
/*
                      The geometry routines
*/
#include "peptide.h"
/* This routine rotates the vector a about n by theta
(counterclockwise is +)
 r' = r \cos(theta) + n(n.r)(1-\cos(theta)) + nxr \sin(theta)
*/
vector vector rotate (vector a, vector n, double cos theta, double
sin_theta)
 double fact;
 vector ret, v;
 fact = (n.x*a.x + n.y*a.y + n.z*a.z) * (1.0 - cos_theta);
 v = vector cross(n,a);
 ret.x = a.x*cos theta + n.x*fact + v.x*sin theta;
 ret.y = a.y*cos_theta + n.y*fact + v.y*sin_theta;
 ret.z = a.z*cos_theta + n.z*fact + v.z*sin_theta;
 return(ret);
/* This routine returns main-chain b0
  i=0 noncyclic case should never happen--it won't be right
*/
```

```
vector get_main_b0(atom_list *atom, regrowth *main, int i)
 vector x, y;
 if (main[i].prev == NULL) {
   x.x = x.y = 0.0;
   x.z = 1.0;
   return(x);
  }
             atom [main[i].unit->list num
main[i].unit->head.atom_num].position;
                                                         У
atom[main[i].prev->bond[main[i].prev->n_bonds-1]->tail.atom num +
          main(i).prev->list num).position;
 .x.x -= y.x;
 x.y = y.y;
 x.z = y.z;
 return(vector scale(x, 1.0));
/* This routine returns main-chain p0
  i=0 noncyclic case should never happen--it won't be right
*/
vector get_main_p0(atom_list *atom, regrowth *main, int i)
 vector x;
  if (main[i].prev == NULL) {
   x.x = x.y = x.z = 0.0;
   return(x);
  }
atom[main[i].prev->bond[main[i].prev->n bonds-1]->tail.atom num +
          main[i].prev->list_num].position;
 return(x);
/* This routine returns side-chain b0 */
vector get_side_b0(atom_list *atom, regrowth *side, int i)
 vector x, y;
             atom[side[i].unit->list_num
side(i).unit->head.atom_num].position;
```

```
y = atom[side[i].prev->list num
side[i].prev->head.atom_num].position;
  x.x -= y.x;
  x.y -= y.y;
  x.z = y.z;
  return(vector scale(x, 1.0));
/* This routine returns side-chain p0 */
vector get side_p0(atom list *atom, regrowth *side, int i)
{
  vector x;
   x = atom[side[i].prev->list_num +
side[i].prev->head.atom_num].position;
  return(x);
}
/* This routine gives the Flory rotation matrix
void flory rot matrix(double theta, double phi, double m[3][3])
{
  double cost, sint, cosp, sinp;
  cost = cos(theta); sint = sin(theta);
  cosp = cos(phi); sinp = sin(phi);
  m[0][0] = cost;
  m[0][1] = sint;
  m[0][2] = 0.0;
  m[1][0] = sint*cosp;
 m[1][1] = -cost*cosp;
 m(1)[2] = sinp;
 m[2][0] = sint*sinp;
 m[2][1] = -cost*sinp;
 m[2][2] = -cosp;
/* This routine does the Flory rotation
*/
vector flory rot (double theta, double phi, vector a)
 vector t;
 double cost, sint, cosp, sinp, tmp;
  cost = cos(theta); sint = sin(theta);
```

```
cosp = cos(phi); sinp = sin(phi);
  tmp = sint*a.x - cost*a.y;
  t.x = cost*a.x + sint*a.y;
  t:y = cosp*tmp + sinp*a.z;
  t.z = sinp*tmp - cosp*a.z;
  return(t);
/* This routine does the inverse Flory rotation
*/
vector flory_rotinv(double theta, double phi, vector a)
 vector t;
  double cost, sint, cosp, sinp, tmp;
  cost = cos(theta); sint = sin(theta);
  cosp = cos(phi); sinp = sin(phi);
  tmp = cosp*a.y + sinp*a.z;
  t.x = cost*a.x + sint*tmp;
  t.y = sint*a.x - cost*tmp;
  t.z = sinp*a.y - cosp*a.z;
  return(t);
}
/* This routine constructs the lab transformation to go from 1 to
*/
void flory lab(double m[3][3], vector r, vector l)
  double sin theta, cos_theta;
  vector n;
  r = vector scale(r, 1.0);
  l = vector_scale(1, 1.0);
  n = vector_cross(1,r);
  cos_theta = vector_dot(1,r);
  sin_theta = vector_length(n);
  if (sin theta < EPS) {
    n.x = 1.0;
  } else {
    n.x /= sin theta;
    n.y /= sin_theta;
    n.z /= sin_theta;
```

```
}
  m[0][0] = \cos theta + n.x*n.x*(1.0-\cos theta)
                        n.x*n.y*(1.0-cos_theta) - sin_theta*n.z;
  m[0][1] =
                        n.x*n.z*(1.0-cos_theta) + sin_theta*n.y;
  m[0][2] =
                        n.y*n.x*(1.0-cos theta) + sin theta*n.z;
 m[1][0] =
 m[1][1] = \cos theta + n.y*n.y*(1.0-cos_theta)
                        n.y*n.z*(1.0-cos theta) - sin_theta*n.x;
 m[1][2] =
                        n.z*n.x*(1.0-cos theta) - sin_theta*n.y;
 m[2][0] =
                        n.z*n.y*(1.0-cos_theta) + sin_theta*n.x;
 m[2][1] =
 m[2][2] = \cos theta + n.z*n.z*(1.0-\cos theta)
/* This routine constructs the inverse lab transformation
*/
void flory labinv(double m[3][3], vector r, vector l)
 double sin theta, cos_theta;
 vector n;
 r = vector_scale(r, 1.0);
 1 = vector_scale(1, 1.0);
 n = vector_cross(1,r);
  cos theta = vector_dot(1,r);
  sin theta = vector_length(n);
  if (sin theta < EPS) {
   n.x = 1.0;
  } else {
   n.x /= sin theta;
   n.y /= sin theta;
   n.z /= sin_theta;
 m[0][0] = cos_theta + n.x*n.x*(1.0-cos_theta)
 m[1][0] =
                        n.x*n.y*(1.0-cos theta) - sin theta*n.z;
 m[2][0] =
                        n.x*n.z*(1.0-cos_theta) + sin_theta*n.y;
 m[0][1] =
                        n.y*n.x*(1.0-cos theta) + sin theta*n.z;
 m[1][1] = cos_theta + n.y*n.y*(1.0-cos_theta)
 m[2][1] =
                        n.y*n.z*(1.0-cos theta) - sin theta*n.x;
                        n.z*n.x*(1.0-cos_theta) - sin_theta*n.y;
 m[0][2] =
 m[1][2] =
                        n.z*n.y*(1.0-cos_theta) + sin_theta*n.x;
 m[2][2] = \cos th ta + n.z*n.z*(1.0-\cos_theta)
```

```
/* This routine returns a vector cross product
vector vector_cross(vector a, vector b)
  vector ret;
  ret.x = a.y*b.z - a.z*b.y;
  ret.y = a.z*b.x - a.x*b.z;
  ret.z = a.x*b.y - a.y*b.x;
  return(ret);
}
/* This function scales the vector v so that |v| = r
* /
vector vector scale(vector v, double r)
  double ftmp;
  ftmp = sqrt(v.x*v.x + v.y*v.y + v.z*v.z);
  v.x *= r/ftmp;
  v.y *= r/ftmp;
  v.z = r/ftmp;
  return(v);
/* This routine returns mxn in m
*/
void mxm(double m[3][3], double n[3][3])
  int i,j,k;
  double a[3][3];
  for (i=0; i<3; i++)
    for (j=0; j<3; j++) {
     a[i][j] = 0.0;
     for (k=0; k<3; k++) a[i][j] += m[i][k]*n[k][j];
  for (i=0; i<3; i++)
    for (j=0; j<3; j++)
     m[i][j] = a[i][j];
/* This routine deturns det(m), where m is 5x5
*/
double det5(doubl m[5][5])
```

```
int i,j,k;
   double a[5][5], fact;
   for (i=0; i<5; i++)
    for (j=0; j<5; j++)
       a[i][j] = m[i][j];
  for (i=0; i<4; i++) {
    for (k=i+1; k<5; k++) {
      fact = a[k][i] / a[i][i];
      for (j=i; j<5; j++) a[k][j] -= fact*a[i][j];
  }
  return(a[0][0]*a[1][1]*a[2][2]*a[3][3]*a[4][4]);
/* This routine returns det(m), where m is 3x3
*/
double det(double m[3][3])
  return (m[0][0]*m[1][1]*m[2][2] + m[0][1]*m[1][2]*m[2][0] +
         m[0][2]*m[1][0]*m[2][1] - m[2][0]*m[1][1]*m[0][2] -
         m[1][0]*m[0][1]*m[2][2] - m[0][0]*m[2][1]*m[1][2]);
/* This routine returns Mb
*/
vector mxb(double m[3][3], vector b)
  vector t;
  t.x = m[0][0]*b.x + m[0][1]*b.y + m[0][2]*b.z;
  t.y = m[1][0]*b.x + m[1][1]*b.y + m[1][2]*b.z;
  t.z = m[2][0]*b.x + m[2][1]*b.y + m[2][2]*b.z;
  return(t);
/* This routine returns Mb
*/
vector bxm(double m[3][3], vector b)
 vector t;
```

```
t.x = m[0][0]*b.x + m[1][0]*b.y + m[2][0]*b.z;
  t.y = m[0][1]*b.x + m[1][1]*b.y + m[2][1]*b.z;
  t.z = m[0][2]*b.x + m[1][2]*b.y + m[2][2]*b.z;
  return(t);
/* This routine returns b1.b2
* /
double vector dot(vector b1, vector b2)
  return(b1.x*b2.x + b1.y*b2.y + b1.z*b2.z);
/* This routine returns |v|
*/
double vector length(vector v)
  return(sqrt(v.x*v.x + v.y*v.y + v.z*v.z));
/* This routine returns |v|^2
*/
double vector length2 (vector v)
 return (v.x*v.x + v.y*v.y + v.z*v.z);
              RANDOM NUMBER GENERATOR - RANDOM C
*************
/*
  This is the pseudo-random number library.
*/
#include <time.h>
  This function returns a random number in [0,1).
  It uses a linear-congruential method.
 ran(0.0) initializes the random number seed with a time dependant
valu
 and returns the value of the s ed that the generator
recognizes.
```

ran(1.0) returns the next number in the random sequence. Other arguments initialize the seed with the user-supplied value. Initializing the generator with a seed from the sequence, will cause the subsequent ran(1.0) to generate the next value of the sequence. This is usefull, for example, to shut down and start up the generator without a loss of continuity in the sequence. Values r 1 or < 0 are not recommended. It has a period of M. ***** / double ran(double dummy) static long int ix; double rm = 566927.0, rm2 = 1.0/rm;long int k = 5701, j = 3621, m = 566927, tmp; /* make sure parameters not too far off */ if (dummy > 2.0) dummy = 2.0;if (dummy < -2.0) dummy = -2.0; if (dummy != 1.0) { if ((tmp = dummy*rm) < m)ix = tmp;else ix = m-1;if (ix < 0)ix = 0;} else ix = (j*ix + k) % m;return(ix * rm2); This function returns a pseudo-random number in (0,1). This is a more robust pseudo-random number generator than a simple linearcongruential gererator is.

It uses three linear congruential generators to get one random number.

ran2(0.0) initializes the generator with time-dependent values.

```
ran2(1.0) returns a pseudo-random number.
  Other arguments are used as an initializing seed.
  Arguments r 1 or s 0 are ill-advised.
  It has a period of (m1-1)(m2-1)(m3-1)/4.
*/
double ran2 (double dummy)
 double f1=1.0/30269.0 ,f2=1.0/30307.0, f3=1.0/30323.0, tmp;
 int m1=30269, m2=30307, m3=30323, seed, itmp;
 static x,y,z;
    /* make sure parameters not too far off */
 if (dummy > 1.1) dummy = 1.1;
 if (dummy < -1.1) dummy = -1.1;
 if (dummy != 1.0)
 {
                /* initialize with user's seed value */
     if ((itmp = dummy*ml) < ml)</pre>
       seed = itmp;
     else
       seed = m1-1;
   if (seed < 1) seed = 1;
                               /* initialize first generator */
   x = seed;
                               /* initialize second generator */
   Y = 172 * (x % 176) - 35 * (x/176);
   if (y < 0) y += m2;
                               /* initialize third generator */
   z = 170 * (y % 178) - 63 * (y/178);
   if (z < 0) z += m3;
 }
                                     /* first generator */
x = 171 * (x % 177) -
                         2 * (x/177);
 if (x < 0) x += m1;
                                     /* second generator */
Y = 172 * (y % 176) - 35 * (y/176);
if (y < 0) y += m2;
                                     /* third generator */
z = 170 * (z % 178) - 63 * (z/178);
if (z < 0) z += m3;
```

```
/* amalgamated result */
  itmp = tmp = x*f1 + y*f2 + z*f3;
 return(tmp - itmp);
}
                     C INCLUDE FILES
************************
**********
             GLOBAL VARIABLE TYPES - PEP_TYPE.H
********
/* Global types used in the program */
typedef enum {FALSE, TRUE} logical;
typedef enum {BAD, G, A, V, L, I, S, T, D, E, N, Q, K, H, R, F, Y,
W, C, M, P)
     acid label;
typedef enum {UNKNOWN, nonCunit, Cunit} unit_label;
typedef struct {
              double x,y,z;
             ) vector;
typedef struct {
              vector axis;
              int atom num;
              int bond[MAX_BONDS];
             } connector;
typedef struct bond struct {
              connector tail;
              struct rigid_unit struct *next;
            } bond_type;
typedef char *string;
typedef struct {
              char name [NAME_LENGTH];
              char type[NAME LENGTH];
              double charge, ri, ei;
```

```
vector position;
                  acid label residue;
                  int residue_num;
                } atom info;
typedef struct rigid_unit_struct {
                  unit label type;
                  connector head;
                  int list_num;
                  int n_bonds;
                  bond_type **bond;
                  int n atoms;
                  atom info *atom;
                } rigid_unit;
typedef struct {
                  atom info *p;
                  vector position;
                } atom list;
typedef struct {
                  char type1 [NAME_LENGTH], type2 [NAME_LENGTH],
                       type3 [NAME_LENGTH], type4 [NAME LENGTH];
                 double v0[3], phi0[3];
                } torsion_data;
typedef struct torsion_list_struct {
                 int num[4];
                 torsion data *p;
                 int degen;
                 struct torsion list struct *next;
               } torsion list;
typedef struct {
                 char type[NAME LENGTH];
                 double ri, ei;
               } lj data;
typedef struct {
                 char type1[NAME_LENGTH], type2[NAME_LENGTH];
                 double a, b;
               } hbond data;
typedef struct hbond_list_struct {
                 int num[2];
                 hbond data *p;
```

```
struct hbond_list_struct *next;
             } hbond_list;
typedef struct {
               rigid_unit *unit, *prev;
             } regrowth;
*******************
                GLOBAL VARIABLES - PEP_VAR.H
**********
/* Global variables used in the program */
#if defined(MAIN)
#define EXT extern
#else
#define EXT
#endif
EXT torsion data **torsion_data_list;
EXT lj_data **lj_data_list;
EXT hbond_data **hbond_data_list;
#undef EXT
                GLOBAL FUNCTIONS - PEPTIDE.H
/* Include files needed by peptide code */
#include <stdio.h>
#include <float.h>
#include <math.h>
#include <fcntl.h>
#include <stdio.h>
#include <memory.h>
#include <malloc.h>
#include <string.h>
#include <search.h>
#include <stdlib.h>
#include <errno.h>
#include <string.h>
#include <time.h>
```

```
#include <varargs.h>
/* global constants */
#define BETA 1.6886683 /* kB T at 298K */
#define MAX_BONDS 8
#define PI 3.1415927
#define EPS 1.0E-9
#define NAME LENGTH 10
#define KMAX 100
#define MAX ROOTS 100
#define DPHI .01
/* global macros */
\#define\ INTERVAL(a,n1,n2)\ ((a) >= (n1) \&\& (a) < (n2))
/* Include files relevant to this program */
#include "pep_type.h"
#include "pep_var.h"
/* random.c */
double ran(double dummy);
double ran2 (double dummy);
/* peptide1.c */
void out of memory(void);
void get sequence(string **sequence, int *n peptides);
rigid unit *read peptide data(string sequence, int *n atoms total,
                              int *max_atoms per_unit);
                                        acid label
rigid unit *read unit(string file,
                                                     label.
                                                              int
residue num,
                     int *n atoms total, int *max atoms per unit);
void couple unit(rigid unit *unit1, rigid_unit *unit2);
rigid_unit
              *modify_cystine_ends(rigid_unit
                                                   *unit,
                                                              int
n_amino acids,
                                int *n atoms total);
void get_main_side(rigid_unit *unit, regrowth *main, regrowth
*side,
                   int *n main, int *n side);
void read torsion data(void);
void read lj data(void);
void read hbond data(void);
void write car file(int n_amino_acids, int n_atoms_total, atom list
*atom,
```

string file);

```
string getline(string line, int len, FILE *fp);
void strip(string string);
void decomma(string string);
void capitalize(string s);
void amino acid code 3(acid_label label, string code_3);
void amino acid code 1(acid label label, char code 1);
acid_label amino_acid_code(char code_1);
/* peptide2.c */
        initialize connection table(int **bond_table,
void
                                                             int
n atoms total);
void make connection_table(int **bond_table, int *table_num,
                           rigid unit *unit, rigid_unit *start);
void add_connection(int **bond_table, int i1, int i2);
void print_connection_table(int **bond_table, int n_atoms_total);
void get_torsions(torsion_list **p,
                                        int **bond_table,
*table num,
                  atom list *atom, rigid unit *unit, rigid unit
*start);
torsion list *add torsion(int **bond table, atom list *atom, int
i, int j,
                          int k, int 1);
logical lookup torsion data(string type1, string type2, string
type3,
                            string type4, torsion_data **p);
void print_torsions(torsion_list *list, atom_list *atom);
double torsion(vector pl, vector p2, vector p3, vector p4);
void assign_lj_parameters(rigid_unit *unit, rigid_unit *start);
logical lookup_lj_data(string type, double *ri, double *ei);
logical lookup_lj data(string type, double *ri, double *ei);
void get_hbonds(hbond_list **list, atom_list *atom, int n_atoms);
logical lookup hbond_data(string type1, string type2, hbond_data
void print hbonds(hbond_list *1, atom_list *atom);
void assign_atom_pointers(int *list_num, rigid_unit *unit,
rigid_unit *start,
                         atom_list *atom);
/* peptide3.c */
void old_unit(int *list_num, int n0, int n1, int n2, double
*logrosen,
```

```
rigid unit *unit, rigid unit *start, torsion list *t,
              hbond list *1, atom_list *atom, vector *twig[],
vector p0,
              vector b0);
void do_unit(int *list_num, int n0, int n1, int n2, double
*logrosen,
             riqid unit *unit, rigid unit *start, torsion list *t,
             hbond list *1, atom list *atom, vector *twig[], vector
p0,
             vector b0, double *e);
void do backbone f(int i, int n main, int n atoms total,
                   double *logrosen,
                   regrowth *main, regrowth *side,
                   torsion list *t, hbond list *1,
                   atom list *atom, vector *twig[],
                   double *e, logical new);
void do backbone f rigid(int i, int n main, int n_atoms_total,
                         double *logrosen,
                         regrowth *main, regrowth *side,
                         torsion_list *t, hbond_list *1,
                         atom_list *atom, atom_info *atom_tmp,
                         vector *twig(),
                         double *e, logical new);
void do_backbone_b(int i, int n_main, int n_atoms total,
                   double *logrosen,
                   regrowth *main, regrowth *side,
                   torsion_list *t, hbond_list *l,
                   atom_list *atom, vector *twig[],
                   double *e, logical new);
void do backbone b rigid(int i, int n main, int n atoms_total,
                         double *logrosen,
                         regrowth *main, regrowth *side,
                         torsion list *t, hbond list *1,
                         atom_list *atom, atom_info *atom_tmp,
vector *twig[],
                         double *e, logical new);
void do_unit_sub(int *list_num, int n0, int n1, int n2, double
*logrosen,
                 rigid unit *unit, torsion list *t, hbond_list *1,
```

```
atom_list *atom, vector *twig[], vector pl, vector
  b1,
                   vector
                           p0, vector b0,
                                              double *e, vector
  p[MAX_BONDS],
                  vector b[MAX_BONDS], logical new);
 void add_rigid_unit(rigid_unit *unit, vector *pos,
                     vector pl, vector bl, vector p0,
                     vector b0, vector point[MAX_BONDS],
                     vector bond[MAX_BONDS],
                     double cos_theta2, double sin_theta2);
 vector align(vector p, vector r0, vector r1, vector n, double
 cos_theta,
              double sin_theta, vector n2, double cos_theta2, double
 sin_theta2);
 /* peptide4.c */
 double delta_energy(torsion_list *t, hbond_list *1, atom_list
 *atom.
                     vector *twig, int n_atoms, int n0, int n1, int
 n2,
                     int n twig);
double energy(torsion_list *t, hbond_list *l, atom_list *atom,
               int n_atoms_total);
double d_nonbond_energy(torsion_list *t, atom_list *atom, vector
 *twig,
                        int n_atoms, int n0, int n1, int n2, int
n_twiq);
double nonbond_energy(torsion_list *t, atom_list *atom,
                                                              int
n_atoms_total);
double d_hbond_energy(hbond_list *1, atom_list *atom, vector *twig,
                      int n_atoms, int n0, int n1, int n2, int
n_twig);
double hbond_energy(hbond_list *1, atom_list *atom);
double d_torsion_energy(torsion_list *t, atom_list *atom, vector
*twig,
                      int n_atoms, int n0, int n1, int n2, int
n_twig);
double torsion_energy(torsion_list *t, atom_list *atom);
/* peptide5.c */
void do_mc(rigid_unit *unit, torsion_list *t, hbond_list *1,
```

```
atom list *atom, atom list *atom2, atom info *atom tmp,
           vector *twig[], regrowth *main, regrowth *side,
           int n amino_acids, int n_atoms_total, int n_main, int
n_side,
           logical cyclic);
void read restart(atom list *atom, int n atoms total);
void read cycle(torsion list *t, hbond_list *l,
                atom list *atom, regrowth *main, regrowth *side,
                vector *twig[], int n main, int n side,
n_atoms_total);
void regrow_main(torsion_list *t, hbond list *1,
                 atom_list *atom, atom_list *atom2,
                 atom_info *atom_tmp, vector *twig[],
                 regrowth *main, regrowth *side,
                 int n main, int n atoms total, double *e);
void regrow_side(torsion_list *t, hbond_list *l,
                 atom_list *atom, atom_list *atom2, vector *twig[],
                 regrowth *main, regrowth *side,
                 int n_side, int n_atoms_total, double *e);
/* peptide6.c */
void rotate main(atom list *atom, atom list *atom2, vector *twig[],
                 regrowth *main, regrowth *side, torsion_list *t,
                 hbond list *1, int n main, int n atoms total,
double *e);
void get rot params(atom list *atom, regrowth *main, int i0, int
n main);
void get_rot rosenbluth(atom_list *atom, atom list *atom2,
                        vector *twig[], regrowth *main,
                       torsion list *t, hbond list *1, int i0, int
n main,
                       int n atoms total, int *n, int *j, double
*logrosen,
                       double *e);
double jac(vector r[7]);
vector rotate r1(atom list *atom, regrowth *main, int i0, int
n main);
void get_r(double phi1, double phi2, double phi3, double phi4,
double phi5);
void do rotation (atom list *atom, vector *twig, regrowth *main, int
```

```
iO,
                 int n main, int n_atoms total);
void get phil(double phi[MAX_ROOTS][6], int *n);
void get root (double x0, double x1, double *p1, double *p2, double
*p3,
             double *p4, double *p5, int n);
void F5init(vector q2, double *phi1);
void F5(double phi1, double phi2[4], double phi3[4],
                                                         double
phi4[4],
       double phi5[4], double f[4], logical valid[4]);
/* peptide7.c */
vector vector rotate(vector a, vector n, double cos theta, double
sin theta);
vector get main_b0(atom_list *atom, regrowth *main, int i);
vector get_main_p0(atom_list *atom, regrowth *main, int i);
vector get side b0(atom_list *atom, regrowth *side, int i);
vector get side p0(atom list *atom, regrowth *side, int i);
void flory_rot_matrix(double theta, double phi, double m[3][3]);
vector flory rot (double theta, double phi, vector a);
vector flory rotinv(double theta, double phi, vector a);
void flory lab(double m[3][3], vector r, vector 1);
void flory labinv(double m[3][3], vector r, vector l);
vector vector cross(vector a, vector b);
vector vector scale(vector v, double r);
void mxm(double m[3][3], double n[3][3]);
double det5(double m[5][5]);
double det (double m[3][3]);
vector mxb(double m[3][3], vector b);
vector bxm(double m[3][3], vector b);
double vector dot(vector b1, vector b2);
double vector_length(vector v);
double vector length2 (vector v);
****************
            DATA FILES DEFINING GEOMETRIC STRUCTURE
```

*****	*****	******	*****	******
	DATA FII	LE FOR UNIT A	- UNITA.DAT	
******	*****	******	*****	******
! data fi	le for rigid un	it Athe NH2	terminus	
1 !rigid	unit in this st	ructure		
! ATOM IN	iformation —			
! rigid u	mit 0			
3 !atoms	in this rigid u	nit		
N	0.039039567 -	0.028048204	0.000005808 ALAr	n 1 NT
N -0	.463			
HN1 -	0.294595420	0.946419656	0.000007165 ALA	n 1 H
H	0.126	•		
HN2 -	0.309849501 -	0.509882152	-0.840834498 ALA	n 1 H
H	0.126			
! BOND IN	FORMATION			
! rigid u	nit 0			
0 1 2 -1	-1 !ending of	incoming bond-	-doesn't mean any	thing, but
must not	be 1			
0 0 .000	000001!beginning	of incoming	bond just a	an overall
displacem	nent			
1 !bond o	out from this un	it		
-1 !don't	know which uni	t this bond go	es to	
0 1 2 -1	-1 !beginning o	f outgoing bac	kbone bond	
1.4989595	-0.0433369	47 -0.000000	042 !ending of ou	toing bond
******	****	*****	******	******
	DATA FII	E FOR UNIT B	- UNITB.DAT	
******	*****	******	******	******
! data fi	le for rigid un	it Bthe CH a	lpha carbon unit	
1 !rigid	unit in this st	ructure		
! ATOM IN	FORMATION .			
! rigid u	nit 0			
2 !atoms	in this rigid u	nit		
CA	4.047343731	2.755753756	-0.000011837 ALA	2 CT
C 0	. 035			
НА	3.779272556	3.294512749	-0.928205431 ALA	2 HC
H O	.032			

- ! BOND INFORMATION
- ! rigid unit 0
- 0 1 -1 -1 -1!ending of incoming backbone bond
- 3.370934725 1.461895347 -0.000009674 !beginning of incoming backbone bond
- 2 !bonds out from this unit
- -1 !don't know which unit this bond goes to
- 0 1 -1 -1 -1 !beginning of outgoing side-chain bond
- 3.538550615 3.547572851 1.217100978 !ending of outgoin side-chain bond
- -1 !don't know which unit this bond goes to
- 0 1 -1 -1 -1!beginning of outgoing backbone bond
- 5.547336102 2.582198620 -0.000015057 !ending of outgoing backbone bond

DATA FILE FOR UNIT C - UNITC.DAT

- ! data file for rigid unit C -- the OCNH amide bond unit
- 1 !rigid unit in this structure

2.054825068

- ! ATOM INFORMATION
- ! rigid unit 0

C

- 4 !atoms in this rigid unit
- C 0.616 O 1.320880890 2.356072187 0.011419594 ALAn 1 0

0.000001071 ALAn 1

C

1.360626340

- O -0.504 N 3.370934725 1.461895347 -0.000009674 ALA 2 N
 - N -0.463
- HN 3.917454243 0.530382395 -0.000003380 ALA 2 H
 - H 0.252
- ! BOND INFORMATION
- ! rigid unit 0
- 0 1 2 -1 -1 !ending of incoming main-chain bond
- 1.498959541 -0.043336947 -0.000000042 !beginning of incoming main-chain bond
- 1 !bond out from this unit
- -1 !don't know which unit this bond goes to

2 0 3 -1 -1 !beginning of outgoing main-chain bond					
4.047343731 2.755753756 -0.000011837 !ending of outging					
main-chain bond					

DATA FILE FOR UNIT D - UNITD.DAT					

! data file for rigid unit Dthe HCO terminus					
1 !rigid unit in this structure					
! ATOM INFORMATION					
! rigid unit 0					
3 !atoms in this rigid unit					
C 8.274295807 5.082911491 -0.000008575 ALAN 3 C					
C 0.616					
HC 9.361082077 5.166533947 -0.000010758 ALAN 3 HC					
н 0.000					
O 7.540351391 6.078356743 0.011415332 ALAN 3 O					
O -0.504					
! BOND INFORMATION					
! rigid unit 0					
0 1 2 -1 -1 !ending of incoming main-chain bond					
7.718430996 3.678948641 -0.000013665 !beginning of incoming					
main-chain bond					
0 !bonds out from this unit					

DATA FILE FOR ALANINE - A.DAT					

! The side-chain structure file for Alanine					
1 !rigid unit in side-chain					
! ATOM INFORMATION					
! rigid unit 0					
4 !atoms in this rigid unit					
CB 3.178086281 3.790203094 1.217109203 ALA 2					
CT C -0.098					
HB1 3.502361059 4.845792770 1.274110079 ALA 2					
HC H 0.038					

WO 96/30849	PCT/US96/04229
-------------	----------------

HB2 2.072028160 3.800241470 1.180677295 ALA 2

HC H 0.038

HB3 3.465983868 3.309211969 2.172164917 ALA 2

HC H 0.038

! BOND INFORMATION

! rigid unit 0

0 1 2 3 -1 !ending of incoming bond for unit 0 and nn

3.783586502 3.069634676 -0.000003090 !beginning of bond for unit 0

0 !bonds out from rigid unit 0

DATA FILE FOR CYSTEINE - C.DAT

- ! The side-chain structure file for Cysteine
- ! Do not modify the atom order in this file
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit

CB	3.185384274	3.813543320	1.210355163	CYSH 2

CT C -0.060

HB1 2.082855701 3.742515087 1.217666388 CYSH 2

HC H 0.038

HB2 3.528102398 3.371057510 2.168041706 CYSH 2

HC H 0.038

- ! rigid unit 1
- 4 !atoms in this rigid unit

	SG	3.628824234	5.564641953	1.168115854	CYSH 2
--	----	-------------	-------------	-------------	--------

SH S 0.827

LG1 2.774378061 6.223292828 1.382826447 CYSH 2

LP L -0.481

LG2 4.018448353 5.879447937 0.188784361 CYSH 2

LP L -0.481

HG 4.543437004 5.521058083 2.133599997 CYSH 2

HS H 0.135

! BOND INFORMATION

! rigid unit 0

- 0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn
- 3.783586502 3.069634914 -0.000003354 !beginning of bond for unit 0
- 1 !bonds out from rigid unit 0
- 1 !unit 0 is bonded to unit 1
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.628824234 5.564641953 1.168115854 !ending of outgoing bond for unit 0
- ! rigid unit 1
- 0 1 2 3 -1 !ending of incoming bond for unit 1 and nn
- 3.185384274 3.813543320 1.210355163 !beginning of bond for unit 1
- 0 !bonds out from rigid unit 1

DATA FILE FOR ASPARTATE - D.DAT

- ! The side-chain structure file for Aspartate
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit
- CB 3.195193052 3.859569550 1.198083878 ASP 2
- CT C -0.398
- HB1 2.099623203 3.734851122 1.256908774 ASP 2
- HC H 0.071
- HB2 3.574837923 3.424842119 2.144523859 ASP 2
- HC H 0.071
- ! rigid unit 1
- 3 !atoms in this rigid unit
- CG 3.488366127 5.366341114 1.240691185 ASP 2
- C C 0.714
- OD1 3.752036572 5.965095997 2.273211718 ASP 2
- 02 0 -0.721
- OD2 3.445515871 5.949848175 0.005213364 ASP 2
- 02 0 -0.721
- ! BOND INFORMATION
- ! rigid unit 0

0 1 2 -1 -1 ! nding of incoming bond for unit 0 and nn

- 3.783586502 3.069634438 -0.000003352 !beginning of bond for unit 0
- 1 !bonds out from rigid unit 0
- 1 !unit 0 is bonded to unit 1
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.488366127 5.366341114 1.240691185 !ending of outgoing bond for unit 0
- ! rigid unit 1
- 0 1 2 -1 -1 !ending of incoming bond for unit 1 and nn
- 3.195193052 3.859569550 1.198083878 !beginning of bond for unit 1
- 0 !bonds out from rigid unit 1

DATA FILE FOR GLUTAMINE - E.DAT

- ! The side-chain structure file for Glutamine
- 3 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit

0086 1.242457986 GLU 2
7

CT C -0.184

HB1 3.453276873 4.884052753 1.160096049 GLU 2

HC H 0.092

HB2 2.103818655 3.775332928 1.193925381 GLU 2

HC H 0.092

- ! rigid unit 1
- 3 !atoms in this rigid unit

CG	3.670672178	3.303917646	2.650651217 GLU	2
----	-------------	-------------	-----------------	---

CT C -0.398

HG1 3.495624304 2.214699984 2.732162237 GLU 2

HC H 0.071

HG2 4.766538143 3.410970449 2.754028797 GLU 2

HC H 0.071

- ! rigid unit 2
- 3 !atoms in this rigid unit

CD	3.044564962	3.944746017	3.891577959 GLU 2	
C	C 0.714			
OEl	3.318646908	3.594962835	5.031950951 GLU 2	
02	0 -0.721			
OE2	2.157183647	4.937835217	3.607111931 GLU 2	
02	0 -0.721			
! BOND	INFORMATION			
! rigi	d unit 0			
0 1 2	-1 -1 !ending of	incoming bond f	or unit 0 and nn	
3.783	586502 3.06963	4438 -0.00000	03351 !beginning of bon	d
for un	it O			
1 !bon	ds out from rigid	unit 0		
1 !uni	t 0 is bonded to	unit 1		
0 1 2	-1 -1 ! beginni	ng of outgoing	bond and nn	
3.6706	72178 3.303917	646 2.650651	217 !ending of outgoing	3
bond f	or unit 0			
! rigi	d unit 1			
0 1 2	-1 -1 !ending of	incoming bond f	or unit 1 and nn	
3.2101	91 72 7 3.806 7 700	1.2424579	86 !beginning of bond for	r
unit 1				
1 !bon	ds out from rigid	unit 1		
2 !uni	t 1 is bonded to	unit 2		
0 1 2	-1 -1 ! beginni	ng of outgoing	bond and nn	
3.044	564962 3.944746	3.891577	959 !ending of outgoing	3
bond f	or unit 1			
! rigi	d unit 2			
0 1 2	-1 -1 !ending of	incoming bond f	or unit 1 and nn	

- 3.670672178 3.303917646 2.650651217 !beginning of bond for unit 2
- 0 !bonds out from rigid unit 2

DATA FILE FOR PHENYLALANINE - F.DAT

- ! The side-chain structure file for Phenylalanine
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0

3 !atom	ns in this rigid w	nit		
CB	3.271046400	3.829343796	1.261018753 PHE 2	
CT	C -0.100			
HB1	3.711064339	3.375446320	2.172759056 PHE 2	
нС	н 0.108			
HB2	3.680548668	4.858696938	1.261503935 PHE 2	
HC	н 0.108			
! rigid	l unit 1			
11 !atc	oms in this rigid	unit		
CG	1.746863961	3.913921356	1.435816050 PHE 2	
CA	C -0.100			
CD1	1.070973635	2.894981861	2.116770267 PHE 2	
CA	C -0.150			
HD1	1.621361971	2.061387062	2.533305407 PHE 2	
HC	H 0.150			
CD2	1.019180536	4.963639259	0.869901121 PHE 2	
CA	C -0.150			
HD2	1.528048277	5.750367641	0.331381440 PHE 2	
HC	H 0.150			
CE1	-0.315989435	2.915796280	2.214086056 PHE 2	
CA	C -0.150			
HE1	-0.830357015	2.108316422	2.715482712 PHE 2	
HC	H 0.150			
CE2	-0.369023502	4.989082813	0.977358818 PHE 2	
CA	C -0.150			
HE2	-0.928361893	5. 79 853 677 7	0.531342983 PHE 2	
HC	H 0.150			
CZ	-1.036266327	3.964326382	1.646436572 PHE 2	
CA	C -0.150			
HZ	-2.113304853	3.975853443	1.718335271 PHE 2	
HC	H 0.150			
! BOND	INFORMATION			

[!] BOND INFORMATION

[!] rigid unit 0

^{0 1 2 -1 -1 !}ending of incoming bond and nn

^{3.783586264 3.069634914 -0.000003353 !}beginning of bond

^{1 !}bonds out

^{1 !}unit bonded to

^{0 1 2 -1 -1 !} beginning of outgoing bond and nn

^{1.746863961 3.913921356 1.435816050 !}ending of outgoing

bond

- ! rigid unit 1
- 0 1 3 -1 -1 !ending of incoming bond and nn
- 3.271046400 3.829343796 1.261018753 !beginning of bond
- 0 !bonds out

DATA FILE FOR GLYCINE - G.DAT

- ! The side-chain structure file for Glycine
- 1 !rigid unit in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 1 !atom in this rigid unit

HA2 2.054570675 -0.518772364 -0.887896836 GLYN 1

HC H 0.032

- ! BOND INFORMATION
- ! rigid unit 0
- 0 -1 -1 -1 -1 !ending of incoming bond for unit 0 and nn
- 1.612465143 -0.031237146 -0.000000015 !beginning of incoming bond for unit 0
- 0 !bonds out from rigid unit 0

DATA FILE FOR HISTIDINE - H.DAT

- ____
- ! The side-chain structure file for Histidine
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit
- CB 3.239844084 3.731920242 1.277127385 HIS 2
- CT C -0.098
- HB1 2.644425392 3.025787830 1.893024564 HIS 2
- HC H 0.038
- HB2 4.064783096 4.071127415 1.934927344 HIS 2
- HC H 0.038

! rigi	d unit 1			•
-	ms in this rigid	unit		
CG	_		0.978080690 HI	S 2
CC	C 0.251			
ND1	2.062596560	5.403582573	-0.290515751 HI	S 2
NB	N -0.502			
CE1	1.272076607	6.440367222	0.045922592 HI	5 2
CR	C 0.241			
NE2	1.048720956	6.674089432	1.367565274 HI	S 2
NA	N -0.146			
CD2	1.767608762	5.675839901	1.972463250 HI	S 2
CM	C -0.184			
HE1	0.858503580	7.036557198	-0.757577479 HI	S 2
HC	H 0.036			
HE2	0.480951071	7.411210537	1.809884906 HI	5 2
Н	H 0.228			
HD2	1.867301583	5.485908508	3.037219763 HI	S 2
HC	H 0.114			
	INFORMATION			
_	d unit 0			
	-1 -1 !ending of			
		438 -0.000003	353 !beginning of	bond for
unit 0				
	ds out from rigid			
	t 0 is bonded to			
	-1 -1 ! beginni			
		2319 0.9780	80690 !ending of	outgoing
	or unit 0			
	d unit 1			
	-1 -1 !ending of	_		
	99199 3.8303978	1.236912	012 !beginning of	bond for
unit 1				
0 !bon	ds out from rigid	unit 1		
*****	******	******	******	****
	DATA FIL	E FOR ISOLEUCI	NE - I.DAT	

! The side-chain structure file for Isoleucine

```
4 !rigid units in side-chain
! ATOM INFORMATION
! rigid unit 0
2 !atoms in this rigid unit
CB
       3.184130907 3.905461311 1.203313947 ILE 2
      C -0.012
CT
       3.579479933 3.448693275 2.135145664 ILE 2
HB
      H 0.022
HC
! rigid unit 1
4 !atoms in this rigid unit
CG2
        3.632628202
                     5.399640560
                                 1.184555411 ILE 2
       C -0.085
CI
HG21
      3.256929159 5.962747097 2.057613134 ILE 2
HC
      H 0.029
HG22
      4.728721142 5.525658131 1.229067683 ILE 2
HC
      H 0.029
HG23
      3.277012348 5.929985046 0.281316549 ILE 2
      H 0.029
HC
! rigid unit 2
3 !atoms in this rigid unit
CG1
        1.625806093
                     3.868085861 1.310235620 ILE 2
CT
      C -0.049
HG11
      1.169472456 4.395492077 0.450418025 ILE
HC
      H 0.027
      1.273633957 2.823534966 1.211708426 ILE 2
HG12
HC
      H 0.027
! rigid unit 3
4 !atoms in this rigid unit
CD1
       1.028863907 4.391342163 2.632859945 ILE 2
CT
      C -0.085
HD11
     -0.068560459 4.262083530
                                  2.654643297 ILE 2
HC
      H 0.028
HD12
      1.436750174 3.852109432 3.508637428 ILE
HC
      H 0.028
HD13
      1.222232699
                    5.468014240 2.787941933 ILE 2
HC
      H 0.028
! BOND INFORMATION
! rigid unit 0
```

- 0 1 -1 -1 -1 !ending of incoming bond and nn

WO 96/30849 PCT/US96/04229 3.783586502 3.069634438 -0.000003350 !beginning of bond 2 !bonds out 1 !unit bond d to 0 1 -1 -1 -1 ! beginning of outgoing bond and nn 3.632628202 5.399640560 1.184555411 !ending of outgoing bond 2 !unit bonded to 0 1 -1 -1 -1 ! beginning of outgoing bond and nn 1.625806093 3.868085861 1.310235620 !ending of outgoing bond ! rigid unit 1 0 1 2 3 -1 !ending of incoming bond and nn 3.184130907 3.905461311 1.203313947 !beginning of incoming bond 0! bonds out ! rigid unit 2 0 1 2 -1 -1 !ending of incoming bond and nn 3.184130907 3.905461311 1.203313947 !beginning of incoming bond 1 !bonds out 3 !unit bonded to 0 1 2 -1 -1 ! beginning of outgoing bond and nn 1.028863907 4.391342163 2.632859945 !ending of outgoing bond ! rigid unit 3 0 1 2 3 -1 !ending of incoming bond and nn 1.625806093 3.868085861 1.310235620 !beginning of bond 0 !bonds out ********* DATA FILE FOR LYSINE - K.DAT ************* ! The side-chain structure file for Lysine 5 !rigid units in side-chain ! ATOM INFORMATION ! rigid unit 0

- 3 !atoms in this rigid unit
- CB 3.218223095 3.829745770 1.231236458 LYS 2

CI	C -0.098		,	
HB1	2.112416506	3.764609814	1.234413505 LYS	2
HC	H 0.038			
HB2	3.536234617	3.317805290	2.163102627 LYS	2
HC	H 0.038			
! rigid	unit 1			
3 !atoms	s in this rigid w	mit		
CG	3.638167858	5.320005417	1.281187057 LYS	2
CT	C -0.160			
HG1	4.741127968	5.406830788	1.274424553 LYS	2
HC	H 0.116			
HG2	3.295989990	5.833013058	0.360635072 LYS	2
HC	H 0.116			
! rigid	unit 2			
3 !atoms	s in this rigid v	nit		
CD	3.153400660	6.084614754	2.516160011 LYS	2
CT	C -0.180			
HD1	2.046517849	6.074027538	2.552636147 LYS	2
HC	H 0.122			
HD2	3.501233101	5.571547031	3.435809374 LYS	2
HC	H 0.122			
! rigid	unit 3			
3 !atoms	s in this rigid v	nit		
CE	3.699187756	7.518018246	2.469964743 LYS	2
CT	C -0.038			
HE1	4.805956841	7.515174866	2.558616400 LYS	2
HC	H 0.098			
HE2	3.475801945	8.000639915	1.495867610 LYS	2
HC	H 0.098			
! rigid	unit 4			
4 !atoms	s in this rigid u	unit		
NZ	3.098134756	8.306216240	3.560437918 LYS	2
N3	N -0.138			
HZ1	3.463554621	9.268757820	3.530759573 LYS	2
Н3	H 0.294			
HZ2	2.074491024	8.324481964	3.447653770 LYS	2
Н3	H 0.294			
HZ3	3.335658073	7.877095222	4.466163158 LYS	2
нз	H 0.294			

- ! BOND INFORMATION
- ! rigid unit 0
- 0 1 2 -1 -1 !ending of incoming bond and nn
- 3.783586502 3.069634914 -0.000003353 !beginning of bond
- 1 !bonds out
- 1 !unit bonded to
 - 0 1 2 -1 -1 ! beginning of outgoing bond and nn
 - 3.638167858 5.320005417 1.281187057 !ending of outgoing bond
 - ! rigid unit 1
 - 0 1 2 -1 -1 !ending of incoming bond and nn
 - 3.218223095 3.829745770 1.231236458!beginning of bond
 - 1 !bonds out
 - 2 !unit bonded to
 - 0 1 2 -1 -1 ! beginning of outgoing bond and nn
 - 3.153400660 6.084614754 2.516160011 !ending of outgoing bond
 - ! rigid unit 2
 - 0 1 2 -1 -1 !ending of incoming bond and nn
 - 3.638167858 5.320005417 1.281187057 !beginning of bond
 - 1 !bonds out
 - 3 !unit bonded to
 - 0 1 2 -1 -1 ! beginning of outgoing bond and nn
 - 3.699187756 7.518018246 2.469964743 !ending of outgoing bond
 - ! rigid unit 3
 - 0 1 2 -1 -1 !ending of incoming bond and nn
 - 3.153400660 6.084614754 2.516160011!beginning of bond
 - 1 !bonds out
 - 4 !unit bonded to
 - 0 1 2 -1 -1 ! beginning of outgoing bond and nn
 - 3.098134756 8.306216240 3.560437918 !ending of outgoing bond
 - ! rigid unit 4
 - 0 1 2 3 -1 !ending of incoming bond and nn
 - 3.699187756 7.518018246 2.469964743!beginning of bond
 - 0 !bonds out

DATA FILE FOR LEUCINE - L.DAT

! The s	side-chain structu	re file for Le	eucine	
4 !rigi	d units in side-c	hain		
! ATOM	INFORMATION			
! rigid	unit 0			
3 !atom	ns in this rigid w	mit		
СВ	3.217977524	3.860693455	1.213688374 LEU	2
CT	C -0.061			
HB1	3.617908239	3.413237095	2.146348953 LEU	2
HC	н 0.033			
HB2	3.641148329	4.884153843	1.193638206 LEU	2
HC	Н 0.033			
! rigid	l unit 1			
2 !atom	ns in this rigid u	nit		
CG	1.676206470	3.974944353	1.357627273 LEU	2
CT	C -0.010			
HG	1.273801684	2.962582827	1.570222020 LEU	2
HC	H 0.031			•
! rigid	l unit 2			
4 !atom	ns in this rigid u	nit		
CD1	1.322771311	4.880306721	2.545703411 LEU	2
CT	C -0.107			
HD11	0.229164675	4.936426640	2.704123735 LEU	2
HC	H 0.034			
HD12	1.758654118	4.507015228	3.491832256 LEU	2
HC	H 0.034			
HD13	1.684926391	5.916738033	2.406197309 LEU	2
HC	H 0.034			
! rigid	lunit 3			
4 !atom	s in this rigid u	nit		
CD2	0.998154640	4.504262924	0.083184890 LEU	2
CT	C -0.107			
HD21	-0.093163513	4.622812748	0.214309067 LEU	2
HC	H 0.034			
HD22	1.406615853	5.481475830	-0.234147355 LEU	2
HC	H 0.034			
HD23	1.130140185	3.802904606	-0.761629283 LEU	2

```
HC
   H 0.034
! BOND INFORMATION
! rigid unit 0
0 1 2 -1 -1 !ending of incoming bond and nn
3.783586502 3.069634438 -0.000003367!beginning of bond
1 !bonds out
1 !unit bonded to
0 1 2 -1 -1 ! beginning of outgoing bond and nn
1.676206470 3.974944353 1.357627273 !ending of outgoing
bond
! rigid unit 1
0 1 -1 -1 -1 !ending of incoming bond and nn
 3.184130907 3.905461311 1.203313947 !beginning of incoming
bond
2! bonds out
2 !unit bonded to
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
1.322771311 4.880306721 2.545703411 !ending of outgoing
bond
3 !unit bonded to
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
0.998154640 4.504262924 0.083184890 !ending of outgoing
bond
! rigid unit 2
0 1 2 3 -1 !ending of incoming bond and nn
1.676206470 3.974944353 1.357627273 !beginning of incoming
bond
0 !bonds out
! rigid unit 3
0 1 2 3 -1 !ending of incoming bond and nn
1.676206470 3.974944353 1.357627273 !beginning of bond
0 !bonds out
*********
```

DATA FILE FOR METHIONINE - M. DAT

- ! The side-chain structure file for Methionine
- 4 !rigid units in side-chain

```
! ATOM INFORMATION
! rigid unit 0
3 !atoms in this rigid unit
        3.219568014
                     3.840672970 1.225060582 MET
CB
CT
      C -0.151
HB1
       3.547865868
                    3.348565578
                                   2.163037539 MET
HC
      H 0.027
HB2
        3.671003819 4.850576401
                                   1.262409329 MET
HC
      H 0.027
! rigid unit 1
3 !atoms in this rigid unit
        1.685955524 4.011272907
                                   1.265707970 MET
CG
     C -0.054
CT
HG1
       1.291312337
                    4.382569790
                                   0.302083224 MET 2
HC
      H 0.0652
HG2
      1.199923158 3.034499168
                                   1.452733874 MET
HC
      H 0.0652
! rigid unit 2
3 !atoms in this rigid unit
SD
        1.234688163 5.162067413
                                   2.574714422 MET 2
S
      S 0.737
LD1
       1.486726403 6.202064514
                                   2.319993973 MET 2
LP
      L -0.381
LD2
      1.747960329 4.937880516 3.521441460 MET 2
LP
      L -0.381
! rigid unit 3
4 !atoms in this rigid unit
CE
      -0.532971203 4.837210655
                                   2.617241383 MET 2
      C -0.134
CT
HE1
      -0.987815082
                    4.991072178
                                   1.622043610 MET
HC
          0.0652
      H
HE2
      -1.033426285
                    5.510134220
                                   3.335405111 MET
HC
      H
          0.0652
HE3
      -0.725545764 3.794905424
                                   2.929581165 MET 2
HC
          0.0652
      H
! BOND INFORMATION
```

- ! rigid unit 0
- 0 1 2 -1 -1 ! nding of incoming bond and nn
- 3.783586502 3.069634438 -0.000003354 !beginning of bond

- PCT/US96/04229 WO 96/30849 1 !bonds out 1 !unit bonded to 0 1 2 -1 -1 ! beginning of outgoing bond and nn 1.685955524 4.011272907 1.265707970 !ending of outgoing bond ! rigid unit 1 0 1 2 -1 -1 !ending of incoming bond and nn 3.219568014 3.840672970 1.225060582 !beginning of bond 1 !bonds out 2 !unit bonded to 0 1 2 -1 -1 ! beginning of outgoing bond and nn 1.234688163 5.162067413 2.574714422 !ending of outgoing bond ! rigid unit 2 0 1 2 -1 -1 !ending of incoming bond and nn 1.685955524 4.011272907 1.265707970 !beginning of bond 1 !bonds out 3 !unit bonded to 0 1 2 -1 -1 ! beginning of outgoing bond and nn -0.532971203 4.837210655 2.617241383 !ending of outgoing poug ! rigid unit 3 0 1 2 3 -1 !ending of incoming bond and nn 1.234688163 5.162067413 2.574714422!beginning of bond 0 !bonds out DATA FILE FOR APSARAGINE - N.DAT **********
- ! The side-chain structure file for Asparagine
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit
- CB 3.222899199 3.830397844 1.236912012 ASN 2
- CT C -0.086
- HB1 3.611397266 3.364436865 2.163546562 ASN 2
- HC H 0.038

HB2	3.616078854	4.863478184	1.264652491 AS	N 2	
HC	н 0.038				
! rigid	l unit 1				
5 !atom	ns in this rigid w	nit			
CG	1.698638678	3.892561436	1.381467938 AS	N 2	
C	C 0.675				
OD1	1.085211635	3.155725241	2.139311790 AS	N 2	
0	0 -0.470				
ND2	1.031797171	4.746669292	0.652490914 AS	N 2	
N	N -0.867				
HD21	0.019928589	4.602556705	0.711063743 AS	N 2	
H	H 0.344				
HD22	1.562326550	5.282481670	-0.034363598 AS	N 2	
H	H 0.344				
! BOND	INFORMATION				
! rigid	l unit 0	•			
0 1 2 -	-1 -1 !ending of i	ncoming bond f	or unit 0 and nn		
3.78358	3.06963443	38 -0.0000033	53 !beginning of	bond for	
unit 0					
1 !bond	is out from rigid	unit 0			
1 !unit	0 is bonded to u	nit 1			
0 1 2 -	1 -1 ! beginnin	ng of outgoing	bond and nn		
1.69863	3.8925614	1.38146	7938 !ending of	outgoing	
bond for unit 0					
! rigid unit 1					
0 1 2 -1 -1 !ending of incoming bond for unit 1 and nn					
3.22289	9199 3.8303978	1.2369120	12 !beginning of	bond for	
unit 1					
0 !bonds out from rigid unit 1					
*****			***********	*****	
DATA FILE FOR GLUTAMINE - Q.DAT					

- ! The side-chain structure file for Glutamine
- 3 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit

PCT/US96/04229 WO 96/30849

CB	3.221223593	3.805351734	1.236027122	GLN 2	
CT	C -0.098				
HB1	2.115758896	3.733683825	1.223282218	GLN 2	
HC	н 0.038				
HB2	3.538368225	3.258102417	2.148239136	GLN 2	
HC	н 0.038				
! rigid	unit 1				
3 !atom	s in this rigid ι	ınit			
CG	3.619170427	5.311230183	1.384292126	GLN 2	
CT	C -0.102				
HG1	4.719832420	5.417502403	1.395145655	GLN 2	
HC	H 0.057				
HG2	3.298108339	5.879051685	0.491232127	GLN 2	
HC	H 0.057				
! rigid	unit 2		•		
5 !atom	s in this rigid w	nit			
CD	3.148421526	6.090956688	2.618209839	GLN 2	
С	C 0.675				
OE1	3.471138716	7.255728722	2.789397001	GLN 2	
0	0 -0.470				
NE2	2.408394814	5.500250816	3.521779537	GLN 2	
N	N -0.867				
HE21	2.231919527	4.508390427	3.353902817	GLN 2	
H	H 0.344				
HE22	2.192787886	6.069860935	4.342392445	GLN 2	
H	H 0.344				
! BOND INFORMATION					
! rigid unit 0					
0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn					
3.78358	3.06963443	88 -0.00000335	3 !beginning	of bond for	
unit 0					
1 !bonds out from rigid unit 0					

- 1 !bonds out from rigid unit 0
- 1 !unit 0 is bonded to unit 1
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.619170427 5.311230183 1.384292126 !ending of outgoing bond for unit 0
- ! rigid unit 1
- 0 1 2 -1 -1 !ending of incoming bond for unit 1 and nn
- 3.221223593 3.805351734 1.236027122 !beginning of bond for

unit 1

- 1 !bonds out from rigid unit 0
- 2 !unit 1 is bonded to unit 2
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.148421526 6.090956688 2.618209839 !ending of outgoing

bond for unit 2

- ! rigid unit 2
- 0 1 2 -1 -1 !ending of incoming bond for unit 2 and nn
- 3.619170427 5.311230183 1.384292126 !beginning of bond for unit 2
- 0 !bonds out from rigid unit 2

DATA FILE FOR ARGININE - R.DAT

- ! The side-chain structure file for Arginine
- 4 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit

CB	3.207483053	3.819248199	1.232642174 ARG	2

CT C -0.080

HB1 2.121760130 3.616136551 1.319550753 ARG 2

HC H 0.056

HB2 3.644849300 3.393733978 2.159598827 ARG 2

HC H 0.056

- ! rigid unit 1
- 3 !atoms in this rigid unit

00	7 43776666	r 357305537	. 01/(01/05) 300	_
CG	3.412360668	5.357305527	1.216631651 ARG	- 2

CT C -0.103

HG1 4.487451553 5.614737511 1.132990837 ARG 2

HC H 0.074

HG2 2.938670874 5.796108723 0.315252036 ARG 2

HC H 0.074

- ! rigid unit 2
- 3 !atoms in this rigid unit

CD 2.850392818 6.038671017 2.471077681 ARG 2

CT C -0.228

HD1	1.769480824	5.816972256	2.580044270 ARG	2
HC	H 0.133		,	
HD2	3.353989840	5.649005413	3.379585028 ARG	2
HC	H 0.133			
! rigid	unit 3			
9 !atom	s in this rigid	unit		
NE	3.069616079	7.502031326	2.345978022 ARG	2
N2	N -0.324			
HE	3.539865971	7.837357998	1.493146777 ARG	2
Н3	Н 0.269			
CZ	2.710799694	8.413488388	3.240067959 ARG	2
CA	C 0.760			
NH1	2.972572088	9.643490791	2.971310854 ARG	2
N2	N -0.624			
HH11	3.439955235	9.745957375	2.068439484 ARG	2
Н3	H 0.361			
HH12	2.697422743	10.348603249	3.651821136 ARG	2
Н3	H 0.361			
NH2	2.114365101	8.144207001	4.363539696 ARG	2
N2	N -0.624			
HH21	1.888047814	8.930854797	4.969158173 ARG	2
Н3	H 0.361			
HH22	1.947107434	7.146794796	4.499028206 ARG	2
H3	Н 0.361			

- ! BOND INFORMATION
- ! rigid unit 0
- 0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn
- 3.783586502 3.069634914 -0.000003315 !beginning of bond for unit 0
- 1 !bond out from rigid unit 0
- 1 !unit 0 is bonded to unit 1
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.412360668 5.357305527 1.216631651 !ending of outgoing bond for unit 0
- ! rigid unit 1
- 0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn
- 3.207483053 3.819248199 1.232642174 !beginning of bond for unit 1
- 1 !bond out from rigid unit 1

- 2 !unit 1 is bond d to unit 2
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 2.850392818 6.038671017 2.471077681 !ending of outgoing bond
- ! rigid unit 2
- 0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn
- 3.412360668 5.357305527 1.216631651 !beginning of bond for unit 2
- 1 !bond out from rigid unit 2
- 3 !unit 2 is bonded to unit 3
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 3.069616079 7.502031326 2.345978022 !ending of outgoing bond
- ! rigid unit 3
- 0 1 2 -1 -1 !ending of incoming bond for unit 0 and nn
- 2.850392818 6.038671017 2.471077681!beginning of bond for unit 3
- 0 !bonds out from rigid unit 3

DATA FILE FOR SERINE - S.DAT

- ! The side-chain structure file for Serine
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 3 !atoms in this rigid unit
- CB 3.203660250 3.871555328 1.191825747 SER 2
- CT C 0.018
- HB1 3.445731640 4.945727825 1.071671009 SER 2
- HC H 0.119
- HB2 2.097403765 3.828571320 1.202566266 SER 2
- HC H 0.119
- ! rigid unit 1
- 2 !atoms in this rigid unit
- OG 3.711599350 3.433972597 2.457015276 SER 2
- OH 0 -0.550
- HG 3.430009127 2.523327112 2.580434084 SER 2

но н 0.310

- . ! BOND INFORMATION
 - ! rigid unit 0
 - 0 1 2 -1 -1 ! nding of incoming bond for unit 0 and nn
 - 3.783586502 3.069634438 -0.000003353 !beginning of bond for unit 0
 - 1 !bonds out from rigid unit 0
 - 1 !unit 0 is bonded to unit 1
 - 0 1 2 -1 -1 ! beginning of outgoing bond and nn
 - 3.711599350 3.433972597 2.457015276 !ending of outgoing bond for unit 0
 - ! rigid unit 1
 - 0 1 -1 -1 -1 !ending of incoming bond for unit 1 and nn
 - 3.203660250 3.871555328 1.191825747 !beginning of bond for unit 1
 - 0 !bonds out from rigid unit 1

DATA FILE FOR THREONINE - T.DA

- ! The side-chain structure file for Threonine
- 3 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0
- 2 !atoms in this rigid unit
- CB 3.220216751 3.864162445 1.226425409 THR 2
- CT C 0.170
- HB 3.504307270 3.322291374 2.154003382 THR 2
- HC H 0.082
- ! rigid unit 1
- 2 !atoms in this rigid unit
- OG1 1.802008867 3.940322876 1.161503792 THR 2
- OH O -0.550
- HG1 1.520381451 4.374082565 1.972538352 THR 2
- HO H 0.310
- ! rigid unit 2
- 4 !atoms in this rigid unit
- CG2 3.680637360 5.331728935 1.361316323 THR 2

```
CT
    C -0.191
HG21
      3.224400043 5.832503796 2.234619141 THR 2
     H 0.065
HC
HG22
      4.774106026 5.420624733 1.502453089 THR 2
HC
     H 0.065
      3.418393373 5.928008556 0.466874599 THR 2
HG23
HC
       H 0.065
! BOND INFORMATION
! rigid unit 0
0 1 -1 -1 -1 !ending of incoming bond and nn
3.783586502 3.069634438 -0.000003353 !beginning of bond
2 !bonds out
1 !unit 0 is bonded
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
1.802008867 3.940322876 1.161503792 !ending of outgoing
bond for unit 0
2 !unit 0 is bonded
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
3.680637360 5.331728935 1.361316323 !ending of outgoing
bond for unit 0
! rigid unit 1
0 1 -1 -1 !ending of incoming bond and nn
 3.220216751
               3.864162445 1.226425409 !beginning of bond
for unit 1
0 !bonds out
! rigid unit 2
0 1 2 3 -1 !ending of incoming bond and nn
 3.220216751 3.864162445 1.226425409 !beginning of bond
for unit 1
0 !bonds out
                DATA FILE FOR VALINE - V.DAT
```

- ! The side-chain structure file for Valine
- 3 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0

```
2 !atoms in this rigid unit
                      3.852613449 1.247815728 VAL 2
CB
        3.211601496
CT
       C -0.012
        3.447319269 3.248452187 2.150032282 VAL 2
      H 0.024
HC
! rigid unit 1
4 !atoms in this rigid unit
CG1
       1.676198244
                     4.045934200 1.217347741 VAL 2
       C -0.091
CT
HG11
      1.351996183 4.697401524 0.384493083 VAL 2
HC
      H 0.031
HG12
      1.142809749 3.084587097 1.106773376 VAL 2
HC
      H 0.031
HG13
      1.300095797 4.498250008 2.155061245 VAL 2
HC
       H 0.031
! rigid unit 2
4 !atoms in this rigid unit
CG2
       3.797980547 5.269292355 1.500991821 VAL 2
CT
       C -0.091
HG21
       3.634918213
                    5.953960419 0.647068620 VAL
HC
       H 0.031
HG22
      3.359194279
                    5.751780510 2.395626068 VAL 2
HC
      H 0.031
HG23
      4.886912346 5.247161865 1.696415067 VAL 2
HC
       H 0.031
! BOND INFORMATION
! rigid unit 0
0 1 -1 -1 -1 !ending of incoming bond and nn
3.783586502
             3.069634438 -0.000003354 !beginning of bond
2 !bonds out
1 !unit bonded to
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
1.676198244 4.045934200 1.217347741!ending of outgoing
bond
2 !unit bonded to
0 1 -1 -1 -1 ! beginning of outgoing bond and nn
3.797980547
             5.269292355
                            1.500991821!ending of outgoing
bond
! rigid unit 1
```

- 0 1 2 3 -1 !ending of incoming bond and nn
- 3.211601496 3.852613449 1.247815728 !beginning of outgoing bond
- 0 !bonds out
- ! rigid unit 2
- 0 1 2 3 -1 !ending of incoming bond and nn
- 3.211601496 3.852613449 1.247815728 !beginning of outgoing bond
- 0 !bonds out

DATA FILE FOR TRYPTOPHAN - W.DAT

- ! The side-chain structure file for Tryptophan
- 2 !rigid units in side-chain
- ! ATOM INFORMATION
- ! rigid unit 0

3 !atoms in this rigid unit

CB	3.247885227	3.809360981	1.256884575 TRP	2
CT	C -0.098			

HB1 3.555066347 3.270197153 2.175767183 TRP 2 HC H 0.038

HB2 3.728011608 4.802421093 1.350249052 TRP 2

HC H 0.038

- ! rigid unit 1
- 15 !atoms in this rigid unit

CG	1.731538415	4.025276661	1.276940465 TRP	2

C* C -0.135

0.792832434 CD1 3.205200195 1.936712861 TRP 2

CW C 0.044

NE1 -0.527979255 3.628766537 1.692452073 TRP 2

NA N -0.352

CE2 -0.376119167 4.727549076 0.861387193 TRP 2

CN C 0.154

CD2 0.994750261 4.975831032 0.602216363 TRP 2

CB C 0.146

2.330861330 HD1 1.058894038 2.516448259 TRP 2

HC H 0.093

HE1 -1.402328849 3.197247982 2.011827707 TRP 2

W U 90/3084	9		PCI/US9	0/04229			
Н	H 0.271						
CE3	1.387488961	6.039774895	-0.250452638 TRE	2			
CA	C -0.173						
HE3	2.430646658	6.226261139	-0.463923573 TRF	2			
HC	H 0.086						
C Z 3	0.392907262	6.841813087	-0.810243368 TRP	2			
CA	C -0.066						
HZ3	0.674497783	7.661212444	-1.455789328 TRP	2			
HC	H 0.057						
CH2	-0.963685811	6.602497578	-0.548699141 TRP	2			
CA	C -0.077						
HH2	-1.710847259	7.243553162	-0.992942095 TRP	2			
HC	H 0.074						
CZ2	-1.364877820	5.549452305	0.277642310 TRP	2			
CA	C -0.168						
HZ2	-2.410887718	5.363564491	0.470484644 TRP	2			
HC	H 0.084						
! BOND	INFORMATION						
! rigid	unit 0						
0 1 2 -1 -1 !ending of incoming bond and nn							
3.7835	86740 3.069634	914 -0.00000	3497 !beginning o	f bond			
1 !bond	s out						
1 !unit	0 is bonded						
0 1 2 -1 -1 ! beginning of outgoing bond and nn							
1.731538415 4.025276661 1.276940465!ending of outgoing							
bond for unit 0							
! rigid unit 1							
0 1 4 -1 -1 !ending of incoming bond and nn							
	85227 3.809360	981 1.25688	4575 !beginning	of bond			
	for unit 1						
0 !bonds out							

DATA FILE FOR TYROSINE - Y.DAT

- ! The side-chain structure fil for Tyrosine
- 3 !rigid units in side-chain
- ! ATOM INFORMATION

```
! rigid unit 0
3 !atoms in this rigid unit
        3.293353796
                      3.842515945
                                   1.259159327 TYR 2
CT
       C -0.098
HB1
        3.703839302 3.358918667
                                   2.169649363 TYR
HC
      H 0.038
HB2
       3.749134064
                    4.852351665
                                   1.277104497 TYR
HC
       H
          0.038
! rigid unit 1
10 !atoms in this rigid unit
CG
        1.778211594 4.019127369
                                   1.411828637 TYR 2
CA
       C -0.030
CD1
       1.068759203 3.196300983
                                   2.292453527 TYR
CA
       C -0.002
HD1
       1.585003138
                    2.435774803
                                   2.862824917 TYR 2
HC
       H 0.064
CD2
       1.095163584
                    4.989490032 0.672801077 TYR
CA
       C -0.002
HD2
       1.629922271
                    5.630218983 -0.014210327 TYR
HC
      H 0.064
CE1
      -0.309100747 3.338460445 2.427857637 TYR
CA
       C -0.264
HE1
      -0.845880806
                     2.691843510
                                  3.105883360 TYR
HC
      H 0.102
CZ
      -0.983952701 4.304777145
                                  1.686211467 TYR 2
С
       C 0.462
CE2
      -0.283983082
                    5.129064560
                                  0.809688389 TYR 2
CA
       C -0.264
HE2
      -0.814125061
                    5.873366833
                                  0.234044328 TYR 2
HC
       H 0.102
! rigid unit 1
2 !atoms in this rigid unit
OH
       -2.337103367 4.443373203 1.815491915 TYR 2
OH
      0 -0.528
HH
      -2.648404837 3.798558235 2.453088284 TYR 2
HO
      H 0.334
! BOND INFORMATION
! rigid unit 0
```

- 0 1 2 -1 -1 !ending of incoming bond and nn

3.783586264 3.069634914 -0.000003354 !beginning of bond

- 1 !bonds out
- 1 !unit bonded to
- 0 1 2 -1 -1 ! beginning of outgoing bond and nn
- 1.778211594 4.019127369 1.411828637!ending of outgoing

bond for unit 0

- ! rigid unit 1
 - 0 1 3 -1 -1 !ending of incoming bond and nn
 - 3.293353796 3.842515945 1.259159327 !beginning of bond

for unit 1

- 1 !bonds out
- 2 !unit bonded to
- 7 5 8 -1 -1 ! beginning of outgoing bond and nn
- -2.337103367 4.443373203 1.815491915 !ending of outgoing bond for unit 0
- ! rigid unit 2
- 0 1 -1 -1 -1 !ending of incoming bond and nn
- -0.983952701 4.304777145 1.686211467 !beginning of bond

for unit 1

0 !bonds out

DATA FILE FOR INITIAL PROTOTYPE - CX6C.CAR

!BIOSYM archive 3

PBC=OFF

!DATE Thu Mar 2 10:02:29 1995

SG 0.051616628 8.775964550 2.653307337 CYSn 1

S S 0.824

LG1 -0.116704460 8.906803991 3.732450018 CYSn 1

LP L -0.405

LG2 -0.816371929 8.216369655 2.274560255 CYSn 1

LP L -0.405

CB 1.625257994 7.970290997 2.280061368 CYSn 1

CT C -0.098

HB1 1.743097230 7.117856362 2.972980432 CYSn 1

HC H 0.050

HB2 2.457560406 8.667686711 2.506611212 CYSn 1

HC	H 0.050				
CA	1.664891168	7.503978115	0.811322158	CYSn	1
CT	C 0.035				
HA	2.715618613	7.453348875	0.469159517	CYSn	1
HC	H 0.032				
N	0.954382540	8.512673633	0.003030230	CYSn	1
NT	N -0.463				
С	1.063568189	6.132700222	0.616111991	CYSn	1
С	C 0.616				
0	0.248707622	5.654726837	1.414398016	CYSn	1
0	0 -0.504				
N	1.449902196	5.479885680	-0.464156147	GLY	2
N	N -0.463				
HN	2.157106102	5.992384244	-1.099457509	GLY	2
Н	H 0.252				
CA	0.868490592	4.154014497	-0.652902307	GLY	2
CT	C 0.035				
HA1	1.550908149	3.403064022	-0.212395307	GLY	2
HC	H 0.032				
HA2	-0.097660558	4.132736815	-0.116611463	GLY	2
HC	H 0.032				
С	0.730531165	3.827591429	-2.120728786	GLY	2
С	C 0.616				
0	1.559375145	4.206208097	-2.957020570	GLY	2
0	0 -0.504				
N	-0.320742949	3.103195380	-2.456098946	GLY	3
N	N -0.463				
HN	-0.976177839	2.817016114	-1.646836012	GLY	3
Н	H 0.252				
CA	-0.454134161	2.787581074	-3.875321662	GLY	3
CT	C 0.035				
HA1	-0.907422830	1.783240810	-3.972773051	GLY	3
HC	H 0.032				
HA2	-1.127648566	3.540414569	-4.323795441	GLY	3
HC	H 0.032				
С	0.896974016	2.736484179	-4.547627543	GLY	3
С	C 0.616				
0	1.315189212	1.712629073	-5.101282348	GLY	3
0	0 -0.504				

WO 96/30	0849		PCT/US9	6/04229
N	1.599575272	3.853622667	-4.520184621 GLY	4
N	N -0.463			
HN	1.137216234	4.691535216	-4.019658253 GLY	4
Н	H 0.252			
CA	2.905944550	3.804217731	-5.170228610 GLY	4
CI	C 0.035			
HA1	3.056204584	2.789614618	-5.584558431 GLY	4
HC	Н 0.032			
HA2	2.897891721	4.540755026	-5.994216851 GLY	4
HC	H 0.032			
C	4.014980067	4.050747291	-4.175561433 GLY	4
C	C 0.616			
0	4.978871195	4.780583329	-4.436272241 GLY	4
0	0 -0.504			
N	3.887759074	3.450944950	-3.006608050 GLY	5
N	N -0.463			
HN	3.003276191	2.844372268	-2.879487738 GLY	5
H	H 0.252			
CA	4.960071382	3.689311240	-2.044877031 GLY	5
CT	C 0.035			
HA1	5.709592998	2.881830301	-2.144167698 GLY	5
HC	H 0.032			
HA2	5.427393718	4.658369322	-2.297948016 GLY	5
HC	H 0.032			
С	4.437174470	3.643619035	-0.629041435 GLY	5
С	C 0.616			
0	3.798322352	2.676595378	-0.197242766 GLY	5
0	0 -0.504			
N	4.713663113	4.691871185	0.124033264 GLY	6
N	N -0.463			
HIN	5.286002166	5.476492875	-0.348403798 GLY	6
Н	H 0.252		•	
CA	4.208080753	4.647691975	1.492986659 GLY	6
CT	C 0.035			
HA1	3.303800182	4.010943092	1.515218779 GLY	6
HC	H 0.032			
HA2	4.993057374	4.194323221	2.125265975 GLY	6
HC	H 0.032			
С	3.799265981	6.023038258	1.963510280 GLY	6

WO 96/30	849		PCT/US96/04229
С	C 0.616		
0	4.006824522	7.036283245	1.285298717 GLY 6
0	0 -0.504		
N	3.195690211	6.077750863	3.136158080 GLY 7
N	N -0.463		
HN	3.055107813	5.133307510	3.640799839 GLY 7
H	H 0.252		
CA	2.800412417	7.407555656	3.591101372 GLY 7
CT	C 0.035		
HA1	1.946687677	7.303619509	4.286815466 GLY 7
HC	H 0.032		
HA2	3.660862081	7.847316876	4.127520148 GLY 7
HC	H 0.032		
С	2.334578164	8.258959996	2.434291753 GLY 7
С	C 0.616		
0	2.337411236	9.494643783	2.487154063 GLY 7
0	0 -0.504		
N	1.936206121	7.605756209	1.358640986 CYSN 8
N	N -0.463		
HN	1.983632457	6.528240768	1.414418956 CYSN 8
Н	Н 0.252		
CA	1.485796919	8.428968216	0.240136508 CYSN 8
CT	C 0.035		
HA	0.399931102	8.271042216	0.100059529 CYSN 8
НС	H 0.032		
С		8.018162291	-1.043072620 CYSN 8
С	C 0.616		
CB		9.902481747	0.610166221 CYSN 8
	C -0.098		
HB1		10.016688002	1.140264476 CYSN 8
HC	H 0.050		
HB2		10.541353385	-0.293951287 CYSN 8
HC	H 0.050		
SG	0.440719361	10.532225816	1.688457720 CYSN 8
	S 0.824		
	-0.404239097	10.957145937	1.126774557 CYSN 8
LP	L -0.405	-	
LG2		11.329491558	2.359427872 CYSN 8
LP	L -0.405		

end

end	
********	******
********	*****
END OF LISTING	
*********	*********
**********	********
*************	*******
********	******
DATA FILE WEINER FORCES -	AMBER.FRC
**********	*******
**********	******
!BIOSYM forcefield 2	
#version amber.frc 1.0 19-Oct-90	
#version amber.frc 1.1 8-Aug-92	
#define amber	
> This is the new format version of the	amber forcefield
!Ver Ref Function Labe	1
!	
1.0 1 atom_types	
1.0 1 atom_types	amber
1.0 1 atom_types 1.0 1 equivalence	amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition	amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond	amber amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle	amber amber amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3	amber amber amber amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane	amber amber amber amber amber amber amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6)	amber amber amber amber amber amber amber amber amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12)	amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12) #atom_types amber	amber
1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12) #atom_types amber > Atom type definitions for any variant > Masses from CRC 1973/74 pages B-250. !Ver Ref Type Mass Element C	amber
1.0 1 atom_types 1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12) #atom_types amber > Atom type definitions for any variant > Masses from CRC 1973/74 pages B-250.	amber
1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12) #atom_types amber > Atom type definitions for any variant > Masses from CRC 1973/74 pages B-250. !Ver Ref Type Mass Element C	amber of amber
1.0 1 equivalence 1.0 1 hbond_definition 1.0 1 quadratic_bond 1.0 1 quadratic_angle 1.0 1 torsion_3 1.0 1 out_of_plane 1.0 1 nonbond(12-6) 1.0 1 hydrogen_bond(10-12) #atom_types amber > Atom type definitions for any variant > Masses from CRC 1973/74 pages B-250. !Ver Ref Type Mass Element C	amber of amber

1.0	1	C2	12.000000	С
1.0	3	С3	15.000000	С
1.0	1	CA	12.000000	С
1.0	1	CB	12.000000	С
1.0	1	CC	12.000000	C
1.0	3	CD	13.000000	С
1.0	3	CE	13.000000	С
1.0	3	CF	13.000000	С
1.0	3	CG	13.000000	С
1.0	3	CH	13.000000	С
1.0	3	CI	13.000000	С
1.0	3	CJ	13.000000	С
1.0	1	CK	12.000000	С
1.0	1	CM	12.000000	С
1.0	1	CN	12.000000	C
1.0	3	CP ·	13.000000	C
1.0	1	CÕ	12.000000	С
1.0	1	CR	12.000000	С
1.0	1	CT	12.000000	C
1.0	1	CV	12.000000	С
1.0	1	CM	12.000000	С
1.0	1	H	1.007825	H
1.0	1	H2	1.007825	H
1.0	1	Н3	1.007825	Н
1.0	1	HC	1.007825	H
1.0	1	НО	1.007825	H
1.0	1	HS	1.007825	H
1.0	3	LP	3.000000	H
1.0	1	N	14.003070	N
1.0	1	N*	14.003070	N
1.0	1	N2	14.003070	N
1.0	1	N3	14.003070	N
1.0	1	NA	14.003070	N
1.0	1	NB	14.003070	N
1.0	1	NC	14.003070	N
1.0	1	NP	14.003070	N
1.0	1	NT	14.003070	N
1.0	1	0	15.994910	0
1.0	1	02	15.994910	0

WO 90	5/30849					PCT/US96/04229
1.0	1	ОН	15.994910	0		
1.0	1	os	15.994910	0		
1.0	1	P	30.993760	P		
1.0	1	s	31.972070	s		
1.0	1	SH	31.972070	s		
1.0	3	CO	40.080000	Ca		
1.0	3	HW	1.008000	Н		
1.0	3	IM	35.450000	Cl		
1.0	3	CU	63.550000	Cu	L	
1.0	3	I	22.990000	I		
1.0	3	MG	24.305000	Mg	•	
1.0	3	OW	16.000000	0		
1.0	3	QC	132.90000	Cs		
1.0	3	QK	39.100000	к		
1.0	3	QL	6.940000	Li		
1.0	3	QN	22.990000	Na		
1.0	3	QR	85.470000	Rb	,	
1.1	4	CS	12.000000	С		carbohydrate sp3 carbon
1.1	4	AC	12.000000	С		carbohydrate alpha-anomeric
carbo	n					
1.1	4	BC	12.000000	С		carbohydrate beta-anomeric
carbo	n					
1.1	4	HT	1.007825	Н		carbohydrate sp3 hydro
1.1	4	AH	1.007825	H		carbohydrate alpha-anomeric
hydro	gen					
1.1	4	BH	1.007825	H		carbohydrate beta-anomeric
hydro	gen					
1.1	4	HY	1.00782	5	H	carbohydrate hydroxyl
hydro	gen					
1.1	4	OT	15.99491	0	0	carbohydrate hydroxyl
oxyge	n					
1.1	4	OA	15.994910	0		carbohydrate alpha-anomeric
oxyge	n					
1.1	4	OB	15.994910	0		carbohydrate beta-anomeric
oxyge	n					
1.1	4	OE	15.994910	0		carbohydrate ring oxygen
1.0	1	h\$	1.007825	H		Hydrogen atom for aTOMATIC
PARAM	ETER	assign	ment			
1.0	1	с\$	12.000000	C		Carbon atom for automatic

WO 96/30849 PCT/U	S96/04229
-------------------	-----------

parameter assignment

- 1.0 1 n\$ 14.003070 N Nitrogen atom for automatic parameter assignment
- 1.0 1 o\$ 15.994910 O Oxyg n atom for automatic parameter assignment
- 1.0 1 s\$ 31.972070 S Sulfur atom for automatic parameter assignment
- 1.0 1 p\$ 30.993760 P Phosphorous atom for automatic parameter assignment #equivalence amber
- > Equivalence table for any variant of amber

Equivalences

!			,				
!Ver	Ref	Type	NonB	Bond	Angle	Torsion	OOP
!							
1.0	1	С	С	С	С	С	С
1.0	1	C*	C*	C*	C*	C*	C*
1.0	1	C2	C2	C2	C2	C2	C2
1.0	1	C3	C3	C3	C3	C3	C3
1.0	1	CA	CA	CA	CA	CA	CA
1.0	1	CB	CB	CB	CB	CB	CB
1.0	1	CC	CC	CC	CC	CC	CC
1.0	1	æ	CD	CD	CD	CD	CD
1.0	1	CE	CE	CE	CE	CE	CE
1.0	1	CF	CF	CF	CF	CF	CF
1.0	1	CG	CG	CG	CG	CG	CG
1.0	1	CH	CH	CH	CH	CH	CH
1.0	1	CI	CI	CI	CI	CI	CI
1.0	1	CJ	CJ	CJ	CJ	CJ	CJ
1.0	1	CK	CK	CK	CK	CK	CK
1.0	1	CM	CM	CM	CM	CM	CM
1.0	1	CN	CN	CN	CN	CN	CN
1.0	1	CP	CP	CP	CP	CP	CP
1.0	1	CQ	CQ	CQ	CŌ	CQ	CQ
1.0	1	CR	CR	CR	CR	CR	CR
1.0	1	CT	CT	CT	CT	CT	CT
1.0	1	CV	CV	CV	CV	CV	CV
1.0	1	CM	CW	CM	CM	CW	CW
1.0	1	H	H	Н	H	H	H

WO 96/3	30849 1	H2	H 2	Н2	Н2	Н2	PCT/US96/04229 H2
1.0	1	Н3	нз	Н3	нз	Н3	нз
1.0	1	HC	HC	нС	HC	HC	нс
1.0	1	но	но	но	НО	НО	но
1.0	1	HS	нѕ	HS	HS	HS	HS
1.0	1	LP	LP	LP	LP	LP	LP
1.0	1	N	N	N	N	N	N
1.0	1	N*	N*	N*	N*	N*	И¥
1.0	1	N2	N2	N2	N2	N2	N2
1.0	1	И3	N3	N 3	из	N3	N3
1.0	1	NA	NA	NA	NA	NA	NA
1.0	1	NB	NB	NB	NB	NB	NB
1.0	1	NC	NC	NC	NC	NC	NC
1.0	1	NP	NP	NP	NP	NP	NP
1.0	1	NT	NT	NT	NT	NT	NT
1.0	1	0	0	0	0	0	0
1.0	1	02	02	02	02	02	02
1.0	1	OH	OH	ОН	OH	OH	ОН
1.0	1	os	os	os	os	os	os
1.0	1	P	P	P	P	P	P
1.0	1	S	S	S	S	S	S
1.0	1	SH	SH	SH	SH	SH	SH
1.0	3	I	I	I	I	I	I
1.0	3	CU	CU	CU	CU	CU	CU
1.0	3	IM	IM	IM	IM	IM	IM
1.0	3	CO	CO	CO	CO	CO	C0
1.0	3	HW	HW	HW	HW	HW	HW
1.0	3	MG	MG	MG	MG	MG	MG
1.0	3	OW	OM	OM	OW	OM	OM
1.0	3	QC	ОС	QC	QC	QC	QC
1.0	3	QK	QK	QK	QK	QK	QK
1.0	3	QL	QL	QL	QL	QL	QL
1.0	3	QN	ØИ	QИ	QN	QN	QN
1.0	3	QR	QR	QR	QR	QR	QR
1.1	4	CS	CS	CS	CS	CS	CS
1.1	4	AC	AC	AC	AC	AC	AC
1.1	4	BC	BC	BC	BC	BC	BC
1.1	4	HT	HT	HT	HT	HT	HT
1.1	4	AH	AH	AH	AH	AH	AH

VO 96/308	49									PCT/US9	6/04 22 9
1.1	4	вн	вн	B	Н		вн		BH		вн
1.1	4	HY	HY	H	ΙΥ		HY		HY		HY
1.1	4	OT	OT	C	T		OT		OT		OT
1.1	4	OA	OA	C	A		OA		OA		OA
1.1	4	OB	OB	0	B		OB		OB		OB
1.1	4	OE	OE	O	E		OE		OE		OE
1.0	1	h\$	h\$	ħ	\$		h\$		h\$		h\$
1.0	1	С\$	c\$	c	\$		С\$		C\$		c\$
1.0		•	•	n	\$		n\$		n\$		n\$
1.0		ο\$			\$		0\$		0\$		ο\$
1.0		s \$					s\$		s\$		s\$
1.0		p\$	_	_	\$		p\$		p\$		p\$
	_	inition									
		distan									
		angle									
		donors				H2		HS			
		accept			NC	02	0	OH	S	SH	
_		_bond									
		(R - R			.	^		7/7	•		
:ver		I 				.0	_	K2			
	3					572	5	53.0	000		
	3		HW				5				
1.0			N3			71		67.0			
1.0		C3				10		22.0			
1.0	1	C	C2		1.5			17.0	000		
1.0	1	С	C3		1.5	220		17.0			
1.0	1	С	CA		1.4	000	4	69.0	000		
1.0	1	С	CB		1.4	190	4	47.0	000		
1.0	1	С	CD		1.4	000	4	69.0	000		
1.0	1	С	CH		1.5	220	3	17.0	000		
1.0	1	С	CJ		1.4	440	4	10.0	000		
1.0	1	C	CM		1.4	440	4	10.0	000		
1.0	3	C	CT		1.5	220	3	17.0	000		
1.0	1	C	N		1.3	350	4	90.0	000		
1.0	1	C	N*		1.3	830	4	24.0	000		
1.0	1	С	NA		1.3	880	4	18.0	000		
1.0	1	C	NC		1.3	580	4	57.0	000		
1.0	1	С	0		1.2	290	5	70.0	000		

PCT/US96/04229
PC

1.0	1	С	02	1.2500	656.0000
1.0	1	С	OH	1.3640	450.0000
1.0	1	C*	C2	1.4950	317.0000
1.0	1	C*	CB	1.4590	388.0000
1.0	1	C*	CG	1.3520	546.0000
1.0	1	C*	CT	1.4950	317.0000
1.0	1	C*	CW	1.3520	546.0000
1.0	1	C*	HC	1.0800	340.0000
1.0	1	C2	C2	1.5260	260.0000
1.0	1	C2	C3	1.5260	260.0000
1.0	1	C2	CA	1.5100	317.0000
1.0	1	C2	CC	1.5040	317.0000
1.0	1	C2	CH	1.5260	260.0000
1.0	1	C2	N	1.4490	337.0000
1.0	1	C2	N2	1.4630	337.0000
1.0	1	C2	N 3	1.4710	367.0000
1.0	1	C2	NT	1.4710	367.0000
1.0	1	C2	OH	1.4250	386.0000
1.0	1	C2	os	1.4250	320.0000
1.0	1	C2	S	1.8100	222.0000
1.0	1	C2	SH	1.8100	222.0000
1.0	1	C3	CH	1.5260	260.0000
1.0	1	C3	CM	1.5100	317.0000
1.0	1	C3	N	1.4490	337.0000
1.0	1	C3	N*	1.4750	337.0000
1.0	1	C 3	N2	1.4630	337.0000
1.0	1	C3	м3	1.4710	367.0000
1.0	1	C3	OH	1.4250	386.0000
1.0	1	C3	os	1.4250	320.0000
1.0	1	C3	S	1.8100	222.0000
1.0	1	CA	CA	1.4000	469.0000
1.0	1	CA	CB	1.4040	469.0000
1.0	1	CA	CD	1.4000	469.0000
1.0	1	CA	CJ	1.4330	427.0000
1.0	1	CA	CM	1.4330	427.0000
1.0	1	CA	CN	1.4000	469.0000
1.0	1	CA	CT	1.5100	317.0000
1.0	1.	CA	HC	1.0800	340.0000
1.0	1	CA	N2	1.3400	481.0000

1.0	1	CA	NA	1.3810	427.0000
1.0	1	CA	NC	1.3390	483.0000
1.0	1	CB	CB	1.3700	520.0000
1.0	1	CB	æ	1.4000	469.0000
1.0	1	CB	CN	1.4190	447.0000
1.0	1	CB	N*	1.3740	436.0000
1.0	1	CB	NB	1.3910	414.0000
1.0	1	CB	NC	1.3540	461.0000
1.0	1	CC	CF	1.3750	512.0000
1.0	1	CC	CG	1.3710	518.0000
1.0	1	CC	CT	1.5040	317.0000
1.0	1	CC	CV	1.3750	512.0000
1.0	1	CC	CW	1.3710	518.0000
1.0	1	CC	NA	1.3850	422.0000
1.0	1	CC	NB	1.3940	410.0000
1.0	1	CD	CD	1.4000	469.0000
1.0	1	CD	CN	1.4000	469.0000
1.0	1	CE	N*	1.3710	440.0000
1.0	1	CE	NB	1.3040	529.0000
1.0	1	CF	NB	1.3940	410.0000
1.0	1	CG	NA	1.3810	427.0000
1.0	1	CH	CH	1.5260	260.0000
1.0	1	CH	N	1.4490	337.0000
1.0	1	CH	N*	1.4750	337.0000
1.0	1	CH	NT	1.4710	367.0000
1.0	1	CH	OH	1.4250	386.0000
1.0	1	CH	os	1.4250	320.0000
1.0	1	CI	NC	1.3240	502.0000
1.0	1	CJ	CJ	1.3500	549.0000
1.0	1	CJ	CM	1.3500	549.0000
1.0	1	CJ	N*	1.3650	448.0000
1.0	1	CK	HC	1.0800	340.0000
1.0	1	CK	N*	1.3710	440.0000
1.0	1	CK	NB	1.3040	529.0000
1.0	1	CM	CM	1.3500	549.0000
1.0	1	CM	CT	1.5100	317.0000
1.0	1	CM	HC	1.0800	340.0000
1.0	1	CM	N*	1.3650	448.0000
1.0	1	CN .	NA	1.3800	428.0000

1.0	1	CP	NA	1.3430	477.0000
1.0	1	CP	NB	1.3350	488.0000
1.0	1	CO	HC	1.0800	340.0000
1.0	1	CQ	NC	1.3240	502.0000
1.0	1	CR	HC	1.0800	340.0000
1.0	1	CR	NA	1.3430	477.0000
1.0	1	CR	NB	1.3350	488.0000
1.0	1	CT	CT	1.5260	310.0000
1.0	1	CT	HC	1.0900	331.0000
1.0	3	CT	N	1.4490	337.0000
1.0	1	CT	N*	1.4750	337.0000
1.0	1	CT	N2	1.4630	337.0000
1.0	1	CT	N3	1.4710	367.0000
1.0	1	CT	ОН	1.4100	320.0000
1.0	1	CT	os	1.4100	320.0000
1.0	1	CT	s	1.8100	222.0000
1.0	1	CT	SH	1.8100	222.0000
1.0	1	CV	HC	1.0800	340.0000
1.0	1	CV	NB	1.3940	410.0000
1.0	1	CW	HC	1.0800	340.0000
1.0	1	CM	NA	1.3810	427.0000
1.0	1	Н	N	1.0100	434.0000
1.0	1	H	N2	1.0100	434.0000
1.0	1	H	NA	1.0100	434.0000
1.0	1	H	N*	1.0100	434.0000
1.0	1	H2	N	1.0100	434.0000
1.0	1	H2	N2	1.0100	434.0000
1.0	1	H2	NT	1.0100	434.0000
1.0	1	Н3	N2	1.0100	434.0000
1.0	1	Н3	N3	1.0100	434.0000
1.0	1	HO	OH	0.9600	553.0000
1.0	1	HO	os	0.9600	553.0000
1.0	1	HS	SH	1.3360	274.0000
1.0	3	LP	S	0.6790	150.0000
1.0	3	LP	SH	0.6790	150.0000
1.0	1	02	P	1.4800	525.0000
1.0	1	OH	P	1.6100	230.0000
1.0	1	os	P	1.6100	230.0000
1.0	1	S	S	2.0380	166.0000

1.1	4	OH	HO	0.9600	553.0000
1.1	4	OT	HY	0.9720	460.5000
1.1	4	OA	HY	0.9720	460.5000
1.1	4	OB	HY	0.9720	460.5000
1.1	4	CS	HT	1.0990	337.3000
1.1	4	AC	AH	1.0990	337.3000
1.1	4	BC	BH	1.0990	337.3000
1.1	4	AC	HT	1.0990	337.3000
1.1	4	BC	HT	1.0990	337.3000
1.1	4	AC	AO	1.4110	334.3000
1.1	4	BC	OB	1.3900	334.3000
1.1	4	CS	OA	1.4400	334.3000
1.1	4	CS	OB	1.4400	334.3000
1.1	4	CS	CS	1.5230	214.8000
1.1	4	CS	CT	1.5230	214.8000
1.1	4	AC	CS	1.5230	214.8000
1.1	4	BC	CS	1.5230	214.8000
1.1	4	CS	OT	1.4110	334.3000
1.1	4	CS	OE	1.4270	296.7000
1.1	4	AC	OE	1.4270	296.7000
1.1	4	BC	OE	1.4270	296.7000
1.1	4	CS	N	1.4490	355.0000
1.1	4	H	N	1.0100	434.0000
1.1	4	С	N	1.3350	490.0000
1.1	4	C	0	1.2290	570.0000
1.1	4	С	CS	1.5220	335.0000
1.0	1	C\$1	C\$1	1.5260	260.0000
1.0	1	C\$2	C\$2	1.4000	469.0000
1.0	1	C\$3	C\$3	1.3700	520.0000
1.0	ı	C\$5	C\$5	1.2040	590.0000
1.0	1	C\$1	0\$1	1.4250	386.0000
1.0	1	C\$2	0\$2	1.2500	280.0000
1.0	1	C\$3	0\$3	1.2300	300.0000
1.0	1	C\$1	N \$1	1.4490	337.0000
1.0	1	C\$2	N\$2	1.3810	427.0000
1.0	1	C\$5	N \$5	1.1580	649.0000
1.0	1	C\$1	S\$1	1.8100	222.0000
1.0	1	C\$1	H\$1	1.0900	331.0000

1.0	1	0\$1	0\$1		1.4800 59	90.0000
1.0	1	0\$3	0\$3		1.2080 55	90.000
1.0	1	0\$1	N\$1		1.2400 30	00.000
1.0	1	0\$2	N\$2		1.1900 45	50.0000
1.0	1	0\$3	N\$3		1.1860 55	90.0000
1.0	1	0\$1	H\$1		0.9600 55	53.0000
1.0	1	N\$1	N\$1		1.1300 30	00.000
1.0	1	N\$1	H\$1		1.0100 43	34.0000
1.0	1	S\$1	S\$1		2.0380 16	6.0000
1.0	1	S\$1	H\$1		1.3360 27	74.0000
1.0	1	0\$1	P\$1		1.6100 23	30.0000
1.0	1	O\$ 2	P\$2		1.4800 52	25.0000
1.0	1	P\$1	H\$1		1.5000 20	00.000
#quad:	ratic	_angle	amb	er		
> E =	K2 *	(Theta	- The	ta0) ^	2	
!Ver	Ref	I	J	K	Theta0	K2
!						
1.0	3	HW	OW	HW	104.5200	100.0000
1.0	3	0	C	0	126.0000	80.0000
1.0	3	С	CH	N 3	109.7000	80.0000
1.0	3	CH	CH	N3	109.7000	80.0000
1.0	3	C	CT	N3	112.0000	80.0000
1.0	3	CH	N3	Н3	109.5000	35.0000
1.0	3	CT	N3	CT	113.0000	50.0000
1.0	3	P	os	P	120.5000	100.0000
1.0	1	С	C2	C2	112.4000	63.0000
1.0	1	С	C2	CH	112.4000	63.0000
1.0	1	С	C2	N	110.3000	80.0000
1.0	1	С	C2	NT	111.2000	80.0000
1.0	1	С	CA	CA	120.0000	85.0000
1.0	1	С	CA	HC	120.0000	35.0000
1.0	1	С	CB	CB	119.2000	85.0000
1.0	1	С	CB	NB	130.0000	70.0000
1.0	1	C	æ	æ	120.0000	85.0000
1.0	1	C	CH	C2	111.1000	63.0000
1.0	1	С	CH	C3	111.1000	63.0000
1.0	1	C	CH ·	CH	111.1000	63.0000
1.0	1	C	CH	N	110.1000	63.0000
1.0	1	С	CH	NT	109.7000	80.0000

WO 96/30	849					PCT/US96/04229
1.0	1	С	CJ	CJ	120.7000	85.0000
1.0	1	C	CM	C3	119.7000	85.0000
1.0	1	C	CM	CJ	120.7000	85.0000
1.0	1	С	CM	CM	120.7000	85.0000
1.0	1	С	CM	CT	119.7000	70.0000
1.0	1	С	CM	HC	119.7000	35.0000
1.0	1	С	CT	CT	111.1000	63.0000
1.0	1	С	CT	нС	109.5000	35.0000
1.0	1	С	CT	N	110.1000	63.0000
1.0	1	С	N	C2	121.9000	50.0000
1.0	1	С	N	C3	121.9000	50.0000
1.0	1	С	N	CH	121.9000	50.0000
1.0	1	С	N	CT	121.9000	50.0000
1.0	1	С	N	Н	119.8000	35.0000
1.0	1	С	N	Н2	120.0000	35.0000
1.0	1	С	N*	CH	117.6000	70.0000
1.0	1	C	N*	CJ	121.6000	70.0000
1.0	1	С	N*	CM	121.6000	70.0000
1.0	1	С	N*	CT	117.6000	70.0000
1.0	1	С	N*	Н	119.2000	35.0000
1.0	1	С	NA	С	126.4000	70.0000
1.0	1	С	NA	CA	125.2000	70.0000
1.0	1	С	NA	H	116.8000	35.0000
1.0	1	С	NC	CA	120.5000	70.0000
1.0	1	C	OH	HO	113.0000	35.0000
1.0	1	C*	C2	CH	115.6000	63.0000
1.0	1	C*	CB	CA	134.9000	85.0000
1.0	1	C*	CB	CD	134.9000	85.0000
1.0	1	C*	CB	CN	108.8000	85.0000
1.0	1	C*	CG	NA	108.7000	70.0000
1.0	1	C*	CT	HC	109.5000	35.0000
1,.0	1	C*	CW	HC	120.0000	35.0000
1.0	1	C*	CM	NA	108.7000	70.0000
1.0	1	C2	С	N	116.6000	70.0000
1.0	1	C2	C	0	120.4000	0000.08
1.0	1	C2	C	02	117.0000	70.0000
1.0	1	C2	C*	CB	128.6000	70.0000
1.0	1	C2	C*	CG	125.0000	70.0000
1.0	1	C2	C*	CW	125.0000	70.0000

•	U 90/3084:	,					PC1/US90/0422
	1.0	1	C2	C2	C2	112.4000	63.0000
	1.0	1	C2	C2	СН	112.4000	63.0000
	1.0	1	C2	C2	N	111.2000	80.0000
	1.0	1	C2	C2	N2	111.2000	80.0000
	1.0	1	C2	C2	N3	111.2000	80.0000
	1.0	1	C2	C2	NT	111.2000	80.0000
	1.0	1	C2	C2	os	109.5000	80.0000
	1.0	1	C2	C2	S	114.7000	50.0000
	1.0	1	C2	CA	CA	120.0000	70.0000
	1.0	ı	C2	CA	CD	120.0000	70.0000
	1.0	1	C2	CC	CF	131.9000	70.0000
	1.0	1	C2	CC	CG	129.0000	70.0000
	1.0	1	C2	CC	CV	131.9000	70.0000
	1.0	1	C2	CC	CM	129.0000	70.0000
	1.0	1	C2	CC	NA	122.2000	70.0000
	1.0	1	C2	CC	NB	121.0000	70.0000
	1.0	1	C2	CH	C3	111.5000	63.0000
	1.0	1	C2	CH	CH	111.5000	63.0000
	1.0	1	C2	CH	N	109.7000	80.0000
	1.0	1 ,	C2	CH	N*	109.5000	80.0000
	1.0	1	C2	CH	NT	109.7000	80.0000
	1.0	1	C2	CH	OH	109.5000	80.0000
	1.0	1	C2	CH	os	109.5000	80.0000
	1.0	1	C2	N	СН	118.0000	50.0000
	1.0	1	C2	N	H	118.4000	38.0000
	1.0	1	C2	N2	CA	123.2000	50.0000
	1.0	1	C2	N2	H2	118.4000	35.0000
	1.0	1	C2	N2	Н3	118.4000	35.0000
	1.0	1	C2	м3	Н3	109.5000	35.0000
	1.0	1	C2	NT	H2	109.5000	35.0000
	1.0	1	C2	OH	НО	108.5000	55.0000
	1.0	1	C2	os	C2	111.8000	100.0000
	1.0	1	C2	os	C3	111.8000	100.0000
	1.0	1	C2	os	НО	108.5000	55.0000
	1.0	1	C2	os	P	120.5000	100.0000
	1.0	1	C2	S	C3	98.9000	62.0000
	1.0	3	C2	S	LP	96.7000	150.0000
	1.0	1	C2	S	S	103.7000	68.0000
	1.0	1	C2	SH	HS	96.0000	44.0000

WO 96/30849

PCT/US96/04229

1.0	3	C2	SH	LP	96.7000	150.0000
1.0	1	C 3	С	N	116.6000	70.0000
1.0	1	C3	C	0	120.4000	80.0000
1.0	1	C3	С	02	117.0000	70.0000
1.0	1	C3	C2	CH	112.4000	63.0000
1.0	1	C3	C2	os	109.5000	80.0000
1.0	1	C 3	CH	C3	111.5000	63.0000
1.0	1	C3	CH	CH	111.5000	63.0000
1.0	1	C 3	CH	N	109.5000	80.0000
1.0	1	C3	CH	NT	109.7000	80.0000
1.0	1	C 3	СН	OH	109.5000	80.0000
1.0	1	C 3	CM	CJ	119.7000	85.0000
1.0	1	C3	N	Н	118.4000	38.0000
1.0	1	C3	N*	CB	125.8000	70.0000
1.0	1	C3	N*	CE	128.8000	70.0000
1.0	1	C3	N*	CK	128.8000	70.0000
1.0	1	C3	N2	CA	123.2000	50.0000
1.0	1	C3	N2	H2	118.4000	35.0000
1.0	1	C3	ΝЗ	Н3	109.5000	35.0000
1.0	1	C3	OH	HO	108.5000	55.0000
1.0	1	C3	os	P	120.5000	100.0000
1.0	3	C3	S	LP	96.7000	150.0000
1.0	1	C3	s	S	103.7000	68.0000
1.0	1	C3	SH	HS	96.0000	44.0000
1.0	3	C3	SH	LP	96.7000	150.0000
1.0	1	CA	C	CA	120.0000	85.0000
1.0	1	CA	С	OH	120.0000	70.0000
1.0	1	CT	C	OH	117.0000	70.0000
1.0	3	CT	С	02	117.0000	70.0000
1.0	1	CA	C2	CH	114.0000	63.0000
1.0	1	CA	CA	CA	120.0000	85.0000
1.0	1	CA	CA	CB	120.0000	85.0000
1.0	1	CA	CA	CN	120.0000	85.0000
1.0	1	CA	CA	CT	120.0000	70.0000
1.0	1	CA	CA	HC	120.0000	35.0000
1.0	1	CA	CB	CB	117.3000	85.0000
1.0	1	CA	CB	CN	116.2000	85.0000
1.0	1	CA	CB	NB	132.4000	70.0000
1.0	1	CA	CD	CD	120.0000	85.0000

1.0	1	CA	CJ	CJ	117.0000	85.0000
1.0	1	CA	CM	CM	117.0000	85.0000
1.0	1	CA	CM	HC	123.3000	35.0000
1.0	1	CA	CN	CB	122.7000	85.0000
1.0	1	CA	CN	NA	132.8000	70.0000
1.0	1	CA	CT	CT	114.0000	63.0000
1.0	1	CA	CT	HC	109.5000	35.0000
1.0	1	CA	N2	CT	123.2000	50.0000
1.0	1	CA	N2	H	120.0000	35.0000
1.0	1	CA	N2	H2	120.0000	35.0000
1.0	1	CA	N2	нз	120.0000	35.0000
1.0	1	CA	NA	H	118.0000	35.0000
1.0	1	CA	NC	CB	112.2000	70.0000
1.0	1	CA	NC	CI	118.6000	70.0000
1.0	1	CA	NC	CÕ	118.6000	70.0000
1.0	ı	CB	C	NA	111.3000	70.0000
1.0	1	CB	С	0	128.8000	80.0000
1.0	1	CB	C*	CG	106.4000	85.0000
1.0	1	CB	C*	CT	128.6000	70.0000
1.0	1	CB	C*	CW	106.4000	85.0000
1.0	ı	CB	C*	HC	126.8000	35.0000
1.0	1	CB	CA	HC	120.0000	35.0000
1.0	1	CB	CA	N2	123.5000	70.0000
1.0	1	CB	CA	иС	117.3000	70.0000
1.0	1	CB	CB	N*	106.2000	70.0000
1.0	1	CB	CB	NB	110.4000	70.0000
1.0	1	CB	CB	NC	127.7000	70.0000
1.0	1	CB	CD	æ	120.0000	85.0000
1.0	1	CB	CN	CD ,	122.7000	85.0000
1.0	1	CB	CN	NA	104.4000	70.0000
1.0	1	CB	N*	CE	105.4000	70.0000
1.0	1	CB	N*	CH	125.8000	70.0000
1.0	1	CB	N*	CK	105.4000	70.0000
1.0	1	CB	N*	CT	125.8000	70.0000
1.0	1	CB	N*	H	127.3000	35.0000
1.0	1	CB	NB	CE	103.8000	70.0000
1.0	1	CB	NB	CK	103.8000	70.0000
1.0	1	CB	NC	CI	111.0000	70.0000
1.0	1	CB	NC	CQ	111.0000	70.0000

WO 96/308	349					PCT/US96/04229
1.0	1	CC	C2	CH	113.1000	63.0000
1.0	1	CC	CF	NB	109.9000	70.0000
1.0	1	CC	CG	NA	105.9000	70.0000
1.0	1	CC	CT	CT	113.1000	63.0000
1.0	1	CC	CT	HC	109.5000	35.0000
1.0	ı	CC	CV	HC	120.0000	35.0000
1.0	1	CC	CV	NB	109.9000	70.0000
1.0	1	CC	CW	HC	120.0000	35.0000
1.0	1	CC	CW	NA	105.9000	70.0000
1.0	1	CC	NA	CP	107.3000	70.0000
1.0	1	CC	NA	CR	107.3000	70.0000
1.0	1	CC	NA	H	126.3000	35.0000
1.0	1	CC	NB	CP	105.3000	70.0000
1.0	1	CC	NB	CR	105.3000	70.0000
1.0	1	CD	С	CD	120.0000	85.0000
1.0	1	CD	C	OH	120.0000	70.0000
1.0	1	CD	CA	CD	120.0000	85.0000
1.0	1	CD	CB	CN	116.2000	85.0000
1.0	1	CD	CD	CD	120.0000	85.0000
1.0	1	CD	CD	CN	120.0000	85.0000
1.0	1	æ	CN	NA	132.8000	70.0000
1.0	1	CE	N*	CH	128.8000	70.0000
1.0	1	CE	N*	CT	128.8000	70.0000
1.0	1	CE	И÷	Н	127.3000	35.0000
1.0	1	CF	CC	NA	105.9000	70.0000
1.0	1	CF	NB	CP	105.3000	70.0000
1.0	1	CF	NB	CR	105.3000	70.0000
1.0	1	CG	CC	NA 	108.7000	70.0000
1.0	1	CG	CC	NB	109.9000	70.0000
1.0	1	CG	NA	CN	111.6000	70.0000
1.0	1	CG	NA	CP	107.3000	70.0000
1.0	1	CG	NA	CR	107.3000	70.0000
1.0	1	CG	NA	Н	126.3000	35.0000
1.0	1	CH	C	И	116.6000	70.0000
1.0	1	CH	C	0	120.4000	80.0000
1.0	1	CH	C	O2	117.0000	65.0000
1.0	1	CH	C	OH	115.0000	70.0000
1.0	1	CH	C2	CH	112.4000	63.0000

1.0 1 CH C2 OH 109.5000 80.0000

W	96/30849	•					PCT/US96/04229
	1.0	1	CH	C2	os	109.5000	80.0000
	1.0	1	CH	C2	S	114.7000	50.0000
	1.0	1	CH	C2	SH	108.6000	50.0000
	1.0	1	CH	CH	CH	111.5000	63.0000
	1.0	1	CH	CH	N	109.7000	80.0000
	1.0	1	СН	CH	N*	109.5000	80.0000
	1.0	1	CH	CH	NT	109.7000	80.0000
	1.0	1	CH	CH	OH	109.5000	80.0000
	1.0	1	CH	CH	os	109.5000	80.0000
	1.0	1	СН	N	H	118.4000	38.0000
	1.0	1	CH	N+	CJ	121.2000	70.0000
	1.0	1	CH	N*	CK	128.8000	70.0000
	1.0	1	СН	NT	H2	109.5000	35.0000
	1.0	1	CH	OH	HO	108.5000	55.0000
	1.0	1	CH	os	CH	111.8000	100.0000
	1.0	1	CH	os	HO	108.5000	55.0000
	1.0	1	CH	os	P	120.5000	100.0000
	1.0	1	CJ	С	NA	114.1000	70.0000
	1.0	1	CJ	С	0	125.3000	80.0000
	1.0	1	CJ	CA	N2	120.1000	70.0000
	1.0	1	CJ	CA	NC	121.5000	70.0000
	1.0	1	CJ	CJ	N*	121.2000	70.0000
	1.0	1	CJ	CM	CI	119.7000	85.0000
	1.0	1	CJ	N*	CT	121.2000	70.0000
	1.0	1	CJ	N*	Н	119.2000	35.0000
	1.0	1	CK	N*	CT	128.8000	70.0000
	1.0	1	CM	C	NA	114.1000	70.0000
	1.0	1	CM	С	0	125.3000	80.0000
	1.0	1	CM	CA	N2	120.1000	70.0000
	1.0	1	CM	CA	NC	121.5000	70.0000
	1.0	1	CM	CJ	N*	121.2000	70.0000
	1.0	1	CM	CM	CT	119.7000	70.0000
	1.0	1	CM	CM	HC	119.7000	35.0000
	1.0	1	CM	CM	N*	121.2000	70.0000
	1.0	1	CM	CT	HC	109.5000	35.0000
	1.0	1	CM	N*	CT	121.2000	70.0000
	1.0	1	CM	N*	H	119.2000	35.0000
	1.0	1	CN	CA	HC	120.0000	35.0000
	1.0	1	CN	NA	CM	111.6000	70.0000

1.0	1	CN	NA	H	123.1000	35.0000
1.0	1	CP	NA	H	126.3000	35.0000
1.0	1	CR	NA	CW	107.3000	70.0000
1.0	1	CR	NA	н	126.3000	35.0000
1.0	1	CR	NB	CV	105.3000	70.0000
1.0	1	CT	С	N	116.6000	70.0000
1.0	1	CT	С	0	120.4000	80.0000
1.0	1	CT	. C*	CM	125.0000	70.0000
1.0	· 1	CI	CC	CV	131.9000	70.0000
1.0	1	CT	CC	CW	129.0000	70.0000
1.0	1	CT	CC	NA	122.2000	70.0000
1.0	1	CT	CC	NB	121.0000	70.0000
1.0	1	CT	CT	CT	109.5000	40.0000
1.0	1	CT	CT	C*	115.6000	63.0000
1.0	1	CT	CT	HC	109.5000	35.0000
1.0	1	CT	CT	N	109.7000	80.0000
1.0	1	CT	CT	N*	109.5000	50.0000
1.0	1	CT	CT	N2 .	111.2000	80.0000
1.0	1	CT	CT	из	111.2000	80.0000
1.0	1	CT	CT	OH	109.5000	50.0000
1.0	1	CT	CT	os	109.5000	50.0000
1.0	1	CT	CT	S	114.7000	50.0000
1.0	1	CT	CT	SH	108.6000	50.0000
1.0	1	CT	N	CT	118.0000	50.0000
1.0	1	CI	N	H	118.4000	38.0000
1.0	1	CI	N2	Н3	118.4000	35.0000
1.0	1	CT	N3	Н3	109.5000	35.0000
1.0	1	CT	OH	HO	108.5000	55.0000
1.0	1	CT	os	CT	109.5000	60.0000
1.0	1	CT	os	P	120.5000	100.0000
1.0	1	CT	S	CT	98.9000	62.0000
1.0	3	CT	S	LP	96.7000	150.0000
1.0	1	CT	S	S	103.7000	68.0000
1.0	1	CT	SH	HS	96.0000	44.0000
1.0	3	CT	SH	LP	96.7000	150.0000
1.0	1	CV	CC	NA	105.9000	70.0000
1.0	1	CW	C*	HC	126.8000	35.0000
1.0	1	CW	CC	NA	108.7000	70.0000
1.0	1	CM	CC	NB	109.9000	70.0000

PCT/US96/04229
7

1.0	1	CM	NA	H	125.3000	35.0000
1.0	1	н	N	H	120.0000	35.0000
1.0	1	Н2	N2	H2	120.0000	35.0000
1.0	1	H2	NT	H2	109.5000°	35.0000
1.0	1	н3	N	нз	120.0000	35.0000
1.0	1	Н3	N2	нз	120.0000	35.0000
1.0	1	Н3	N 3	нз	109.5000	35.0000
1.0	1	HC	CK	N*	123.0000	35.0000
1.0	1	HC	CK	NB	123.0000	35.0000
1.0	1	HC	CM	N*	119.1000	35.0000
1.0	1	HC	CQ	NC	115.4000	35.0000
1.0	1	HC	CR	NA	120.0000	35.0000
1.0	1	HC	CR	NB	120.0000	35.0000
1.0	1	HC	CT	HC	109.5000	35.5000
1.0	1	HC	CT	N	109.5000	38.0000
1.0	1	HC	CT	N+	109.5000	35.0000
1.0	1	HC	CT	N2	109.5000	35.0000
1.0	1	HC	CT	N3	109.5000	35.0000
1.0	1	HC	CT	OH	109.5000	35.0000
1.0	1	HC	CT	os	109.5000	35.0000
1.0	1	HC	CT	S	109.5000	35.0000
1.0	1	HC	CT	SH	109.5000	35.0000
1.0	1	HC	CV	NB	120.0000	35.0000
1.0	1	HC	CW	NA	120.0000	35.0000
1.0	ı	HO	OH	HO	104.5000	47.0000
1.0	1	HO	OH	P	108.5000	45.0000
1.0	1	HS	SH	HS	92.1000	35.0000
1.0	3	HS	SH	LP	96.7000	150.0000
1.0	3	LP	S	LP	160.0000	150.0000
1.0	3	LP	S	S	96.7000	150.0000
1.0	3	LP	SH	LP	160.0000	150.0000
1.0	1	N	C	0	122.9000	80.0000
1.0	1	N+	C	AK	115.4000	70.0000
1.0	1	N*	C	NC	118.6000	70.0000
1.0	1	N*	С	0	120.9000	80.0000
1.0	1	N*	CB	NC	126.2000	70.0000
1.0	1	N*	CE	NB	113.9000	70.0000
1.0	1	N*	CH	os	109.5000	80.0000
1.0	1	N*	CK	NB	113.9000	70.0000

WO 96/308	349					PCT/US96/0422
1.0	1	N*	CT	os	109.5000	50.0000
1.0	1	N2	CA	N2	120.0000	70.0000
1.0	1	N2	CA	NA	116.0000	70.0000
1.0	1	N2	CA	NC	119.3000	70.0000
1.0	1	NA	С	0	120.6000	80.0000
1.0	1	NA	CA	NC	123.3000	70.0000
1.0	1	NA	CP	NA	110.7000	70.0000
1.0	1	NA	CP	NB	111.6000	70.0000
1.0	1	NA	CR	NA	110.7000	70.0000
1.0	1	NA	CR	NB	111.6000	70.0000
1.0	1	NC	C	0	122.5000	80.0000
1.0	1	NC	CI	NC	129.1000	70.0000
1.0	ı	NC	CÕ	ИC	129.1000	70.0000
1.0	1	0	С	02	126.0000	80.0000
1.0	1	0	С	ОН	126.0000	80.0000
1.0	ı	02	С	02	126.0000	80.0000
1.0	1	02	P	02	119.9000	140.0000
1.0	1	02	P	OH	108.2000	45.0000
1.0	1	02	P	os	108.2000	100.0000
1.0	1	OH	P	os	102.6000	45.0000
1.0	1	os	P	os	102.6000	45.0000
1.1	4	HO	OH	HO	104.5000	47.0000
1.1	4	CS	OT	HY	109.3500	53.6000
1.1	4	AC	OA	HY	109.3500	53.6000
1.1	4	BC	OB	HY	109.3500	53.6000
1.1	4	CS	OT	CS	117.0000	60.0000
1.1	4	AC	OA	CS	115.0000	62.0000
1.1	4	BC	OB	CS	116.4000	62.0000
1.1	4	CS	OE	AC	113.8000	90.7000
1.1	4	CS	OE	BC	111.9000	90.7000
1.1	4	HT	CS	HT	107.8500	33.6000
1.1	4	AH	AC	HT	107.8500	33.6000
1.1	4	BH	BC	HT	107.8500	33.6000
1.1	4	HT	CS	CS	108.7200	43.0000
1.1	4	HC	CT	CS	108.7200	43.0000
1.1	4	HT	CS	CT	108.7200	43.0000
1.1	4	AH	AC	CS	108.7200	43.0000
1.1	4	BH	BC	CS	108.7200	43.0000
1.1	4	HT	CS	AC	108.7200	43.0000

1.1	4	HT	CS	BC	108.7200	43.0000
1.1	4	HT	CS	OT	109.8900	45.9000
1.1	4	HA	AC	OA	109.8900	45.9000
1.1	4	BH	BC	OB	109.8900	45.9000
1.1	4	HT	AC	OA	109.8900	45.9000
1.1	4	HT	BC	OB	109.8900	45.9000
1.1	4	HT	CS	OA	109.8900	45.9000
1.1	4	HT	CS	OB	109.8900	45.9000
1.1	4	HT	CS	OE	107.2400	45.2000
1.1	4	HT	CS	С	109.5000	35.0000
1.1	4	AH	AC	OE	107.2400	45.2000
1.1	4	BH	BC	OE	107.2400	45.2000
1.1	4	HT	AC	OE	107.2400	45.2000
1.1	4	HT	BC	OE	107.2400	45.2000
1.1	4	CS	CS	CS	110.7000	38.0000
1.1	4	CS	CS	CT	110.7000	38.0000
1.1	4	CS	CS	AC	110.7000	38.0000
1.1	4	CS	CS	BC	110.7000	38.0000
1.1	4	CS	CS	OT	110.1000	75.7000
1.1	4	CS	CT	ОН	110.1000	75.7000
1.1	4	CS	CS	OA	110.1000	75.7000
1.1	4	CS	CS	OB	110.1000	75.7000
1.1	4	CS	С	0	120.4000	80.0000
1.1	4	AC	CS	OT	110.1000	75.7000
1.1	4	BC	CS	OT	110.1000	75.7000
1.1	4	BC	CS	OB	110.1000	75.7000
1.1	4	BC	CS	OA	110.1000	75.7000
1.1	4	AC	CS	OB	110.1000	75.7000
1.1	4	AC	CS	OA	110.1000	75.7000
1.1	4	CS	AC	OA	110.1000	75.7000
1.1	4	CS	BC	OB	110.1000	75.7000
1.1	4	CS	CS	OE	109.4000	81.0000
1.1	4	CT	CS	OE	109.4000	81.0000
1.1	4	CS	AC	OE	109.4000	81.0000
1.1	4	CS	BC	OE	109.4000	81.0000
1.1	4	CS	OE	CS	113.8000	90.7000
1.1	4	OE	CS	OT	111.5500	92.6000
1.1	4	OE	AC	OA	111.5500	92.6000
1.1	4	OE	BC	OB	107.4000	92.6000

	_					normico.	C 10 4000
WO 96/3084		BC.	CS	N	109.7000	PCT/US9 80.0000	0/04229
1.1	4	BC	CS	N	109.7000	80.0000	
1.1	4	CS	CS	N	109.7000		
1.1	4	HT CS	N	Н	118.4000	38.0000	
1.1	4	CS	N	C	121.9000		
1.1	4	C	N	н	119.8000	35.0000	
1.1	4		C	0	122.9000	80.0000	
1.1	4	N	C ·	CS	116.6000	70.0000	
1.1	4	N			109.5000	63.0000	
1.0	1	\$\$ \$\$	C\$4	\$\$ **		85.0000	
1.0	1	\$\$	C\$3	\$\$			
1.0	1	\$\$ **	C\$2	\$\$	180.0000		
1.0	1	\$\$ **	O\$2	\$\$ \$\$	109.5000		
1.0	1	\$\$	N\$4	\$\$	109.5000		
1.0	1	\$\$	N\$3	\$\$	114.0000	60.0000	
1.0	1	\$\$	N\$2	\$\$	120.0000		
1.0	1	\$\$	S\$2	\$\$	109.5000		
1.0	1	\$\$		\$\$	109.5000		
1.0	1	C\$\$				44.0000	
1.0		C\$\$		C\$\$	99.0000	62.0000	
1.0		C\$\$		S\$\$	96.0000	44.0000	
	_	amb				D- (0 (-))	. 1
> E =	SUM (n=	1,3) {	V(n)	* [1 +	cos(n*Pni ·	Phi0(n))) }
177	D-£	-	-	v	•	V1 F	hi0
	Ref	I	J	K PhiO	L	A1 E	1110
	Phi0		Λ3	PILLO			
!							
1 0		•	ري <i>ه</i>	CD	*	0.0000	0 0
		*		0 0.0		0.0000	0.0
				C2		0.0000	n n
				0 180.0		0.0000	0.0
				CA		0.0000	0 0
				0 0.0		0.0000	0.0
1.0				СВ		0.0000	0 0
				0 0.0		0.000	J. J
				CD CD		0.0000	0 0
				0.0		0.0000	3.0
				CH		0.0000	ח ח
						0.0000	0.0
0.0000	, υ.	U	0.000	0.0	•		

WO 96/30849						PCT/US96/	04229
1.0 1		* 0	C (J .	*	0.0000	0.0
3.1000 1	80.0	0.	0000	0.0			
1.0 1		* (c cı	M	*	0.0000	0.0
3.1000 1	80.0	0.	0000	0.0			
1.0 1		* (c c	r	*	0.0000	0.0
0.0000	0.0	0.	0000	0.0			
1.0 1		* (C N	I	*	0.0000	0.0
10.0000	180.0	0	.0000	0.0			
1.0 1		* (: N	*	*	0.0000	0.0
5.8000 1	0.08	0.	0000	0.0			
1.0 1		* (z n	A	*	0.0000	0.0
5.4000 1	.80.0	0.	0000	0.0			
1.0 1		* (n N	C	*	0.0000	0.0
8.0000 1	0.08	0.	0000	0.0			
1.0 1		* (01	H	*	0.0000	0.0
1.8000 1	80.0	0.	0000	0.0			
1.0 1						0.0000	0.0
0.0000	0.0	0.	0000	0.0			
1.0 1						0.0000	0.0
4.8000 1							
1.0 1						0.0000	0.0
23.6000							
1.0 1					*	0.0000	0.0
0.0000							
1.0 1						0.0000	0.0
23.6000			.0000				
1.0 1						0.0000	0.0
0.0000							
1.0 1			2 0		*	0.0000	0.0
0.0000			0000				
1.0 1					*	0.0000	0.0
0.0000						0.000	• •
1.0 1			C2 C1			0.0000	0.0
0.0000			0000			0.000	0.0
1.0 1			22 N			0.0000	U.U
0.0000						0.000	0 0
1.0 1			22 N			0.0000	0.0
0.0000						0.000	0 0
1.0 1		- (2 N	٠ و	*	0.0000	0.0

WO 96/30849	PCT/US96/04229

0.0000	0.0	1.4000 0.0		
1.0	1 *	C2 NT *	0.0000 0.0)
0.0000	0.0	1.0000 0.0		
1.0	1 *	C2 OH *	0.0000 0.0)
0.0000	0.0	0.5000 0.0		
1.0	1 *	C2 OS *	0.0000 0.0)
0.0000	0.0	1.4500 0.0		
1.0	1 *	C2 S *	0.0000 0.0)
	0.0			
1.0	1 *	C2 SH *	0.0000 0.0)
0.0000	0.0	0.7500 0.0		
1.0	1 *	CA CA *	0.0000 0.0)
5.3000	180.0	0.0000 0.0		
1.0	1 *	CA CB *	0.0000 0.	. 0
10.2000	180.0	0.0000 0.0		
1.0	1 *	CA CD *	0.0000 0.0)
5.3000	180.0	0.0000 0.0		
1.0	1 *	CA CJ *	0.0000 0.0)
3.7000	180.0	0.0000 0.0		
1.0	1 *	CA CM *	0.0000 0.0)
3.7000	180.0	0.0000 0.0		
		CA CN *	0.0000 0.	. 0
		0.0000 0.0		
		CA CT *	0.0000 0.0)
		0.0000 0.0		
		CA N2 *	0.0000 0.0)
6.8000	180.0	0.0000 0.0		
		CA NA *	0.0000 0.0)
		0.0000 0.0		
		CA NC *	0.0000 0.0)
		0.0000 0.0		
		CB CB *	0.0000 0.	. 0
		0.0000 0.0		
	1 *	CB CN *	0.0000 0.	. 0
		0.0000 0.0		
		CB N* *	0.0000 0.0)
		0.0000 0.0		
		CB NB *	0.0000 0.0)
5.1000	180.0	0.0000 0.0		

WO 96/30849	PCT/US96/04229

1.0 3	t CB	NC	*	0.0000	0.0
8.3000 180.0	0.0000	0.0			
1.0 1	* CC	CF	*	0.0000	0.0
14.3000 180.0	0.0000	0.	0		
1.0 1	± CC	CG	*	0.0000	0.0
15.9000 180.0	0.000	0.	0		
1.0 1	* CC	CT	*	0.0000	0.0
0.0000 0.0	0.0000	0.0			
1.0 1	* CC	CA	*	0.0000	0.0
14.3000 180.0	0.0000	0.	0		
1.0 1	* CC	CM	*	0.0000	0.0
15.9000 180.0	0.000	0.	0		
1.0 1	* CC	NA	*	0.0000	0.0
5.6000 180.0	0.0000	0.0			
1.0 1	· cc	NB	*	0.0000	0.0
4.8000 180.0	0.0000	0.0			
1.0 1	· CD	CD	*	0.0000	0.0
5.3000 180.0	0.0000	0.0			
1.0 1	* CD	CN	*	0.0000	0.0
5.3000 180.0	0.0000	0.0			
1.0 1	CE	N*	*	0.0000	0.0
6.7000 180.0	0.0000	0.0			
1.0 1	* CE	NB	*	0.0000	0.0
20.0000 180.0	0.0000	0.0	O		
1.0 1	* CF	NB	*	0.0000	0.0
4.8000 180.0					
1.0 1	• CG	NA	*	0.0000	0.0
6.0000 180.0	0.0000	0.0			
1.0 1	CH	CH	*	0.0000	0.0
0.0000 0.0	2.0000	0.0			
1.0 1	+ CH	N	*	0.0000	0.0
0.0000 0.0	0.0000	0.0			
1.0 1	CH	N*	*	0.0000	0.0
0.0000 0.0	0.0000	0.0			
1.0 1	CH	NT	*	0.0000	0.0
0.0000 0.0	1.0000	0.0			
1.0 1	CH	OH	*	0.0000	0.0
0.0000 0.0	0.5000	0.0			
1.0 1	CH	OS	*	0.0000	0.0

WO 96/30849	PCT/US96/04229
-------------	----------------

0.0000 0.0	1.4500 0.0		
1.0 1 *	CI NC *	0.0000	0.0
13.5000 180.0	0.0000 0.0		
1.0 1 *	CJ CJ +	0.0000	0.0
24.4000 180.0	0.0000 0.0		
1.0 1 *	CJ CM *	0.0000	0.0
24.4000 180.0	0.0000 0.0		
1.0 1 *	CJ N* *	0.0000	0.0
7.4000 180.0	0.0000 0.0		
1.0 1 *	CK N* *	0.0000	0.0
6.7000 180.0	0.0000 0.0		
1.0 1 *	CK NB *	0.0000	0.0
20.0000 180.0	0.0000 0.0		
1.0 1 *	CM CM *	0.0000	0.0
24.4000 180.0	0.0000 0.0		
1.0 1 *	CM CT *	0.0000	0.0
0.0000 0.0	0.0000 0.0		
1.0 1 *	CM N* *	0.0000	0.0
7.4000 180.0			
1.0 1 *	CN NA *	0.0000	0.0
12.2000 180.0			
1.0 1 *	CP NA *	0.0000	0.0
9.3000 180.0			
1.0 1 *	CP NB *	0.0000	0.0
10.0000 180.0	0.0000 0.0		
1.0 1 *	CQ NC *	0.0000	0.0
13.5000 180.0	0.0000 0.0		
1.0 1 *		0.0000	0.0
9.3000 180.0			
	CR NB *	0.0000	0.0
10.0000 180.0	0.0000 0.0	•	
1.0 1 *	CT CT +	0.0000	0.0
0.0000 0.0	1.3000 0.0		
1.0 1 *	CT N *	0.0000	0.0
0.0000 0.0			
	CT N* *	0.0000	0.0
0.0000 0.0			
1.0 1 *		0.0000	0.0
0.0000 0.0	0.0000 0.0		

WO 96/3084	9							1	PCT/US96	/04229
1.0	1		*	CT	и3		*	0.00	000	0.0
0.0000				1.4000		0.0				
1.0	1		*	CT	ОН	•	*	0.00	000	0.0
0.0000		0.0		0.5000		0.0				
1.0	1		*	CT	os		*	0.00	000	0.0
0.0000		0.0		1.1500		0.0				
1.0	1		*	CT	S		*	0.00	000	0.0
0.0000		0.0		1.0000		0.0				
1.0	1	•	*	CT	SH	i	*	0.00	000	0.0
0.,0000		0.0		0.7500		0.0				
1.0	1		*	CV	NB	•	*	0.00	000	0.0
4.8000	1	80.0		0.0000		0.0				
1.0	1		*	CW	NA		*	0.00	000	0.0
				0.0000						
				ОН				0.00	000	0.0
0.0000										
1.0				os				0.00	000	0.0
				0.7500						
1.0				C				0.00	000	0.0
				0.2000						
1.0				С				0.00	000	0.0
				0.1000						
1.0				С				0.00	000	0.0
				0.1000				0.00		0 0
1.0				C			CH	0.00	000	0.0
				0.1000			Off	0.00	100	0 0
				C2 2.0000				0.00	700	0.0
				C2				0.00	000	0.0
				2.0000				0.00		0.0
				C2				0.00	000	0.0
				2.0000						
				C2				0.00	000	0.0
				1.0000						
				C2				0.00	000	0.0
				1.0000						
•				C2				0.00	000	0.0
				1.0000						
				C2				0.00	000	0.0

WO 96/30849)					PCT/US96/	04229
0.0000	0.0		0.0000	0.0			
			C2			0.0000	0.0
			0.0000				
1.0	1	os	CH	C2	ОН	0.0000	0.0
0.5000	0.0		1.0000	0.0			
1.0	1	ОН	CH	CH	ОН	0.0000	0.0
0.5000	0.0		0.5000	0.0			
1.0	ı	os	CH	CH	ОН	0.0000	0.0
0.5000	0.0		0.5000	0.0			
1.0	1	os	CH	CH	os	0.0000	0.0
0.5000	0.0		0.5000	0.0			
1.0	1	HC	CM	CM	CT	0.0000	0.0
1.7100	180.0		0.0000	0.0			
1.0	1	С	CM	CM	HC	0.0000	0.0
6.5900	180.0		0.0000	0.0			
1.0	1	N*	CM	CM	CT	0.0000	0.0
6.5900	180.0		0.0000	0.0			
1.0	1	CA	CM	CM	HC	0.0000	0.0
6.5900	180.0		0.0000	0.0			
1.0	1	N*	CM	CM	CA	0.0000	0.0
9.5100	180.0		0.0000	0.0			
			CM			0.0000	0.0
1.7100	180.0		0.0000	0.0			
			CM			0.0000	0.0
9.5100	180.0		0.0000	0.0			
1.0						0.0000	0.0
			0.0000				
			CT			0.0000	0.0
			0.0670				
			CT			0.0000	0.0
			0.0670				
			CT			0.0000	0.0
			0.0670				
			os			0.0000	0.0
			0.3830				
			CT			0.0000	0.0
			0.1440				
1.0	1	os	CT	CT	OH	0.0000	0.0

PCT/US96/04229

WO 96/30849

0.5000 0.0

0.0

0.1440

WO 96/30849	•							PCT/US96/	04229
1.0	1		ОН	CT	CT		ОН	0.000	0.0
				0.1440					
1.0	1		н	N	С		0	0.6500	0.0
2.5000	18	30.0		0.0000		0.0			
1.0	1		C2	os	C2		C3	0.0000	0.0
0.1000		0.0		0.7250		0.0			
1.0	1		C2	os	C2		C2	0.0000	0.0
0.1000		0.0		1.4500		0.0			
1.0	1		C3	os	C2		C3	0.0000	0.0
0.1000		0.0		1.4500		0.0			
1.0	1		CH	os	СН		C2	0.0000	0.0
0.1000		0.0		0.7250		0.0			
1.0	1		CH	os	CH		CH	0.0000	0.0
0.1000		0.0		0.7250		0.0			
1.0	1		C2	os .	CH		C2	0.0000	0.0
0.1000		0.0		0.7250		0.0			
1.0	1		C3 (os	CH		C3	0.0000	0.0
0.1000		0.0		0.7250		0.0			
1.0	1		CH	os	CH		N*	0.0000	0.0
0.0000		0.0		0.7250		0.0			
1.0	1		C2	OS	CH		C3	0.0000	0.0
0.1000		0.0		0.7250		0.0			
				Þ				0.0000	0.0
0.7500		0.0		0.2500		0.0			
				P				0.0000	0.0
				0.2500					
				P				0.0000	0.0
				0.2500					
				P				0.0000	0.0
				0.2500					
				P				0.0000	0.0
0.7500				0.2500					
				P				0.0000	0.0
				0.2500					
				P				0.0000	0.0
				0.2500					
				P				0.0000	0.0
				0.2500					
1.0	1		LP	S	S		LP	0.0000	0.0

WO 96/30849			PCT/US96/04229
0.0000	0.0	0.0000 0.0	
1.0 1	LP	s s c	2 0.0000 0.0
0.0000	0.0	0.0000 0.0	
1.0 1	C2	s s c	2 0.0000 0.0
3.5000	0.0	0.6000 0.0	
1.0 1	CT	s s c	T 0.0000 0.0
3.5000	0.0	0.6000 0.0	
1.0 1	LP	s s c	T 0.0000 0.0
0.0000	0.0	0.0000 0.0	
1.1 4	*	CS CS *	0.0000 0.0
0.0000	0.0	1.0210 0.0	
1.1 4	*	CS CT +	0.0000 0.0
0.0000	0.0	1.0210 0.0	
1.1 4	*	AC CS +	0.0000 0.0
0.0000	0.0	1.0210 0.0	
1.1 4	*	BC CS *	0.000 0.0
0.0000	0.0	1.0210 0.0	
1.1 4	*	CS OT *	0.0000 0.0
0.0000		0.4430 0.0	
1.1 4		CS OE *	0.0000 0.0
0.0000			
1.1 4		AC OE *	0.0000 0.0
0.0000		0.9280 0.0	
1.1 4		BC OE *	0.0000 0.0
		0.9280 0.0	
		AC OA +	0.0000 0.0
		0.0000 0.0	
		BC OB *	0.0000 0.0
		0.0000 0.0	
1.1 4		CS OA *	0.0000 0.0
		0.00 0000.0	
		CS OB *	0.0000 0.0
1.1 4		CS N *	0.0000
		0.0000 0.0	0.0000 0.0
		C N +	0.0000
		0.0000 0.0	0.0000 0.0
		C CS +	0.0000
		0.0000 0.0	0.0000 0.0
2.0000		0.000	

WO 96/30849 PCT/US96/04229							
1.1	4 (DE A	.C OA		CS	2.1500	300.0
0.0000	0.0	0.	0000	0.0			
1.1	4 7	AH A	.C OA		CS	0.0000	0.0
1.7500	60.0	0.	0000	0.0			
1.1	4 (CS A	.C OA		CS	0.0000	0.0
0.0000	0.0	0.	8500	0.0			
1.1	4 (DE A	.C OA		HY	2.1500	300.0
0.0000	0.0	0.	0000	0.0			
1.1	4 7	AH A	C OA		НҮ	0.0000	0.0
1.7500	60.0	0.	0000	0.0			
1.1	4 (CS A	C OA		НҮ	0.0000	0.0
0.0000	0.0	0.	8500	0.0			
	4 0		C OB			-1.0500	0.0
0.0000	0.0	0.	0000	0.0			
	4 E					0.0000	0.0
	240.0						
	4 (0.0000	0.0
	0.0		4000				
	4 (C OB			-1.0500	0.0
	0.0		0000				
	4 E		C OB			0.0000	0.0
	240.0						
	4 (C OB			0.0000	0.0
	0.0					0.0000	0 0
	4 F					0.0000	0.0
	0.0					0.0000	0 0
	4 F					0.0000	0.0
	4 E					0.6500	0 0
	180.0					0.0500	0.0
	4 F					0.0000	0.0
	0.0						
	1 \$					0.0000	0.0
	0.0						-
	1 \$					0.0000	0.0
	180.0						
	1 3					0.0000	0.0
	180.0				•		
			45 56	_	^^	0 0000	0 0

C\$5 C\$5 \$\$

1.0 1 \$\$

0.0000 0.0

0.0000 180.0			
	C\$1 O\$1 \$\$	0.0000	0.0
0.0000 0.0			
	C\$1 N\$1 \$\$	0.0000	0.0
0.0000 0.0			
1.0 1 \$\$		0.0000	0.0
5.8000 180.0			
1.0 1 \$\$		0.0000	0.0
10.0000 180.0			
1.0 1 \$\$		0.0000	0.0
0.0000 0.0			
1.0 1 \$\$		0.0000	0.0
3.5000 0.0			
1.0 1 \$\$		0.0000	0.0
0.0000 0.0			
1.0 1 \$\$		0.0000	0.0
0.0000 0.0			
1.0 1 \$\$		0.0000	0.0
0.0000 0.0			
	N\$1 N\$1 \$\$	0.0000	0.0
0.0000 0.0			
#out_of_plane amb			
	cos(n*Chi - Chi0)]		
	J K L	Kchi	n
Chi0			
!	**** ****	~ ~ * ~ * *	
1.0 3 C*	NA CA CA	0.0000	2
180.0000			_
1.0 1 N3	C CH C2	7.0000	3
180.0000			_
1.0 1 C3	CA CH C3	7.0000	3
180.0000			_
1.0 1 C	NT CH C3	14.0000	3
180.0000			
1.0 1 N3	C CH CH	7.0000	3
180.0000			_
1.0 1 H2	N2 CH H2	0.0000	3
180.0000			

Wo	96/30849						PCT/US96/04229
1.	0 1	+	СН	C2	*	14.0000	
180	.0000					21.0000	3
1.0	0 1	*	CH	СН	*	14.0000	3
	.0000					,	3
	1	*	CC	CC	*	0.0000	2
	0000						_
	1	*	CC	CB	*	0.0000	2
	0000	_					
	0000	С	N	CH	*	14.0000	3
	1	4 20					
180.		C2	N	CH	*	1.0000	2
	1	CTT.					
180.	_	CT	N	CT	*	1.0000	2
	1	Н2	N	110	_		•
180.0			14	H2	*	1.0000	2
1.0	•	N2	CA	N2	*		
180.0	0000		C.	142	-	10.5000	2
1.0		02	С	02	*	10 5000	
180.0	000		_	O.L		10.5000	2
1.0	ı	C	NT	СН	*	14.0000	-
180.0	000					14.0000	3
1.0	1	С	N3	CH	*	14.0000	3
180.0	000						3
1.0	1	0	C	*	*	10.5000	2
180.0							2
1.0	1	HC	C*	*	*	0.0000	2
180.0							_
1.0 180.0(1	HC	CM	*	*	0.0000	2 .
1.0							
180.00	1	CB	CN	*	*	0.0000	2
1.0	1	CN	c m				
180.00		CIV	CB	*	*	0.0000	2
1.0	1	C*	СВ	*			
180.00		•	CD	•	*	0.0000	2
1.0	1	CA	СВ	*	•		
180.00		-		-	-	0.0000	2
1.0	1	CA .	CN	*	*	0.0000	_
						0.0000	2

WO 96/30	849						PCT/US96/	04229
180.0	000							
1.0	1	NA	CN	*	*	0.0000		2
180.0	000							
1.0	1	HC	CA	*	*	2.0000)	2
180.00	000							
1.0	1	H	N	*	*	1.0000)	2
180.0	000							
1.0	1	H2	N2	*	*	1.0000)	2
180.00	000							
1.0	1	Н3	N2	•	*	1.0000)	2
180.00	000							
1.0	1	H2	NT	*	*	1.0000)	2
180.00	000							
1.0	1	Н	NA	*	*	1.0000)	2
180.00	000							
1.0	1	\$\$	\$\$	\$\$	\$\$	10.0000)	2
180.00	000							
#nonbo	ond(12-	6) amb	er					
@type	r-eps							
@combi	ination	arith	metic					
> E =	EPSij	* { (R:	ij*/Ri	j)^12 -	2(Rij*	/Rij)^6 }		
> wher	re EPS	ij = s	qrt (El	PSi * E	EPSj)			
>	Ri	$j^* = (1$	Ri* + F	Rj*)/2				
!Ver	Ref	I		Ri*		EPSi		
!			-				-	
1.0	3	IM		5.000	00	0.10000		
1.0	3	CU		2.400	00	0.05000		
1.0	3	I		4.800	00	0.40000		
1.0	3	OW		3.536	50	0.15200		
1.0	3	MG		2.340	00	0.10000		
1.0	3	C0		3.200	0	0.10000		
1.0	3	QC		6.800	00	0.00008		
1.0	3	QK		5.320	0	0.00033		
1.0	3	QL.		2.280	0	0.01800		
1.0	3	QN		3.740	00	0.00280		
1.0	3	QR		5.920	0	0.00017		
1.0	1	С		3.700	0	0.12000		
1.0	1	C*		3.700	0	0.12000		
					0			

1.0	1	C3	4.0000	0.15000
1.0	1	CA	3.7000	0.12000
1.0	1	CB	3.7000	0.12000
1.0	1	CC	3.7000	0.12000
1.0	1	CD	3.7000	0.12000
1.0	1	CE	3.7000	0.12000
1.0	1	CF	3.7000	0.12000
1.0	1	CG	3.7000	0.12000
1.0	1	CH .	3.7000	0.09000
1.0	1	CI	3.7000	0.12000
1.0	1	CJ	3.7000	0.12000
1.0	1	CK	3.7000	0.12000
1.0	1	CM	3.7000	0.12000
1.0	1	CN	3.7000	0.12000
1.0	1	CP	3.7000	0.12000
1.0	1	CQ	3.7000	0.12000
1.0	1	CR	3.7000	0.12000
1.0	1	CT	3.6000	0.06000
1.0	1	CV	3.7000	0.12000
1.0	1	CW	3.7000	0.12000
1.0	1	H	2.0000	0.02000
1.0	1	H2	2.0000	0.02000
1.0	1	.Н3	2.0000	0.02000
1.0	1	HC	3.0800	0.01000
1.0	1	НО	2.0000	0.02000
1.0	1	HS	2.0000	0.02000
1.0	1	LP	2.4000	0.01600
1.0	1	N	3.5000	0.16000
1.0	1	N*	3.5000	0.16000
1.0	1	N2	3.5000	0.16000
1.0	1	N3	3.7000	0.08000
1.0	1	NA	3.5000	0.16000
1.0	1	NB	3.5000	0.16000
1.0	1	NC	3.5000	0.16000
1.0	1	NP	3.5000	0.16000
1.0	1	NT	3.7000	0.12000
1.0	1	0	3.2000	0.20000
1.0	1	02	3.2000	0.20000
1.0	.1	OH	3.3000	0.15000

1.0	1	os		3.3000	0.15000
1.0	1	Þ		4.2000	0.20000
1.0	1	S		4.0000	0.20000
1.0	1	SH		4.0000	0.20000
1.1	4	CS		3.6000	0.09030
1.1	4	AC		3.6000	0.09030
1.1	4	BC		3.6000	0.09030
1.1	4	С		3.7000	0.12000
1.1	4	Н		2.0000	0.02000
1.1	4	HY		1.6000	0.04980
1.1	4	HT		2.9360	0.00450
1.1	4	HO		2.0000	0.02000
1.1	4	AH		2.9360	0.00450
1.1	4	BH		2.9360	0.00450
1.1	4	OT		3.2000	0.15910
1.1	4	OA		3.2000	0.15910
1.1	4	OB		3.2000	0.15910
1.1	4	OE		3.2000	0.15910
1.1	4	OH		3.3000	0.15000
1.1	4	0		3.2000	0.20000
1.1	4	N		3.5000	0.16000
#hydr	ogen_	bond(10	-12)	amber	
> E =	Aij/	r^12 -	Bij/r [*]	`10	
!Ver	Ref	I	J	A	В
!					
1.0	3	Н	os	7557.0000	2385.00
1.0	3	Н	OW	7557.0000	2385.00
1.0	3	H2	os	7557.0000	2385.00
1.0	3	H2	OW	7557.0000	2385.00

!Ver	Ref	I	J	A	В
!					
1.0	3	Н	os	7557.0000	2385.0000
1.0	3	Н	OW	7557.0000	2385.0000
1.0	3	H2	os	7557.0000	2385.0000
1.0	3	H2	OW	7557.0000	2385.0000
1.0	3	HW	NB	7557.0000	2385.0000
1.0	3	HW	NC	10238.0000	3071.0000
1.0	3	HW	0	7557.0000	2385.0000
1.0	3	HW	02	4019.0000	1409.0000
1.0	3	HW	OH	7557.0000	2385.0000
1.0	3	HW	os	7557.0000	2385.0000
1.0	3	HW	S	265720.0000	35429.0000
1.0	3	HW	SH	265720.0000	35429.0000
1.0	1	Н	NB	7557.0000	2385.0000
1.0	1	Н	NC	10238.0000	3071.0000

WO 96/3	0849				PCT/US96/04229
1.0	1	н	02	4019.0000	1409.0000
1.0	1	н	0	7557.0000	2385.0000
1.0	1	н	ОН	7557.0000	2385.0000
1.0	3	H	S	265720.0000	35429.0000
1.0	3	H	SH	265720.0000	35429.0000
1.0	1	HO	NB	7557.0000	2385.0000
1.0	1	HO	NC	7557.0000	2385.0000
1.0	ı	НО	02	4019.0000	1409.0000
1.0	1	но	0	7557.0000	2385.0000
1.0	1	HO	ОН	7557.0000	2385.0000
1.0	3	но	S	265720.0000	35429.0000
1.0	3	но	SH	265720.0000	35429.0000
1.0	1	H2	NB	4019.0000	1409.0000
1.0	1	H2	NC	4019.0000	1409.0000
1.0	1	H2	02	4019.0000	1409.0000
1.0	1	H2	0	10238.0000	3071.0000
1.0	1	H2	OH	4019.0000	1409.0000
1.0	3	H2	S	265720.0000	35429.0000
1.0	3	H2	SH	265720.0000	35429.0000
1.0	1	H3	NB	4019.0000	1409.0000
1.0	1	Н3	NC	4019.0000	1409.0000
1.0	1	Н3	02	4019.0000	1409.0000
1.0	1	H 3	0	7557.0000	2385.0000
1.0	1	Н3	OH	7557.0000	2385.0000
1.0	3	Н3	S	265720.0000	35429.0000
1.0	3	Н3	SH	265720.0000	35429.0000
1.0	1	HS	NB	14184.0000	3082.0000
1.0	1	HS	NC	14184.0000	
1.0	1	HS	02		3082.0000
1.0	1	HS	0		3082.0000
1.0	1	HS	OH	14184.0000	
1.0	3	HS		265720.0000	
1.0		HS		265720.0000	35429.0000
#bond	_incr	ements			
!Ver		I	J	DeltaIJ	DeltaJI
!					****
	5				
1.1		CA	CA		0.000
1.1	5	СВ	CB	0.000	0.000

1.1	5	C5	C6	0.000	0.000
1.1	5	CT	CT	0.000	0.000
1.1	5	нт	CT	0.066	-0.066
1.1	5	н	NT	0.133	-0.133
1.1	5	NT	CT	-0.189	0.189
1.1	5	CA	OH	0.334	-0.334
1.1	5	CT	os	0.237	-0.237
1.1	5	HC	CT	0.066	-0.066
1.1	6	CS	CS	0.000	0.000
1.1	6	AC	CS	0.000	0.000
1.1	6	BC	CS	0.000	0.000
1.1	6	CS	CT	0.000	0.000
1.1	6	CS	os	0.200	-0.200
1.1	5	N*	CS	-0.183	0.183
1.1	6	OT	HY	-0.400	0.400
1.1	6	OA	HY	-0.400	0.400
1.1	6	ОВ	HY	-0.400	0.400
1.1	6	CS	HT	-0.100	0.100
1.1	5	AC	AH	-0.100	0.100
1.1	6	BC	BH	-0.100	0.100
1.1	6	AC	HT	-0.100	0.100
1.1	6	ВС	HT	-0.100	0.100
1.1	6	AC	CA	0.250	-0.250
1.1	6	BC	OB	0.250	-0.250
1.1	6	CS	OA	0.250	-0.250
1.1	6	CS	OB	0.250	-0.250
1.1	6	CS	OT	0.250	-0.250
1.1	6	CS	OE	0.200	-0.200
1.1	6	AC	OE	0.200	-0.200
1.1	5	BC	OE	0.200	-0.200
1.1	6	OW	HW	-0.380	0.380
1.1	5	N*	CT	-0.183	0.183
1.1	5	P	os	0.254	-0.254
1.1	5	CB	N*	0.130	-0.130
1.1	5	CK	N*	-0.253	0.253
1.1	5	NC	СВ	-0.335	0.335
1.1	5	NB	СВ	0.020	-0.020
1.1	5	СВ	CA	0.000	-0.000
1.1	5	CK	NB	0.566	-0.566

WO 96/30849	PCT/US96/04229

1.1	5	CK	HC	-0.051	0.051
1.1	5	N2	CA	-0.162	0.162
1.1	5	NC	CA	-0.430	0.430
1.1	5	H2	N2	0.318	-0.318
1.1	5	CQ	NC	0.341	-0.341
1.1	5	CQ	HC	0.005	-0.005
1.1	5	02	P	-0.913	0.413
1.1	5	С	N*	-0.044	0.044
1.1	5	CM	N*	0.137	-0.137
1.1	5	NA	C	-0.255	0.255
1.1	5	0	C	-0.492	0.492
1.1	5	NA	H	-0.282	0.282
1.1	5	CM	C	-0.150	0.150
1.1	5	CM	CT	0.055,	-0.055
1.1	5	CM	HC	-0.101	0.101
1.1	5	H2	CT	0.119	-0.119
1.1	5	C.	NC	0.424	-0.424
1.1	5	CM	CA	-0.409	0.409
1.1	5	N2	HC	-0.037	0.037
1.1	5	OH	CT	-0.263	0.263
1.1	5	HO	OH	0.303	-0.303
1.1	5	C	CB	-0.005	0.005
1.1	5	NA	CA	-0.215	0.215
1.1	5	CT	N	0.171	-0.171
1.1	5	H	N	0.274	-0.274
1.1	5	C	CT	0.095	-0.095
1.1	5	C	N	0.139	-0.139
1.1	5	N2	CT	0.044	-0.044
1.1	5	Н3	N2	0.551	-0.351
1.1	5	02	C	-0.792	0.292
1.1	5	S	CT	-0.023	0.023
1.1	5	LP	S	-0.403	0.403
1.1	5	SH	CT	-0.033	0.033
1.1	5	HS	SH	0.127	-0.127
1.1	5	SH	LP	0.489	-0.489
1.1	5	CC	CT	0.007	-0.007
1.1	5	NB	CC	-0.256	0.256
1.1	5	CW	CC	0.018	-0.018
1.1	5	CR	NB	0.251	-0.251

WO 96/308	49				
1.1	5	NA	CR	-0.066	0.066
1.1	5	CR	HC	-0.067	0.067
1.1	5	CW	NA	-0.057	0.057
1.1	5	CW	HC	-0.099	0.099
1.1	5	NA	CC	-0.020	0.020
1.1	5	NA	PS	0.423	-0.423
1.1	5	CV	CC	0.035	-0.035
1.1	5	CV	NB	0.227	-0.227
1.1	5	CV	HC	-0.042	0.042
1.1	5	ИЗ	CT	0.905	0.095
1.1	5	N3	Н3	-0.326	0.326
1.1	5	CA	CT	-0.033	0.033
1.1	5	CA	HC	-0.101	0.101
1.1	5	C*	CT	0.005	-0.005
1.1	5	C*	CM	-0.192	0.192
1.1	5	CB	C*	-0.045	0.045
1.1	5	CN	NA	0.176	-0.176
1.1	5	CN	CA	0.074	-0.074
1.1	5	CB	CN	0.104	-0.104

PCT/US96/04229

1.1 5 #reference 1

1.1 5

creation of file

#reference 2

Lone pair lp had incorrect mass of 0.001097.

С

CA

OH C

Angle CT-C-02 was by error included twice.

Torsion OH-C2-C2-OH was written as two separate lines.

-0.181 0.181

0.081

-0.081

Hence only one of the energy terms was included.

@Author Jon Hurley

@Date 13-December-90

#reference 3

parameter set modified with the addtional parameters from kollman's parm89a rev a force field file note that the HW...OW hydrogen bond parameters and the HW van der waals parameters are not included in the files since they are equal to zero in parm89a. @Author tom thacher

@Date 11-March-92

#refer nce 4

homans' carbohydrate potential
@Author Tom Thacher
@Date 7-July-1992
#reference 5
bond increments
@Author Tom Thacher
@Date 7-July-1992
#end

********** ************ END OF LISTING DATA FILE FOR H BOND FORCES - HBOND.DAT **************** 47 !data items !BIOSYM forcefield 2 !version amber.frc 1.0 19-Oct-90 !version amber.frc 1.1 8-Aug-92 !define amber ! This is the new format version of the amber forcefield !hbond definition amber !1.0 1 distance 2.5000 !1.0 1 angle 90.0000 !1.0 1 donors H HO H2 H3 HS !1.0 1 acceptors NB NC O2 O OH S SH !hydrogen_bond(10-12) amber $! E = Aij/r^12 - Bij/r^10$!Ver Ref I J В A !--------------_____ 1.0 3 os 7557.0000 2385.0000 H 1.0 3 H OW 7557.0000 2385.0000 1.0 3 H2 OS 7557.0000 2385.0000 1.0 3 H2 OW 7557.0000 2385.0000

7557.0000

2385.0000

1.0 3

HW

NB

1.0	3	HW	NC	10238.0000	3071.0000
1.0	3	HW	0	7557.0000	2385.0000
1.0	3	HW	02	4019.0000	1409.0000
1.0	3	HW	ОН	7557.0000	2385.0000
1.0	3	HW	os	7557.0000	2385.0000
1.0	3	HW	S	265720.0000	35429.0000
1.0	3	HW	SH	265720.0000	35429.0000
1.0	1	H	NB	7557.0000	2385.0000
1.0	1	H	NC	10238.0000	3071.0000
1.0	1	н	02	4019.0000	1409.0000
1.0	1	H	0	7557.0000	2385.0000
1.0	1	Н	ОН	7557.0000	2385.0000
1.0	3	Н	S	265720.0000	35429.0000
1.0	3	H	SH	265720.0000	35429.0000
1.0	1	но	NB	7557.0000	2385.0000
1.0	1	HO	NC	7557.0000	2385.0000
1.0	1	но	02	4019.0000	1409.0000
1.0	1	HO	0	7557.0000	2385.0000
1.0	1	но	OH	7557.0000	2385.0000
1.0	3	HO	S	265720.0000	35429.0000
1.0	3	но	SH	265720.0000	35429.0000
1.0	1	H2	NB	4019.0000	1409.0000
1.0	1	H2	NC	4019.0000	1409.0000
1.0	1	H2	02	4019.0000	1409.0000
1.0	1	H2	0	10238.0000	3071.0000
1.0	1	H2	ОН	4019.0000	1409.0000
1.0	3	H2	S	265720.0000	35429.0000
1.0	3	H2	SH	265720.0000	35429.0000
1.0	1	нз	NB	4019.0000	1409.0000
1.0	ı	Н3	NC	4019.0000	1409.0000
1.0	1	Н3	02	4019.0000	1409.0000
1.0	1	Н3	0	7557.0000	2385.0000
1.0	1	нз	ОН	7557.0000	2385.0000
1.0	3	нз	S	265720.0000	35429.0000
1.0	3	Н3	SH	265720.0000	35429.0000
1.0	1	HS	NB	14184.0000	3082.0000
1.0	1	HS	NC	14184.0000	3082.0000
1.0	1	HS	02	14184.0000	3082.0000
1.0	1	HS	0	14184.0000	3082.0000

```
1.0 1 HS OH 14184.0000 3082.0000
1.0 3 HS S 265720.0000 35429.0000
1.0 3 HS SH 265720.0000 35429.0000
```

DATA FILE FOR LENNARD JONES FORCES - LJ_PARAM.DAT

```
74 !total atoms
```

!BIOSYM forcefield 2

!version amber.frc 1.0 19-Oct-90

!version amber.frc 1.1 8-Aug-92

!define amber

! This is the new format version of the amber forcefield

!nonbond(12-6) amber

!type r-eps

!combination arithmetic

! $E = EPSij * { (Rij*/Rij)^12 - 2(Rij*/Rij)^6 }$

! where EPSij = sqrt(EPSi * EPSj)

! $Rij^* = (Ri^* + Rj^*)/2$

•		$KIJ_{\bullet} = (KI$." + KJ"//2	
!Ver	Ref	I	Ri*	EPSi
!				
1.0	3	IM	5.0000	0.10000
1.0	3	CU	2.4000	0.05000
1.0	3	I	4.8000	0.40000
1.0	3	OW	3.5360	0.15200
1.0	3	MG	2.3400	0.10000
1.0	3	C0	3.2000	0.10000
1.0	3	QC	6.8000	0.00008
1.0	3	QK	5.3200	0.00033
1.0	3	QL	2.2800	0.01800
1.0	3	ØИ	3.7400	0.00280
1.0	3	QR	5.9200	0.00017
1.0	1	С	3.7000	0.12000
1.0	1	C*	3.7000	0.12000
1.0	1	C2	3.8400	0.12000
1.0	1	C3	4.0000	0.15000
1.0	1	CA	3.7000	0.12000
1.0	1	CB	3.7000	0.12000

WO 96/3	30849			
1.0	1	CC	3.7000	0.12000
1.0) 1	CD	3.7000	0.12000
1.0	1	CE	3.7000	0.12000
1.0	1	CF	3.7000	0.12000
1.0	1	CG	3.7000	0.12000
1.0) 1	СН	3.7000	0.09000
1.0	1	CI	3.7000	0.12000
1.0	1	CJ	3.7000	0.12000
1.0	1	CK	3.7000	0.12000
1.0	1	CM	3.7000	0.12000
1.0	1	CN	3.7000	0.12000
1.0	1	CP	3.7000	0.12000
1.0	1	CQ	3.7000	0.12000
1.0	1	CR	3.7000	0.12000
1.0	1	CT	3.6000	0.06000
1.0	1	CV	3.7000	0.12000
1.0	1	CW	3.7000	0.12000
1.0	1	H	2.0000	0.02000
1.0	1	H2	2.0000	0.02000
1.0	1	Н3	2.0000	0.02000
1.0	1	HC	3.0800	0.01000
1.0	1	НО	2.0000	0.02000
1.0	• 1	HS	2.0000	0.02000
1.0	1	LP	2.4000	0.01600
1.0		N	3.5000	0.16000
1.0		N*	3.5000	0.16000
1.0		N2	3.5000	0.16000
1.0		из	3.7000	0.08000
1.0		NA	3.5000	0.16000
1.0		NB	3.5000	0.16000
1.0		NC	3.5000	0.16000
1.0		NP	3.5000	0.16000
1.0		NT	3.7000	0.12000
1.0		0	3.2000	0.20000
1.0		02	3.2000	0.20000
1.0	1	OH	3.3000	0.15000

1.0

1.0

1.0

1

1

1

os

P

S

PCT/US96/04229

3.3000

4.2000

4.0000

0.15000

0.20000

0.20000

1.0	1	SH	4.0000	0.20000
1.1	4	CS	3.6000	0.09030
1.1	4	AC	3.6000	0.09030
1.1	4	BC	3.6000	0.09030
1.1	4	C .	3.7000	0.12000
1.1	4	H	2.0000	0.02000
1.1	4	HY	1.6000	0.04980
1.1	4	HT	2.9360	0.00450
1.1	4	HO	2.0000	0.02000
1.1	4	HA	2.9360	0.00450
1.1	4	BH	2.9360	0.00450
1.1	4	OT	3.2000	0.15910
1.1	4	OA	3.2000	0.15910
1.1	4	OB	3.2000	0.15910
1.1	4	OE	3.2000	0.15910
1.1	4	OH	3.3000	0.15000
1.1	4	0	3.2000	0.20000
1.1	4	N	3.5000	0.16000

DATA FILE FOR TORSION FORCES - TORSION.DAT

```
179 ! total entries in this data file
!BIOSYM forcefield
!version amber.frc 1.0 19-Oct-90
!version amber.frc 1.1 8-Aug-92
!define amber
! This is the new format version of the amber forcefield
!torsion 3 amber
! E = SUM(n=1,3) \{ V(n) * [1 + cos(n*Phi - Phi0(n))] \}
!Ver Ref I J
                   K
                                 V1 Phi0
V2 Phi0 V3 Phi0
          ---- ---- ----
             -----
1.0 1 0
              C C2 N
                                 0.0000 0.0
0.0000 0.0 0.2000 180.0
1.0 1 0
             C CH C2
                              0.0000 0.0
0.0000 0.0 0.1000 180.0
```

WO 96/30	849				Dema	2040
1 0	7	. 0	•	av.		S96/04229
		0.0		CH N	0.0000	0.0
				0 180.0 CH CH	• • • • •	
) 180.0	0.0000	0.0
				С2 ОН	2 2222	
		0.0		0.0	0.0000	0.0
				. С2 ОН	0.0000	
				0.0	0.0000	0.0
				C2 OS	0.0000	0 0
0.5000				0.0	0.0000	0.0
				CH OS	0.0000	0.0
0.5000		0.0		0.0	3.0000	0.0
1.0	1	os		СН ОН	0.0000	0.0
0.5000		0.0	1.0000	0.0		0.0
1.0	1	ОН	C2	СН ОН	0.0000	0.0
0.5000		0.0	1.0000	0.0		
1.0	1	C2	C2	S LP	0.0000	0.0
0.0000		0.0	0.0000	0.0		
				SH LP	0.0000	0.0
				0.0		
				C2 OH	0.0000	0.0
				0.0		
				Сн он	0.0000	0.0
				0.0		
1.0				СН ОН	0.0000	0.0
				0.0		
0.5000	1	OS	CH	CH OS	0.0000	0.0
1.0				0.0		
		0.0		CM CT	0.0000	0.0
1.0				CM HC		
		_		0.0	0.0000	0.0
1.0				CM CT	0.0000	
6.5900				0.0	0.0000	0.0
1.0				CM HC	0.0000	0 0
				0.0	0.0000	0.0
				CM CA	0.0000	0.0
				0.0	0.0000	υ.υ
				CM HC	0.0000	0 0
				_		5.0

WO 96/30849	PCT/US96/04229
-------------	----------------

1.7100	180.0		0.0000	0.0			
1.0	1	N*	CM	CM	С	0.0000	0.0
9.5100	180.0		0.0000	0.0			
			CM			0.0000	0.0
6.5900	180.0		0.0000	0.0			
1.0	1	N	CT	C	0	0.0000	0.0
0.0000			0.0670				
			CT			0.0000	0.0
			0.0670				
			CT			0.0000	0.0
			0.0670				
1.0	1	CT	os	CT	CT	0.0000	0.0
0.2000	180.0		0.3830	0.0			
1.0			CT			0.0000	0.0
0.5000	0.0		0.1440	0.0			
1.0			CT			0.0000	0.0
			0.1440				
			CT			0.0000	0.0
			0.1440				
			N			0.6500	0.0
			0.0000				
			os			0.0000	0.0
0.1000	0.0		0.7250	0.0			
			OS			0.0000	0.0
			1.4500				
			os			0.0000	0.0
			1.4500				
			os		C2	0.0000	0.0
0.1000	0.0		0.7250				
1.0			os			0.0000	0.0
			0.7250				
1.0			os			0.0000	0.0
0.1000			0.7250				
1.0	1		os		C3	0.0000	0.0
0.1000			0.7250				
			os			0.0000	0.0
			0.7250				
1.0	1	C2	os		C3	0.0000	0.0
0.1000	0.0		0.7250	0.0			

WO 96/3084	49							PCT	/US96/04229
1.0	1		ОН	P	os		C3	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		os	P	os		C2	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		OH	P	os		C2	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		os	P	os		CT	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		os	P	os		CH	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		os	P	os		C3	0.0000	0.0
0.7500		0.0		0.2500		0.0			
1.0	1		OH	P	os		CH	0.0000	0.0
0.7500		0.0		0.2500		0.0			
				P				0.0000	0.0
				0.2500					
				S				0.0000	0.0
				0.0000					
				S				0.0000	0.0
				0.0000					
				S				0.0000	0.0
				0.6000					
				S				0.0000	0.0
				0.6000				0.000	
				S				0.0000	0.0
				0.0000				2.1500	300.0
				0.0000				2.1500	300.0
				AC				0.0000	0 0
				0.0000				0.000	0.0
				AC				0.0000	0.0
				0.8500				0,000	0.0
				AC				2.1500	300.0
				0.0000				2.3300	
				AC				0.0000	0.0
				0.0000					
				AC				0.0000	0.0
				0.8500				•	- · ·
				BC				-1.0500	0.0

0.0000	0.0		0.0000	0.0			
					CS	0.0000	0.0
1.2500	240.0		0.0000	0.0			
1.1	4	CS	BC	OB	CS	0.0000	0.0
0.0000	0.0		1.4000	0.0			
1.1	4	OE	BC	OB	HY	-1.0500	0.0
0.0000	0.0		0.0000	0.0			
1.1	4	BH	BC	OB	HY	0.0000	0.0
1.2500	240.0		0.0000	0.0			
1.1	4	CS	BC	OB	HY	0.0000	0.0
0.0000	0.0		1.4000	0.0			
1.1	4	HT	AC	OA	CS	0.0000	0.0
0.0000	0.0		0.8500	0.0			
1.1	4	HT	BC	OB	CS	0.0000	0.0
0.0000	0.0		1.4000	0.0			
1.1	4	H	N	С	0	0.6500	0.0
2.5000	180.0		0.0000	0.0			
1.1	4	HT	CS	C	0	0.0000	0.0
0.0000	0.0		0.0670	180.0			
1.0	3	*	CB	CD	*	0.0000	0.0
5.3000	180.0		0.0000	0.0			
1.0	1	*	C	C2	*	0.0000	0.0
0.0000	0.0		0.0000	180.0			
1.0	1	*	С	CA	*	0.0000	0.0
5.3000	180.0		0.0000	0.0			
1.0	1	*	C	CB	•	0.0000	0.0
4.4000	180.0		0.0000	0.0			
1.0	1	*	С	B	*	0.0000	0.0
5.3000	180.0		0.0000	0.0			
1.0	1	*	C	CH	*	0.0000	0.0
0.0000	0.0		0.0000	0.0			
1.0	1	*	C	CJ	*	0.0000	0.0
3.1000	180.0		0.0000	0.0			
1.0	1	*	C	CM	*	0.000	0.0
3.1000	180.0		0.0000	0.0			
1.0	1	*	С	CT	*	0.0000	0.0
0.0000	0.0		0.0000	0.0			
			C			0.0000	0.0
10.0000	180.	0	0.0000	0.0	o		

WO 96/3084	9					PCT/US96	/04229
1.0	1	*	С	N*	*	0.0000	0.0
5.8000	180.0		0.0000	0.0			
1.0	1	*	С	NA	*	0.0000	0.0
5.4000	180.0		0.0000	0.0)		
1.0	1	*	С	NC	*	0.0000	0.0
8.0000	180.0		0.0000	0.0)		
1.0	1	* .	С	OH	*	0.0000	0.0
1.8000	180.0		0.0000	0.0			
1.0	1	*	C*	C2	*	0.0000	0.0
0.0000	0.0		0.0000	0.0)		
1.0	1	*	C*	CB	*	0.0000	0.0
4.8000	180.0		0.0000	0.0)		
1.0	1	*	C*	CG	*	0.0000	0.0
23.6000	180.	0	0.0000	0.	. 0		
1.0	1	*	C*	CT	*	0.0000	0.0
0.0000	0.0		0.0000	0.0)		
1.0	1	*	C*	CW	*	0.0000	0.0
23.6000	180.	0	0.0000	0.	. 0		
1.0	1	*	C2	C2	*	0.0000	0.0
			2.0000				
			C2			0.0000	0.0
			0.0000				
1.0			C2			0.0000	0.0
0.0000			0.0000				
			C2			0.0000	0.0
0.0000			2.0000				
			C2			0.0000	0.0
			0.0000				
1.0			C2			0.0000	0.0
			0.0000				
1.0			C2			0.0000	0.0
			1.4000				
1.0			C2			0.0000	0.0
			1.0000			0.0000	
1.0			C2			0.0000	0.0
			0.5000			0.0000	
			C2			0.0000	0.0
			1.4500			0.000	0 0
1.0	1	*	C2	S	*	0.0000	0.0

0.0000 0.0	1.0000 0.0		
1.0 1 *	C2 SH *	0.0000	0.0
0.0000 0.0	0.7500 0.0		
1.0 1 *	CA CA *	0.0000	0.0
5.3000 180.0	0.0000 0.0		
1.0 1 *	CA CB +	0.0000	0.0
10.2000 180.0	0.0000 0.0		
1.0 1 *	CA CD +	0.0000	0.0
5.3000 180.0	0.0000 0.0		
1.0 1 *	CA CJ *	0.0000	0.0
3.7000 180.0	0.0000 0.0		
1.0 1 +	CA CM +	0.0000	0.0
3.7000 180.0	0.0000 0.0		
1.0 1 *	CA CN *	0.0000	0.0
10.6000 180.0	0.0000 0.0		
1.0 1 *	CA CT *	0.0000	0.0
0.0000 0.0	0.0000 0.0		
1.0 1 *	CA N2 +	0.0000	0.0
6.8000 180.0	0.0000 0.0		
1.0 1 *	CA NA *	0.0000	0.0
6.0000 180.0	0.0000 0.0		
1.0 1 *	CA NC *	0.0000	0.0
9.6000 180.0	0.0000 0.0	-	
1.0 1 *	CB CB *	0.0000	0.0
	0.0000 0.0		
1.0 1 *	CB CN +	0.0000	0.0
20.0000 180.0	0.0000 0.0		
1.0 1 *	CB N* *	0.0000	0.0
6.6000 180.0	0.0000 0.0		
1.0 1 *	CB NB *	0.0000	0.0
5.1000 180.0	0.0000 0.0		
1.0 3 *	CB NC *	0.0000	0.0
8.3000 180.0	0.0000 0.0		
1.0 1 *	CC CF *	0.0000	0.0
14.3000 180.0	0.0000 0.0		
1.0 1 *	CC CG +	0.0000	0.0
15.9000 180.0	0.0000 0.0		
	CC CT +	0.0000	0.0
0.0000 0.0	, 0.0000 0.0		

1.0 1 * CC CV * 0.0000 0. 14.3000 180.0 0.0000 0.0	0
14.3000 180.0 0.0000 0.0	
1.0 1 * CC CW * 0.0000 0.	0
15.9000 180.0 0.0000 0.0	
1.0 1 * CC NA * 0.0000 0.0	
5.6000 180.0 0.0000 0.0	
1.0 1 * CC NB * 0.0000 0.0	
4.8000 180.0 0.0000 0.0	
1.0 1 * CD CD * 0.0000 0.0	
5.3000 180.0 0.0000 0.0	
`1.0 1 * CD CN * 0.0000 0.0	
5.3000 180.0 0.0000 0.0	
1.0 1 * CE N* * 0.0000 0.0	
6.7000 180.0 0.0000 0.0	
1.0 1 * CE NB * 0.0000 0.0	0
20.0000 180.0 0.0000 0.0	
1.0 1 * CF NB * 0.0000 0.0	
4.8000 180.0 0.0000 0.0	
1.0 1 * CG NA * 0.0000 0.0	
6.0000 180.0 0.0000 0.0	
1.0 1 * CH CH * 0.0000 0.0	
0.0000 0.0 2.0000 0.0	
1.0 1 * CH N * 0.0000 0.0	
0.0000 0.0 0.0000 0.0	
1.0 1 * CH N* * 0.0000 0.0	
0.0000 0.0 0.0000 0.0	
1.0 1 * CH NT * 0.0000 0.0	
0.0000 0.0 1.0000 0.0	
1.0 1 * CH OH * 0.0000 0.0	
0.0000 0.0 0.5000 0.0	
1.0 1 * CH OS * 0.0000 0.0	
0.0000 0.0 1.4500 0.0	
1.0 1 * CI NC * 0.0000 0.0	0
13.5000 180.0 0.0000 0.0	
1.0 1 * CJ CJ * 0.0000 0.0)
24.4000 180.0 0.0000 0.0	
1.0 1 * CJ CM * 0.0000 0.0)
24.4000 180.0 0.0000 0.0	
1.0 1 * CJ N* * 0.0000 0.0	

7.4000 180.0	0.0000 0.0		
1.0 1 *	CK N* *	0.0000	0.0
6.7000 180.0	0.0000 0.0		
1.0 1 *	CK NB *	0.0000	0.0
20.0000 180.0	0.0000 0.0		
1.0 1 *	CM CM *	0.0000	0.0
24.4000 180.0	0.0000 0.0		
1.0 1 *	CM CT +	0.0000	0.0
0.0000 0.0	0.0000 0.0		
1.0 1 *	CM N* *	0.0000	0.0
7.4000 180.0	0.0000 0.0		
1.0 1 *	CN NA *	0.0000	0.0
12.2000 180.0			
1.0 1 *	CP NA *	0.0000	0.0
	0.0000 0.0		
	CP NB *	0.0000	0.0
	0.0000 0.0		
	_	0.0000	0.0
13.5000 180.0			
	CR NA *	0.0000	0.0
	0.0000 0.0		
		0.0000	0.0
10.0000 180.0			
	CT CT *	0.0000	0.0
0.0000 0.0			
1.0 1 *	CT N *	0.0000	0.0
	0.0000 0.0		
1.0 1 *		0.0000	0.0
0.0000 0.0			
1.0 1 *	CT N2 *	0.0000	0.0
0.0000 0.0			
1.0 1 *	CT N3 *	0.0000	0.0
0.0000 0.0	1.4000 0.0		
1.0 1 *	CT OH *	0.0000	0.0
	0.5000 0.0		• -
1.0 1 *	CT OS *	0.0000	0.0
0.0000 0.0			
	CT S *	0.0000	0.0
0.0000 0.0	1.0000 0.0		

WO 96/3084	19						PCT/	US96/04229
1.0	1		*	CT	SH	*	0.0000	0.0
				0.7500				0.0
1.0	1		*	CV	NB	*	0.0000	0.0
4.8000	:	180.0		0.0000	Ο.	. 0		
1.0	1		*	CW	NA	*	0.0000	0.0
6.0000	:	180.0		0.0000	Ο.	. 0		
1.0	1		*	OH	P	*	0.0000	0.0
0.0000		0.0		0.7500	Ο.	. 0		
1.0	1		*	os	P	*	0.0000	0.0
0.0000		0.0		0.7500	0.	0		
1.1	4		*	CS	CS	*	0.0000	0.0
0.0000		0.0		1.0210	Ο.	0	·	
1.1	4		*	CS	CT	*	0.0000	0.0
0.0000		0.0		1.0210	0.	0		
1.1	4		*	AC	CS	*	0.0000	0.0
0.0000		0.0		1.0210	0.	0		
1.1	4		*	BC	CS	*	0.0000	0.0
0.0000		0.0		1.0210	0.	0		
1.1	4		*	CS	OT	*	0.0000	0.0
0.0000		0.0		0.4430	0.	0		
1.1				CS			0.0000	0.0
				0.9280	0.	0		
1.1				AC	OE	*	0.0000	0.0
0.0000				0.9280		_		
1.1				BC			0.0000	0.0
				0.9280				
				AC			0.0000	0.0
				0.0000				
1.1				BC			0.0000	0.0
0.0000				0.0000				
1.1				CS			0.0000	0.0
0.0000				0.0000				
1.1				CS			0.0000	0.0
0.0000								
1.1				CS			0.0000	0.0
				0.0000				
				С			0.0000	0.0
				0.0000				
1.1	4	*		С	CS	*	0.0000	.0.0

```
0.0000 0.0 0.0000 0.0

1.0 1 * CT NT * 0.0000 0.0

0.0000 0.0 1.8000 0.0
```

DATA FILE - CX6C.CAR

!BIOSYM archive 3

PBC=OFF

!DATE	Thu Mar 2 10:02:	:29 1995	
SG	0.051616628	8.775964550	2.653307337 CYSn 1
S	S 0.824		
LG1	-0.116704460	8.906803991	3.732450018 CYSn 1
LP	L -0.405		
LG2	-0.816371929	8.216369655	2.274560255 CYSn 1
ĽР	L -0.405		
CB	1.625257994	7.970290997	2.280061368 CYSn 1
CT	C -0.098		
HBl	1.743097230	7.117856362	2.972980432 CYSn 1
HC	H 0.050		
HB2	2.457560406	8.667686711	2.506611212 CYSn 1
HC	H 0.050		
CA	1.664891168	7.503978115	0.811322158 CYSn 1
CT	C 0.035		
НА	2.715618613	7.453348875	0.469159517 CYSn 1
HC	H 0.032		
N	0.954382540	8.512673633	0.003030230 CYSn 1
NT	N -0.463		
С	1.063568189	6.132700222	0.616111991 CYSn 1
C	C 0.616		
0	0.248707622	5.654726837	1.414398016 CYSn 1
0	0 -0.504		
N	1.449902196	5.479885680	-0.464156147 GLY 2
N	N -0.463		
HN	2.157106102	5.992384244	-1.099457509 GLY 2
Н	H 0.252		
CA	0.868490592	4.154014497	-0.652902307 GLY 2
CT	C 0.035		

WO 96/30849			PCT/US96/04229
HA1	1.550908149	3.403064022	-0.212395307 GLY 2
HC	H 0.032		
HA2	-0.097660558	4.132736815	-0.116611463 GLY 2
HC	H 0.032		
c	0.730531165	3.827591429	-2.120728786 GLY 2
С	C 0.616		
0	1.559375145	4.206208097	-2.957020570 GLY 2
0	0 -0.504		
N	-0.320742949	3.103195380	-2.456098946 GLY 3
N	N -0.463		
HN	-0.976177839	2.817016114	-1.646836012 GLY 3
H	H 0.252		
CA	-0.454134161	2.787581074	-3.875321662 GLY 3
CT	C 0.035		
HA1	-0.907422830	1.783240810	-3.972773051 GLY 3
HC	H 0.032		
HA2	-1.127648566	3.540414569	-4.323795441 GLY 3
HC	H 0.032		
C	0.896974016	2.736484179	-4.547627543 GLY 3
С	C 0.616		
0	1.315189212	1.712629073	-5.101282348 GLY 3
0	0 -0.504		
N	1.599575272	3.853622667	-4.520184621 GLY 4
N	N -0.463		
HN	1.137216234	4.691535216	-4.019658253 GLY 4
H	H 0.252		
CA	2.905944550	3.804217731	-5.170228610 GLY 4
	C 0.035		
HA1	3.056204584	2.789614618	-5.584558431 GLY 4
	H 0.032		
HA2	2.897891721	4.540755026	-5.994216851 GLY 4
HC	н 0.032		
С	4.014980067	4.050747291	-4.175561433 GLY 4
С	C 0.616		
0	4.978871195	4.780583329	-4.436272241 GLY 4
0	0 -0.504		
N	3.887759074	3.450944950	-3.006608050 GLY 5
N	N -0.463		
HN	3.003276191	2.844372268	-2.879487738 GLY 5

WO 96/30849 PCT/US96/04				
Н	H 0.252			
CA	4.960071382	3.689311240	-2.044877031 GLY 5	
CT	C 0.035			
HAl	5.709592998	2.881830301	-2.144167698 GLY 5	
HC	H 0.032			
HA2	5.427393718	4.658369322	-2.297948016 GLY 5	
HC	H 0.032			
С	4.437174470	3.643619035	-0.629041435 GLY 5	
C	C 0.616			
0	3.798322352	2.676595378	-0.197242766 GLY 5	
0	0 -0.504			
N	4.713663113	4.691871185	0.124033264 GLY 6	
N	N -0.463	•		
HN	5.286002166	5.476492875	-0.348403798 GLY 6	
H	H 0.252			
CA	4.208080753	4.647691975	1.492986659 GLY 6	
CT	C 0.035	•		
HAl	3.303800182	4.010943092	1.515218779 GLY 6	
HC	H 0.032			
HA2	4.993057374	4.194323221	2.125265975 GLY 6	
HC	H 0.032			
С	3.799265981	6.023038258	1.963510280 GLY 6	
С	C 0.616			
0	4.006824522	7.036283245	1.285298717 GLY 6	
0	0 -0.504			
N	3.195690211	6.077750863	3.136158080 GLY 7	
N	N -0.463			
HN	3.055107813	5.133307510	3.640799839 GLY 7	
H	H 0.252			
CA	2.800412417	7.407555656	3.591101372 GLY 7	
CT	C 0.035			
HA1	1.946687677	7.303619509	4.286815466 GLY 7	
HC	H 0.032			
HA2	3.660862081	7.847316876	4.127520148 GLY 7	
HC	Н 0.032			
С	2.334578164	8.258959996	2.434291753 GLY 7	
С	C 0.616			
0	2.337411236	9.494643783	2.487154063 GLY 7	
0	0 -0.504			

WO 96/30	849		PCT/US96/04229
N	1.936206121	7.605756209	1.358640986 CYSN 8
N	N -0.463		
HIN	1.983632457	6.528240768	1.414418956 CYSN 8
H	H 0.252		
CA	1.485796919	8.428968216	0.240136508 CYSN 8
CT	C 0.035		
HA	0.399931102	8.271042216	0.100059529 CYSN 8
HC	H 0.032		
С	2.167493478	8.018162291	-1.043072620 CYSN 8
С	C 0.616		
CB	1.746659419	9.902481747	0.610166221 CYSN 8
CT	C -0.098		
HB1	2.709270705	10.016688002	1.140264476 CYSN 8
HC	H 0.050		
HB2	1.816139488	10.541353385	-0.293951287 CYSN 8
HC	H 0.050		
SG	0.440719361	10.532225816	1.688457720 CYSN 8
S	S 0.824		
LG1	-0.404239097	10.957145937	1.126774557 CYSN 8
LP	L -0.405		
LG2	0.793091788	11.329491558	2.359427872 CYSN 8
LP	L -0.405		
end			

PCT/US96/04229 WO 96/30849

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
 - (i) APPLICANT: Deem, Michael W. Rothberg, Jonathan H. Went, Gregory T.
 - (ii) TITLE OF INVENTION: CONSENSUS CONFIGURATIONAL BIAS MONTE CARLO METHOD AND SYSTEM FOR PHARMACOPHORE STRUCTURE DETERMINATION
 - (iii) NUMBER OF SEQUENCES: 10
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Pennie & Edmonds
 - (B) STREET: 1155 Avenue of the Americas

 - (C) CITY: New York (D) STATE: New York
 - (E) COUNTRY: USA
 - (F) ZIP: 10036-2711
 - (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible

 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: On Even Date Herewith
 - (C) CLASSIFICATION:
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Misrock, S. Leslie
 - (B) REGISTRATION NUMBER: 18,872
 - (C) REFERENCE/DOCKET NUMBER: 7934-007
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (212) 790-9090
 - (B) TELEFAX: (212) 869-9741/8864 (C) TELEX: 66141 PENNIE
- (2) INFORMATION FOR SEO ID NO:1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids (B) TYPE: amino acid

 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: peptide
 - (ix) FEATURE:
 - (A) NAME/KEY: Disulfide-bond
 - (B) LOCATION: 1..8
 - (D) OTHER INFORMATION: /note= "A disulfide bond is formed between the cysteine residues."
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
 - Cys Xaa Xaa Xaa Xaa Xaa Cys

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
ACTTCGAAAT TAATACGACT CACTATAGGG AGACCACAAC GGTTTCCCTC CAGAAATAAT	60
TITGTTTAAC TITAACTITA AGAAGGAGAT ATACATATGC AT	102
(2) INFORMATION FOR SEQ ID NO:3:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 83 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(*i) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
CCCAGACCCG CCCCCAGCAT TGTGGGTTCC AACGCCCTCT AGACAMNNMN NMNNMNNMNN	60
HNNACAATGT ATATCTCCTT CTT	83
(2) INFORMATION FOR SEQ ID NO:4:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
TEGTETGACE TECCTEARCE TECCEACART GETGGEGGGG GETETGGT	48
(2) INFORMATION FOR SEQ ID NO:5:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA	

	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:5:	
ATC	AAGTT	TG CCTTTACCAG CATTGTGGAG CGCGTTTTCA TC	42
(2)	INFO	RMATION FOR SEQ ID NO:6:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown	
	(ii)	MOLECULE TYPE: peptide	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:6:	
	Met 1	His Cys Xaa Xaa Xaa Xaa Xaa Cys 5 10	
(2)	INFO	RMATION FOR SEQ ID NO:7:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown	
	(ii)	MOLECULE TYPE: peptide	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:7:	
	Сув 1	Gly Gly Gly Gly Gly Cys 5	
(2)	INFO	RMATION FOR SEQ ID NO:8:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown	
	(ii)	MOLECULE TYPE: DNA	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:8:	
NNKI	NNKNN	ки икинкинкин кинкинкинк	30
(2)	INFO	RMATION FOR SEQ ID NO:9:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ACTTCGAAAT TAATACGACT CACTATAGGG AGACCACAAC GGTTTCC

47

- (2) INFORMATION FOR SEQ ID NO:10:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids (B) TYPE: amino acid
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: peptide
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys Asn Thr Leu Lys Gly Asp Cys Gly 1

WHAT IS CLAIMED IS:

1. A method of determining a consensus pharmacophore structure comprising the steps of:

- 5 (a) identifying from one or more diversity libraries a plurality of compounds that bind to a target molecule,
 - (b) measuring one or more distances in one or more of the compounds, and
- (c) determining a consensus pharmacophore structure for the compounds.
 - The method of claim 1 wherein said compounds are peptides, peptide derivatives, or peptide analogs.

15

- 3. The method of claim 2 wherein said compounds are peptides containing one or more cystines.
- 4. The method of claim 3 wherein the peptides comprise the sequence CX₆C (SEQ ID NO:1).
 - 5. The method of claim 1 further comprising a step of selecting a plurality of candidate pharmacophores based on rules of chemical homology, the selected plurality of candidate pharmacophores being used in step (c) to determine the consensus pharmacophore structure.
- The method of claim 5 wherein the rules of homology determine that two candidate pharmacophores are homologous if they have chemically similar side chains.
 - 7. The method of claim 1 which further comprises after said identifying step, a screening step involving a genetic selection technique.

35

25

8. The method of claim 1 wher in the step of measuring distance comprises making solid phase nuclear magnetic

resonance measurements on selected nuclei in a nuclear magn tic resonance spectrometer upon a sample comprising on of the compounds.

5 9. The method of claim 8 wherein the step of measuring distances further comprises making rotational echo double resonance nuclear magnetic resonance measurements of internuclear dipole-dipole interaction strength between selected nuclei in the compound in the sample.

10

- 10. The method of claim 8 wherein the sample further comprises a substrate having a surface to which the compound is attached.
- 15 11. The method of claim 8 wherein the sample is cooled below room temperature.
 - 12. The method of claim 8 wherein the compound is bound to the target molecule.

- 13. The method of claim 10 wherein a plurality of the compound is attached to the surface at a surface density such that the inter-nuclear dipole-dipole interactions between different molecules is less than 10% of the inter-nuclear dipole-dipole interaction within one molecule.
- 14. The method of claim 10 wherein the substrate has pores of sufficient size to permit the target to diffuse and bind to the compound in the sample.
- 15. The method of claim 9 wherein rotational echo double resonance nuclear magnetic resonance measurements can be made on the compound bound to the target or hydrated or in a dry nitrogen atmosphere.

16. The method of claim 10 wherein the compound is a peptide, and a plurality of the peptide is attached to the substrate surface, which has a purity of the peptide of at least 95% and wherein the surface density of the peptide is no more than one peptide per 100 Å² of substrate surface.

- 17. The method of claim 10 wherein the substrate is selected from the group consisting of p-MethylBenzhydrilamine
 10 resin, divinylbenzyl polystyrene resin, and glass beads.
 - 18. The method of claim 8 wherein the selected nuclei are selected from the group consisting of ¹³C, ¹⁵N, ¹⁹F, and ³¹P.
- 15 19. The method of claim 9 wherein the nuclear magnetic resonance spectrometer comprises magnetic excitation means, a sample rotor, and free induction decay observing means, and the step of making rotational echo double resonance nuclear magnetic resonance measurements further comprises the steps of:
 - (a) spinning the sample in the sample rotor,
 - (b) initially exciting magnetically the selected nuclei to be observed,
- (c) providing subsequently one π spin flip magnetic excitation during each rotor period to each of the selected nuclei, the pulses to the different nuclei having fixed phase delays,
 - (d) observing the free induction decay signal as a function of the number of rotor periods; and
- (e) finding the dipole-dipole strength between the selected nuclei, whereby the internuclear distance between the selected nuclei can be obtained.
- 20. The method of claim 1 wherein the step of measuring
 35 distances comprises making liquid phase nuclear magnetic resonance measurements.

21. A method of determining a consensus pharmacophore structure comprising the st ps of:

- (a) identifying from one or more diversity libraries a plurality of compounds that bind to a target molecule,
- (b) determining a consensus pharmacophore structure for the compounds.
- 22. A method of determining a consensus pharmacophorestructure comprising the steps of:
 - (a) measuring one or more distances in one or more compounds that bind to a target molecule, and
 - (b) determining a consensus pharmacophore structure for the compounds.

15

20

25

- 23. The method of claim 21 or 22 further comprising a step of selecting a plurality of candidate pharmacophores based on rules of chemical homology, the selected plurality of candidate pharmacophores being used in step (b) to determine the consensus pharmacophore structure.
- 24. The method of claim 23 wherein the compounds have limited conformational degrees of freedom at the temperature of interest, and wherein the step of determining a consensus pharmacophore structure for each compound further comprises, performing a consensus configurational bias Monte Carlo method, said Monte Carlo method comprising the steps of:
- (a) generating a proposed structure for a compound identified from said one or more diversity libraries by making conformational alterations consistent with the conformational degrees of freedom, the alterations being made to a representation of the compound's current chemical and conformational structure to generate a proposed representation, the proposed structure being g n rated with a bias

toward more acceptable configurations of lower en rgy, wh reby the method is made more efficient,

- (b) acc pting and st ring the proposed structure according to a probability depending on an energy determined for the proposed structure, and
- (c) repeating these steps until sufficient structures have been stored for each compound to permit statistically significant determination of an equilibrium structure for each compound.

10

15

- 25. A method of determining one or more lead compounds for use as a drug that binds to a target molecule comprising the steps of:
- (a) identifying from one or more diversity libraries a plurality of compounds that bind to a target molecule;
 - (b) determining a consensus pharmacophore structure for the compounds; and
- (c) determining one or more lead compounds for use as a drug which share a pharmacophore specification with the determined consensus pharmacophore structure.
- 26. A method of determining one or more lead compounds for use as a drug that binds to a target molecule comprising25 the steps of:
 - (a) measuring one or more distances in one or more compounds that bind to a target molecule;
 - (b) determining a consensus pharmacophore structure for the compounds; and
- 30 (c) determining one or more lead compounds for use as a drug which share a pharmacophore specification with the determined consensus pharmacophore structure.
- 27. The method according to claim 25 or 26 wherein said step of determining one or more lead compounds comprises modifying a compound id ntified as binding to the targ t mol cul, said modification being done outside of the

pharmacophore structure, to rend r the compound more attractive for use as a drug.

- 28. The method of claim 5 wherein the compounds have limited conformational degrees of freedom at a temperature of interest, and wherein the step of determining a consensus pharmacophore structure for the compounds further comprises performing a consensus configurational bias Monte Carlo method, said Monte Carlo method comprising the steps of:
 - (a) generating a proposed structure for a compound identified from said one or more diversity libraries by making conformational alterations consistent with the conformational degrees of freedom, the alterations being made to a representation of the compound's current chemical and conformational structure to generate a proposed representation, the proposed structure being generated with a bias toward more acceptable configurations of lower energy,

15

20

- (b) accepting and storing the proposed structure according to a probability depending on an energy determined for the proposed structure, and
- (c) repeating these steps until sufficient structures have been stored for each compound to permit statistically significant determination of an equilibrium structure for each compound.
- 29. The method of claim 28 wherein the limited conformational degrees of freedom comprise torsional rotations about mutual bonds between otherwise rigid subunits of the compound, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position, the torsional rotations respecting any conformational constraints present.

30. The method of claim 28 wherein the compound is a peptide, p ptide derivative, or peptide analog.

- 31. The method of claim 28 wherein the conformational alterations comprise constrained, concerted torsional rotations or removal of a side chain and regrowth of the side chain with a new torsional conformation.
- 32. The method of claim 31 wherein the constrained, concerted torsional rotations are constrained so that no more than four rigid units are spatially displaced.
- 33. The method of claim 28 wherein determining the energy for the proposed structure of one compound comprises
 including one or more constraint terms which represent knowledge of measured structure for the compound.
- 34. The method of claim 33 wherein the constraint terms comprise a weighted sum of squares of differences of the20 actual and measured structures.
- 35. The method of claim 28 wherein the energy is determined for the proposed structure of one compound by a method comprising including consensus terms which represent knowledge that the identified compounds all bind to the same target, the compounds being otherwise treated independently by the method.
- 36. The method of claim 35 wherein the consensus terms are a weighted sum of squares of differences in the atomic positions of a candidate pharmacophore from the average values of these positions in all the compounds.
- 37. The method of claim 35 wherein the step of determining the consensus pharmacophore structure comprises determining from the plurality of selected candidate pharmac phores a candidate pharmacophore for which the

consensus terms are relatively small compared to the total energy.

38. The method of claim 35 wherein the step of determining the consensus pharmacophore structure comprises determining from the plurality of selected candidate pharmacophores a candidate pharmacophore for which the consensus terms are minimum compared to other selected regions.

10

30

(c)

- 39. The method of claim 28 wherein the equilibrium structure is determined by a method comprising averaging selected generated and accepted structures for each compound.
- 15 40. The method of claim 39 wherein the averaging of structures comprises clustering selected generated and accepted structures into sets of similar structures and averaging these sets for each member.
- 20 41. A method of identifying a compound that binds to a target molecule comprising the following steps in the order stated:
 - (a) contacting compounds of a phage display or polysomebased diversity library with a target molecule;

contacting one or more first fusion proteins, each

- (b) identifying one or more compounds in the library that bind to the target molecule;
 - first fusion protein comprising an identified compound, with a second fusion protein comprising the target molecule or a binding portion thereof, in which binding of the first fusion protein to the second fusion protein results in an increase in activity or activation of a transcriptional promoter or an origin of replication; and
- (d) identifying one or more of the compounds that when present in said first fusion protein result in said increase in activity r activation.

42. A m thod of making solid state nuclear magnetic resonanc measurements comprising measuring int rnuclear dipoledipol interaction strengths between selected nuclei in a compound, said compound being attached to the surface of a substrate.

43. The method of claim 42 which further comprises before said measuring step the step of synthesizing a plurality of said compound on the surface of the substrate.

10

5

- 44. The method of claim 43 wherein said plurality of the compound is at least 95% pure.
- 45. The method of claim 42 wherein a plurality of said compound is attached to the substrate surface, with at least 10 Å spacing between molecules of the compound.
- 46. The method of claim 42 wherein the substrate has pores of sufficient size to permit a molecule to diffuse and bind to the compound.
- 47. The method of claim 42 wherein the substrate has a surface density of the compound such that the internuclear dipole-dipole interactions between different molecules of the compound is less than 10% of the internuclear dipole-dipole interaction within one molecule of the compound.
- 48. The method of claim 42 wherein the compound is a peptide, peptide derivative, or peptide analog.
 - 49. The method of claim 42 wherein the substrate is selected from the group consisting of p-MethylBenzhydrilamine resin, divinylbenzyl polystyrene resin, and a glass bead.

35

50. The method of claim 42 wherein said measuring step compris s using a nuclear magnetic resonance

spectrometer, said spectrometer comprising magnetic excitation means, a sample rot r, and free induction decay observing means; and said measurement of internuclear dipole-dipole interaction is done by a method comprising the steps of:

(a) spinning the sample in the sample rotor;

5

10

25

- (b) initially exciting magnetically the selected nuclei to be observed;
- (c) providing subsequently one or more π spin flip magnetic excitations during each rotor period to one or both of the selected nuclei, wherein pulses to the different nuclei have fixed phase delays;
 - (d) observing a free induction decay signal as a function of the number of rotor periods; and
- (e) determining the dipole-dipole strength between the selected nuclei, whereby the internuclear distance between the selected nuclei can be obtained.
- 51. A method of configurational bias Monte Carlo

 20 determination of the structure of a compound having
 limited conformational degrees of freedom at a
 temperature of interest, the method comprising the steps
 of:
 - (a) generating a proposed structure for the compound by making conformational alterations consistent with the conformational degrees of freedom, the alterations being made to a representation of the compound's current chemical and conformational structure to generate a proposed representation;
- 30 (b) accepting and storing the proposed structure according to a probability depending on an energy determined for the proposed structure; and
 - (c) repeating these steps until sufficient structures have been stored to permit statistically significant determination of an equilibrium structure.

52. The method of claim 51 wherein the conformational degre s of freedom compris torsional rotations about mutual bonds between otherwise rigid subunits of the compound, each rigid unit's representation comprising its

- interconnections and atomic composition, each atom's representation comprising its type and position, the torsional rotations respecting any conformational constraints present.
- 10 53. The method of claim 51 wherein the compound is a peptide, peptide derivative, or peptide analog.
- 54. The method of claim 51 wherein the conformational alterations comprise constrained, concerted torsional rotations.
 - 55. The method of claim 54 wherein the constrained, concerted torsional rotations are constrained so that no more than four rigid units are spatially displaced.

- 56. The method of claim 51 wherein the conformational alterations comprise removal of a side chain and regrowth of the side chain with a new torsional conformation.
- 25 57. The method of claim 51 wherein the proposed structures are generated with a bias toward more acceptable configurations of lower energy.
- 58. The method of claim 51 wherein the energy is determined for the proposed structure by a method comprising including constraint terms which represent knowledge of measured structure for the compound.
- 59. The method of claim 58 wherein the constraint terms35 comprise a weighted sum of squares of differences of the actual and measured structures.

5

60. The method of claim 51 applied to a plurality of compounds f limited c nf rmational degrees of freedom all of which bind to th sam target molecule wherein the method further comprises a step of selecting a plurality of candidate pharmacophores based on rules of chemical homology.

- 61. The method of claim 60 wherein the energy is determined for the proposed structure of one of the plurality of compounds by a method comprising including consensus terms which represent knowledge that the compounds all bind to the same target molecule.
- 62. The method of claim 61 wherein the consensus terms are a
 weighted sum of squares of differences in the atomic
 positions of a candidate pharmacophore of said one of the
 plurality of compounds from the average values of these
 positions in all the compounds.
- 20 63. The method of claim 61 which further comprises a step of determining a consensus pharmacophore structure by determining from the plurality of selected candidate pharmacophores that candidate pharmacophore for which the consensus terms are minimum compared to other candidate pharmacophores.
- 64. The method of claim 60 which further comprises a step of determining a consensus pharmacophore structure by determining from the plurality of selected candidate
 30 pharmacophores that candidate pharmacophore for which the consensus terms are relatively small compared to the total energy.
- 65. The method of claim 63 or 64 which further comprises a step of determining one or more lead compounds for use as a drug which shar a pharmacophore specification with the determined consensus pharmacophor structure.

66. The method of claim 51 wherein the equilibrium structure is det rmined by a method comprising averaging selected generated and accepted structures.

- 5 67. The method of claim 66 wherein the averaging of structures comprises clustering selected generated and accepted structures into sets of similar structures and averaging these sets.
- 10 68. An apparatus for configurational bias Monte Carlo determination of the structure of a compound having limited conformational degrees of freedom at a temperature of interest, the apparatus comprising:
 - (a) memory means for storing

15

20

25

30

- (i) data structures representing the compound's chemical and conformational structure consistently with the compound's degrees of freedom,
 - (ii) similar data structures representing the compound's proposed structure and prior structures, and
 - (iii) parameters representing atomic interactions,
 and
- (b) processor means for executing programs for
- (i) generating a proposed structure by making conformational alterations consistent with the conformational degrees of freedom and with a bias toward more acceptable configurations of lower energy,
 - (ii) accepting and storing the proposed structure according to a probability depending on an energy determined for the proposed structure, and
- (iii) repeating these steps until sufficient structures have been stored to permit statistically significant determination of an equilibrium structure.

69. The apparatus of claim 68 wherein the conformational degrees of freedom comprise torsional rotations about mutual bonds between otherwise rigid subunits of the compound, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position, the torsional rotations respecting any conformational constraints present.

- 10 70. The apparatus of claim 68 wherein the compound is a peptide, peptide derivative, or peptide analog.
- 71. The apparatus of claim 68 wherein the memory, processor, and control means are configured from a workstation typ digital computer comprising RAM memory, disk memory, processor, and input and display devices.
- 72. The apparatus of claim 68 wherein the conformational alterations made by the processor means further comprise constrained, concerted torsional rotations or removal of a side chain and regrowth of the side chain with a new torsional conformation.
- 73. The apparatus of claim 72 wherein the constrained,25 concerted torsional rotations are constrained so that no more than four rigid units are spatially displaced.
- 74. The apparatus of claim 68 wherein the processor means determines an energy for the proposed structure by a method comprising including constraint terms which represent knowledge of measured structure for the compound.
- 75. The apparatus of claim 74 wherein the constraint terms

 comprise a weighted sum of squares of differences of the actual and measured structures.

5

76. The apparatus of claim 68 applied to a plurality of comp unds of limited conformational degrees of fre dom all of which bind to the sam target molecule, and wherein the processor means further comprises programs for selecting a plurality of candidate pharmacophores based on rules of chemical homology.

- 77. The apparatus of claim 76 wherein the processor means determines an energy for the proposed structure of any one compound by a method comprising including consensus terms which represent knowledge that the compounds all bind to the same target molecule.
- 78. The apparatus of claim 77 wherein the consensus terms are
 a weighted sum of squares of differences in the atomic
 positions of the candidate pharmacophore of said one
 compound from the average values of these positions in
 all the compounds.
- 20 79. The apparatus of claim 77 wherein the processor means further comprises programs for determining a consensus pharmacophore structure by determining from the plurality of selected candidate pharmacophores a candidate pharmacophore for which the consensus terms are minimum compared to other candidate pharmacophores.
- 80. The apparatus of claim 77 wherein the processor means further comprises programs for determining a consensus pharmacophore structure by determining from the plurality of selected candidate pharmacophores a candidate pharmacophore for which the consensus terms are relatively small compared to the total energy.
- 81. The apparatus of claim 79 or 80 wherein the processor35 means further comprises programs for determining ne or more lead compounds for use as a drug that share a

pharmacophore specification with the cons nsus pharmac ph re structure.

- 82. The apparatus of claim 68 wherein the processor means determines an equilibrium structure by a method comprising averaging selected generated and accepted structures.
- 83. The apparatus of claim B2 wherein the averaging of

 10 structures further comprises clustering selected

 generated and accepted structures into sets of similar

 structures and averaging these sets.
- 84. In a digital computer, apparatus for configurational bias

 15 Monte Carlo determination of the structure of at least
 one compound having limited conformational degrees of
 freedom at a temperature of interest, said apparatus
 comprising:
 - (a) first memory means for storing data structures representing the compound's chemical and conformational structure consistently with the compound's degrees of freedom,

20

- (b) second memory means for storing similar data structures representing the compound's proposed structure,
- (c) third memory means for storing similar data structures representing the compound's prior structures,
- (d) first processor means for generating a proposed structure by making conformational alterations consistent with the conformational degrees of freedom and with a bias toward conformations of lower energy,
- (e) second processor means for accepting and storing the proposed structure according to a probability depending on an energy determined for the proposed structure, and

(f) third processor means for controlling and repeating th generation and acceptance until suffici nt structures have be n stored to permit statistically significant determination of an equilibrium structure.

- 85. The digital computer apparatus of claim 84 wherein the conformational degrees of freedom comprise torsional rotations about mutual bonds between otherwise rigid
- subunits of the compound, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position, the torsional rotations respecting any conformational constraints present.

15

5

- 86. The digital computer apparatus of claim 84 wherein the compound is a peptide, peptide derivative, or peptide analog.
- 20 87. The digital computer apparatus of claim 84 wherein the digital computer is a workstation type digital computer comprising RAM memory, disk memory, processor, and input and display devices.
- 25 88. The digital computer apparatus of claim 84 wherein the conformational alterations generated by the first processor means comprise constrained, concerted torsional rotations or removal of a side chain and regrowth of the side chain with a new torsional conformation.

30

89. The digital computer apparatus of claim 88 wherein the constrained, concerted torsional rotations are constrained so that no more than four rigid units are spatially displaced.

35

90. The digital computer apparatus of claim 84 wherein the second processor means determines an energy for the

proposed structure by a method comprising including constraint terms which represent knowledge of measured structure for the compound.

- 5 91. The digital computer apparatus of claim 90 wherein the constraint terms comprise a weighted sum of squares of differences of the actual and measured structures.
- 92. The digital computer apparatus of claim 84 in which said at least one compound is a plurality of compounds of limited conformational degrees of freedom all of which bind to the same target and wherein data are stored in said first memory means representing the chemical and conformational structure of said plurality of compounds and wherein the apparatus further comprises additional processor means for selecting a plurality of candidate pharmacophores based on rules of chemical homology.
- 93. The digital computer apparatus of claim 92 wherein the second processor means determines an energy for the proposed structure of one of said plurality of compounds by a method comprising including consensus terms which represent knowledge that the compounds all bind to the same target molecule.

25

- 94. The digital computer apparatus of claim 92 wherein the consensus terms are a weighted sum of squares of differences in the atomic positions of a candidate pharmacophore of said one of the plurality of compounds from the average values of these positions in all the compounds.
- 95. The digital computer apparatus of claim 93 wherein the apparatus further comprises processor means for determining a consensus pharmacophore structure by determining from the plurality of selected candidate pharmacoph r s a candidat pharmacophore for which the

consensus terms are relatively small compared to th total energy.

- 96. The digital computer apparatus of claim 93 wherein the apparatus further comprises processor means for determining a consensus pharmacophore structure by determining from the plurality of selected candidate pharmacophores a candidate pharmacophore for which the consensus terms are minimum compared to other candidate pharmacophores.
- 97. The digital computer apparatus of claims 95 or 96 wherein the apparatus further comprises processor means for determining one or more lead compounds for use as a drug that share a pharmacophore specification with the consensus pharmacophore structure.
- 98. The digital computer apparatus of claim 84 wherein the third processor means determines an equilibrium structure by a method comprising averaging selected generated and accepted structures.
- 99. The digital computer apparatus of claim 98 wherein the averaging of structures comprises clustering selected
 25 generated and accepted structures into sets of similar structures and averaging these sets.
- 100. In a digital computer, apparatus for configurational bias Monte Carlo determination of the structure of a plurality of compounds having limited conformational degrees of freedom, each compound having a backbone and side chains, said apparatus comprising:
 - (a) first memory means for storing data structures representing each compound's chemical and conformational structure consistently with that compound's degrees of freedom and constraints,

5

25

30

35

(b) second mem ry m ans f r storing similar data structures representing a proposed structure for one or more of the compounds,

- (c) third memory means for storing similar data structures representing prior structures of the plurality of compounds,
- first processor means for generating a proposed (d) structure of a randomly selected compound by making conformational alterations consistent with the 10 conformational degrees of freedom, the conformational alterations being randomly distributed between alterations that alter the structure of a randomly selected side chain of the selected compound and alterations that alter the 15 structure of a randomly selected region of the backbone of the selected compound, the proposed structure being stored in the second memory means, the proposed structure being generated with a bias toward more acceptable structures of lower energy, whereby the method is made more efficient, 20
 - (e) second processor means for accepting a proposed structure according to a probability depending on an energy determined for the proposed structure, the energy including terms representing physical interactions and terms representing heuristic information about the compound's structure, the heuristic information comprising knowledge about measured distances in one or more compounds of said plurality and about the plurality of the compounds binding to a same target molecule,
 - (f) third processor means for controlling and repeating these steps until sufficient structures have been generated and accepted to permit statistically significant determination of an equilibrium structure.

101. The digital computer of claim 100 wherein the conformational degrees of freedom comprise torsional rotations about mutual bonds between otherwise rigid subunits of the compound, each rigid unit's

- representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position, the torsional rotations respecting any conformational constraints present.
- 10 102. The digital computer of claim 100 wherein the compound is a peptide, peptide derivative, or peptide analog.
- 103. A method of configurational bias Monte Carlo determination of the structure of a compound selected from the group consisting of a peptide, peptide derivative, and peptide analog, the method comprising the steps of:
 - (a) representing the conformation of the compound by interconnected rigid units capable of torsional rotation about common bonds, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position,
- (b) generating a proposed structure by making conformational alterations consistent with the compound's structure,

- (c) accepting a proposed structure according to a probability depending on an energy determined for the proposed structure, and
- (d) repeating these steps until sufficient structures have been generated and accepted to permit statistically significant determination of an equilibrium structure.
- 35 104. An apparatus for configurational bias Monte Carlo determination of the structure f a compound selected

fr m the group consisting of a peptide, peptide
derivative, and peptide analog, the apparatus c mprising:

(a) memory means for storing

5

10

15

20

- (i) data structures representing the compound's conformation as interconnected rigid units capable of torsional rotation about common bonds, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position,
- (ii) similar data structures representing the compound's proposed structure and prior structures, and
- (iii) parameters representing atomic interactions, and
- (b) processor means for executing programs for
 - generating a proposed structure by making conformational alterations consistent with the compound's structure and with a bias toward more acceptable configurations of lower energy,
 - (ii) accepting a proposed structure according to a probability depending on an energy determined for the proposed structure, and
 - (iii) repeating these steps until sufficient structures have been generated and accepted to permit statistically significant determination of an equilibrium structure.
- 105. In a digital computer, apparatus for configurational bias
 30 Monte Carlo determination of the structure of a compound selected from the group consisting of a peptide, peptide derivative, and peptide analog, said apparatus comprising:
- (a) first memory means for storing data structures representing the compound's structure as interconnected rigid units capable of t raional rotation about common b nds, each rigid unit's

5

20

representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position,

- (b) second memory means for storing similar data structures representing the compound's proposed structure.
- (c) third memory means for storing similar data structures representing the compound's prior structures,
- (d) first processor means for generating a proposed structure by making conformational alterations consistent with the compound's structure and constraints and with a bias toward conformations of lower energy,
- (e) second processor means for accepting a proposed structure according to a probability depending on an energy determined for the proposed structure, and
 - (f) third processor means for controlling and repeating these steps until sufficient structures have been generated and accepted to permit statistically significant determination of an equilibrium structure.
- Monte Carlo determination of the structure of a plurality of compounds selected from the group consisting of peptides, peptide derivatives, and peptide analogs, each compound having a backbone and side chains, said apparatus comprising:
- (a) first memory means for storing data structures representing each compound's structure as interconnected rigid units capable of torsional rotation about common bonds, each rigid unit's representation comprising its interconnections and atomic composition, each atom's representation comprising its type and position,

5

10

15

(b) s cond memory m ans for storing similar data structures representing a proposed structure for one or more of th compounds,

- (c) third memory means for storing similar data structures representing prior structures of the plurality of the compounds,
- (d) first processor means for generating a proposed structure of a randomly selected compound by making conformational alterations consistent with the compound's structure, the conformational alterations being randomly distributed between alterations that alter the structure of a randomly selected side chain of the selected compound and alterations that alter the structure of a randomly selected region of the backbone of the selected compound, the proposed structure being stored in the second memory means, the proposed structure being generated with a bias toward more acceptable structures of lower energy,
- structure according to a probability depending on an energy determined for the proposed structure, the energy including terms representing physical interactions and terms representing heuristic information about the compound's structure, the heuristic information comprising knowledge about measured distances in one or more compounds of said plurality and about the plurality of the compounds binding to a same target molecule,
- (f) third processor means for controlling and repeating
 these steps until sufficient structures have been
 generated and accepted to permit statistically
 significant determination of an equilibrium
 structure.
- 35 107. The method of claim 42 wherein the nuclear magnetic res nance is rotational echo double r sonance.

WO 96/30849

PCT/US96/04229

108. The method of claim 1 wherein the diversity libraries are structurally constrained organic diversity libraries.




FIG.1

SUBSTITUTE SHEET (RULE 26)




FIG.2A

SUBSTITUTE SHEET (RULE 26)






FIG.3
SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)







FIG.6

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)






FIG. 10

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)
12 / 2 1



SUBSTITUTE SHEET (RULE 26)




FIG.13

SUBSTITUTE SHEET (RULE 26)




FIG. 14
SUBSTITUTE SHEET (RULE 26)
15 / 2 1





FIG. 15
SUBSTITUTE SHEET (RULE 26)
16 / 2 1



SUBSTITUTE SHEET (RULE 26)
17 / 2 1






FIG. 17
SUBSTITUTE SHEET (RULE 26)
18 / 2 1




SUBSTITUTE SHEET (RULE 26)
19 / 2 1



SUBSTITUTE SHEET (RULE 26)

20 / 2 1



SUBSTITUTE SHEET (RULE 26)
21 / 2 1

International application No. PCT/US96/04229

A. CL	ASSIFICATION OF SUBJECT MATTER :G06F 17/50, 159:00; G06G 7/58; G01N 24/12, :	20/50	
US CL	:364/413.01, 496, 578; 436/173, 501, 518; 435/7.	.1	
	to International Patent Classification (IPC) or to be	oth national classification and IPC	
	LDS SEARCHED		
	documentation searched (classification system follow	_	
U.S. :	364/413.01, 496, 578; 436/173, 501, 518; 435/7.1	l	
Documenta	ntion searched other than minimum documentation to	the extent that such documents are included	f in the fields searched
Electronic	data base consulted during the international search (name of data base and, where practicable	, search terms used)
APS, ST			
C. DOC	CUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.
X A	HODGKIN et al. A Monte Carlo Procedure: Application to the Hur of Computer Aided Molecular De	man PAF Receptor, Journal	22-24, 26, 27, 51-106
	515-534, see pages 517-521.		1-21, 25, 28- 41, 108
X 	WILSON et al. The Calculation and Synthesis of a Template Molecule. Tetrahedron. 1993, Vol. 49, No. 17, pages 3655-		51-106
A	3663, see entire document.	10, 1101 17, pages 0000	1-41, 108
Р, А	SEPETOV et al. Library of librari combinatorial library desig "pharmacophore" motifs. Proce Academy of Sciences. June 1995 5430, see abstract.	n and screening of eedings of the National	1-41, 108
X Furthe	er documents are listed in the continuation of Box (2. See patent family annex.	
A* does	earl categories of cited documents. ument defining the general state of the art which is not considered to particular relevance.	"I" later document published after the inter- date and not in conflict with the applica- principle or theory underlying the inve	ion but cited to understand the
L* does	ner document published on or after the international filing date nment which may throw doubts on priority claims or which is I to establish the publication date of another citation or other	'Y' document of particular relevance; the claimed invention cannot be considered to vector cannot be considered to involve an inventive step when the document is taken alone.	
I* the inem	ral reason (as specified) intent reterring to an oral doclosure, use, exhibition or other	'V' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
docu the p	ment published prior to the international filing date but rater than promis, date claimed	*&* document member of the same patent i	unily.
Oate of the actual completion of the international search 03 JULY 1996		Date of mailing of the international search report 25 JUL 1996	
ame and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer LUG W	Fried to
acsimile No (703) 305-3230		Telephone No. 7037 308-0196	

International application No. PCT/US96/04229 :

tion). DOCUMENTS CONSIDERED TO BE RELEVANT		
Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No
BIANCHI et al. A Conformationally Homogenous Combinatorial Peptide Library. Journal of Molecular Biology. 1995, Vol. 247, pages 154-160, see abstract.		1-41, 108
US 5,265,030 (SKOLNICK ET AL.) 23 November 1993, see column 2, line 21-column 3, line 20.		68-102, 104-106
GARBOW et al. Determination of the Molecular Confirmation of Melanostatin Using 13C,15N-REDOR NMR Spectroscopy. Journal of the American Chemical Society. 1993, Vol. 115, pages 238-244, see Experimental Section.		42-50, 107
Adsorbed on Silica and Hydroxyapatite Surfaces. Journal	of the	42-50, 107
	Peptide Library. Journal of Molecular Biology. 1995, V pages 154-160, see abstract. US 5,265,030 (SKOLNICK ET AL.) 23 November 1993 column 2, line 21-column 3, line 20. GARBOW et al. Determination of the Molecular Confirm Melanostatin Using 13C,15N-REDOR NMR Spectroscop of the American Chemical Society. 1993, Vol. 115, page 244, see Experimental Section. FERNANDEZ et al. Magnetic Resonance Studies of Pol Adsorbed on Silica and Hydroxyapatite Surfaces. Journal American Chemical Society. 1992, Vol. 114, pages 9634	Peptide Library. Journal of Molecular Biology. 1995, Vol. 247, pages 154-160, see abstract. US 5,265,030 (SKOLNICK ET AL.) 23 November 1993, see column 2, line 21-column 3, line 20. GARBOW et al. Determination of the Molecular Confirmation of Melanostatin Using 13C,15N-REDOR NMR Spectroscopy. Journal of the American Chemical Society. 1993, Vol. 115, pages 238-244, see Experimental Section. FERNANDEZ et al. Magnetic Resonance Studies of Polypeptides Adsorbed on Silica and Hydroxyapatite Surfaces. Journal of the American Chemical Society. 1992, Vol. 114, pages 9634-9642,

International application No. PCT/US96/04229

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
Claims Nos.; because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows:			
Please See Extra Sheet.			
1. X As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			
f f f i v over to very elektronia version and annual and			

International application No. PCT/US96/04229

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-41 and 108, drawn to a method of determining a consensus pharmacophore structure.

Group II, claim(s) 42-50 and 107, drawn to a method of making solid state magnetic resonance methods.

Group III, claim(s) 51-67 and 103, drawn to a method of configurational Monte Carlo determination.

Group IV, claims 68-102 and 104-106, drawn to an apparatus for configurational bias Monte Carlo determination.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I and Groups II and III do not share a special technical feature as each has different steps and different end results. The method of Group I requires screening of a diversity library and generation of a pharmacophore, neither of which is required by the methods of Groups II and III. The distances required for the pharmacophore generation of Group I could be obtained by methods other than through the use of solid-state NMR methods ofGroup II, such as by solution NMR or X-ray crystallography. In addition, the method of Group I as claimed does not require the method of Group III as claimed, as the dependant claim of Group I which specifies the Monte Carlo method (claim 24) requires generating a proposed structure based on data for diversity libraries, whereas the method of Group II does not require the use of diversity libraries. Thus, Groups II and III lack the special technical feature of Group I, i.e. using a diversity library to generate a consensus pharmacophore structure.

Groups II and III are related as separate methods, as Group II is drawn to a method of making NMR measurements, while the method of Group III is drawn to a method of configurational monte earlo analysis. Thus, Groups II and III do not share a technical feature.

Groups I and II are related to Group IV as separate methods and product, as the methods of Groups I and II as claimed do not require the apparatus of Group IV as claimed.

Groups III and IV are related as separate method and product. The method of Group III as claimed does not require the use of the apparatus of Group IV as claimed. In addition, the apparatus of Group IV could be used in methods other than the method of Group III such as use generating structures using NMR data obtained from a compound in solution phase.